Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy

ABSTRACT

The present invention relates to pyrrolidine derivatives of the formula (I), 
                         
or a physiologically tolerated salt thereof.
 
     The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

CROSS-REFERENCE TO RELATED APPLICATIONS

This claims priority to U.S. Patent Application No. 61/789,382, filed on Mar. 15, 2013, the entire contents of which are fully incorporated herein by reference.

The present invention relates to pyrrolidine derivatives, pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes.

BACKGROUND OF THE INVENTION

The pyrrolidine motif is an important pharmacophore possessing biological activity against a number of different targets and thus has found use in various advanced pharmaceutical research compounds and clinical candidates (such as Factor Xa inhibitors, NK3 receptor antagonists, DPP-IV inhibitors, PDE-IV inhibitors, or MC4 receptorselective agonists).

A pyrrolidine compound already known in the art as type IV phosphodiesterase inhibitor (PDE-IV) is for example:

WO 9508534, US 2006074123, WO 2001047915, US 20020169196, WO 2001047879 and WO 2001047914 describe further PDE-IV inhibitors having related structures.

Further, the synthesis of certain trisubstituted pyrrolidine derivatives has been reported in Baumann Marcus, et al., ACS Comb. Sci. 2011, 13, 405-413.

Dysfunction of glutamatergic pathways has been implicated in a number of disease states in the human central nervous system (CNS) including but not limited to schizophrenia, cognitive deficits, dementia, Parkinson disease, Alzheimer disease and bipolar disorder. A large number of studies in animal models lend support to the NMDA hypofunction hypothesis of schizophrenia.

NMDA receptor function can be modulated by altering the availability of the co-agonist glycine. This approach has the critical advantage of maintaining activity-dependent activation of the NMDA receptor because an increase in the synaptic concentration of glycine will not produce an activation of NMDA receptors in the absence of glutamate. Since synaptic glutamate levels are tightly maintained by high affinity transport mechanisms, an increased activation of the glycine site will only enhance the NMDA component of activated synapses.

Two specific glycine transporters, GlyT1 and GlyT2 have been identified and shown to belong to the NaCl-dependent family of neurotransmitter transporters which includes taurine, gamma-aminobutyric acid (GABA), proline, monoamines and orphan transporters. GlyT1 and GlyT2 have been isolated from different species and shown to have only 50% identity at the amino acid level. They also have a different pattern of expression in mammalian central nervous system, with GlyT2 being expressed in spinal cord, brainstem and cerebellum and GlyT1 present in these regions as well as forebrain areas such as cortex, hippocampus, septum and thalamus. At the cellular level, GlyT2 has been reported to be expressed by glycinergic nerve endings in rat spinal cord whereas GlyT1 appears to be preferentially expressed by glial cells. These expression studies have led to the suggestion that GlyT2 is predominantly responsible for glycine uptake at glycinergic synapses whereas GlyT1 is involved in monitoring glycine concentration in the vicinity of NMDA receptor expressing synapses. Recent functional studies in rat have shown that blockade of GlyT1 with the potent inhibitor (N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl])-sarcosine (NFPS) potentiates NMDA receptor activity and NMDA receptor-dependent long-term potentiation in rat.

Molecular cloning has further revealed the existence of three variants of GlyT1, termed GlyT-1a, GlyT-1b and GlyT-1c, each of which displays a unique distribution in the brain and peripheral tissues. The variants arise by differential splicing and exon usage, and differ in their N-terminal regions.

The physiological effects of GlyT1 in forebrain regions together with clinical reports showing the beneficial effects of GlyT1 inhibitor sarcosine in improving symptoms in schizophrenia patients suggest that selective GlyT1 inhibitors represent a new class of antipsychotic drugs.

Glycine transporter inhibitors are already known in the art, for example:

(see also Hashimoto K., Recent patents on CNS Drug Discovery, 2006, 1, 43-53; Harsing L. G. et al., Current Medicinal Chemistry, 2006, 13, 1017-1044; Javitt D. C., Molecular Psychiatry (2004) 9, 984-997; Lindsley, C. W. et al., Current Topics in Medicinal Chemistry, 2006, 6, 771-785; Lindsley C. W. et al., Current Topics in Medicinal Chemistry, 2006, 6, 1883-1896).

Further glycine transporter inhibitors are known from the following documents.

WO 2009024611 describes 4-benzylaminoquinolines of formula:

WO 2009121872 describes tetrahydroisoquinoline of formula:

WO 2010092180 describes aminotetraline derivatives of formula:

WO 2010092181 describes heterocyclic compounds of formula:

WO 2012020131 describes aminoindane derivatives of formula:

WO 2012020130 describes phenalkylamine derivatives of formula:

WO 2012020133 describes tetraline and indane derivatives of formula:

WO 2012152915 describes benzazepine derivatives of formula:

WO 2012020134 describes phenalkylamine derivatives of formula:

and of formula:

US 20130035323 describes aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of formula:

It was one object of the present invention to provide further glycine transporter inhibitors.

SUMMARY OF THE INVENTION

The present invention relates to pyrrolidine derivatives of the formula (I)

wherein

-   R¹ is C₁-C₈-alkyl, (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, (optionally substituted     C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted     C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted     C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally     substituted C₃-C₁₂-heterocyclyl; -   R^(2a), R^(2b)     -   are independently hydrogen, halogen, or C₁-C₃-alkyl; or -   R^(2a), R^(2b)     -   together with the carbon atom to which they are bound may form a         C═O; -   R^(3a)     -   is C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl,         hydroxy, C₁-C₆-alkoxy, halogenated C₁-C₆-alkoxy,         C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy,         C₆-C₁₂-aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy,         optionally substituted C₆-C₁₂-aryloxy, C₃-C₁₂-heterocyclyloxy,         or optionally substituted C₃-C₁₂-heterocyclyl; -   R^(3b) is hydrogen, C₁-C₆-alkyl, or hydroxy; -   Y¹ is >CR⁶— or >N—; -   R⁶ is hydrogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, (optionally     substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl,     C₁-C₄-alkoxy-C₁-C₆-alkyl, or hydroxy; -   R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰,     —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹²,     optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³,     —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b),     —NR^(8e)SO₂R¹⁷, —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹,     —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted     C₃-C₁₂-heterocyclyl; -   R^(7a), R^(7b)     -   are independently hydrogen or C₁-C₆-alkyl; -   n1 is 1, 2, 3, or 4; -   R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl, or optionally     substituted C₃-C₁₂-heterocyclyl; -   R^(7c), R^(7d)     -   are independently hydrogen or C₁-C₆-alkyl; -   n2 is 1, 2, 3, or 4; -   R^(11a) is C₁-C₈-alkyl, (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl,     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally     substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted     C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; -   R^(11b)     -   is hydrogen or C₁-C₆-alkyl; -   R^(7e), R^(7f)     -   are independently hydrogen or C₁-C₆-alkyl; -   n3 is 1, 2, 3, or 4; -   R¹²     -   is optionally substituted C₆-C₁₂-aryl or optionally substituted         C₃-C₁₂-heterocyclyl; -   R^(8a), R^(8b), R^(8c), R^(8d), R^(8e)     -   are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl,         or -   R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O; -   R^(9a), R^(9b)     -   are independently hydrogen, halogen, C₁-C₆-alkyl, hydroxy, or         C₁-C₆-alkoxy; -   n4 is 0, 1, 2, 3, or 4; -   R¹³ is hydrogen, C₁-C₈-alkyl, halogenated C₁-C₆-alkyl, (optionally     substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl,     C₁-C₆-alkoxy-C₁-C₆-alkyl, optionally substituted C₃-C₁₂-cycloalkyl,     C₂-C₆-alkenyl, optionally substituted C₃-C₆-cycloalkenyl, optionally     substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy,     C₁-C₆-alkoxy-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy,     optionally substituted C₃-C₁₂-heterocyclyloxy, optionally     substituted C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; -   R¹⁴ is C₁-C₈-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, (optionally substituted     C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl,     C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted     C₆-C₁₂-aryloxy)-C₁-C₄-alkyl, C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl,     C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl,     C₁-C₆-alkylaminocarbonyl-C₁-C₄-alkyl, optionally substituted     (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted     C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally     substituted C₃-C₁₂-heterocyclyl; -   R¹⁵ is C₁-C₈-alkyl, optionally substituted C₆-C₁₂-aryl, or     optionally substituted C₃-C₁₂-heterocyclyl; -   R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl,     optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally     substituted C₆-C₁₂-aryl, or optionally substituted     C₃-C₁₂-heterocyclyl; -   R^(16b) is hydrogen or C₁-C₆-alkyl; -   R¹⁷ is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally     substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted     C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; -   R^(9c), R^(9d)     -   are independently hydrogen, halogen, or C₁-C₆-alkyl; -   n5 is 0, 1, 2, 3, or 4; -   R¹⁸ is hydrogen, C₁-C₈-alkyl, optionally substituted     C₃-C₁₂-cycloalkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl,     halogenated C₁-C₆-alkoxycarbonyl, C₆-C₁₂-aryloxycarbonyl,     C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl,     C₆-C₁₂-arylaminocarbonyl, optionally substituted C₆-C₁₂-aryl,     C₁-C₆-alkylamine, (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino, (halogenated     C₁-C₆-alkyl)amino, (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino,     (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino, C₁-C₆-dialkylamine, optionally     substituted C₆-C₁₂-arylamine, or optionally substituted     C₃-C₁₂-heterocyclyl; -   R¹⁹ is optionally substituted C₆-C₁₂-aryl or optionally substituted     C₃-C₁₂-heterocyclyl; -   R^(20a) is C₁-C₈-alkyl, (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl,     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally     substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted     C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; -   R^(20b) is hydrogen or C₁-C₈-alkyl; -   R²¹ is optionally substituted C₆-C₁₂-aryl, or optionally substituted     C₃-C₁₂-heterocyclyl; and -   R^(5a), R^(5b)     -   are independently hydrogen, halogen, or C₁-C₃-alkyl, or -   R^(5a), R^(5b)     -   together with the carbon atom to which they are bound may form a         C═O,         or a physiologically tolerated salt thereof.

Said compounds of formula (I), i.e., the pyrrolidine derivatives of formula (I) and their physiologically tolerated salts, are glycine transporter inhibitors and thus useful as pharmaceuticals.

The present invention thus further relates to the compounds of formula (I) for use in therapy.

The present invention also relates to pharmaceutical compositions which comprise a carrier and a compound of formula (I).

In particular, said compounds, i.e., the pyrrolidine derivatives and their physiologically tolerated salts, are inhibitors of the glycine transporter GlyT1.

The present invention thus further relates to the compounds of formula (I) for use in inhibiting the glycine transporter.

The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GlyT1 and corresponding methods of inhibiting the glycine transporter GlyT1.

Glycine transport inhibitors and in particular inhibitors of the glycine transporter GlyT1 are known to be useful in treating a variety of neurologic and psychiatric disorders.

The present invention thus further relates to the compounds of formula (I) for use in treating a neurologic or psychiatric disorder.

The present invention further relates to the compounds of formula (I) for use in treating pain.

The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating a neurologic or psychiatric disorder and corresponding methods of treating said disorders. The present invention also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating pain and corresponding methods of treating pain.

DETAILED DESCRIPTION OF THE INVENTION

Provided that the pyrrolidine derivatives of the formula (I) of a given constitution may exist in different spatial arrangements, for example if they possess one or more centers of asymmetry, polysubstituted rings or double bonds, or as different tautomers, the invention relates to the corresponding enantiomeric mixtures, in particular racemates, diastereomeric mixtures and tautomeric mixtures, as well as to the respective essentially pure enantiomers, diastereomers and tautomers of the compounds of formula (I) and/or of their salts.

According to one embodiment, an enantiomer of the pyrrolidine derivatives of the present invention has the following formula:

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), R⁴, Y¹, R^(5a), R^(5b) are as defined herein.

According to another embodiment, an enantiomer of the pyrrolidine derivatives of the present invention has the following formula:

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), R⁴, Y¹, R^(5a), R^(5b) are as defined herein.

If Y¹ is >CR⁶— it is preferred that R^(3a) and R⁴ are in trans position.

Accordingly, the invention relates in particular to an enantiomer of the pyrrolidine derivatives having the following formula:

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), R⁴, R⁶, R^(5a), R^(5b) are as defined herein.

Preferably, the invention relates to an enantiomer of the pyrrolidine derivatives having the following formula:

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), R⁴, R⁶, R^(5a), R^(5b) are as defined herein.

The physiologically tolerated salts of the pyrrolidine derivatives of the formula (I) are especially acid addition salts with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, C₁-C₄-alkylsulfonic acids, such as methanesulfonic acid, cycloaliphatic sulfonic acids, such as S-(+)-10-camphor sulfonic acid, aromatic sulfonic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid. Other utilizable acids are described, e.g., in Fortschritte der Arzneimittelforschung [Advances in drug research], Volume 10, pages 224 ff., Birkhäuser Verlag, Basel and Stuttgart, 1966. The physiologically tolerated salts of the isoindoline derivatives also include salts of a physiologically tolerated anion with an isoindoline derivatives wherein one or more than one nitrogen atom is quaternized, e.g. with an alkyl residue (e.g. methyl or ethyl).

The present invention moreover relates to compounds of formula (I) as defined herein, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope (e.g., hydrogen by deuterium, ¹²C by ¹³C, ¹⁴N by ¹⁵N, ¹⁶O by ¹⁸O) and preferably wherein at least one hydrogen atom has been replaced by a deuterium atom.

Of course, such compounds contain more of the respective isotope than this naturally occurs and thus is anyway present in the compounds (I).

Stable isotopes (e.g., deuterium, ¹³C, ¹⁵N, ¹⁸O) are nonradioactive isotopes which contain one or more additional neutron than the normally abundant isotope of the respective atom. Deuterated compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the non-deuterated parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).

Incorporation of a heavy atom particularly substitution of deuterium for hydrogen, can give rise to an isotope effect that could alter the pharmacokinetics of the drug. This effect is usually insignificant if the label is placed at a metabolically inert position of the molecule.

Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These changes may influence the fate of the drug at different steps along its passage through the body. Absorption, distribution, metabolism or excretion can be changed. Absorption and distribution are processes that depend primarily on the molecular size and the lipophilicity of the substance. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction.

Drug metabolism can give rise to large isotopic effect if the breaking of a chemical bond to a deuterium atom is the rate limiting step in the process. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. In any reaction in which the breaking of this bond is the rate limiting step, the reaction will proceed slower for the molecule with the heavy isotope due to “kinetic isotope effect”. A reaction involving breaking a C—D bond can be up to 700 percent slower than a similar reaction involving breaking a C—H bond. If the C—D bond is not involved in any of the steps leading to the metabolite, there may not be any effect to alter the behavior of the drug. If a deuterium is placed at a site involved in the metabolism of a drug, an isotope effect will be observed only if breaking of the C—D bond is the rate limiting step. There is evidence to suggest that whenever cleavage of an aliphatic C—H bond occurs, usually by oxidation catalyzed by a mixed-function oxidase, replacement of the hydrogen by deuterium will lead to observable isotope effect. It is also important to understand that the incorporation of deuterium at the site of metabolism slows its rate to the point where another metabolite produced by attack at a carbon atom not substituted by deuterium becomes the major pathway a process called “metabolic switching”.

Deuterium tracers, such as deuterium-labeled drugs and doses, in some cases repeatedly, of thousands of milligrams of deuterated water, are also used in healthy humans of all ages, including neonates and pregnant women, without reported incident (e.g. Pons G and Rey E, Pediatrics 1999 104: 633; Coward W A et al., Lancet 1979 7: 13; Schwarcz H P, Control. Clin. Trials 1984 5(4 Suppl): 573; Rodewald L E et al., J. Pediatr. 1989 114: 885; Butte N F et al. Br. J. Nutr. 1991 65: 3; MacLennan A H et al. Am. J. Obstet. Gynecol. 1981 139: 948). Thus, it is clear that any deuterium released, for instance, during the metabolism of compounds of this invention poses no health risk.

The weight percentage of hydrogen in a mammal (approximately 9%) and natural abundance of deuterium (approximately 0.015%) indicates that a 70 kg human normally contains nearly a gram of deuterium. Furthermore, replacement of up to about 15% of normal hydrogen with deuterium has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci. 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Higher deuterium concentrations, usually in excess of 20%, can be toxic in animals. However, acute replacement of as high as 15%-23% of the hydrogen in humans' fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in “Dosimetry & Treatment Planning for Neutron Capture Therapy”, Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)).

Increasing the amount of deuterium present in a compound above its natural abundance is called enrichment or deuterium-enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.

The hydrogens present on a particular organic compound have different capacities for exchange with deuterium. Certain hydrogen atoms are easily exchangeable under physiological conditions and, if replaced by deuterium atoms, it is expected that they will readily exchange for protons after administration to a patient. Certain hydrogen atoms may be exchanged for deuterium atoms by the action of a deuteric acid such as D₂SO₄/D₂O. Alternatively, deuterium atoms may be incorporated in various combinations during the synthesis of compounds of the invention. Certain hydrogen atoms are not easily exchangeable for deuterium atoms. However, deuterium atoms at the remaining positions may be incorporated by the use of deuterated starting materials or intermediates during the construction of compounds of the invention.

Deuterated and deuterium-enriched compounds of the invention can be prepared by using known methods described in the literature. Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure. Relevant procedures and intermediates are disclosed, for instance in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; U.S. Pat. Nos. 7,538,189; 7,534,814; 7,531,685; 7,528,131; 7,521,421; 7,514,068; 7,511,013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; 20090082471, the methods are hereby incorporated by reference.

The organic moieties mentioned in the above definitions of the variables are—like the term halogen—collective terms for individual listings of the individual group members. The prefix C_(n)-C_(m) indicates in each case the possible number of carbon atoms in the group.

Unless indicated otherwise, the term “substituted” means that a radical is substituted with 1, 2 or 3, especially 1, substituent which, according to a particular embodiment of the invention, are independently selected from the group consisting of halogen, C₁-C₄-alkyl, C₃-C₆-aryl-C₁-C₄-alkyl, halogenated-C₁-C₄-alkyl, hydroxy-C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), C₁-C₄-alkoxy-C₁-C₄-alkyl, amino-C₁-C₄-alkyl, C₃-C₁₂-heterocyclyl-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₂-C₄-alkenyl, —CN, C₁-C₄-alkoxycarbonyl, aminocarbonyl, C₁-C₄-alkylaminocarbonyl, alkylamino)carbonyl, C₆-C₁₂-arylaminocarbonyl, C₃-C₁₂-heterocyclylaminocarbonyl, C₆-C₁₂-aryl, oxo (═O), OH, C₁-C₄-alkoxy, halogenated-C₁-C₄-alkoxy, C₃-C₇-cycloalkoxy, carboxy-C₁-C₄-alkoxy, C₆-C₁₂-aryl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy, SH, alkylthio, C₁-C₄-alkylsulfonyl, C₁-C₄-alkylaminosulfonyl, di-C₁-C₄-alkylaminosulfonyl, C₃-C₆-arylsulfonyl, aminosulfonyl, C₃-C₆-arylaminosulfonyl, C₃-C₁₂-heterocyclylaminosulfonyl, NH₂, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, C₆-C₁₂-aryl-C₁-C₄-alkylamino, C₁-C₄-alkylcarbonylamino, C₃-C₆-arylcarbonylamino, C₃-C₁₂-heterocyclylcarbonylamino, C₁-C₆-alkylsulfonylamino, C₃-C₆-arylsulfonylamino, C₃-C₁₂-heterocyclylsulfonylamino and C₃-C₁₂-heterocyclyl, wherein aryl and heterocyclyl may be unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.

The term halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine.

C₁-C₄-Alkyl is a straight-chain or branched alkyl group having from 1 to 4 carbon atoms. Examples of an alkyl group are methyl, C₂-C₄-alkyl such as ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl or tert-butyl. C₁-C₂-Alkyl is methyl or ethyl, C₁-C₃-alkyl is additionally n-propyl or iso-propyl.

C₁-C₆-Alkyl is a straight-chain or branched alkyl group having from 1 to 6 carbon atoms. Examples include methyl, C₂-C₄-alkyl as mentioned herein and also pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

C₁-C₈-Alkyl is a straight-chain or branched alkyl group having from 1 to 8 carbon atoms. Examples include methyl, C₂-C₄-alkyl as mentioned herein and also pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,2,3-trimethylbutyl 1-ethyl-2-methylbutyl, 1-methyl-2-ethylbutyl, octyl, 1-methyl-heptyl, 2-methylheptyl, 3-methyl-heptyl, 4-methyl-heptyl, 5-methylheptyl, 6-methylheptyl, 1-methyl-2-ethylpentyl, 1,1-dimethylhexyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 1,4-dimethylhexyl, 2,2-dimethylhexyl, 2,3-dimethylhexyl, 3,3-dimethylhexyl, 4,5-dimethylhexyl, 1,2,3-trimethylpentyl, 1,2-dimethyl-3-ethylbutyl, 1-ethyl-2-ethylbutyl and 1,3-dimethyl-2-ethylbutyl.

Halogenated C₁-C₆-alkyl is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethyl, dihalogenomethyl, trihalogenomethyl, (R)-1-halogenoethyl, (S)-1-halogenoethyl, 2-halogenoethyl, 1,1-dihalogenoethyl, 2,2-dihalogenoethyl, 2,2,2-trihalogenoethyl, (R)-1-halogenopropyl, (S)-1-halogenopropyl, 2-halogenopropyl, 3-halogenopropyl, 1,1-dihalogenopropyl, 2,2-dihalogenopropyl, 3,3-dihalogenopropyl, 3,3,3-trihalogenopropyl, (R)-2-halogeno-1-methylethyl, (S)-2-halogeno-1-methylethyl, (R)-2,2-dihalogeno-1-methylethyl, (S)-2,2-dihalogeno-1-methylethyl, (R)-1,2-dihalogeno-1-methylethyl, (S)-1,2-dihalogeno-1-methylethyl, (R)-2,2,2-trihalogeno-1-methylethyl, (S)-2,2,2-trihalogeno-1-methylethyl, 2-halogeno-1-(halogenomethyl)ethyl, 1-(dihalogenomethyl)-2,2-dihalogenoethyl, (R)-1-halogenobutyl, (S)-1-halogenobutyl, 2-halogenobutyl, 3-halogenobutyl, 4-halogenobutyl, 1,1-dihalogenobutyl, 2,2-dihalogenobutyl, 3,3-dihalogenobutyl, 4,4-dihalogenobutyl, 4,4,4-trihalogenobutyl, 1,1-dihalogenopentyl, 4,4-dihalogenopentyl etc. Particular examples include the fluorinated C₁-C₄ alkyl groups as defined, such as trifluoromethyl.

C₃-C₁₂-Cycloalkyl-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a cycloaliphatic radical having from 3 to 12 carbon atoms such as in cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.

C₁-C₆-Alkylcarbonyl-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or 2 carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkylcarbonyl group, in particular by a C₁-C₄-alkylcarbonyl group, such as in methylcarbonylmethyl, methylcarbonylethyl, methylcarbonylpropyl, ethylcarbonylmethyl, n-propylcarbonylmethyl, iso-propylcarbonylmethyl, n-butylcarbonylmethyl, 2-butylcarbonylmethyl or iso-butylcarbonylmethyl.

C₁-C₆-Alkoxycarbonyl-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkoxycarbonyl group, in particular by a C₁-C₄-alkoxycarbonyl group, such as in methoxycarbonylmethyl, methoxycarbonylpropyl, ethoxycarbonylmethyl, n-propoxycarbonylmethyl, n-butoxycarbonylmethyl, 2-butoxycarbonylmethyl or iso-butoxycarbonylmethyl.

C₆-C₁₂-Aryl-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C₆-C₁₂-aryl, such as in benzyl.

Hydroxy-C₁-C₆-alkyl is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two hydroxyl groups, such as in hydroxymethyl, (R)-1-hydroxyethyl, (S)-1-hydroxyethyl, 2-hydroxyethyl, (R)-1-hydroxypropyl, (S)-1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, (R)-2-hydroxy-1-methylethyl, (S)-2-hydroxy-1-methylethyl, 2-hydroxy-1-(hydroxymethyl)ethyl, (R)-1-hydroxybutyl, (S)-1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, (R)-1-hydroxypentyl, (S)-1-hydroxypentyl, 2-hydroxypentyl and 4-hydroxypentyl.

Hydroxy-(halogenated C₁-C₄-alkyl) is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, wherein at least two, e.g. 2, 3, 4 or all of the hydrogen atoms are replaced by a number of identical or different halogen atoms and by one or two hydroxyl groups, such as in hydroxyhalogenomethyl, hydroxydihalogenomethyl, (R)-1-hydroxy-1-halogenoethyl, (S)-1-hydroxy-1-halogenoethyl, (R) 2,2-dihalogeno-1-hydroxyethyl, (S) 2,2-dihalogeno-1-hydroxyethyl, (R) 2,2,2-trihalogeno-1-hydroxyethyl, (S) 2,2,2-trihalogeno-1-hydroxyethyl (R)-1-hydroxy-1-halogenopropyl, (S)-1-hydroxy-1-halogenopropyl, (R)-2-halogeno-2-hydroxypropyl, (S)-2-halogeno-2-hydroxypropyl, 3-halogeno-2-hydroxypropyl, 1,1-dihalogeno-1-hydroxypropyl, 2,2-dihalogeno-1-hydroxypropyl, 3,3,3-trihalogeno-1-hydroxypropyl, (R)-2-halogeno-1-methyl-1-hydroxyethyl, (S)-2-halogeno-1-methyl-1-hydroxyethyl, (R)-2,2-dihalogeno-1-methyl-1-hydroxyethyl, (S)-2,2-dihalogeno-1-methyl-1-hydroxyethyl, (R)-2,2,2-trihalogeno-1-methyl-1-hydroxyethyl, (S)-2,2,2-trihalogeno-1-methyl-1-hydroxyethyl, (R)-1-(halogenomethyl)-1-hydroxyethyl, (S)-1-(halogenomethyl)-1-hydroxyethyl, (R)-1-(dihalogenomethyl)-1-hydroxyethyl, (S)-1-(dihalogenomethyl)-1-hydroxyethyl, (R)-1-(trihalogenomethyl)-1-hydroxyethyl, (S)-1-(trihalogenomethyl)-1-hydroxyethyl, etc. Particular examples include the hydroxyfluorinated C₁-C₄ alkyl groups as defined, such as 1-(trifluoromethyl)-1-hydroxyethyl.

C₁-C₆-Alkoxy-C₁-C₆-alkyl is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably 1 or 2 carbon atoms, wherein one or two hydrogen atoms are replaced by one or two alkoxy groups having 1 to 6, preferably 1 to 4, in particular 1 or 2 carbon atoms, such as in methoxymethyl, (R)-1-methoxyethyl, (S)-1-methoxyethyl, 2-methoxyethyl, (R)-1-methoxypropyl, (S)-1-methoxypropyl, 2-methoxypropyl, 3-methoxypropyl, (R)-2-methoxy-1-methylethyl, (S)-2-methoxy-1-methyl ethyl, 2-methoxy-1-(methoxymethyl)ethyl, (R)-1-methoxybutyl, (S)-1-methoxybutyl, 2-methoxybutyl, 3-methoxybutyl, 4-methoxybutyl, (R)-1-methoxypentyl, (S)-1-methoxypentyl, 2-methoxypentyl, 3-methoxypentyl, 4-methoxypentyl, (R)-1-methoxyhexyl, (S)-1-methoxyhexyl, 2-methoxyhexyl, 3-methoxyhexyl, 4-methoxyhexyl, ethoxymethyl, (R)-1-ethoxyethyl, (S)-1-ethoxyethyl, 2-ethoxyethyl, (R)-1-ethoxypropyl, (S)-1-ethoxypropyl, 2-ethoxypropyl, 3-ethoxypropyl, (R)-2-ethoxy-1-methylethyl, (S)-2-ethoxy-1-methyl ethyl, 2-ethoxy-1-(ethoxymethyl)ethyl, (R)-1-ethoxybutyl, (S)-1-ethoxybutyl, 2-ethoxybutyl, 3-ethoxybutyl, 4-ethoxybutyl, (R)-1-ethoxypentyl, (S)-1-ethoxypentyl, 2-ethoxypentyl, 3-ethoxypentyl, 4-ethoxypentyl, 5-ethoxypentyl, (R)-1-ethoxyhexyl, (S)-1-ethoxyhexyl, 2-ethoxyhexyl, 3-ethoxyhexyl and 6-ethoxybutyl.

C₆-C₁₂-Aryloxy-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a radical of the formula R—O—, wherein R is an aryl group having from 6 to 12, in particular 6 carbon atoms as defined herein. Examples include phenoxymethyl, (4-F-phenoxy)methyl.

Amino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by an amino group, such as in aminomethyl, 2-aminoethyl.

C₁-C₆-Alkylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkylamino group, in particular by a C₁-C₄-alkylamino group, such as in methylaminomethyl, ethylaminomethyl, n-propylaminomethyl, iso-propylaminomethyl, n-butylaminomethyl, 2-butylaminomethyl, isobutylaminomethyl or tert-butylaminomethyl.

Di-C₁-C₆-Alkylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-C₁-C₆-Alkylamino group, in particular by a di-C₁-C₄-alkylamino group, such as in dimethylaminomethyl.

C₁-C₆-Alkylcarbonylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkylcarbonylamino group, in particular by a C₁-C₄-alkylcarbonylamino group, such as in methylcarbonylaminomethyl, ethylcarbonylaminomethyl, n-propylcarbonylaminomethyl, iso-propylcarbonylaminomethyl, n-butylcarbonylaminomethyl, 2-butylcarbonylaminomethyl, iso-butylcarbonylaminomethyl or tert-butylcarbonyl aminomethyl.

C₁-C₆-Alkylaminocarbonylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkylaminocarbonylamino group, in particular by a C₁-C₄-alkylaminocarbonylamino group, such as in methylaminocarbonylaminomethyl, ethylaminocarbonylaminomethyl, n-propylaminocarbonylaminomethyl, iso-propylaminocarbonylaminomethyl, n-butylaminocarbonylaminomethyl, 2-butylaminocarbonylaminomethyl, iso-butylaminocarbonylaminomethyl or tertbutylaminocarbonylaminomethyl.

Di-C₁-C₆-alkylaminocarbonylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a di-C₁-C₆-alkylaminocarbonylamino group, in particular by a di-C₁-C₄-alkylaminocarbonylamino group, such as in dimethylaminocarbonylaminomethyl, dimethylaminocarbonylaminoethyl, dimethylaminocarbonylamino-propyl.

C₁-C₆-Alkylsulfonylamino-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a C₁-C₆-alkylsulfonylamino group, in particular by a C₁-C₄-alkylsulfonylamino group, such as in methylsulfonylaminomethyl, ethylsulfonylaminomethyl, n-propylsulfonylaminomethyl, iso-propylsulfonylaminomethyl, n-butylsulfonylaminomethyl, 2-butylsulfonylaminomethyl, iso-butylsulfonylaminomethyl or tertbutylsulfonylaminomethyl.

(C₆-C₁₂-Aryl-C₁-C₆-alkyl)amino-C₁-C₄ alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by a (C₆-C₁₇-aryl-C₁-C₆-alkyl)amino group, in particular a (C₆-C₁₂-aryl-C₁-C₂-alkyl)amino group, such as in benzylaminomethyl.

C₃-C₁₂-Heterocyclyl-C₁-C₄-alkyl is a straight-chain or branched alkyl group having 1 to 4 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 or 2 carbon atoms, in particular 1 or two carbon atoms, wherein one hydrogen atom is replaced by C₃-C₁₂-heterocyclyl, such as in N-pyrrolidinylmethyl, N-piperidinylmethyl, N-morpholinylmethyl, tetrahydropyran-2-yl-methyl.

C₃-C₁₂-Cycloalkyl is a cycloaliphatic radical having from 3 to 12 carbon atoms. In particular, 3 to 6 carbon atoms form the cyclic structure, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The cyclic structure may be unsubstituted or may carry 1, 2, 3 or 4 C₁-C₄ alkyl radicals, preferably one or more methyl radicals.

Carbonyl is >C═O.

C₁-C₆-Alkylcarbonyl is a radical of the formula R—C(O)—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include acetyl, propionyl, n-butyryl, 2-methylpropionyl, pivaloyl.

Halogenated C₁-C₆-alkylcarbonyl is C₁-C₆-alkylcarbonyl as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms. Examples include fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl. Further examples are 1,1,1-trifluoroeth-2-ylcarbonyl, 1,1,1-trifluoroprop-3-ylcarbonyl.

C₆-C₁₂-Arylcarbonyl is a radical of the formula R—C(O)—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include benzoyl.

C₁-C₆-Alkoxycarbonyl is a radical of the formula R—O—C(O)—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methoxycarbonyl and tert-butoxycarbonyl.

Halogenated C₁-C₆-alkoxycarbonyl is a C₁-C₆-alkoxycarbonyl as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

C₆-C₁₂-Aryloxycarbonyl is a radical of the formula R—O—C(O)—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenoxycarbonyl.

Cyano is —C≡N.

Aminocarbonyl is NH₂C(O)—.

C₁-C₆-Alkylaminocarbonyl is a radical of the formula R—NH—C(O)—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms as defined herein. Examples include methylaminocarbonyl.

(Halogenated C₁-C₄-alkyl)aminocarbonyl is a C₁-C₄-alkylaminocarbonyl as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different hydrogen atoms.

C₆-C₁₂-Arylaminocarbonyl is a radical of the formula R—NH—C(O)—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylaminocarbonyl.

C₂-C₆-Alkenyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl(2-methylprop-2-en-1-yl) and the like. C₃-C₅-Alkenyl is, in particular, allyl, 1-methylprop-2-en-1-yl, 2-buten-1-yl, 3-buten-1-yl, methallyl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl or 2-ethylprop-2-en-1-yl, 2-hexen-1-yl.

C₃-C₆-Cycloalkenyl is a carbocyclic radical having at least one carbon-carbon double bond and from 3 to 6 carbon atoms. In particular, 3 to 6 carbon atoms form the cyclic structure, such as 2-cyclopenten-1-yl, 2-cyclohexen-1-yl. The cyclic structure may be unsubstituted or may carry 1, 2, 3 or 4 C₁-C₄ alkyl radicals, preferably one or more methyl radicals.

C₂-C₆-Alkynyl is a singly unsaturated hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, e.g. ethynyl, 2-propyn-1-yl, 1-propyn-1-yl, 2-propyn-2-yl and the like. C₃-C₅-Alkynyl is, in particular, 2-propyn-1-yl, 2-butyn-1-yl, 3-butyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl.

C₁-C₅-Alkylene is straight-chain or branched alkylene group having from 1 to 5 carbon atoms. Examples include methylene and ethylene. A further example is propylene.

C₂-C₄-Alkenylene is straight-chain or branched alkenylene group having from 2 to 4 carbon atoms.

C₂-C₄-Alkynylene is straight-chain or branched alkynylene group having from 2 to 4 carbon atoms. Examples include propynylene.

C₆-C₁₂-Aryl is a 6- to 12-membered, in particular 6- to 10-membered, aromatic cyclic radical which can be a monocyclic aromatic ring, for example, phenyl etc., or a fused polycyclic aromatic ring comprising a first monocyclic aromatic ring and one or more carbocycles which are saturated, partially unsaturated or aromatic, for example, naphthyl, indenyl, tetrahydronaphthyl, indanyl.

C₃-C₁₂-Arylene is an aryl diradical. Examples include phen-1,4-ylene and phen-1,3-ylene.

Hydroxy is —OH.

Oxo is ═O.

C₁-C₆-Alkoxy is a radical of the formula R—O—, wherein R is a straight-chain or branched alkyl group having from 1 to 6, in particular 1 to 4 carbon atoms. Examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, 2-butoxy, iso-butoxy (2-methylpropoxy), tert.-butoxy pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexyloxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 4-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and 1-ethyl-2-methylpropoxy.

Halogenated C₁-C₆-alkoxy is a straight-chain or branched alkoxy group having from 1 to 6, preferably from 1 to 4, in particular 1 or 2 carbon atoms, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms, such as in halogenomethoxy, dihalogenomethoxy, trihalogenomethoxy, (R)-1-halogenoethoxy, (S)-1-halogenoethoxy, 2-halogenoethoxy, 1,1-dihalogenoethoxy, 2,2-dihalogenoethoxy, 2,2,2-trihalogenoethoxy, (R)-1-halogenopropoxy, (S)-1-halogenopropoxy, 2-halogenopropoxy, 3-halogenopropoxy, 1,1-dihalogenopropoxy, 2,2-dihalogenopropoxy, 3,3-dihalogenopropoxy, 3,3,3-trihalogenopropoxy, (R)-2-halogeno-1-methylethoxy, (S)-2-halogeno-1-methylethoxy, (R)-2,2-dihalogeno-1-methylethoxy, (S)-2,2-dihalogeno-1-methylethoxy, (R)-1,2-dihalogeno-1-methylethoxy, (S)-1,2-dihalogeno-1-methylethoxy, (R)-2,2,2-trihalogeno-1-methylethoxy, (S)-2,2,2-trihalogeno-1-methylethoxy, 2-halogeno-1-(halogenomethyl)ethoxy, 1-(dihalogenomethyl)-2,2-dihalogenoethoxy, (R)-1-halogenobutoxy, (S)-1-halogenobutoxy, 2-halogenobutoxy, 3-halogenobutoxy, 4-halogenobutoxy, 1,1-dihalogenobutoxy, 2,2-dihalogenobutoxy, 3,3-dihalogenobutoxy, 4,4-dihalogenobutoxy, 4,4,4-trihalogenobutoxy, etc. Particular examples include the fluorinated C₁-C₄ alkoxy groups as defined, such as trifluoromethoxy.

C₁-C₆-Hydroxyalkoxy is an alkoxy radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by hydroxy. Examples include 2-hydroxyethoxy, 3-hydroxypropoxy, 2-hydroxypropoxy, 1-methyl-2-hydroxyethoxy and the like.

C₁-C₆-Alkoxy-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4 carbon atoms, preferably 1 or 2 carbon atoms as defined herein, wherein one or two hydrogen atoms are replaced by one or two alkoxy radicals having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methoxymethoxy, 2-methoxyethoxy, 1-methoxyethoxy, 3-methoxypropoxy, 2-methoxypropoxy, 1-methyl-1-methoxyethoxy, ethoxymethoxy, 2-ethoxyethoxy, 1-ethoxyethoxy, 3-ethoxypropoxy, 2-ethoxypropoxy, 1-methyl-1-ethoxyethoxy and the like.

Amino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an amino group. Examples include 2-aminoethoxy.

C₁-C₆-Alkylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylaminomethoxy, ethylaminomethoxy, n-propylaminomethoxy, iso-propylaminomethoxy, n-butylaminomethoxy, 2-butylaminomethoxy, iso-butylaminomethoxy, tert-butylaminomethoxy, 2-(methylamino)ethoxy, 2-(ethylamino)ethoxy, 2-(n-propylamino)ethoxy, 2-(iso-propylamino)ethoxy, 2-(n-butylamino)ethoxy, 2-(2-butylamino)ethoxy, 2-(iso-butylamino)ethoxy, 2-(tertbutylamino)ethoxy.

Di-C₁-C₆-alkylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a di-alkylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include dimethylaminomethoxy, diethylaminomethoxy, N-methyl-N-ethylamino)ethoxy, 2-(dimethylamino)ethoxy, 2-(diethylamino)ethoxy, 2-(N-methyl-N-ethylamino)ethoxy.

C₁-C₆-Alkylcarbonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylcarbonylamino group wherein the alkyl group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylcarbonylaminomethoxy, ethylcarbonylaminomethoxy, n-propylcarbonylaminomethoxy, iso-propylcarbonylaminomethoxy, n-butylcarbonylaminomethoxy, 2-butylcarbonylaminomethoxy, iso-butylcarbonylaminomethoxy, tert-butylcarbonylaminomethoxy, 2-(methylcarbonylamino)ethoxy, 2-(ethylcarbonylamino)ethoxy, 2-(n-propylcarbonylamino)ethoxy, 2-(iso-propylcarbonylamino)ethoxy, 2-(n-butylcarbonylamino)ethoxy, 2-(2-butylcarbonylamino)ethoxy, 2-(iso-butylcarbonylamino)ethoxy, 2-(tert-butylcarbonylamino)ethoxy.

C₆-C₁₂-Arylcarbonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C₆-C₁₂-arylcarbonylamino group as defined herein. Examples include 2-(benzoylamino)ethoxy.

C₁-C₆-Alkoxycarbonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkoxycarbonylamino group wherein the alkoxy group has from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methoxycarbonylaminomethoxy, ethoxycarbonylaminomethoxy, n-propoxycarbonylaminomethoxy, iso-propoxycarbonylaminomethoxy, n-butoxycarbonylaminomethoxy, 2-butoxycarbonylaminomethoxy, iso-butoxycarbonylaminomethoxy, tertbutoxycarbonylaminomethoxy, 2-(methoxycarbonylamino)ethoxy, 2-(ethoxycarbonylamino)ethoxy, 2-(n-propoxycarbonylamino)ethoxy, 2-(iso-propoxycarbonylamino)ethoxy, 2-(n-butoxycarbonylamino)ethoxy, 2-(2-butoxycarbonylamino)ethoxy, 2-(isobutoxycarbonylamino)ethoxy, 2-(tert-butoxycarbonylamino)ethoxy.

C₂-C₆-Alkenyloxy is a radical of the formula R—O—, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms. Examples include vinyloxy, allyloxy (2-propen-1-yloxy), 1-propen-1-yloxy, 2-propen-2-yloxy, methallyloxy (2-methylprop-2-en-1-yloxy) and the like. C₃-C₅-Alkenyloxy is, in particular, allyloxy, 1-methylprop-2-en-1-yloxy, 2-buten-1-yloxy, 3-buten-1-yloxy, methallyloxy, 2-penten-1-yloxy, 3-penten-1-yloxy, 4-penten-1-yloxy, 1-methylbut-2-en-1-yloxy or 2-ethylprop-2-en-1-yloxy.

C₆-C₁₂-Aryl-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C₆-C₁₂-aryl group as defined herein. Examples include benzyloxy.

C₁-C₆-Alkylsulfonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylsulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include 2-(methylsulfonylamino)ethoxy, 2-(ethylsulfonylamino)ethoxy, 2-[(2-methylpropyl)sulfonylamino]ethoxy.

(Halogenated C₁-C₆-alkyl)sulfonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by an alkylsulfonylamino group having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein, wherein the alkyl group is halogenated. Examples include 2-(trifluoromethylsulfonylamino)ethoxy.

C₆-C₁₂-Arylsulfonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C₆-C₁₂-arylsulfonylamino group as defined herein. Examples include 2-(phenylsulfanylamino)ethoxy, 2-(naphthylsulfonylamino)ethoxy.

(C₆-C₁₂-Aryl-C₁-C₆-alkyl)sulfonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a (C₆-C₁₂-aryl-C₁-C₆-alkyl)sulfonylamino group, preferably by a (C₆-C₁₂-aryl-C₁-C₂-alkyl)sulfonylamino group. Examples include 2-(benzylsulfonylamino)ethoxy.

C₃-C₁₂-Heterocyclylsulfonylamino-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C₃-C₁₂-heterocyclylsulfonylamino group as defined herein. Examples include 2-(pyridin-3-ylsulfonylamino)ethoxy.

C₃-C₁₂-Heterocyclyl-C₁-C₄-alkoxy is an alkoxy radical having from 1 to 4, preferably 1 or 2 carbon atoms as defined herein, wherein one hydrogen atom is replaced by a C₃-C₁₂-heterocyclyl group as defined herein. Examples include 2-(N-pyrrolidinyl)ethoxy, 2-(N-morpholinyl)ethoxy and 2-(N-imidazolyl)ethoxy.

C₁-C₂-Alkylenedioxo is a radical of the formula —O—R—O—, wherein R is a straight-chain or branched alkylene group having from 1 or 2 carbon atoms as defined herein. Examples include methylenedioxo.

C₆-C₁₂-Aryloxy is a radical of the formula R—O—, wherein R is an aryl group having from 6 to 12, in particular 6 carbon atoms as defined herein. Examples include phenoxy.

C₃-C₁₂-Heterocyclyloxy is a radical of the formula R—O—, wherein R is a C₃-C₁₂-heterocyclyl group having from 3 to 12, in particular from 3 to 7 carbon atoms as defined herein. Examples include pyridin-2-yloxy.

C₁-C₆-Alkylthio is a radical of the formula R—S—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylthio, ethylthio, propylthio, butylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2-trimethylpropylthio, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

Halogenated C₁-C₆-alkylthio is a radical of the formula R—S—, wherein R is a halogenated alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include halogenomethylthio, dihalogenomethylthio, trihalogenomethylthio, (R)-1-halogenoethylthio, (S)-1-halogenoethylthio, 2-halogenoethylthio, 1,1-dihalogenoethylthio, 2,2-dihalogenoethylthio, 2,2,2-trihalogeno ethylthio, (R)-1-halogenopropylthio, (S)-1-halogenopropylthio, 2-halogenopropylthio, 3-halogenopropylthio, 1,1-dihalogenopropylthio, 2,2-dihalogenopropylthio, 3,3-dihalogenopropylthio, 3,3,3-trihalogenopropylthio, (R)-2-halogeno-1-methylethylthio, (S)-2-halogeno-1-methylethylthio, (R)-2,2-dihalogeno-1-methylethylthio, (S)-2,2-dihalogeno-1-methylethylthio, (R)-1,2-dihalogeno-1-methylethylthio, (S)-1,2-dihalogeno-1-methylethylthio, (R)-2,2,2-trihalogeno-1-methylethylthio, (S)-2,2,2-trihalogeno-1-methylethylthio, 2-halogeno-1-(halogenomethyl)ethylthio, 1-(dihalogenomethyl)-2,2-dihalogenoethylthio, (R)-1-halogenobutylthio, (S)-1-halogenobutylthio, 2-halogenobutylthio, 3-halogenobutylthio, 4-halogenobutylthio, 1,1-dihalogenobutylthio, 2,2-dihalogenobutylthio, 3,3-dihalogenobutylthio, 4,4-dihalogenobutylthio, 4,4,4-trihalogenobutylthio, etc. Particular examples include the fluorinated alkylthio groups as defined, such as trifluoromethylthio.

C₁-C₆-Alkylsulfinyl is a radical of the formula R—S(O)—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 2,2-dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, 1,1-dimethylpropylsulfinyl, 1,2-dimethylpropylsulfinyl, 1-methylpentylsulfinyl, 2-methylpentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, 1,1-dimethylbutylsulfinyl, 1,2-dimethylbutylsulfinyl, 1,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1-ethylbutylsulfinyl, 2-ethylbutylsulfinyl, 1,1,2-trimethylpropylsulfinyl, 1,2,2-trimethylpropylsulfinyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

C₁-C₆-Alkylsulfonyl is a radical of the formula R—S(O)₂—, wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, 1-methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexyl sulfonyl, 1,1-dimethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1-dimethylbutylsulfonyl, 1,2-dimethylbutylsulfonyl, 1,3-dimethylbutylsulfonyl, 2,2-dimethylbutylsulfonyl, 2,3-dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 2-ethylbutylsulfonyl, 1,1,2-trimethylpropylsulfonyl, 1,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

(Halogenated C₁-C₆-alkyl)sulfonyl is a C₁-C₆-alkylsulfonyl as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

C₆-C₁₂-Arylsulfonyl is a radical of the formula R—S(O)₂—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylsulfonyl.

(C₆-C₁₂-Aryl-C₁-C₄-alkyl)sulfonyl is a radical of the formula R—S(O)₂—, wherein R is a C₆-C₁₂-aryl-C₁-C₄-alkyl radical, in particular a C₆-C₁₂-aryl-C₁-C₂-alkyl radical as defined herein. Examples include benzylsulfonyl.

C₃-C₁₂-Heterocyclylsulfonyl is a radical of the formula R—S(O)₂—, wherein R is C₃-C₁₂-heterocyclyl as defined herein.

Aminosulfonyl is NH₂—S(O)₂—.

C₁-C₆-Alkylaminosulfonyl is a radical of the formula R—NH—S(O)₂— wherein R is an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, iso-propylaminosulfonyl, n-butylaminosulfonyl, 2-butylaminosulfonyl, iso-butylaminosulfonyl, tert-butylaminosulfonyl.

Di-C₁-C₆-alkylaminosulfonyl is a radical of the formula RR′N—S(O)₂— wherein R and R′ are independently of each other an alkyl radical having from 1 to 6, preferably from 1 to 4 carbon atoms as defined herein. Examples include dimethylaminosulfonyl, diethylaminosulfonyl, N-methyl-N-ethylaminosulfonyl.

C₆-C₁₂-Arylaminosulfonyl is a radical of the formula R—NH—S(O)₂— wherein R is an aryl radical having from 6 to 12, preferably 6 carbon atoms as defined herein.

Amino is NH₂.

C₁-C₆-Alkylamino is a radical of the formula R—NH— wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylamino, ethylamino, n-propylamino, iso-propylamino, n-butylamino, 2-butylamino, iso-butylamino, tertbutylamino.

(Halogenated C₁-C₆-alkyl)amino is a C₁-C₆-alkylamino as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

Di-C₁-C₆-alkylamino is a radical of the formula RR′N— wherein R and R′ are independently of each other an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include dimethylamino, diethylamino, N-methyl-N-ethylamino.

Di-(halogenated C₁-C₆-alkyl)amino is a di-C₁-C₆-alkylamino as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

C₁-C₆-Alkylcarbonylamino is a radical of the formula R—C(O)—NH—, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include acetamido (methylcarbonylamino), propionamido, n-butyramido, 2-methylpropionamido (iso-propylcarbonylamino), 2,2-dimethylpropionamido and the like.

(Halogenated C₁-C₆-alkyl)carbonylamino is a C₁-C₆-alkylcarbonylamino as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

C₆-C₁₂-Arylcarbonylamino is a radical of the formula R—C(O)—NH—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylcarbonylamino.

C₂-C₆-Alkenylamino is a radical of the formula R—NH—, wherein R is a straight-chain or branched alkenyl group having from 2 to 6, in particular 2 to 4 carbon atoms. Examples include vinylamino, allylamino (2-propen-1-ylamino), 1-propen-1-ylamino, 2-propen-2-ylamino, methallylamino (2-methylprop-2-en-1-ylamino) and the like. C₃-C₅-Alkenylamino is, in particular, allylamino, 1-methylprop-2-en-1-ylamino, 2-buten-1-ylamino, 3-buten-1-ylamino, methallylamino, 2-penten-1-ylamino, 3-penten-1-ylamino, 4-penten-1-ylamino, 1-methylbut-2-en-1-ylamino or 2-ethylprop-2-en-1-ylamino.

C₆-C₁₂-Arylamino is a radical of the formula R—NH—, wherein R is an aryl group having from 6 to 12, in particular 6 carbon atoms as defined herein. Examples include phenylamine.

C₁-C₆-Alkylsulfonylamino is a radical of the formula R—S(O)₂—NH—, wherein R is an alkyl radical having from 1 to 6, in particular from 1 to 4 carbon atoms as defined herein. Examples include methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, iso-propylsulfonylamino, n-butylsulfonylamino, 2-butylsulfonylamino, iso-butylsulfonylamino, tert-butylsulfonylamino.

(Halogenated C₁-C₆ alkyl)sulfonylamino is a C₁-C₆-alkylsulfonylamino as defined herein, wherein at least one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by 1, 2, 3, 4 or a corresponding number of identical or different halogen atoms.

C₆-C₁₂-Arylsulfonylamino is a radical of the formula R—S(O)₂—NH—, wherein R is an aryl radical having from 6 to 12 carbon atoms as defined herein. Examples include phenylsulfonylamino.

Nitro is —NO₂.

C₃-C₁₂-Heterocyclyl is a 3- to 12-membered heterocyclic radical including a saturated heterocyclic radical, which generally has 3, 4, 5, 6, or 7 ring forming atoms (ring members), an unsaturated non-aromatic heterocyclic radical, which generally has 5, 6 or 7 ring forming atoms, and a heteroaromatic radical (heteroaryl), which generally has 5, 6 or 7 ring forming atoms. The heterocyclic radicals may be bound via a carbon atom (C-bound) or a nitrogen atom (N-bound). Preferred heterocyclic radicals comprise 1 nitrogen atom as ring member atom and optionally 1, 2 or 3 further heteroatoms as ring members, which are selected, independently of each other from O, S and N. Likewise preferred heterocyclic radicals comprise 1 heteroatom as ring member, which is selected from O, S and N, and optionally 1, 2 or 3 further nitrogen atoms as ring members.

Examples of C₃-C₁₂-heterocyclyl include:

C- or N-bound 3-4-membered, saturated rings, such as 2-oxiranyl, 2-oxetanyl, 3-oxetanyl, 2-aziridinyl, 3-thiethanyl, 1-azetidinyl, 2-azetidinyl, 3-azetidinyl;

C-bound, 5-membered, saturated rings, such as tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydropyrrol-2-yl, tetrahydropyrrol-3-yl, tetrahydropyrazol-3-yl, tetrahydro-pyrazol-4-yl, tetrahydroisoxazol-3-yl, tetrahydroisoxazol-4-yl, tetrahydroisoxazol-5-yl, 1,2-oxathiolan-3-yl, 1,2-oxathiolan-4-yl, 1,2-oxathiolan-5-yl, tetrahydroisothiazol-3-yl, tetrahydroisothiazol-4-yl, tetrahydroisothiazol-5-yl, 1,2-dithiolan-3-yl, 1,2-dithiolan-4-yl, tetrahydroimidazol-2-yl, tetrahydroimidazol-4-yl, tetrahydrooxazol-2-yl, tetrahydrooxazol-4-yl, tetrahydrooxazol-5-yl, tetrahydrothiazol-2-yl, tetrahydrothiazol-4-yl, tetrahydrothiazol-5-yl, 1,3-dioxolan-2-yl, 1,3-dioxolan-4-yl, 1,3-oxathiolan-2-yl, 1,3-oxathiolan-4-yl, 1,3-oxathiolan-5-yl, 1,3-dithiolan-2-yl, 1,3-dithiolan-4-yl, 1,3,2-dioxathiolan-4-yl;

C-bound, 6-membered, saturated rings, such as tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl, 1,4-dioxan-2-yl, 1,3-dithian-2-yl, 1,3-dithian-4-yl, 1,3-dithian-5-yl, 1,4-dithian-2-yl, 1,3-oxathian-2-yl, 1,3-oxathian-4-yl, 1,3-oxathian-5-yl, 1,3-oxathian-6-yl, 1,4-oxathian-2-yl, 1,4-oxathian-3-yl, 1,2-dithian-3-yl, 1,2-dithian-4-yl, hexahydropyrimidin-2-yl, hexahydropyrimidin-4-yl, hexahydropyrimidin-5-yl, hexahydropyrazin-2-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl, tetrahydro-1,3-oxazin-2-yl, tetrahydro-1,3-oxazin-4-yl, tetrahydro-1,3-oxazin-5-yl, tetrahydro-1,3-oxazin-6-yl, tetrahydro-1,3-thiazin-2-yl, tetrahydro-1,3-thiazin-4-yl, tetrahydro-1,3-thiazin-5-yl, tetrahydro-1,3-thiazin-6-yl, tetrahydro-1,4-thiazin-2-yl, tetrahydro-1,4-thiazin-3-yl, tetrahydro-1,4-oxazin-2-yl, tetrahydro-1,4-oxazin-3-yl, tetrahydro-1,2-oxazin-3-yl, tetrahydro-1,2-oxazin-4-yl, tetrahydro-1,2-oxazin-5-yl, tetrahydro-1,2-oxazin-6-yl;

N-bound, 5-membered, saturated rings, such as tetrahydropyrrol-1-yl(pyrrolidin-1-yl), tetrahydropyrazol-1-yl, tetrahydroisoxazol-2-yl, tetrahydroisothiazol-2-yl, tetrahydroimidazol-1-yl, tetrahydrooxazol-3-yl, tetrahydrothiazol-3-yl;

N-bound, 6-membered, saturated rings, such as piperidin-1-yl, hexahydropyrimidin-1-yl, hexahydropyrazin-1-yl(piperazin-1-yl), hexahydropyridazin-1-yl, tetrahydro-1,3-oxazin-3-yl, tetrahydro-1,3-thiazin-3-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-oxazin-4-yl(morpholin-1-yl), tetrahydro-1,2-oxazin-2-yl;

C-bound, 5-membered, partially unsaturated rings, such as 2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,5-dihydrofuran-2-yl, 2,5-di-hydrofuran-3-yl, 4,5-dihydrofuran-2-yl, 4,5-dihydrofuran-3-yl, 2,3-dihydro-thien-2-yl, 2,3-dihydrothien-3-yl, 2,5-dihydrothien-2-yl, 2,5-dihydrothien-3-yl, 4,5-dihydrothien-2-yl, 4,5-dihydrothien-3-yl, 2,3-dihydro-1H-pyrrol-2-yl, 2,3-dihydro-1H-pyrrol-3-yl, 2,5-dihydro-1H-pyrrol-2-yl, 2,5-dihydro-1H-pyrrol-3-yl, 4,5-dihydro-1H-pyrrol-2-yl, 4,5-dihydro-1H-pyrrol-3-yl, 3,4-dihydro-2H-pyrrol-2-yl, 3,4-dihydro-2H-pyrrol-3-yl, 3,4-dihydro-5H-pyrrol-2-yl, 3,4-dihydro-5H-pyrrol-3-yl, 4,5-dihydro-1H-pyrazol-3-yl, 4,5-dihydro-1H-pyrazol-4-yl, 4,5-dihydro-1H-pyrazol-5-yl, 2,5-dihydro-1H-pyrazol-3-yl, 2,5-dihydro-1H-pyrazol-4-yl, 2,5-dihydro-1H-pyrazol-5-yl, 4,5-dihydroisoxazol-3-yl, 4,5-dihydroisoxazol-4-yl, 4,5-dihydroisoxazol-5-yl, 2,5-dihydroisoxazol-3-yl, 2,5-dihydroisoxazol-4-yl, 2,5-dihydroisoxazol-5-yl, 2,3-dihydroisoxazol-3-yl, 2,3-dihydroisoxazol-4-yl, 2,3-dihydroisoxazol-5-yl, 4,5-dihydroisothiazol-3-yl, 4,5-dihydroisothiazol-4-yl, 4,5-dihydroisothiazol-5-yl, 2,5-dihydroisothiazol-3-yl, 2,5-dihydroisothiazol-4-yl, 2,5-dihydroisothiazol-5-yl, 2,3-dihydroisothiazol-3-yl, 2,3-dihydroisothiazol-4-yl, 2,3-dihydroisothiazol-5-yl, 4,5-dihydro-1H-imidazol-2-yl, 4,5-dihydro-1H-imidazol-4-yl, 4,5-dihydro-1H-imidazol-5-yl, 2,5-dihydro-1H-imidazol-2-yl, 2,5-dihydro-1H-imidazol-4-yl, 2,5-dihydro-1H-imidazol-5-yl, 2,3-dihydro-1H-imidazol-2-yl, 2,3-dihydro-1H-imidazol-4-yl, 4,5-dihydro-oxazol-2-yl, 4,5-dihydrooxazol-4-yl, 4,5-dihydrooxazol-5-yl, 2,5-dihydrooxazol-2-yl, 2,5-dihydrooxazol-4-yl, 2,5-dihydrooxazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 4,5-dihydrothiazol-2-yl, 4,5-dihydrothiazol-4-yl, 4,5-dihydrothiazol-5-yl, 2,5-dihydrothiazol-2-yl, 2,5-dihydrothiazol-4-yl, 2,5-dihydrothiazol-5-yl, 2,3-dihydrothiazol-2-yl, 2,3-dihydrothiazol-4-yl, 2,3-dihydrothiazol-5-yl, 1,3-dioxol-2-yl, 1,3-dioxol-4-yl, 1,3-dithiol-2-yl, 1,3-dithiol-4-yl, 1,3-oxathiol-2-yl, 1,3-oxathiol-4-yl, 1,3-oxathiol-5-yl;

C-bound, 6-membered, partially unsaturated rings, such as 2H-3,4-dihydropyran-6-yl, 2H-3,4-dihydropyran-5-yl, 2H-3,4-dihydropyran-4-yl, 2H-3,4-dihydropyran-3-yl, 2H-3,4-dihydropyran-2-yl, 2H-3,4-dihydrothiopyran-6-yl, 2H-3,4-dihydrothiopyran-5-yl, 2H-3,4-dihydrothiopyran-4-yl, 2H-3,4-dihydrothiopyran-3-yl, 2H-3,4-dihydrothiopyran-2-yl, 1,2,3,4-tetrahydropyridin-6-yl, 1,2,3,4-tetrahydropyridin-5-yl, 1,2,3,4-tetrahydropyridin-4-yl, 1,2,3,4-tetra-hydropyridin-3-yl, 1,2,3,4-tetrahydropyridin-2-yl, 2H-5,6-dihydropyran-2-yl, 2H-5,6-dihydropyran-3-yl, 2H-5,6-dihydropyran-4-yl, 2H-5,6-dihydropyran-5-yl, 2H-5,6-dihydropyran-6-yl, 2H-5,6-dihydrothiopyran-2-yl, 2H-5,6-dihydrothiopyran-3-yl, 2H-5,6-dihydrothiopyran-4-yl, 2H-5,6-dihydrothiopyran-5-yl, 2H-5,6-dihydrothiopyran-6-yl, 1,2,5,6-tetrahydropyridin-2-yl, 1,2,5,6-tetrahydropyridin-3-yl, 1,2,5,6-tetrahydropyridin-4-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,5,6-tetrahydropyridin-6-yl, 2,3,4,5-tetrahydropyridin-2-yl, 2,3,4,5-tetrahydropyridin-3-yl, 2,3,4,5-tetrahydropyridin-4-yl, 2,3,4,5-tetrahydropyridin-5-yl, 2,3,4,5-tetrahydropyridin-6-yl, 4H-pyran-2-yl, 4H-pyran-3-yl-, 4H-pyran-4-yl, 4H-thiopyran-2-yl, 4H-thiopyran-3-yl, 4H-thiopyran-4-yl, 1,4-dihydropyridin-2-yl, 1,4-dihydropyridin-3-yl, 1,4-dihydropyridin-4-yl, 2H-pyran-2-yl, 2H-pyran-3-yl, 2H-pyran-4-yl, 2H-pyran-5-yl, 2H-pyran-6-yl, 2H-thiopyran-2-yl, 2H-thiopyran-3-yl, 2H-thiopyran-4-yl, 2H-thiopyran-5-yl, 2H-thiopyran-6-yl, 1,2-dihydropyridin-2-yl, 1,2-dihydro-pyridin-3-yl, 1,2-dihydropyridin-4-yl, 1,2-dihydropyridin-5-yl, 1,2-dihydro-pyridin-6-yl, 3,4-dihydropyridin-2-yl, 3,4-dihydropyridin-3-yl, 3,4-dihydropyridin-4-yl, 3,4-dihydropyridin-5-yl, 3,4-dihydropyridin-6-yl, 2,5-dihydropyridin-2-yl, 2,5-dihydropyridin-3-yl, 2,5-dihydropyridin-4-yl, 2,5-dihydropyridin-5-yl, 2,5-dihydropyridin-6-yl, 2,3-dihydropyridin-2-yl, 2,3-dihydropyridin-3-yl, 2,3-dihydropyridin-4-yl, 2,3-dihydropyridin-5-yl, 2,3-dihydropyridin-6-yl, 2H-5,6-dihydro-1,2-oxazin-3-yl, 2H-5,6-dihydro-1,2-oxazin-4-yl, 2H-5,6-dihydro-1,2-oxazin-5-yl, 2H-5,6-dihydro-1,2-oxazin-6-yl, 2H-5,6-dihydro-1,2-thiazin-3-yl, 2H-5,6-dihydro-1,2-thiazin-4-yl, 2H-5,6-dihydro-1,2-thiazin-5-yl, 2H-5,6-dihydro-1,2-thiazin-6-yl, 4H-5,6-dihydro-1,2-oxazin-3-yl, 4H-5,6-dihydro-1,2-oxazin-4-yl, 4H-5,6-dihydro-1,2-oxazin-5-yl, 4H-5,6-dihydro-1,2-oxazin-6-yl, 4H-5,6-dihydro-1,2-thiazin-3-yl, 4H-5,6-dihydro-1,2-thiazin-4-yl, 4H-5,6-dihydro-1,2-thiazin-5-yl, 4H-5,6-dihydro-1,2-thiazin-6-yl, 2H-3,6-dihydro-1,2-oxazin-3-yl, 2H-3,6-dihydro-1,2-oxazin-4-yl, 2H-3,6-dihydro-1,2-oxazin-5-yl, 2H-3,6-dihydro-1,2-oxazin-6-yl, 2H-3,6-dihydro-1,2-thiazin-3-yl, 2H-3,6-dihydro-1,2-thiazin-4-yl, 2H-3,6-dihydro-1,2-thiazin-5-yl, 2H-3,6-dihydro-1,2-thiazin-6-yl, 2H-3,4-dihydro-1,2-oxazin-3-yl, 2H-3,4-dihydro-1,2-oxazin-4-yl, 2H-3,4-dihydro-1,2-oxazin-5-yl, 2H-3,4-dihydro-1,2-oxazin-6-yl, 2H-3,4-dihydro-1,2-thiazin-3-yl, 2H-3,4-dihydro-1,2-thiazin-4-yl, 2H-3,4-dihydro-1,2-thiazin-5-yl, 2H-3,4-dihydro-1,2-thiazin-6-yl, 2,3,4,5-tetrahydropyridazin-3-yl, 2,3,4,5-tetrahydropyridazin-4-yl, 2,3,4,5-tetrahydropyridazin-5-yl, 2,3,4,5-tetrahydropyridazin-6-yl, 3,4,5,6-tetrahydropyridazin-3-yl, 3,4,5,6-tetrahydropyridazin-4-yl, 1,2,5,6-tetrahydropyridazin-3-yl, 1,2,5,6-tetrahydropyridazin-4-yl, 1,2,5,6-tetra-hydropyridazin-5-yl, 1,2,5,6-tetrahydropyridazin-6-yl, 1,2,3,6-tetrahydro-pyridazin-3-yl, 1,2,3,6-tetrahydropyridazin-4-yl, 4H-5,6-dihydro-1,3-oxazin-2-yl, 4H-5,6-dihydro-1,3-oxazin-4-yl, 4H-5,6-dihydro-1,3-oxazin-5-yl, 4H-5,6-dihydro-1,3-oxazin-6-yl, 4H-5,6-dihydro-1,3-thiazin-2-yl, 4H-5,6-dihydro-1,3-thiazin-4-yl, 4H-5,6-dihydro-1,3-thiazin-5-yl, 4H-5,6-dihydro-1,3-thiazin-6-yl, 3,4,5-6-tetrahydropyrimidin-2-yl, 3,4,5,6-tetrahydropyrimidin-4-yl, 3,4,5,6-tetrahydropyrimidin-5-yl, 3,4,5,6-tetrahydropyrimidin-6-yl, 1,2,3,4-tetrahydropyrazin-2-yl, 1,2,3,4-tetrahydropyrazin-5-yl, 1,2,3,4-tetrahydro-pyrimidin-2-yl, 1,2,3,4-tetrahydropyrimidin-4-yl, 1,2,3,4-tetrahydropyrimidin-5-yl, 1,2,3,4-tetrahydropyrimidin-6-yl, 2,3-dihydro-1,4-thiazin-2-yl, 2,3-dihydro-1,4-thiazin-3-yl, 2,3-dihydro-1,4-thiazin-5-yl, 2,3-dihydro-1,4-thiazin-6-yl, 2H-1,3-oxazin-2-yl, 2H-1,3-oxazin-4-yl, 2H-1,3-oxazin-5-yl, 2H-1,3-oxazin-6-yl, 2H-1,3-thiazin-2-yl, 2H-1,3-thiazin-4-yl, 2H-1,3-thiazin-5-yl, 2H-1,3-thiazin-6-yl, 4H-1,3-oxazin-2-yl, 4H-1,3-oxazin-4-yl, 4H-1,3-oxazin-5-yl, 4H-1,3-oxazin-6-yl, 4H-1,3-thiazin-2-yl, 4H-1,3-thiazin-4-yl, 4H-1,3-thiazin-5-yl, 4H-1,3-thiazin-6-yl, 6H-1,3-oxazin-2-yl, 6H-1,3-oxazin-4-yl, 6H-1,3-oxazin-5-yl, 6H-1,3-oxazin-6-yl, 6H-1,3-thiazin-2-yl, 6H-1,3-oxazin-4-yl, 6H-1,3-oxazin-5-yl, 6H-1,3-thiazin-6-yl, 2H-1,4-oxazin-2-yl, 2H-1,4-oxazin-3-yl, 2H-1,4-oxazin-5-yl, 2H-1,4-oxazin-6-yl, 2H-1,4-thiazin-2-yl, 2H-1,4-thiazin-3-yl, 2H-1,4-thiazin-5-yl, 2H-1,4-thiazin-6-yl, 4H-1,4-oxazin-2-yl, 4H-1,4-oxazin-3-yl, 4H-1,4-thiazin-2-yl, 4H-1,4-thiazin-3-yl, 1,4-dihydropyridazin-3-yl, 1,4-dihydropyridazin-4-yl, 1,4-dihydropyridazin-5-yl, 1,4-dihydropyridazin-6-yl, 1,4-dihydropyrazin-2-yl, 1,2-dihydropyrazin-2-yl, 1,2-dihydropyrazin-3-yl, 1,2-dihydropyrazin-5-yl, 1,2-dihydropyrazin-6-yl, 1,4-dihydropyrimidin-2-yl, 1,4-dihydropyrimidin-4-yl, 1,4-dihydropyrimidin-5-yl, 1,4-dihydropyrimidin-6-yl, 3,4-dihydropyrimidin-2-yl, 3,4-dihydropyrimidin-4-yl, 3,4-dihydropyrimidin-5-yl or 3,4-dihydropyrimidin-6-yl;

N-bound, 5-membered, partially unsaturated rings, such as 2,3-dihydro-1H-pyrrol-1-yl, 2,5-dihydro-1H-pyrrol-1-yl, 4,5-dihydro-1H-pyrazol-1-yl, 2,5-dihydro-1H-pyrazol-1-yl, 2,3-dihydro-1H-pyrazol-1-yl, 2,5-dihydroisoxazol-2-yl, 2,3-dihydroisoxazol-2-yl, 2,5-dihydroisothiazol-2-yl, 2,3-dihydroisoxazol-2-yl, 4,5-dihydro-1H-imidazol-1-yl, 2,5-dihydro-1H-imidazol-1-yl, 2,3-dihydro-1H-imidazol-1-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrothiazol-3-yl;

N-bound, 6-membered, partially unsaturated rings, such as 1,2,3,4-tetrahydropyridin-1-yl, 1,2,5,6-tetrahydropyridin-1-yl, 1,4-dihydro-pyridin-1-yl, 1,2-dihydropyridin-1-yl, 2H-5,6-dihydro-1,2-oxazin-2-yl, 2H-5,6-dihydro-1,2-thiazin-2-yl, 2H-3,6-dihydro-1,2-oxazin-2-yl, 2H-3,6-dihydro-1,2-thiazin-2-yl, 2H-3,4-dihydro-1,2-oxazin-2-yl, 2H-3,4-dihydro-1,2-thiazin-2-yl, 2,3,4,5-tetrahydropyridazin-2-yl, 1,2,5,6-tetrahydropyridazin-1-yl, 1,2,5,6-tetrahydropyridazin-2-yl, 1,2,3,6-tetrahydropyridazin-1-yl, 3,4,5,6-tetrahydropyrimidin-3-yl, 1,2,3,4-tetrahydropyrazin-1-yl, 1,2,3,4-tetrahydropyrimidin-1-yl, 1,2,3,4-tetrahydropyrimidin-3-yl, 2,3-dihydro-1,4-thiazin-4-yl, 2H-1,2-oxazin-2-yl, 2H-1,2-thiazin-2-yl, 4H-1,4-oxazin-4-yl, 4H-1,4-thiazin-4-yl, 1,4-dihydropyridazin-1-yl, 1,4-dihydropyrazin-1-yl, 1,2-dihydropyrazin-1-yl, 1,4-dihydropyrimidin-1-yl or 3,4-dihydropyrimidin-3-yl;

C-bound, 5-membered, heteroaromatic rings, such as 2-furyl, 3-furyl, 5-furyl, 2-thienyl, 3-thienyl, 5-thienyl, pyrrol-2-yl, pyrrol-3-yl, pyrrol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 1,2,3-oxadiazol-imidazol-4-yl, 4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4,-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazolyl-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl, tetrazol-5-yl;

C-bound, 6-membered, heteroaromatic rings, such as pyridin-2-yl, pyridin-3-yl (3-pyridyl), pyridin-4-yl (4-pyridyl), pyridin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-6-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-5-yl, 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl, 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl, 1,2,4,5-tetrazin-3-yl;

N-bound, 5-membered, heteroaromatic rings, such as pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, tetrazol-1-yl.

Heterocyclyl also includes bicyclic heterocycles, which comprise one of the described 5- or 6-membered heterocyclic rings and a further anellated, saturated or unsaturated or aromatic carbocycle, such as a benzene, cyclohexane, cyclohexene or cyclohexadiene ring, or a further anellated 5- or 6-membered heterocyclic ring, this heterocyclic ring being saturated or unsaturated or aromatic. These include quinolinyl, isoquinolinyl, indolyl, indolizinyl, isoindolyl, indazolyl, benzofuryl, benzthienyl, benzo[b]thiazolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, imidazo[b]thiazolyl, thieno[b]pyridyl, imidazo[a]pyridyl, pyrazo[a]pyridyl and pyrrol[d]pyrimidyl. Examples of 5- or 6-membered heteroaromatic compounds comprising an anellated cycloalkenyl ring include dihydroindolyl, dihydroindolizinyl, dihydroisoindolyl, dihydroquinolinyl, dihydroisoquinolinyl, dihydrobenzofuryl, chromanyl, chromanyl, dihydropyrrolo[a]imidazolyl and tetrahydro benzothiazolyl.

C₃-C₁₂-Heteroarylene is a heteroaryl diradical. Examples include pyrid-2,5-ylene and pyrid-2,4-ylene.

With respect to the compounds' capability of inhibiting glycine transporter 1, the variables R¹, R^(2a), R^(2b), R^(3a), R^(3b), R⁴, Y¹, R^(5a), R^(5b), R⁶, R^(7a), R^(7b), R^(7c), R^(7d), R^(7e), R^(7f), R^(8a), R^(8b), R^(8c), R^(8a), R^(8d), R^(8e), R^(9a), R^(9b), R^(9c), R^(9d), R¹⁰, R^(11a), R^(11b), R¹², R¹³, R¹⁴, R¹⁵, R^(16a), R^(16b), R¹⁷, R¹⁸, R¹⁹, R^(20a), R^(20b), R²¹, n1, n2, n3, n4 and n5 preferably have the following meanings which, when taken alone or in combination, represent particular embodiments of the pyrrolidine derivatives of the formula (I) or any other formula disclosed herein.

R¹ is C₁-C₈-alkyl (e.g. methyl; ethyl, or n-propyl), (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropylmethyl), (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g. tetrahydropyran-2-yl-methyl), optionally substituted C₃-C₁₂-cycloalkyl (e.g. cyclobutyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 4-Cl-phenyl, 3-Cl-phenyl, 2,4-dichlorophenyl, 4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-CN-phenyl, 2-aminocarbonyl-phenyl, or 4-OMe-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 2,5-dimethyl-furan-3-yl, 4-methyl-thiophen-2-yl, 5-methyl-thiophen-2-yl, 5-ethyl-thiophen-2-yl, 2,5-dimethyl-thiophen-3-yl, 5-Cl-thiophen-2-yl, 2-methoxycarbonyl-thiophen-3-yl, 3-methoxy-4-methoxycarbonyl-thiophen-2-yl, 1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl, 5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl, 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl, 1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, 2-methylcarbonylamino-1,3-thiazol-5-yl, 3-pyridyl, 2-CF₃-pyrid-5-yl, 2-(morpholin-1-yl)-pyrid-5-yl, 2-OMe-pyrid-5-yl, 1-methylcarbonyl-indolin-5-yl, 1,2-benzoxazol-5-yl, 1,4-dihydroquinoxaline-2,3-dion-6-yl, 6-chloro-imidazo[2,1-b]thiazol-5-yl, 6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl, 3H-1,3-benzoxazol-2-on-5-yl, 3,3-dimethylindolin-2-on-5-yl, indolin-2-on-5-yl, 1,3-dihydrobenzimidazol-2-on-5-yl, 1H-quinazoline-2,4-dion-6-yl, 6-Me-4H-1,4-benzoxazin-3-on-7-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1,3-benzodioxol-5-yl, isoquinoline-5-yl, 3,4-dihydro-1H-quinolin-2-on-6yl, 1-Me-indol-5yl, pyrrolidin-1-yl, 4-Me-piperidin-1-yl, morpholin-1-yl).

Preferably, R¹ is an optionally substituted 5-membered heterocyclic ring containing at least 1 N atom and optionally 1 or 2 further heteroatoms selected from N, O and S (e.g. 1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl, 5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl, 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-iso-propyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl, 1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or 2-methylcarbonylamino-1,3-thiazol-5-yl).

According to one embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 1 or 2N and 1 O (e.g. 5-methyl-1,2-oxazol-4-yl or 3,5-dimethyl-1,2-oxazol-4-yl). According to an alternative embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 1 or 2 N and 1 S (e.g. 2,4-dimethyl-1,3-thiazol-5-yl or 2-methylcarbonylamino-1,3-thiazol-5-yl). According to a further alternative embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 1, 2 or 3 N (e.g. 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-iso-propyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl or 1-Me-1,2,3-triazol-4-yl).

Preferably, R¹ is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹, substituted 5-membered heterocyclic rings containing at least 1 N atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular include 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxycarbonyl and C₁-C₆-alkylcarbonylamino.

Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl.

In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl).

According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

According to a further particular embodiment, 1,2,3-triazolyl is substituted with C₁-C₆-alkyl as described herein. According to a further specific embodiment, R¹ is 1-methyl-1,2,3-triazol-4-yl.

R^(2a), R^(2b) are independently hydrogen, halogen (e.g. F), or C₁-C₃-alkyl (e.g. methyl, ethyl, n-propyl, or iso-propyl), or R^(2a), R^(2b) together with the carbon atom to which they are bound may form a C═O.

According to one particular embodiment R^(2a) is hydrogen, halogen (e.g. F) or C₁-C₃-alkyl (e.g. methyl or ethyl), and R^(2b) is hydrogen. Preferably, R^(2a), R^(2b) are both hydrogen.

R^(3a) is C₃-C₁₂-cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), hydroxy, C₁-C₆-alkoxy (e.g. methoxy, ethoxy, n-propoxy, iso-propoxy, or iso-butoxy) halogenated C₁-C₆-alkoxy (e.g OCF₃), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy (e.g. 2-(N-pyrrolidinyl)ethoxy, 2-(N-morpholinyl)ethoxy, or 2-(N-imidazolyl)ethoxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), C₃-C₁₂-heterocyclyloxy (e.g. pyridin-2-yloxy), or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-2-yl, 3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1yl, 3-Me-piperidin-1yl, 4-Me-piperidin-1yl, 4-F-piperidin-1-yl, 4,4-diF-piperidin-1yl, or azepan-1-yl).

In particular, R^(3a) is C₃-C₁₂-cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-heterocyclyloxy (e.g. pyridin-2-yloxy), or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-2-yl, 3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1yl, 3-Me-piperidin-1yl, 4-Me-piperidin-1yl, 4-F-piperidin-1-yl, 4,4-diF-piperidin-1yl, or azepan-1-yl).

Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, 1,3-oxazol-2-yl, 3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1yl, 3-Me-piperidin-1yl, 4-Me-piperidin-1yl, 4-F-piperidin-1-yl, 4,4-diF-piperidin-1yl, or azepan-1-yl).

According to one preferred embodiment, R^(3a) is optionally substituted C₆-C₁₂-aryl wherein C₆-C₁₂-aryl is phenyl, in particular phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 4-F-phenyl, 2-F-phenyl, 3-F-phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, or 2,4,5-trifluoro-phenyl).

According to a further preferred embodiment, R^(3a) is optionally substituted C₃-C₁₂-heterocyclyl wherein C₃-C₁₂-heterocyclyl is in particular tetrahydrofuranyl or tetrahydropyranyl, preferably unsubstituted tetrahydrofuranyl (e.g. tetrahydrofuran-2-yl) or unsubstituted tetrahydropyranyl (e.g. tetrahydropyran-2-yl).

According to an additional aspect, R^(3a) is not 3,4-di-O-substituted phenyl if R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl). According to a further additional aspect, there is not more than one O-bound substituent on the aryl group if R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

In connection with R^(3a), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy.

Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

In connection with R^(3a), substituted C₆-C₁₂-aryloxy in particular includes C₆-C₁₂-aryloxy, such as phenoxy, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl.

Preferably, the substituent(s) on C₆-C₁₂-aryloxy are independently selected from the group consisting of halogen.

In connection with R^(3a), substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, piperidinyl, isoxazolyl, diazolyl, tetrahydrofuranyl, tetrahydropyranyl, or morpholinyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl.

Preferably, the substituent(s) on C₃-C₁₂-heterocyclyl are independently selected from the group consisting of halogen.

R^(3b) is hydrogen, C₁-C₆-alkyl, or hydroxy. Preferably, R^(3b) is hydrogen.

Y¹ is >CR⁶— or >N—.

Preferably, Y¹ is >CR⁶—.

R⁶ is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, n-propyl, iso-propyl, or iso-butyl), halogenated C₁-C₆-alkyl (e.g. CF₃ or CF₂H), (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl), hydroxy-C₁-C₆-alkyl (e.g. —CH₂OH or —(CH₂)₂OH), C₁-C₄-alkoxy-C₁-C₆-alkyl (e.g. methoxymethyl, 2-ethoxypropyl, or 3-ethoxypropyl), or hydroxy.

In particular, R⁶ is hydrogen, C₁-C₆-alkyl (e.g. methyl or ethyl), C₆-C₁₂-aryl-C₁-C₄-alkyl (e.g. benzyl or phenethyl), hydroxy-C₁-C₆-alkyl (e.g. —CH₂OH, or —(CH₂)₂OH), or hydroxy, i.e., R⁶ is, e.g., hydrogen, methyl, benzyl, hydroxymethyl, or hydroxy.

Preferably, R⁶ is hydrogen.

According to some embodiments, Y¹ is >N—. In particular, Y¹ is >N— if R⁴ is —(CR^(7e)R^(7f))_(n3)R¹².

R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂- aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b), —NR^(8e)SO₂R¹⁷, —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 1-propyl-1,2,3-triazol-4-yl, 4-butyl-1,2,3-triazolyl-1-yl, 4-chloroisoindolin-1-one, 7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl).

In particular, R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), (CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b)), —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 1-propyl-1,2,3-triazol-4-yl, 4-butyl-1,2,3-triazolyl-1-yl, 4-chloroisoindolin-1-one, or 7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl).

Preferably, R⁴ is —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³ or —O(CR^(9c)R^(9d))_(n5)R¹⁸. More preferably, R⁴ is —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³.

In connection with R⁴, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

In connection with R⁴, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, isoxazolyl, diazolyl, 1,2,3-triazolyl, dihydroquinazolyn, or isoindolinyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl and hydroxy.

In particular, R^(5a), R^(5b) are independently hydrogen, halogen, or C₁-C₃— alkyl (e.g. methyl, ethyl, n-propyl, or iso-propyl) or R^(5a), R^(5b) together with the carbon atom to which they are bound may form a C═O.

Preferably, R^(5a) is hydrogen, halogen or C₁-C₃-alkyl (e.g. methyl or ethyl), and R^(5b) is hydrogen. More preferably, R^(5a), R^(5b) are both hydrogen.

According to a one embodiment, R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ia):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(7a), R^(7b)     -   are independently hydrogen or C₁-C₆-alkyl (e.g. methyl or         ethyl), in particular, hydrogen; -   n1 is 1, 2, 3 or 4, in particular 1; and -   R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     3-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, or     3-OCF₃-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     6-CF₃-pyrimid-4-yl, 4-CF₃-pyrid-2-yl, or 2-CF₃-pyrid-4-yl).

In connection with R¹⁰, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy.

In connection with R¹⁰, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, pyrimidyl, or pyridazyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl.

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Ia)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Ia)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Ia)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ia)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ia)—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula—(Ia) are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (Ia) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-iso-propyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(7a), R^(7b)     -   are hydrogen; -   n1 is 1; -   R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     3-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, or     3-OCF₃-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     6-CF₃-pyrimid-4-yl, 4-CF₃-pyrid-2-yl, or 2-CF₃-pyrid-4-yl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a particular embodiment, R¹—in the pyrrolidine derivatives of formula (Ia)—is an optionally substituted 5-membered heterocyclic ring containing 1 or 2 N and 1 O (e.g. 5-methyl-1,2-oxazol-4-yl or 3,5-dimethyl-1,2-oxazol-4-yl). According to an alternative particular embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 1 or 2 N and 1 S (e.g. 2,4-dimethyl-1,3-thiazol-5-yl or 2-methylcarbonylamino-1,3-thiazol-5-yl). According to a further particular alternative embodiment, R¹ is an optionally substituted 5-membered heterocyclic ring containing 1, 2 or 3 N (e.g. 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-iso-propyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl or 1-Me-1,2,3-triazol-4-yl).

Preferably, R¹—in the pyrrolidine derivatives of formula (Ia)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ia)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ia), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ia), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituents on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ia)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl).

Further preferred embodiments of pyrrolidine derivatives of formula (Ia) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl, in particular phenyl, optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl,     3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or     2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(7a), R^(7b)     -   are hydrogen; -   n1 is 1; -   R¹⁰ is hydrogen, C₆-C₁₂-aryl (e.g. phenyl) optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl and     halogenated C₁-C₄-alkoxy, or C₃-C₁₂-heterocyclyl optionally     substituted with 1, 2, or 3 substituents independently selected from     the group consisting of halogenated C₁-C₄-alkyl; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —(CR^(7c)R^(2d))_(n2)NR^(11a)R^(11b). Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ib):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(7c), R^(7d)     -   are independently hydrogen or C₁-C₆-alkyl (e.g. methyl or         ethyl), in particular, hydrogen; -   n2 is 1, 2, 3, or 4, in particular, 1; -   R^(11a) is C₁-C₈-alkyl (e.g. methyl, ethyl, n-propyl, or n-butyl),     (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g.     cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl,     2-ethoxy-ethyl, 2-isopropoxy-ethyl, 1-methyl-2-methoxy-ethyl,     3-methoxypropyl, 3-ethoxy-propyl, or 3-isopropoxy-propyl),     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl),     (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl,     3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl,     3-(aminomethyl)-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     2-Cl-4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl,     3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, or     3-(aminocarbonyl)-phenyl), or optionally substituted     C₃-C₁₂-heterocyclyl; and -   R^(11b) is hydrogen or (e.g. methyl, ethyl, n-propyl or n-butyl).

In particular, R^(11a) is C₁-C₈-alkyl (e.g. n-propyl or n-butyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g. cyclopropyl-methyl) C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl, 2-ethoxy-ethyl, 2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropyloxy-propyl), C₆-C₁₂-aryl-C₁-C₄-alkyl (e.g. benzyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-(aminomethyl)-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, or 3-(aminocarbonyl)phenyl).

In connection with R^(11a) substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, amino-C₁-C₄-alkyl, amino-carbonyl and halogenated C₁-C₄-alkoxy.

In particular, R^(11b) is hydrogen.

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Ib)—are, in particular, both hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Ib)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4 Cl phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Ib)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ib)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ib)—is, in particular, hydrogen.

R^(5a), R^(5b) in the pyrrolidine derivatives of formula (Ib)—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (Ib) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(7c), R^(7d)     -   are hydrogen; -   n2 is 1; -   R^(11a) is C₁-C₈-alkyl (e.g. n-propyl or n-butyl),     C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g. cyclopropylmethyl)     C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl, 2-ethoxy-ethyl,     2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl,     3-ethoxy-propyl, or 3-isopropyloxy-propyl), C₆-C₁₂-aryl-C₁-C₄-alkyl     (e.g. benzyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl,     3-Me-phenyl, 3-(aminomethyl)-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     2-Cl-4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl,     3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, or     3-(aminocarbonyl)-phenyl); -   R^(11b) is hydrogen; and -   R^(5a), R^(5b) are     -   hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ib)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ib)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ib), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ib), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituents on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ib)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl).

Further preferred embodiments of pyrrolidine derivatives of formula (Ib) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or C (e.g.     1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl,     4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or     2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(7c), R^(7d)     -   are hydrogen; -   n2 is 1; -   R^(11a) is C₁-C₈-alkyl (e.g. n-propyl or n-butyl),     C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g. cyclopropylmethyl),     C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl, 2-ethoxy-ethyl,     2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl,     3-ethoxy-propyl, or 3-isopropyloxy-propyl), C₆-C₁₂-aryl-C₁-C₄-alkyl     (e.g. benzyl), or C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, amino-C₁-C₄-alkyl,     aminocarbonyl and halogenated C₁-C₄-alkoxy (e.g. phenyl, 4-F-phenyl,     3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl,     3-(aminomethyl)-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     2-Cl-4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl,     3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, or     3-(aminocarbonyl)-phenyl); -   R^(11b) is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —(CR^(7e)R^(7f))_(n3)R¹². Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ic):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(7e), R^(7f)     -   are independently hydrogen or C₁-C₆-alkyl (e.g. methyl or         ethyl), in particular, hydrogen; -   n3 is 1, 2, 3, or 4, in particular, 1; and -   R¹² is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-Cl-phenyl,     or 3-Br-phenyl) or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     4-CF₃-pyrid-2-yl or 1-propyl-1,2,3-triazol-4-yl).

In connection with R¹², substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

In connection with R¹², substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl or triazolyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₄-alkyl and halogenated C₁-C₄-alkyl.

R^(2a), R^(2b)—in pyrrolidine derivatives of formula (Ic)—are, in particular, hydrogen.

R^(3a)—in pyrrolidine derivatives of formula (Ic)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy). Preferably, R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Ic)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ic)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ic)—is, in particular, hydrogen or hydroxy.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Ic)—are, in particular, hydrogen or together with the carbon atom to which they are bound may form a C═O.

If Y¹—in the pyrrolidine derivatives of formula (Ic)—is >N—R^(5a), R^(5b) together with the carbon atom to which they are bound form, in particular, a C═O.

Particular embodiments of pyrrolidine derivatives of formula (Ic) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl,     cyclopentyl, or cyclohexyl) or optionally substituted C₆-C₁₂-aryl     (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or     2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶ or >N—; -   R⁶ is hydrogen or hydroxy; -   R^(7e), R^(7f)     -   are hydrogen; -   n3 is 1; -   R¹² is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-Cl-phenyl,     or 3-Br-phenyl) or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     4-CF₃-pyrid-2-yl or 1-propyl-1,2,3-triazol-4-yl); and -   R^(5a), R^(5b)     -   are hydrogen or together with the carbon atom to which they are         bound may form a C═O.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ic)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ic)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ic), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ic), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituents on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ic)—is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl).

Further preferred embodiments of pyrrolidine derivatives of formula (Ic) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl and preferably 1-methyl-1,3-diazol-4-yl; -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl) or C₆-C₁₂-aryl     optionally substituted with halogen (e.g. phenyl, 2-Br-phenyl, or     4-F-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶ or >N—; -   R⁶ is hydrogen or hydroxy; -   R^(7e), R^(7f)     -   are hydrogen; -   n3 is 1; -   R¹² is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. phenyl, 3-Cl-phenyl, or 3-Br-phenyl), or     C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     C₁-C₄-alkyl and halogenated C₁-C₄-alkyl (e.g. 4-CF₃-pyrid-2-yl or     1-propyl-1,2,3-triazol-4-yl); and -   R^(5a), R^(5b)     -   are hydrogen or together with the carbon atom to which they are         bound may form a C═O.

According to a further embodiment, R⁴ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-Cl-phenyl, or 2-Cl-phenyl).

In connection with R⁴ being optionally substituted C₆-C₁₂-aryl, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

R^(2a), R^(2b)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1     methyl-5-Cl-1,3-diazol-4-yl, 1-Me-1,2,3-triazol-4-yl,     2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   R⁴ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-Cl-phenyl,     or 2-Cl-phenyl); -   Y¹ is >CR⁶; -   R⁶ is hydrogen; and -   R^(5a), R^(5b) are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl, substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkylcarbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituents on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl).

Further preferred embodiments of the pyrrolidine derivatives wherein R⁴ is optionally substituted C₆-C₁₂-aryl result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl and preferably 1-methyl-1,3-diazol-4-yl; -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with halogen (e.g.     phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   R⁴ is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. phenyl, 4-Cl-phenyl, or 2-Cl-phenyl); -   Y¹ is >CR⁶; -   R⁶ is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Id):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(8a) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, n-propyl,     iso-propyl, pentyl, or hexyl), or C₁-C₆-alkylcarbonyl (e.g.     methylcarbonyl), or -   R⁶, R^(8a)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O (e.g. —C(O)OCH₂—); -   R^(9a), R^(9b)     -   are independently hydrogen, halogen (e.g. F, Cl, or Br),         C₁-C₆-alkyl (e.g. methyl, ethyl, tert-butyl, or         2,3-dimethyl-propyl), hydroxy, or C₁-C₆-alkoxy (e.g. methoxy or         ethoxy); -   n4 is 0, 1, 2, 3, or 4; and -   R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl,     tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or     —CF₂Me), (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl     (e.g. cyclopropyl-methyl or cyclohexyl-methyl),     C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl), optionally     substituted C₃-C₁₂-cycloalkyl (e.g. cyclopropyl,     2-propyl-cyclopropyl, 1-(methoxy-methyl)-cyclopropyl,     2-phenyl-cyclopropyl, cyclopentyl, cyclopentyl,     3,3-dimethylcyclopentyl, cyclohexyl, 3,3-dimethyl-cyclohexyl,     4,4-dimethyl-cyclohexyl, 1-methyl-cyclohexyl, 1-CF₃-cyclopropyl,     4-CF₃-cyclohexyl, 3-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl),     C₂-C₆-alkenyl (e.g. hex-2-enyl), optionally substituted     C₃-C₆-cycloalkenyl (e.g. 1,3,3-trimethylcyclohexen-2-yl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 4-F-phenyl,     3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl,     2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl,     2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl,     3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl,     3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl,     3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃-phenyl,     3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl,     3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl,     3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl,     2-OCHF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl,     3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl,     2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl,     3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl,     3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl,     2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl,     3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl,     3-MeSO₂-phenyl, 3-(piperidin-4-yl)phenyl,     2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl,     3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl,     3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, 2-chlor-indan-5-yl, or     tetralin-6-yl), hydroxy, C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or     n-propyloxy), C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy),     optionally substituted C₆-C₁₂-aryloxy (e.g. 4-F-phenoxy or     4-tertbutyl-phenoxy), optionally substituted C₃-C₁₂-heterocyclyloxy     (e.g. pyridin-2-yloxy), optionally substituted C₃-C₁₂-heterocyclyl     (e.g. propyl-furan-2-yl, 2-CF₃-furan-5-yl,     1,2-dimethyl-5-CN-pyrrol-3-yl, 2,3-diMe-thiophen-5-yl,     2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl, 3-Cl-thiophen-2-yl,     2,5-diCl-thiophen-3-yl, 2-tetrahydropyranyl-thiophen-5-yl,     1,3-thiazol-5-yl, 4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl,     5-Me-1,3-thiazol-2-yl, 4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl,     4-iso-propyl-1,3-thiazol-2-yl, 2,4-diMe-1,3-thiazol-5-yl,     2-phenyl-4-Me-1,3-thiazol-5-yl, 4-phenyl-1,3-thiazol-5-yl,     2-(4-Me-phenyl)-1,3-thiazol-5-yl, 4-(4-F-phenyl)-1,3-thiazol-2-yl,     2-Cl-1,3-thiazol-4-yl, 4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl,     4-Br-1,3-thiazol-2-yl, 4-Me-5-Br-1,3-thiazol-2-yl,     2,4-dichloro-1,3-thiazol-5-yl, 1,5-dimethyl-1,2,4-triazol-3-yl,     pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 4-F-pyrid-2-yl, 5-F-pyrid-2-yl,     6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl, 5-F-pyrid-3-yl, 2-F-pyrid-4-yl,     3,5-diCl-pyrid-4-yl, 4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl,     5-Me-pyrid-2-yl, 4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl,     4-CF₃-pyrid-2-yl, 5-CF₃-pyrid-2-yl, 6-CF₃-pyrid-2-yl,     5-CF₃-pyrid-3-yl, 2-yl 3,5-diF-4-CF₃-pyrid-2-yl,     4-OCH₂CF₃-pyrid-2-yl, 4-OCH₂CF₃-5-F-pyrid-2-yl,     4-OCH₂CF₃-5-Cl-pyrid-2-yl, 4-OBn-5-F-pyrid-2-yl,     3-(4-F-phenyl)-pyrid-5-yl, 2-(4-F-phenyl)-pyrid-3-yl,     4-(pyrid-4-yl)-pyrid-2-yl, 4-(pyrid-3-yl)-pyrid-2-yl,     5-cyclopropyl-pyraz-2-yl, 5-cyclobutyl-pyraz-2-yl,     5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl, 4-CF₃-pyridaz-3-yl,     5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl, 6-Cl-pyrimid-4-yl,     6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl, 6-Pr-pyrimid-4-yl,     6-iPr-pyrimid-4-yl, 4-CF₃-pyrimid-2-yl, 6-CF₃-pyrimid-4-yl,     2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl,     2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl,     6-OEt-pyrimid-4-yl, 6-OPr-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl,     6-OiBu-pyrimid-4-yl, 6-OBu-pyrimid-4-yl, 6-OBn-pyrimid-4-yl,     6-cyclobutyloxy-pyrimid-4-yl, 6-cyclopentyloxy-pyrimid-4-yl,     6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl,     6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl,     6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)-pyrimid-4-yl,     6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)-pyrimid-4-yl,     6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl,     6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)-pyrimid-4-yl,     2-(morpholin-1-yl)-pyrimid-4-yl,     6-(azetidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl,     2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl,     benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl,     3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl,     isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl,     4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl,     2,3-dihydrobenzofuran-5-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl,     pyrazolo[1,5-a]pyridine-3-yl, pyrazolo[1,5-a]pyridine-7-yl,     5-methyl-imidazo[1,2-a]pyridin-8-yl,     5-methyl-imidazo[1,2-a]pyridine-3-yl,     6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl,     6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl,     thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl,     chroman-6-yl, 4,4-dimethylchroman-6-yl,     4,4-dimethyl-1,3-dioxan-2-yl, 2-Me-tetrahydrofuran-3-yl,     tetrahydrofuran-3-yl, tetrahydropyran-4-yl,     4-Me-tetrahydropyran-4-yl, 2,2-diMe-tetrahydropyran-4-yl,     1-iso-propyl-piperidin-4-yl, 1-ethyl-piperidin-3-yl, or     2-CF₃-piperazin-5-yl), or tri(C₁-C₄-alkyl)-silyloxy.

In particular, R^(9a), R^(9b) are independently hydrogen, halogen, C₁-C₆-alkyl (e.g. methyl, ethyl, tert-butyl, or 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g. methoxy).

In particular, R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl, tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or —CF₂Me), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl), optionally substituted C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, 2-propyl-cyclopropyl, 1-(methoxymethyl)-cyclopropyl, 2-phenyl-cyclopropyl, cyclopentyl, cyclopentyl, 3,3-dimethylcyclopentyl, cyclohexyl, 3,3-dimethyl-cyclohexyl, 4,4-dimethyl-cyclohexyl, 1-methyl-cyclohexyl, 1-CF₃-cyclopropyl, 4-CF₃-cyclohexyl, 3-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl), C₂-C₆-alkenyl (e.g. hex-2-enyl), optionally substituted C₃-C₆-cycloalkenyl (e.g. 1,3,3-trimethylcyclohexen-2-yl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 4-F-phenyl, 3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl, 2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl, 3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl, 3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl, 3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃ phenyl, 3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl, 3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl, 3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl, 2-OCF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, 3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl, 2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl, 3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl, 3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl, 2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl, 3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl, 3-MeSO₂-phenyl, 3-(piperidin-4-yl)-phenyl, 2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl, 3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl, 3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, 2-chlor-indan-5-yl, or tetralin-6-yl), C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or n-propyloxy), C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy), optionally substituted C₆-C₁₂-aryloxy (e.g. 4-F-phenoxy or 4-tert-butyl-phenoxy), optionally substituted C₃-C₁₂-heterocyclyl (e.g. e.g. n-propyl-furan-2-yl, 2-CF₃-furan-5-yl, 1,2-dimethyl-5-CN-pyrrol-3-yl, 2,3-diMe-thiophen-5-yl, 2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl, 3-Cl-thiophen-2-yl, 2,5-diCl-thiophen-3-yl, 2-tetrahydropyranyl-thiophen-5-yl, 1,3-thiazol-5-yl, 4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl, 5-Me-1,3-thiazol-2-yl, 4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl, 4-iso-propyl-1,3-thiazol-2-yl, 2,4-diMe-1,3-thiazol-5-yl, 2-phenyl-4-Me-1,3-thiazol-5-yl, 4-phenyl-1,3-thiazol-5-yl, 2-(4-Me-phenyl)-1,3-thiazol-5-yl, 4-(4-F-phenyl)-1,3-thiazol-2-yl, 2-Cl-1,3-thiazol-4-yl, 4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl, 4-Br-1,3-thiazol-2-yl, 4-Me-5-Br-1,3-thiazol-2-yl, 2,4-dichloro-1,3-thiazol-5-yl, 1,5-dimethyl-1,2,4-triazol-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 4-F-pyrid-2-yl, 5-F-pyrid-2-yl, 6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl, 5-F-pyrid-3-yl, 2-F-pyrid-4-yl, 3,5-diCl-pyrid-4-yl, 4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl, 5-Me-pyrid-2-yl, 4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl, 4-CF₃-pyrid-2-yl, 5-CF₃ pyrid-2-yl, 6-CF₃-pyrid-2-yl, 5-CF₃-pyrid-3-yl, 2-CF₃-pyrid-4-yl, 3-F-4-CF₃-pyrid-2-yl, 4-CF₃-5-F-pyrid-2-yl, 4-CF₃-5-Cl-pyrid-2-yl, 3,5-diF-4-CF₃-pyrid-2-yl, 4-OCH₂CF₃-pyrid-2-yl, 4-OCH₂CF₃-5-F-pyrid-2-yl, 4-OCH₂CF₃-5-Cl-pyrid-2-yl, 4-OBn-5-F-pyrid-2-yl, 3-(4-F-phenyl)-pyrid-5-yl, 2-(4-F-phenyl)-pyrid-3-yl, 4-(pyrid-4-yl)-pyrid-2-yl, 4-(pyrid-3-yl)-pyrid-2-yl, 5-cyclopropyl-pyraz-2-yl, 5-cyclobutyl-pyraz-2-yl, 5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl, 4-CF₃-pyridaz-3-yl, 5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl, 6-Cl-pyrimid-4-yl, 6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl, 6-Pr-pyrimid-4-yl, 6-iPr-pyrimid-4-yl, 4-CF₃-pyrimid-2-yl, 6-CF₃-pyrimid-4-yl, 2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl, 2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl, 6-OEt-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl, 6-OiBu-pyrimid-4-yl, 6-OBu-pyrimid-4-yl, 6-OBn-pyrimid-4-yl, 6-cyclobutyloxy-pyrimid-4-yl, 6-cyclopentyloxy-pyrimid-4-yl, 6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl, 6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl, 6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)-pyrimid-4-yl, 6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)-pyrimid-4-yl, 6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl, 6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)-pyrimid-4-yl, 6-(azetidin-3-yl-methoxy)pyrimid-4-yl, 6-(pyrrolidin-3-yl-methoxy)-pyrimid-4-yl, 6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl, 2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl, benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl, 3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl, isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, 2,3-dihydrobenzofuran-5-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl, pyrazolo[1,5-a]pyridine-3-yl, pyrazolo[1,5-a]pyridine-7-yl, 5-methyl-imidazo[1,2-a]pyridin-3-yl, 6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl, 6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl, thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl, chroman-6-yl, 4,4-dimethylchroman-6-yl, 4,4-dimethyl-1,3-dioxan-2-yl, 2-Me-tetrahydrofuran-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, 4-Me-tetrahydropyran-4-yl, 2,2-diMe-tetrahydropyran-4-yl, 1-isopropyl-piperidin-4-yl, 1-ethyl-piperidin-3-yl, or 2-CF₃-piperazin-5-yl), or tri-(C₁-C₄-alkyl)silyloxy.

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Id)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Id)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), hydroxy, C₁-C₆-alkoxy (e.g. methoxy, ethoxy, n-propoxy, iso-propoxy, or iso-butoxy), halogenated C₁-C₆-alkoxy (e.g OCF₃), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy (e.g. 2-(N-pyrrolidinyl)ethoxy, 2-(N-morpholinyl)ethoxy and 2-(N-imidazolyl)ethoxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), C₃-C₁₂-heterocyclyloxy (e.g. pyridin-2-yloxy), or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, or 1,3-oxazol-2-yl). Preferably, R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), hydroxy, C₁-C₆-alkoxy (e.g. methoxy, ethoxy, n-propoxy, iso-propoxy, or iso-butoxy), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy) or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, or 1,3-oxazol-2-yl).

R^(3b)—in the pyrrolidine derivatives of formula (Id)—is, in particular, hydrogen or hydroxy.

Y¹—in the pyrrolidine derivatives of formula (Id)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Id)—is, in particular, hydrogen, C₁-C₆-alkyl (e.g. methyl), or hydroxy-C₁-C₆-alkyl (e.g. —CH₂OH).

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Id)—are, in particular, hydrogen.

Particular embodiments of pyrrolidine derivatives of formula (Id) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g. e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl,     cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl     (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or     2,4,5-trifluoro-phenyl), hydroxy, C₁-C₆-alkoxy (e.g. methoxy,     ethoxy, n-propoxy, isopropoxy, or iso-butoxy),     C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or     cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or     2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy),     optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy)     or optionally substituted C₃-C₁₂-heterocyclyl (tetrahydrofuran-2-yl,     tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl,     1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl,     2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, or     1,3-oxazol-2-yl); -   R^(3b) is hydrogen or hydroxy; -   Y¹ is >CR⁶; -   R⁶ is hydrogen, C₁-C₆-alkyl, or hydroxy-C₁-C₆-alkyl (e.g. —CH₂OH); -   R^(8a) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, n-propyl,     iso-propyl, pentyl, or hexyl), or C₁-C₆-alkylcarbonyl (e.g.     methylcarbonyl), or -   R⁶, R^(8a)     -   are together optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O e.g. —C(O)OCH₂—); -   R^(9a) is hydrogen, halogen (e.g. F), C₁-C₆-alkyl (e.g. methyl,     ethyl, tert-butyl, or 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g.     methoxy or ethoxy); -   R^(9b) is hydrogen; -   n4 is 0, 1, 2, 3, or 4; -   R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl,     tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or     —CF₂Me), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl), optionally     substituted C₃-C₁₂-cycloalkyl (e.g. cyclopropyl,     2-propyl-cyclopropyl, 1-(methoxymethyl)-cyclopropyl,     2-phenyl-cyclopropyl, cyclopentyl, cyclopentyl,     3,3-dimethylcyclopentyl, cyclohexyl, 3,3-dimethyl-cyclohexyl,     4,4-dimethyl-cyclohexyl, 1-methyl-cyclohexyl, 1-CF₃-cyclopropyl,     4-CF₃-cyclohexyl, 3-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl),     C₂-C₆-alkenyl (e.g. hex-2-enyl), optionally substituted     C₃-C₆-cycloalkenyl (e.g. 1,3,3-trimethylcyclohexen-2-yl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 4-F-phenyl,     3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl,     2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl,     2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl,     3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl,     3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl,     3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃-phenyl,     3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl,     3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl,     3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl,     2-OCHF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl,     3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl,     2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl,     3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl,     3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl,     2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl,     3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl,     3-MeSO₂-phenyl, 3-(piperidin-4-yl)phenyl,     2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl,     3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl,     3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, 2-chlor-indan-5-yl, or     tetralin-6-yl), C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or n-propoxy),     C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy), optionally     substituted C₆-C₁₂-aryloxy (e.g. 4-F-phenoxy or     4-tertbutyl-phenoxy), optionally substituted C₃-C₁₂-heterocyclyl     (e.g. e.g. n-propyl-furan-2-yl, 2-CF₃-furan-5-yl,     1,2-dimethyl-5-CN-pyrrol-3-yl, 2,3-diMe-thiophen-5-yl,     2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl, 3-Cl-thiophen-2-yl,     2,5-diCl-thiophen-3-yl, 2-tetrahydropyranyl-thiophen-5-yl,     1,3-thiazol-5-yl, 4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl,     5-Me-1,3-thiazol-2-yl, 4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl,     4-isopropyl-1,3-thiazol-2-yl, 2,4-diMe-1,3-thiazol-5-yl,     2-phenyl-4-Me-1,3-thiazol-5-yl, 4-phenyl-1,3-thiazol-5-yl,     2-(4-Me-phenyl)-1,3-thiazol-5-yl, 4-(4-F-phenyl)-1,3-thiazol-2-yl,     2-Cl-1,3-thiazol-4-yl, 4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl,     4-Br-1,3-thiazol-2-yl, 4-Me-5-Br-1,3-thiazol-2-yl,     2,4-dichloro-1,3-thiazol-5-yl, 1,5-dimethyl-1,2,4-triazol-3-yl,     pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 4-F-pyrid-2-yl, 5-F-pyrid-2-yl,     6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl, 5-F-pyrid-3-yl, 2-F-pyrid-4-yl,     3,5-diCl-pyrid-4-yl, 4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl,     5-Me-pyrid-2-yl, 4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl,     4-CF₃-pyrid-2-yl, 5-CF₃-pyrid-2-yl, 6-CF₃-pyrid-2-yl,     5-CF₃-pyrid-3-yl, 2-CF₃-pyrid-4-yl, 3-F-4-CF₃-pyrid-2-yl,     4-CF₃-5-F-pyrid-2-yl, 4-CF₃-5-Cl-pyrid-2-yl,     3,5-diF-4-CF₃-pyrid-2-yl, 4-OCH₂CF₃-pyrid-2-yl,     4-OCH₂CF₃-5-F-pyrid-2-yl, 4-OCH₂CF₃-5-Cl-pyrid-2-yl,     4-OBn-5-F-pyrid-2-yl, 3-(4-F-phenyl)-pyrid-5-yl,     2-(4-F-phenyl)-pyrid-3-yl, 4-(pyrid-4-yl)-pyrid-2-yl,     4-(pyrid-3-yl)pyrid-2-yl, 5-cyclopropyl-pyraz-2-yl,     5-cyclobutyl-pyraz-2-yl, 5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl,     4-CF₃-pyridaz-3-yl, 5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl,     6-Cl-pyrimid-4-yl, 6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl,     6-Pr-pyrimid-4-yl, 6-iPr-pyrimid-4-yl, 4-CF₃-pyrimid-2-yl,     6-CF₃-pyrimid-4-yl, 2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl,     2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl,     6-OEt-pyrimid-4-yl, 6-OPr-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl,     6-OiBu-pyrimid-4-yl, 6-OBu-pyrimid-4-yl, 6-OBn-pyrimid-4-yl,     6-cyclobutoxy-pyrimid-4-yl, 6-cyclopentoxy-pyrimid-4-yl,     6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl,     6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl,     6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)-pyrimid-4-yl,     6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)-pyrimid-4-yl,     6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl,     6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)-pyrimid-4-yl,     2-(morpholin-1-yl)-pyrimid-4-yl,     6-(azetidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl,     2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl,     benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl,     3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl,     isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl,     4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl,     2,3-dihydrobenzofuran-5-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl,     pyrazolo[1,5-a]pyridine-3-yl, pyrazolo[1,5-a]pyridine-7-yl,     5-methyl-imidazo[1,2-a]pyridin-3-yl,     6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl,     6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl,     thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl,     chroman-6-yl, 4,4-dimethylchroman-6-yl,     4,4-dimethyl-1,3-dioxan-2-yl, 2-Me-tetrahydrofuran-3-yl,     tetrahydrofuran-3-yl, tetrahydropyran-4-yl,     4-Me-tetrahydropyran-4-yl, 2,2-diMe-tetrahydropyran-4-yl,     1-isopropyl-piperidin-4-yl, 1-ethyl-piperidin-3-yl, or     2-CF₃-piperazin-5-yl), or tri-(C₁-C₄-alkyl)-silyloxy; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a particular embodiment, R¹—in the pyrrolidine derivatives of formula (Id)—is an optionally substituted 5-membered heterocyclic ring containing 1 or 2 N and 1 O (e.g. 5-methyl-1,2-oxazol-4-yl or 3,5-dimethyl-1,2-oxazol-4-yl). According to a further particular embodiment, R¹—in the pyrrolidine derivatives of formula (Id)—is an optionally substituted 5-membered heterocyclic ring containing 1 or 2 N and 1 S (e.g. 2,4-dimethyl-1,3-thiazol-5-yl, or 2-methylcarbonylamino-1,3-thiazol-5-yl). According to a further particular embodiment, R¹¹—in the pyrrolidine derivatives of formula (Id)—is an optionally substituted 5-membered heterocyclic ring containing 1, 2 or 3 N (e.g. 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl, or 1-Me-1,2,3-triazol-4-yl).

Preferably, R¹—in the pyrrolidine derivatives of formula (Id)—is an optionally substituted 5-membered heterocyclic ring containing 2 N and, in particular, R¹ is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Id)—is an optionally substituted 5-membered heterocyclic ring containing 3 N and, in particular, R¹ is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Id), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxycarbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl. According to a further particular embodiment, 1,2,3-triazolyl is substituted with C₁-C₆-alkyl as described herein. According to a further specific embodiment, R¹ is 1-methyl-1,2,3-triazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Id), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Id), substituted C₆-C₁₂-aryloxy in particular includes is C₆-C₁₂-aryloxy, such as phenoxy, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Id), substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, piperidinyl, isoxazolyl, diazolyl, tetrahydrofuranyl, tetrahydropyranyl, or morpholinyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl or C₃-C₆-cycloalkyl.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Id)—is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, or cyclohexyl), C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl), or hydroxy, C₁-C₆-alkoxy (e.g. methoxy, or iso-butoxy), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), C₆-C₁₂-aryloxy (e.g. 4-F-phenoxy) optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, or C₃-C₁₂-heterocyclyl, in particular tetrahydrofuranyl or tetrahydropyranyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₃-C₆-cycloalkyl (tetrahydropyran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl, 2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, or 1,3-oxazol-2-yl).

According to a preferred embodiment, R^(9a), R^(9b)—in the pyrrolidine derivatives of formula (Id)—are independently hydrogen, halogen (e.g. F), C₁-C₆-alkyl (e.g. methyl, ethyl, tert-butyl, or 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g. methoxy).

More preferably, R^(9a) is hydrogen, halogen (e.g. F), C₁-C₆-alkyl (e.g. methyl, ethyl, tert-butyl, or 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g. methoxy) and R^(9b) is hydrogen.

In connection with R¹³, substituted C₃-C₁₂-cycloalkyl in particular includes C₃-C₁₂-cycloalkyl, such as cyclopropyl, cyclopentyl, or cyclohexyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₆-C₁₂-aryl.

In connection with R¹³, substituted C₃-C₆-cycloalkenyl in particular includes C₃-C₆-cycloalkenyl, such as cyclohexenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₄-alkyl.

In connection with R¹³, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), CN, C₆-C₁₂-aryl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy, C₁-C₄-alkyl-sulfonyl, C₁-C₄-alkyl-carbonylamino and C₃-C₁₂-heterocyclyl.

In connection with R¹³, substituted C₆-C₁₂-aryloxy in particular includes C₆-C₁₂-aryloxy, such as phenoxy, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl.

In connection with R¹³, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as furanyl, pyrrolyl, thiophenyl, oxazolyl, diazolyl, thiazolyl, triazolyl, pyridyl pyrimidyl, pyrazyl, pyridazyl, benzofuranyl, benzothiophenyl, benzothiazolyl, quinolinyl or isoquinolinyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₆-C₁₂-aryl-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, hydroxy, CN, C₆-C₁₂-aryl optionally substituted with halogen and C₁-C₄-alkyl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₃-C₆-cycloalkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy and C₃-C₁₂-heterocyclyl.

According to a preferred embodiment, R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl, tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or —CF₂Me), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl), C₃-C₁₂-cycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₆-C₁₂-aryl (e.g. cyclopropyl, 2-propyl-cyclopropyl, 1-(methoxy-methyl)-cyclopropyl, 2-phenyl-cyclopropyl, cyclopentyl, 1-methyl-cyclohexyl, 1-CF₃-cyclopropyl, 4-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl), or C₂-C₆-alkenyl (e.g. hex-2-enyl), C₃-C₆-cycloalkenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₄-alkyl (e.g. 1,3,3-trimethylcyclohexen-2-yl), or C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), CN, C₆-C₁₂-aryl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy, C₁-C₄-alkyl-sulfonyl, C₁-C₄-alkyl-carbonylamino and C₃-C₁₂-heterocyclyl, (e.g. phenyl, 2-F-phenyl, 4-F-phenyl, 3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl, 2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl, 3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl, 3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl, 3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃-phenyl, 3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl, 3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl, 3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl, 2-OCHF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, 3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl, 2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl, 3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl, 3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl, 2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl, 3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl, 3-MeSO₂-phenyl, 3-(piperidin-4-yl)phenyl, 2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl, 3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl, 3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, 2-chlor-indan-5-yl, or tetralin-6-yl), or C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or n-propoxy), C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy), C₆-C₁₂-aryloxy optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl (e.g. 4-F-phenoxy or 4-tertbutyl-phenoxy), or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₆-C₁₂-aryl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, hydroxy, CN, C₆-C₁₂-aryl optionally substituted with halogen and C₁-C₄-alkyl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₃-C₆-cycloalkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy and C₃-C₁₂-heterocyclyl (e.g. propyl-furan-2-yl, 2-CF₃-furan-5-yl, 1,2-dimethyl-5-CN-pyrrol-3-yl, 2,3-diMe-thiophen-5-yl, 2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl, 3-Cl-thiophen-2-yl, 2,5-diCl-thiophen-3-yl, 2-tetrahydropyranyl-thiophen-5-yl, 1,3-thiazol-5-yl, 4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl, 5-Me-1,3-thiazol-2-yl, 4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl, 4-isopropyl-1,3-thiazol-2-yl, 2,4-diMe-1,3-thiazol-5-yl, 2-phenyl-4-Me-1,3-thiazol-5-yl, 4-phenyl-1,3-thiazol-5-yl, 2-(4-Me-phenyl)-1,3-thiazol-5-yl, 4-(4-F-phenyl)-1,3-thiazol-2-yl, 2-Cl-1,3-thiazol-4-yl, 4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl, 4-Br-1,3-thiazol-2-yl, 4-Me-5-Br-1,3-thiazol-2-yl, 2,4-dichloro-1,3-thiazol-5-yl, 1,5-dimethyl-1,2,4-triazol-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 4-F-pyrid-2-yl, 5-F-pyrid-2-yl, 6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl, 5-F-pyrid-3-yl, 2-F-pyrid-4-yl, 3,5-diCl-pyrid-4-yl, 4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl, 5-Me-pyrid-2-yl, 4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl, 4-CF₃-pyrid-2-yl, 5-CF₃-pyrid-2-yl, 6-CF₃-pyrid-2-yl, 5-CF₃-pyrid-3-yl, 2-CF₃-pyrid-4-yl, 3-F-4-CF₃-pyrid-2-yl, 4-CF₃-5-F-pyrid-2-yl, 4-CF₃-5-Cl-pyrid-2-yl, 3,5-diF-4-CF₃-pyrid-2-yl, 4-OCH₂CF₃-pyrid-2-yl, 4-OCH₂CF₃-5-F-pyrid-2-yl, 4-OCH₂CF₃-5-Cl-pyrid-2-yl, 4-OBn-5-F-pyrid-2-yl, 3-(4-F-phenyl)pyrid-5-yl, 2-(4-F-phenyl)-pyrid-3-yl, 4-(pyrid-4-yl)-pyrid-2-yl, 4-(pyrid-3-yl)-pyrid-2-yl, 5-cyclopropyl-pyraz-2-yl, 5-cyclobutyl-pyraz-2-yl, 5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl, 4-CF₃-pyridaz-3-yl, 5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl, 6-Cl-pyrimid-4-yl, 6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl, 6-Pr-pyrimid-4-yl, 6-iPr-pyrimid-4-yl, 4-CF₃-pyrimid-2-yl, 6-CF₃-pyrimid-4-yl, 2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl, 2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl, 6-OEt-pyrimid-4-yl, 6-OPr-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl, 6-OiBu-pyrimid-4-yl, 6-OBu-pyrimid-4-yl, 6-OBn-pyrimid-4-yl, 6-cyclobutyloxy-pyrimid-4-yl, 6-cyclopentyloxy-pyrimid-4-yl, 6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl, 6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl, 6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)pyrimid-4-yl, 6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)-pyrimid-4-yl, 6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl, 6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)-pyrimid-4-yl, 2-(morpholin-1-yl)-pyrimid-4-yl, 6-(azetidin-3-yl-methoxy)-pyrimid-4-yl, 6-(pyrrolidin-3-ylmethoxy)-pyrimid-4-yl, 6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl, 2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl, benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl, 3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl, isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, 2,3-dihydrobenzofuran-5-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl, pyrazolo[1,5-a]pyridine-3-yl, pyrazolo[1,5-a]pyridine-7-yl, 5-methyl-imidazo[1,2-a]pyridin-3-yl, 6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl, 6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl, thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl, chroman-6-yl, 4,4-dimethylchroman-6-yl, 4,4-dimethyl-1,3-dioxan-2-yl, 2-Me-tetrahydrofuran-3-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, 4-Me-tetrahydropyran-4-yl, 2,2-diMe-tetrahydropyran-4-yl, 1-isopropyl-piperidin-4-yl, 1-ethyl-piperidin-3-yl, or 2-CF₃-piperazin-5-yl), or tri-(C₁-C₄-alkyl)silyloxy.

Further preferred embodiments of the pyrrolidine derivatives of formula (Id) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl), or 1,2,3-triazolyl     optionally substituted with C₁-C₄-alkyl (e.g.     1-methyl-1,2,3-triazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, or cyclohexyl)     C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen (e.g.     phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, or 2,4,5-trifluoro-phenyl), or     hydroxy, C₁-C₆-alkoxy (e.g. methoxy, or iso-butoxy),     C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy),     C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy),     C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), C₆-C₁₂-aryloxy (e.g.     4-F-phenoxy) optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen, or     C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen or C₃-C₆-cycloalkyl (e.g. tetrahydrofuran-2-yl,     tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl,     1-cyclopropyl-piperidin-4-yl, 1-cyclopropyl-piperidin-3-yl,     2-pyridyl, 3-pyridyl, 3-F-pyrid-2-yl, 1,3-oxazol-4-yl, or     1,3-oxazol-2-yl); -   R^(3b) is hydrogen or hydroxy; -   Y¹ is >CR⁶; -   R⁶ is hydrogen, C₁-C₆-alkyl (e.g. methyl), or hydroxy-C₁-C₆-alkyl     (e.g. —CH₂OH); -   R^(8a) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, n-propyl,     iso-propyl, pentyl, or hexyl), or C₁-C₆-alkylcarbonyl (e.g.     methylcarbonyl), or -   R⁶, R^(8a)     -   are together optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O e.g. —C(O)OCH₂—); -   R^(9a) is hydrogen, halogen, C₁-C₆-alkyl (e.g. methyl, ethyl,     tert-butyl, or 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g. methoxy     or ethoxy); -   R^(9b) is hydrogen; -   n4 is 0, 1, 2, 3, or 4; -   R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl,     tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or     —CF₂Me), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl),     C₃-C₁₂-cycloalkyl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl and C₆-C₁₂-aryl (e.g. cyclopropyl,     2-propyl-cyclopropyl, 1-(methoxy-methyl)cyclopropyl,     2-phenyl-cyclopropyl, cyclopentyl, cyclopentyl,     3,3-dimethylcyclopentyl, cyclohexyl, 3,3-dimethyl-cyclohexyl,     4,4-dimethyl-cyclohexyl, 1-methyl-cyclohexyl, 1-CF₃-cyclopropyl,     4-CF₃-cyclohexyl, 3-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl), or     C₂-C₆-alkenyl (e.g. hex-2-enyl), C₃-C₆-cycloalkenyl optionally     substituted with 1, 2, or 3 substituents independently selected from     the group consisting of C₁-C₄-alkyl (e.g.     1,3,3-trimethylcyclohexen-2-yl), or C₆-C₁₂-aryl optionally     substituted with 1, 2, or 3 substituents independently selected from     the group consisting of halogen, C₁-C₄-alkyl, halogenated     C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), CN, C₆-C₁₂-aryl,     C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy,     C₆-C₁₂-aryloxy, C₁-C₄ alkyl sulfonyl, C₁-C₄-alkylcarbonylamino and     C₃-C₁₂-heterocyclyl, (e.g. phenyl, 2-F-phenyl, 4-F-phenyl,     3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl,     2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl,     2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl,     3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl,     3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl,     3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃-phenyl,     3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl,     3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl,     3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl,     2-OCHF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl,     3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl,     2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl,     3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl,     3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl,     2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl,     3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl,     3-MeSO₂-phenyl, 3-(piperidin-4-yl)-phenyl,     2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl,     3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl,     3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, 2-chlor-indan-5-yl, or     tetralin-6-yl), or C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or     n-propoxy), C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy),     C₆-C₁₂-aryloxy optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen and     C₁-C₄-alkyl (e.g. 4-F-phenoxy or 4-tertbutyl-phenoxy), or     C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl,     C₆-C₁₂-aryl-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, hydroxy, CN, C₆-C₁₂-aryl     optionally substituted with halogen and C₁-C₁-alkyl, C₁-C₄-alkoxy,     halogenated C₁-C₄-alkoxy, C₃-C₆-cycloalkoxy, C₆-C₁₂     aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy and     C₃-C₁₂-heterocyclyl (e.g. e.g. n-propyl-furan-2-yl,     2-CF₃-furan-5-yl, 1,2-dimethyl-5-CN-pyrrol-3-yl,     2,3-diMe-thiophen-5-yl, 2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl,     3-Cl-thiophen-2-yl, 2,5-diCl-thiophen-3-yl,     2-tetrahydropyranyl-thiophen-5-yl, 1,3-thiazol-5-yl,     4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl, 5-Me-1,3-thiazol-2-yl,     4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl,     4-isopropyl-1,3-thiazol-2-yl, 2,4-diMe-1,3-thiazol-5-yl,     2-phenyl-4-Me-1,3-thiazol-5-yl, 4-phenyl-1,3-thiazol-5-yl,     2-(4-Me-phenyl)-1,3-thiazol-5-yl, 4-(4-F-phenyl)-1,3-thiazol-2-yl,     2-Cl-1,3-thiazol-4-yl, 4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl,     4-Br-1,3-thiazol-2-yl, 4-Me-5-Br-1,3-thiazol-2-yl,     2,4-dichloro-1,3-thiazol-5-yl, 1,5-dimethyl-1,2,4-triazol-3-yl,     pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 4-F-pyrid-2-yl, 5-F-pyrid-2-yl,     6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl, 5-F-pyrid-3-yl, 2-F-pyrid-4-yl,     3,5-diCl-pyrid-4-yl, 4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl,     5-Me-pyrid-2-yl, 4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl,     4-CF₃-pyrid-2-yl, 5-CF₃-pyrid-2-yl, 6-CF₃-pyrid-2-yl,     5-CF₃-pyrid-3-yl, 2-CF₃-pyrid-4-yl, 3-F-4-CF₃-pyrid-2-yl,     4-CF₃-5-F-pyrid-2-yl, 4-CF₃-5-Cl-pyrid-2-yl,     3,5-diF-4-CF₃-pyrid-2-yl, 4-OCH₂CF₃-pyrid-2-yl,     4-OCH₂CF₃-5-F-pyrid-2-yl, 4-OCH₂CF₃-5-Cl-pyrid-2-yl,     4-OBn-5-F-pyrid-2-yl, 3-(4-F-phenyl)-pyrid-5-yl,     2-(4-F-phenyl)-pyrid-3-yl, 4-(pyrid-4-yl)pyrid-2-yl,     4-(pyrid-3-yl)-pyrid-2-yl, 5-cyclopropyl-pyraz-2-yl,     5-cyclobutyl-pyraz-2-yl, 5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl,     4-CF₃-pyridaz-3-yl, 5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl,     6-Cl-pyrimid-4-yl, 6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl,     6-Pr-pyrimid-4-yl, 6-iPr-pyrimid-4-yl, 4-CF₃-pyrimid-2-yl,     6-CF₃-pyrimid-4-yl, 2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl,     2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl,     6-OEt-pyrimid-4-yl, 6-OPr-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl,     6-OiBu-pyrimid-4-yl, 6-6-OBn-pyrimid-4-yl,     6-cyclobutyloxy-pyrimid-4-yl, 6-cyclopentyloxy-pyrimid-4-yl,     6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl,     6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl,     6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)pyrimid-4-yl,     6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)-pyrimid-4-yl,     6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl,     6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)pyrimid-4-yl,     2-(morpholin-1-yl)-pyrimid-4-yl,     6-(azetidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl,     2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl,     benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl,     3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl,     isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl,     4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl,     2,3-dihydrobenzofuran-5-yl, 7H-pyrrolo[2,3-d]pyrimidin-4-yl,     pyrazolo[1,5-a]pyridine-3-yl, pyrazolo[1,5-a]pyridine-7-yl,     5-methyl-imidazo[1,2-a]pyridin-3-yl,     6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl,     6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl,     thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl,     chroman-6-yl, 4,4-dimethylchroman-6-yl,     4,4-dimethyl-1,3-dioxan-2-yl, 2-Me-tetrahydrofuran-3-yl,     tetrahydrofuran-3-yl, tetrahydropyran-4-yl,     4-Me-tetrahydropyran-4-yl, 2,2-diMe-tetrahydropyran-4-yl,     1-isopropyl-piperidin-4-yl, 1-ethyl-piperidin-3-yl, or     2-CF₃-piperazin-5-yl), or tri-(C₁-C₄-alkyl)-silyloxy; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a particularly preferred embodiment of the pyrrolidine derivatives of the formula (Id), R^(3a) is phenyl, 4-F-phenyl, tetrahydrofuran-2-yl or tetrahydropyran-2-yl.

According to a further particularly preferred embodiment of the pyrrolidine derivatives of the formula (Id), R¹³ is a group of the formula (Id1):

-   -   wherein     -   X is >CH— or >N—;     -   Z is >C—R^(13c) or >N—;     -   R^(13b) is halogen (e.g. fluoro or chloro), C₁-C₄-alkyl (e.g.         methyl, ethyl, n-propyl, iso-propyl, tert-butyl), halogenated         C₁-C₄-alkyl (e.g. CHF₂, CF₃), hydroxy-(halogenated C₁-C₄-alkyl)         (e.g. 1-OH-1-CF₃-Et), C₆-C₁₂-aryl-C₁-C₄-alkyl (e.g. benzyl),         C₃-C₆-cycloalkyl (e.g. cyclopropyl), CN, C₆-C₁₂-aryl optionally         substituted with halogen or C₁-C₄-alkyl (e.g. phenyl,         2-F-phenyl, 4-F-phenyl, 3-F-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,         2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl), C₁-C₄-alkoxy (e.g.         methoxy, ethoxy, n-propoxy, iso-propoxy), halogenated         C₁-C₄-alkoxy (e.g. —OCHF₂, —OCH₂CF₃, —OCF₃), C₃-C₆-cycloalkoxy         (e.g. cyclobutoxy, cyclopentyloxy, cyclohexyloxy), C₆-C₁₂         aryl-C₁-C₄-alkoxy (e.g. benzyloxy),         C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy (e.g. pyrrolid-3-yl-methoxy,         pyrrolid-2-yl-methoxy, azetid-3-yl-methoxy), C₆-C₁₂-aryloxy         (e.g. phenoxy), C₁-C₄-alkyl-sulfonyl (e.g. methylsulfonyl),         C₁-C₄-alkyl-carbonylamino (e.g. 2-methylcarbonylamino) or         C₃-C₁₂-heterocyclyl (e.g. piperidin-4-yl, pyrid-2-yl,         pyrid-3-yl, pyrid-4-yl, pyrimid-5-yl); and     -   R^(13c) is hydrogen or halogen (e.g. fluoro, chloro).

Especially preferred among the pyrrolidine derivatives of the formula (Id) wherein R¹³ is a group of the formula (Id1) are those wherein X is >CH— or >N—, and Z is >C—R^(13c). According this embodiment it is particularly preferred if X is >CH—, Z is >C—R^(13c) and R^(13c) is hydrogen or fluoro, especially fluoro, or X is >N—, Z is >C—R^(13c) and R^(13c) is hydrogen or fluoro, especially fluoro.

In the pyrrolidine derivatives of the formula (Id) wherein R¹³ is a group of the formula (Id1), R^(8a), n4, R^(9a) and R^(9b) are as defined herein. Preferably, R^(8a) is hydrogen n4 is, in particular, 0 or 1, with n4=0 being particularly preferred. R^(9a) and R^(9b) are preferably both hydrogen if n4 is 1.

According to a further embodiment, R⁴ is —NR^(8b)COR¹⁴. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ie):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(8b) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, iso-propyl, or     n-butyl), or C₁-C₆ alkylcarbonyl (e.g. methylcarbonyl), or -   R⁶, R^(8b)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O; and -   R¹⁴ is C₁-C₈-alkyl (e.g. pentyl, n-butyl, or hexyl), halogenated     C₁-C₆-alkyl (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl,     1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl),     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl),     hydroxy-C₁-C₆-alkyl (e.g. hydroxyl-methyl or 1-hydroxy-pentyl),     C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl, ethoxy-methyl, or     ethoxy-ethyl), (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl     (e.g. phenoxy-methyl or (4-F-phenoxy)-methyl),     C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or     3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g.     3-methoxycarbonyl-propyl), C₁-C₆-alkylaminocarbonyl-C₁-C₄-alkyl     (e.g. 3-methylaminocarbonyl-propyl), optionally substituted     (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g. 2-pyridyl-methyl),     optionally substituted C₃-C₁₂-cycloalkyl (e.g. 1-CF₃-cyclopropyl or     4-CF₃-cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,     4-Cl-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 3,5-diCl-phenyl,     2-Cl-4-F-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl,     2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl,     2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-OMe-phenyl, 3-OMe-phenyl,     2-CN-phenyl, or 3-CN-phenyl, 4-CN-phenyl), or optionally substituted     C₃-C₁₂-heterocyclyl (e.g. 3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or     2-CF₃-pyrazin-5-yl).

In particular, R^(8b) is hydrogen.

In particular, R¹⁴ is C₁-C₈-alkyl (e.g. pentyl, n-butyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl, 1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl), hydroxy-C₁-C₆-alkyl (e.g. hydroxylmethyl or 1-hydroxy-pentyl), (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl (e.g. phenoxy-methyl or (4-F-phenoxy)-methyl), C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or 3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g. 3-methoxycarbonyl-propyl), optionally substituted C₃-C₁₂-cycloalkyl (e.g. 1-CF₃-cyclopropyl or 4-CF₃-cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 3,5-diCl-phenyl, 2-Cl-4-F-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-OMe-phenyl, 3-OMe-phenyl, 2-CN-phenyl, or 3-CN-phenyl, 4-CN-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or 2-CF₃-pyrazin-5-yl).

R^(2a), R^(2b)—in pyrrolidine derivatives of formula (Ie)—are hydrogen.

R^(3a)—in pyrrolidine derivatives of formula (Ie)—is C₃-C₁₂-cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenyloxy or 4-F-phenyloxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl).

R^(3b)—in pyrrolidine derivatives of formula (Ie)—is hydrogen or hydroxy. Preferably, R^(3b) is hydrogen.

Y¹—in pyrrolidine derivatives of formula (Ie)—is >CR⁶.

R⁶—in pyrrolidine derivatives of formula (Ie)—is hydrogen.

R^(5a), R^(5b)—in pyrrolidine derivatives of formula (Ie)—are hydrogen.

Particular embodiments of pyrrolidine derivatives of formula (Ie) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or     C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8b) is hydrogen; -   R¹⁴ is C₁-C₈-alkyl (e.g. pentyl, n-butyl, or hexyl), halogenated     C₁-C₆-alkyl (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl,     1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl),     hydroxy-C₁-C₆-alkyl (e.g. hydroxylmethyl or 1-hydroxy-pentyl),     (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl (e.g.     phenoxy-methyl or (4-F-phenoxy)-methyl),     C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or     3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g.     3-methoxycarbonyl-propyl), optionally substituted C₃-C₁₂-cycloalkyl     (e.g. 1-CF₃-cyclopropyl or 4-CF₃-cyclohexyl), optionally substituted     C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl,     2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diCl-phenyl,     2,4-diCl-phenyl, 3,5-diCl-phenyl, 2-Cl-4-F-phenyl, 2-Me-phenyl,     3-Me-phenyl, 4-Me-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl,     2-OMe-phenyl, 3-OMe-phenyl, 2-CN-phenyl, or 3-CN-phenyl,     4-CN-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or 2-CF₃-pyrazin-5-yl); and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ie)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ie)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ie), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ie), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ie)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkoxy (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or C₃-C₁₂-heterocyclyl (e.g. 2-pyridyl).

In connection with R¹⁴, substituted C₆-C₁₂-aryloxy-C₁-C₄-alkyl in particular includes C₆-C₁₂-aryloxy-C₁-C₄-alkyl, such as benzyloxy, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

In connection with R¹⁴, substituted C₃-C₁₂-cycloalkyl in particular includes C₃-C₁₂-cycloalkyl, such as cyclopropyl or cyclohexyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl.

In connection with R¹⁴, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and C₁-C₄-alkoxy. Preferably the substituents on C₆-C₁₂-aryl are independently selected from the group consisting of C₁-C₄-alkyl and CN.

In connection with R¹⁴, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridazyl or pyrazyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and halogenated C₁-C₄-alkyl.

According to a preferred embodiment, R¹⁴ is C₁-C₈-alkyl (e.g. pentyl, n-butyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl, 1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl), hydroxy-C₁-C₆-alkyl (e.g. hydroxyl-methyl or 1-hydroxy-pentyl), (halogenated C₆-C₁₂-aryloxy)-C₁-C₄-alkyl (e.g. 4-F-phenoxy)-methyl), C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or 3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g. 3-methoxycarbonyl-propyl), C₃-C₁₂-cycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl (e.g. 1-CF₃-cyclopropyl or 4-CF₃-cyclohexyl), C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and C₁-C₄-alkoxy (e.g. phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 3,5-diCl-phenyl, 2-Cl-4-F-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-OMe-phenyl, 3-OMe-phenyl, 2-CN-phenyl, 3-CN-phenyl, or 4-CN-phenyl), or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and halogenated C₁-C₄-alkyl (e.g. 3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or 2-CF₃-pyrazin-5-yl).

Further preferred embodiments of the pyrrolidine derivatives of formula (Ie) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen and C₁-C₄-alkoxy (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl,     3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl,     4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or C₃-C₁₂-heterocyclyl     (e.g. 2-pyridyl)yl; -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8b) is hydrogen; -   R¹⁴ is C₁-C₈-alkyl (e.g. pentyl or n-butyl), halogenated C₁-C₆-alkyl     (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl,     1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl),     hydroxy-C₁-C₆-alkyl (e.g. hydroxylmethyl or 1-hydroxy-pentyl),     (halogenated C₆-C₁₂-aryloxy)-C₁-C₄-alkyl (e.g. 4-F-phenoxy)methyl),     C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or     3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g.     3-methoxycarbonylpropyl), C₃-C₁₂-cycloalkyl optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogenated C₁-C₄-alkyl (e.g. 1-CF₃-cyclopropyl or     4-CF₃-cyclohexyl), C₆-C₁₂-aryl optionally substituted with 1, 2, or     3 substituents independently selected from the group consisting of     halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and C₁-C₄-alkoxy     (e.g. phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl,     3-Cl-phenyl, 4-Cl-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl,     3,5-diCl-phenyl, 2-Cl-4-F-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl,     2-OMe-phenyl, 3-OMe-phenyl, 2-CN-phenyl, or 3-CN-phenyl,     4-CN-phenyl), or C₃-C₁₂-heterocyclyl optionally substituted with 1,     2, or 3 substituents independently selected from the group     consisting of halogen and halogenated C₁-C₄-alkyl(e.g.     3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or 2-CF₃-pyrazin-5-yl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a particularly preferred embodiment, R^(3a) is phenyl, or halogenated phenyl (e.g. 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl), 4-OMe-phenyl, or pyrid-2-yl.

According to a further embodiment, R⁴ is —NR^(8c)COOR¹⁵. Thus, the present invention relates to the pyrrolidine derivatives of the formula (If):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(8c) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, iso-propyl, or     n-butyl), or C₁-C₆-alkylcarbonyl (e.g. methylcarbonyl), or -   R⁶, R^(8c)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O. Preferably R^(8c) is hydrogen; and -   R¹⁵ is C₁-C₈-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or     tert-butyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     4-F-phenyl, 2-Cl-4-F-phenyl or 2-Me-phenyl), or optionally     substituted C₃-C₁₂-heterocyclyl (e.g. 6-pyridazyl or 5-pyrazyl).

In particular, R¹⁵ is C₁-C₈-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or tert-butyl), or optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 2-Cl-4-F-phenyl or 2-Me-phenyl). Preferably, R¹⁵ is C₁-C₆-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or tert-butyl) or C₆-C₁₂-aryl (e.g. phenyl).

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (If)—are, in particular, hydrogen.

-   R^(3a)—in the pyrrolidine derivatives of formula (If)—is, in     particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl,     cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl     (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl,     2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or     2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g.     cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g.     allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g.     benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenyloxy or     4-F-phenyloxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably     R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4 Cl phenyl 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (If)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (If)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (If)—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (If)—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (If) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8c) is hydrogen; -   R¹⁵ is C₁-C₈-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or     tert-bu) or C₆-C₁₂-aryl (e.g. phenyl); and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (If)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (If)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (If), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (If), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a particular embodiment, R^(3a)—in the pyrrolidine derivatives of formula (If)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

Further preferred embodiments of pyrrolidine derivatives of formula (If) result if:

-   R¹ is 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl (e.g.     1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. phenyl, or 4-F-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8c) is hydrogen; -   R¹⁵ is C₁-C₈-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or     tert-butyl) or C₆-C₁₂-aryl (e.g. phenyl); and -   R^(5a), R^(5b)     -   are hydrogen;

According to a further embodiment, R⁴ is —NR^(8d)CONR^(16a)R^(16b). Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ig):

wherein R¹, R^(2a)R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(8d) is hydrogen, C₁-C₆-alkyl (e.g. methyl, ethyl, iso-propyl, or     n-butyl), or C₁-C₆-alkylcarbonyl (e.g. methylcarbonyl), or -   R⁶, R^(8d)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O; -   R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g.     benzyl or (2-Cl-phenyl)-methyl), optionally substituted     (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g. 2-pyridyl-methyl),     optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl,     3-F-phenyl, 2F-phenyl, 4-Cl-phenyl, or 2-Cl-phenyl), or optionally     substituted C₃-C₁₂-heterocyclyl (2-pyridyl, 5-pyrazyl, or     6-pyridazyl); and -   R^(16b) is hydrogen or C₁-C₆-alkyl (e.g. methyl, ethyl, iso-propyl,     or n-butyl).

In particular, R^(8d) is hydrogen.

In particular, R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl or (2-Cl-phenyl)methyl) or optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-F-phenyl, 2F-phenyl, 4-Cl-phenyl, or 2-Cl-phenyl).

In particular, R^(16b) is hydrogen.

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Ig)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Ig)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₃-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₃-C₁₂-aryloxy (e.g. phenyloxy or 4-F-phenyloxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Ig)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ig)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ig)—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Ig)—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (If) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8d) is hydrogen; -   R^(16a) is (optionally substituted C₃-C₁₂-aryl)-C₁-C₄-alkyl (e.g.     benzyl or (2-Cl-phenyl)-methyl) or optionally substituted     C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-F-phenyl, 2F-phenyl,     4-Cl-phenyl, or 2-Cl-phenyl); -   R^(16b) is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ig)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ig)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ig), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ig), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ig)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. 4-F-phenyl).

In connection with R^(16a), substituted C₆-C₁₂-aryl-C₁-C₄-alkyl in particular includes C₃-C₁₂-aryl-C₁-C₄-alkyl, such as benzyl, wherein C₆-C₁₂-aryl, such as phenyl, is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

In connection with R^(16a), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(16a) is C₆-C₁₂-aryl-C₁-C₄-alkyl or C₆-C₁₂-aryl, with C₆-C₁₂-aryl being optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. benzyl or (2-Cl-phenyl)-methyl and phenyl, 4-F-phenyl, 3-F-phenyl, 2F-phenyl, 4-Cl-phenyl, or 2-Cl-phenyl).

Preferred embodiments of the pyrrolidine derivatives of formula (Ig) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R²⁶     -   are hydrogen; -   R^(3a) is C₆-C₁₂ aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. 4-F-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(8d) is hydrogen; -   R^(16a) is C₆-C₁₂-aryl-C₁-C₄-alkyl or C₆-C₁₂-aryl, with C₆-C₁₂-aryl     being optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen (e.g.     benzyl or (2-Cl-phenyl)-methyl and phenyl, 4-F-phenyl, 3-F-phenyl,     2F-phenyl, 4-Cl-phenyl, or 2-Cl-phenyl); -   R^(16b) is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —O(CR^(9e)R^(9d))_(n5)R¹⁸. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ih):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(9c), R^(9d)     -   are independently hydrogen, halogen (e.g. F), or C₁-C₆-alkyl         (e.g. methyl or ethyl); -   n5 is 0, 1, 2, 3, or 4; and -   R¹⁸ is hydrogen, optionally substituted C₁-C₈-alkyl (e.g. methyl,     ethyl, iso-propyl or pentyl), optionally substituted     C₃-C₁₂-cycloalkyl (e.g. cyclopropyl or cyclohexyl),     C₁-C₆-alkylcarbonyl (e.g. methylcarbonyl), C₁-C₆-alkoxycarbonyl     (e.g. methoxycarbonyl or n-butoxycarbonyl), halogenated     C₁-C₆-alkoxycarbonyl (e.g. —C(O)OCF₃), C₆-C₁₂-aryloxycarbonyl (e.g.     phenoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g.     n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated     C₁-C₄-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl),     C₆-C₁₂-arylaminocarbonyl (e.g. phenylaminocarbonyl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl, 4-F-phenyl,     4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl), C₁-C₆-alkylamine     (e.g. n-propylamine), (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino (e.g.     cyclopropylmethyl-amino), (halogenated C₁-C₆-alkyl)amino (e.g.     2,2,2-triF-ethylamine), (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino (e.g.     2-methoxyethylamine), (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino (e.g.     benzylamine), C₁-C₆-dialkylamine (e.g. dimethylamino), optionally     substituted C₆-C₁₂-arylamino (e.g. 4-Cl-phenylamine), or optionally     substituted C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl or     6-CF₃-pyrimid-4-yl).

In particular, R^(9c), R^(9d) are hydrogen.

In particular, n5 is 0, 1, or 2.

In particular, R¹⁸ is hydrogen, optionally substituted C₁-C₈-alkyl (e.g. methyl, ethyl, isopropyl, or pentyl), C₁-C₆-alkoxycarbonyl (e.g. methoxycarbonyl or n-butoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g. n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated C₁-C₆-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl, 4-F-phenyl, 4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl), C₁-C₆-alkylamine (e.g. n-propylamine), (halogenated C₁-C₆-alkyl)amino (e.g. 2,2,2-triF-ethylamine), optionally substituted C₆-C₁₂-arylamine (e.g. 4-Cl-phenylamine), or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl or 6-CF₃-pyrimid-4-yl).

R^(2a), R^(2b) in pyrrolidine derivatives of formula (Ih) are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Ih)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1-yl, 3-Me-piperidin-1-yl, 4-Me-piperidin-1-yl, 4-F-piperidin-1-yl, 4,4-diF-piperidin-1-yl, or azepan-1-yl).

R^(3b)—in the pyrrolidine derivatives of formula (Ih)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ih)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ih)—is, in particular, hydrogen or C₆-C₁₂-aryl-C₁-C₄-alkyl (e.g. benzyl). According to a particular embodiment, R⁶ is hydrogen or benzyl. Preferably, R⁶ is hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Ih)—are, in particular, hydrogen.

Particular embodiments of pyrrolidine derivatives of formula (Ih) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), or     optionally substituted C₃-C₁₂-heterocyclyl (e.g. 3-F-azetidin-1-yl,     morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1yl,     3-Me-piperidin-1yl, 4-Me-piperidin-1yl, 4-F-piperidin-1-yl,     4,4-diF-piperidin-1yl, or azepan-1-yl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(9c), R^(9d)     -   are hydrogen; -   n5 is 0, 1, or 2; -   R¹⁸ is hydrogen, optionally substituted C₁-C₈-alkyl (e.g. methyl,     ethyl, iso-propyl, or pentyl), C₁-C₆-alkoxycarbonyl (e.g.     methoxycarbonyl or butoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g.     n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated     C₁-C₄-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl),     optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl),     C₁-C₆-alkylamine (e.g. n-propylamine), (halogenated     C₁-C₆-alkyl)amino (e.g. 2,2,2-triF-ethylamine), optionally     substituted C₆-C₁₂-arylamine (e.g. 4-Cl-phenylamine), or optionally     substituted C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl or     6-CF₃-pyrimid-4-yl); and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ih)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ih)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ih), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ih), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ih), substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, or azepanyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₃-C₁₂-heterocyclyl are independently selected from the group consisting of halogen and C₁-C₄-alkyl.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ih)—is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. 4-F-phenyl), or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl (e.g. 3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 2-Me-piperidin-1yl, 3-Me-piperidin-1yl, 4-Me-piperidin-1yl, 4-F-piperidin-1-yl, 4,4-diF-piperidin-1yl, or azepan-1-yl).

In connection with R¹⁸, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkyl-sulfonyl.

In connection with R¹⁸, substituted C₆-C₁₂-arylamine in particular includes C₆-C₁₂-arylamine, such as phenylamine, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen.

In connection with R¹⁸, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as 2-pyridyl or 4-pyrimidyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl.

According to a preferred embodiment, R¹⁸ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, iso-propyl, or pentyl), C₁-C₆-alkoxycarbonyl (e.g. methoxycarbonyl or n-butoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g. n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated C₁-C₄-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl), C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkyl-sulfonyl (e.g. phenyl, 3-F-phenyl, 4-F-phenyl, 4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl), or C₁-C₆-alkylamine (e.g. n-propylamine), (halogenated C₁-C₆-alkyl)amino (e.g. 2,2,2-triF-ethylamine), C₆-C₁₂-arylamine optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. 4-Cl-phenylamine), or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl (e.g. 4-CF₃-pyrid-2-yl or 6-CF₃-pyrimid-4-yl).

Further preferred embodiments of the pyrrolidine derivatives of formula (Ih) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. 4-F-phenyl), or C₃-C₁₂-heterocyclyl optionally     substituted with 1, 2, or 3 substituents independently selected from     the group consisting of halogen and C₁-C₄-alkyl (e.g.     3-F-azetidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperidin-1-yl,     2-Me-piperidin-1yl, 3-Me-piperidin-1yl, 4-Me-piperidin-1yl,     4-F-piperidin-1-yl, 4,4-diF-piperidin-1-yl, or azepan-1-yl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(9c), R^(9d)     -   are hydrogen; -   n5 is 0, 1, or 2; -   R¹⁸ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, iso-propyl, or     pentyl), C₁-C₆-alkoxycarbonyl (e.g. methoxycarbonyl or     n-butoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g.     n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated     C₁-C₄-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl),     C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen,     C₁-C₄-alkyl and C₁-C₄-alkyl-sulfonyl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl), or     C₁-C₆-alkylamine (e.g. n-propylamine), (halogenated     C₁-C₆-alkyl)amino (e.g. 2,2,2-triF-ethylamine), C₆-C₁₂-arylamine     optionally substituted with 1, 2, or 3 substituents independently     selected from the group consisting of halogen (e.g.     4-Cl-phenylamine), or C₃-C₁₂-heterocyclyl optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogenated C₁-C₄-alkyl (e.g. 4-CF₃-pyrid-2-yl or     6-CF₃-pyrimid-4-yl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —COR¹⁹. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Ii):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(6b) are as defined herein, and

-   R¹⁹ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl, 3,4-diCl-phenyl,     3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Me-phenyl,     3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl) or optionally     substituted C₃-C₁₂-heterocyclyl (e.g. 2-pyridyl or 6-pyrimidyl).

In particular, R¹⁹ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl, 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl).

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Ii)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Ii)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Ii)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Ii)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Ii)—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Ii)—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (Ii) result if

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R¹⁹ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl, 3,4-diCl-phenyl,     3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Me-phenyl,     3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl); and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Ii)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Ii)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Ii), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Ii), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Ii)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. 4-F-phenyl).

In connection with R¹⁹, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy.

According to a preferred embodiment, R¹⁹ is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy (e.g phenyl, 3-F-phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl, 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl).

Further preferred embodiments of the pyrrolidine derivatives of formula (Ii) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. 4-F-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R¹⁹ C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen,     C₁-C₄-alkyl, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy     (e.g phenyl, 3-F-phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl,     3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl,     3-Me-phenyl, 3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further particular embodiment R⁴ is —CONR^(20a)R^(20b). Thus, the present invention relates to the pyrrolidine derivatives of the formula (II):

wherein R¹, R^(2a), R^(2b), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or     6-Me-heptyl), (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl     (e.g. cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g.     2-methoxy-ethyl, 2-ethoxy-ethyl, 2-isopropyloxy-ethyl,     1-methyl-2-methoxy-ethyl, 3-methoxy-propyl, 3-ethoxy-propyl, or     3-isopropyloxy-propyl), (optionally substituted     C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl, (4-F-phenyl)methyl,     (3-Cl-phenyl)methyl, (4-Cl-phenyl)methy 1, (3,4-diF-phenyl)methy 1,     (3-Cl-4-F-phenyl)methyl, (3-CF₃-phenyl)methyl,     (2-Cl-4-CF₃-phenyl)methyl, (2-Cl-5-CF₃-phenyl)methyl, or     (3-OCF₃-phenyl)methyl)), (optionally substituted     C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g. (pyrid-2-yl)-methyl or     (4-CF₃-pyrid-2-yl)methyl), optionally substituted C₆-C₁₂-aryl (e.g.     phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl,     3-Me-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl,     3-OCF₃-4-F-phenyl, or 3-OCF₃-4-Cl-phenyl), or optionally substituted     C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl); and -   R^(20b) is hydrogen or C₁-C₈-alkyl (e.g. methyl, ethyl, or n-butyl).

In particular, R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or 6-Me-heptyl), (C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl, 2-ethoxy-ethyl, 2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropyloxy-propyl), (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl, (4-F-phenyl)methyl, (3-Cl-phenyl)methyl, (4-Cl-phenyl)methyl, (3,4-diF-phenyl)methyl, (3-Cl-4-F-phenyl)methyl, (3-CF₃-phenyl)methyl, (2-Cl-4-CF₃-phenyl)methyl, (2-Cl-5-CF₃-phenyl)methyl, or (3-OCF₃-phenyl)methyl)), (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g. (pyrid-2-yl)-methyl or (4-CF₃-pyrid-2-yl)methyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, or 3-OCF₃-4-Cl-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl).

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Il)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Il)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

R^(3b)—in the pyrrolidine derivatives of formula (Il)—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives of formula (Il)—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives of formula (Il)—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Il)—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (Il) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or     6-Me-heptyl), (C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g.     cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl,     2-ethoxy-ethyl, 2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl,     3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropyloxy-propyl),     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl,     (4-F-phenyl)methyl, (3-Cl-phenyl)methyl, (4-Cl-phenyl)methyl,     (3,4-diF-phenyl)methyl, (3-Cl-4-F-phenyl)methyl,     (3-CF₃-phenyl)methyl, (2-Cl-4-CF₃-phenyl)methyl,     (2-Cl-5-CF₃-phenyl)methyl, or (3-OCF₃-phenyl)methyl)), (optionally     substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g.     (pyrid-2-yl)-methyl or (4-CF₃-pyrid-2-yl)methyl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl,     3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl,     4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-Cl-4-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, or     3-OCF₃-4-Cl-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl     (e.g. 4-CF₃-pyrid-2-yl); -   R^(20b) is hydrogen or C₁-C₈-alkyl (e.g. methyl, ethyl, or n-butyl);     and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives of formula (Il)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Il)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Il), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives of formula (Il), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Il)—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. 4-F-phenyl).

In connection with R^(20a), substituted C₆-C₁₂-aryl-C₁-C₄-alkyl in particular includes C₆-C₁₂-aryl-C₁-C₄-alkyl, such as benzyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy.

In connection with R^(20a), substituted C₃-C₁₂-heterocyclyl-C₁-C₄-alkyl in particular includes C₃-C₁₂-heterocyclyl-C₁-C₄-alkyl, such as pyridyl-methyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl.

In connection with R^(20a), substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and halogenated C₁-C₄-alkoxy.

In connection with R^(20a), substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl.

According to a preferred embodiment, R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or 6-Me-heptyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g. cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl, 2-ethoxy-ethyl, 2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropyloxy-propyl), C₆-C₁₂-aryl-C₁-C₄-alkyl wherein C₆-C₁₂-aryl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, halogenated C₁-C₄-alkyl and halogenated C₁-C₄-alkoxy (e.g. benzyl, (4-F-phenyl)methyl, (3-Cl-phenyl)methyl, (4-Cl-phenyl)methyl, (3,4-diF-phenyl)methyl, (3-Cl-4-F-phenyl)methyl, (3-CF₃-phenyl)methyl, (2-Cl-4-CF₃-phenyl)methyl, (2-Cl-5-CF₃-phenyl)methyl, or (3-OCF₃-phenyl)methyl)), or C₃-C₁₂-heterocyclyl-C₁-C₄-alkyl wherein C₃-C₁₂-heterocyclyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl (e.g. (pyrid-2-yl)-methyl or (4-CF₃-pyrid-2-yl)methyl), or C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and halogenated C₁-C₄-alkoxy (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, or 3-OCF₃-4-Cl-phenyl), or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogenated C₁-C₄-alkyl (e.g. 4-CF₃-pyrid-2-yl).

Further preferred embodiments of the pyrrolidine derivatives of formula (Il) result if

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen (e.g. 4-F-phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or     6-Me-heptyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g.     cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl,     2-ethoxy-ethyl, 2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl,     3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropyloxy-propyl),     C₆-C₁₂-aryl-C₁-C₄-alkyl wherein C₆-C₁₂-aryl is optionally     substituted with 1, 2, or 3 substituents independently selected from     the group consisting of halogen, halogenated C₁-C₄-alkyl and     halogenated C₁-C₄-alkoxy (e.g. benzyl, (4-F-phenyl)methyl,     (3-Cl-phenyl)methyl, (4-Cl-phenyl)methyl, (3,4-diF-phenyl)methyl,     (3-Cl-4-F-phenyl)methyl, (3-CF₃-phenyl)methyl,     (2-Cl-4-CF₃-phenyl)methyl, (2-Cl-5-CF₃-phenyl)methyl, or     (3-OCF₃-phenyl)methyl)), or C₃-C₁₂-heterocyclyl-C₁-C₄-alkyl wherein     C₃-C₁₂-heterocyclyl is optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogenated C₁-C₄-alkyl (e.g. (pyrid-2-yl)-methyl or     (4-CF₃-pyrid-2-yl)methyl), or C₆-C₁₂-aryl optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, CN and     halogenated C₁-C₄-alkoxy (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl,     3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl,     4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-Cl-4-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, or     3-OCF₃-4-Cl-phenyl), or C₃-C₁₂-heterocyclyl optionally substituted     with 1, 2, or 3 substituents independently selected from the group     consisting of halogenated C₁-C₄-alkyl (e.g. 4-CF₃-pyrid-2-yl); -   R^(20b) is hydrogen or C₁-C₈-alkyl (e.g. n-butyl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment, R⁴ is —SO₂R²¹. Thus, the present invention relates to the pyrrolidine derivatives of the formula (Im):

wherein R¹, R^(2a), R^(3a), R^(3b), Y¹, R^(5a) and R^(5b) are as defined herein, and

-   R²¹ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl,     or 4-Me-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     2-pyridyl).

In particular, R²¹ is C₆-C₁₂-aryl (e.g. phenyl).

R^(2a), R^(2b)—in the pyrrolidine derivatives of formula (Im)—are, in particular, hydrogen.

R^(3a)—in the pyrrolidine derivatives of formula (Im)—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl).

-   R^(3b)—in the pyrrolidine derivatives of formula (Im)—is, in     particular, hydrogen. -   Y¹—in the pyrrolidine derivatives of formula (Im)—is, in particular,     >CR⁶. -   R⁶—in the pyrrolidine derivatives of formula (Im)—is, in particular,     hydrogen. -   R^(5a), R^(5b)—in the pyrrolidine derivatives of formula (Im)—are,     in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of formula (Im) result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl);     -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R^(5a), R^(5b)     -   are hydrogen; and -   R²¹ is C₆-C₁₂-aryl (e.g. phenyl).

Preferably, R¹—in the pyrrolidine derivatives of formula (Im)—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives of formula (Im)—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives of formula (Im), substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives of formula (Im)—is C₆-C₁₂-aryl (e.g. phenyl).

Further preferred embodiments of the pyrrolidine derivatives of formula (Im) result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl (e.g. phenyl); -   R^(3b) is hydrogen; -   Y¹ is >CR⁶; -   R⁶ is hydrogen; -   R²¹ is C₆-C₁₂-aryl (e.g. phenyl); and -   R^(5a), R^(5b)     -   are hydrogen.

According to a further embodiment R⁴ is optionally substituted C₃-C₁₂-heterocyclyl (e.g. 4-chloroisoindolin-1-one; 7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl, 4-butyl-1,2,3-triazol-1-yl, 1-propyl-1,2,3-triazol-4-yl, 5-(4-CF₃-phenyl)-4,5-dihydroisooxazol-3-yl, 5-(4-CF₃-phenyl)-oxazol-2-yl, or 5-(3-Cl-phenyl)-imidazol-2-yl).

R^(3a)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is, in particular, C₃-C₁₂-cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), optionally substituted C₃-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (e.g. cyclopropylmethoxy or cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy or 2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy), optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy or 4-F-phenoxy), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl). Preferably, R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl).

R^(3b)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is, in particular, hydrogen.

Y¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is, in particular, >CR⁶.

R⁶—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is, in particular, hydrogen.

R^(5a), R^(5b)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—are, in particular, hydrogen.

Particular embodiments of the pyrrolidine derivatives of the invention result if:

-   R¹ is an optionally substituted 5-membered heterocyclic ring     containing at least 1 N ring atom and optionally 1 or 2 further     heteroatoms selected from N, O and S (e.g.     1-methyl-2-methoxycarbonyl-pyrrol-5-yl, 1-methyl-pyrrol-3-yl,     5-methyl-1,2-oxazol-4-yl, 3,5-dimethyl-1,2-oxazol-4-yl,     1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl,     1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl,     1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl,     1,3-dimethyl-5-Cl-1,2-diazol-4-yl,     1-isopropyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl,     1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl,     1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl,     1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl,     1-Me-1,2,3-triazol-4-yl, 2,4-dimethyl-1,3-thiazol-5-yl, or     2-methylcarbonylamino-1,3-thiazol-5-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or 2,4,5-trifluoro-phenyl) or     C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl); -   R^(3b) is hydrogen; -   R⁴ is optionally substituted C₃-C₁₂-heterocyclyl (e.g.     4-chloroisoindolin-1-one;     7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl,     4-butyl-1,2,3-triazol-1-yl, 1-propyl-1,2,3-triazol-4-yl,     5-(4-CF₃-phenyl)-4,5-dihydroisooxazol-3-yl,     5-(4-CF₃-phenyl)-oxazol-2-yl, or 5-(3-Cl-phenyl)-imidazol-2-yl); -   Y¹ is >CR⁶; -   R⁶ is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

Preferably, R¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is an optionally substituted 5-membered heterocyclic ring containing 2 N which, in particular, is optionally substituted 1,3-diazolyl.

According to a further preferred embodiment, R¹—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is an optionally substituted 5-membered heterocyclic ring containing 3 N which, in particular, is optionally substituted 1,2,3-triazolyl.

In connection with R¹ and the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl, substituted 5-membered heterocyclic ring containing at least 1 N ring atom and optionally 1 or 2 further heteroatoms selected from N, O and S in particular includes 5-membered heterocyclic rings, such as pyrrolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl and triazolyl, which are substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy-carbonyl and C₁-C₆-alkyl-carbonylamino. Preferably, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of halogen and C₁-C₆-alkyl. In particular, the substituent(s) on the heterocyclic ring are independently selected from the group consisting of C₁-C₆-alkyl, especially C₁-C₄-alkyl (e.g. methyl). According to a particular embodiment, 1,3-diazolyl is substituted with halogen or C₁-C₆-alkyl as described herein. According to a specific embodiment, R¹ is 1-methyl-1,3-diazol-4-yl.

In connection with R^(3a) and the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl, substituted C₆-C₁₂-aryl in particular includes C₆-C₁₂-aryl, such as phenyl or naphthyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy. Preferably, the substituent(s) on C₆-C₁₂-aryl are independently selected from the group consisting of halogen.

In connection with R^(3a) and the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as pyridyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and halogenated C₁-C₄-alkyl.

According to a preferred embodiment, R^(3a)—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is C₆-C₁₂-aryl, in particular phenyl, optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen (e.g. phenyl, 4-F-phenyl), or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl).

In connection with R⁴, substituted C₃-C₁₂-heterocyclyl in particular includes C₃-C₁₂-heterocyclyl, such as triazolyl or isoindolinonyl, which is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and halogenated C₁-C₄-alkyl.

According to a preferred embodiment, R⁴—in the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl—is C₃-C₁₂-heterocyclyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl and halogenated C₁-C₄-alkyl (e.g. 4-chloroisoindolin-1-onyl, 7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl, 4-butyl-1,2,3-triazol-1-yl, or 1-propyl-1,2,3-triazol-4-yl).

Further preferred embodiments of the pyrrolidine derivatives wherein R⁴ is optionally substituted C₃-C₁₂-heterocyclyl result if:

-   R¹ is 1,3-diazolyl optionally substituted with halogen or     C₁-C₄-alkyl (e.g. 1-methyl-1,3-diazol-4-yl); -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3     substituents independently selected from the group consisting of     halogen, or C₃-C₁₂-heterocyclyl (e.g. pyrid-2-yl); -   R^(3b) is hydrogen; -   R⁴ is C₃-C₁₂-heterocyclyl substituted with 1, 2, or 3 substituents     independently selected from the group consisting of halogen,     C₁-C₆-alkyl and halogenated C₁-C₄-alkyl (e.g.     4-chloroisoindolin-1-one;     7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl,     4-butyl-1,2,3-triazol-1-yl, 1-propyl-1,2,3-triazol-4-yl,     5-(4-CF₃-phenyl)-4,5-dihydroisooxazol-3-yl,     5-(4-CF₃-phenyl)-oxazol-2-yl, or 5-(3-Cl-phenyl)-imidazol-2-yl); -   Y¹ is >CR⁶; -   R⁶ is hydrogen; and -   R^(5a), R^(5b)     -   are hydrogen.

Particular embodiments of pyrrolidine derivatives of the invention result if

-   R¹ is optionally substituted 5-membered heterocyclic ring containing     at least 1 N ring atom and optionally 1 or 2 further heteroatoms     selected from N, O and S (e.g. 1-methyl-1,3-diazol-4-yl or     1-methyl-1,2,3-triazol-4-yl; -   R^(2a), R^(2b)     -   are hydrogen; -   R^(3a) is C₃-C₁₂-cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl,     or cyclohexyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     2-Cl-phenyl, 2-Br-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2-F-phenyl,     3-F-phenyl, 4-F-phenyl, 4-OMe-phenyl, or     2,4,5-trifluoro-phenyl)hydroxy, C₁-C₆-alkoxy (e.g. methoxy, ethoxy,     n-propyloxy, iso-propoxy, or iso-butoxy)     C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy (cyclopropylmethoxy,     cyclohexylmethoxy), C₂-C₆-alkenyloxy (e.g. allyloxy,     2-methylprop-2-en-1-oxy), C₆-C₁₂-aryl-C₁-C₄-alkoxy (e.g. benzyloxy),     optionally substituted C₆-C₁₂-aryloxy (e.g. phenoxy, 4-F-phenoxy); -   R^(3b) is hydrogen or hydroxy; -   Y¹ is >CR⁶— or >N—; -   R⁶ is hydrogen, C₁-C₆-alkyl (e.g. methyl or ethyl),     C₃-C₁₂-aryl-C₁-C₂₁-alkyl (e.g. benzyl or phenethyl),     hydroxy-C₁-C₆-alkyl (e.g. —CH₂OH, or —(CH₂)₂OH), or hydroxy; -   R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰,     —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹²,     optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³,     —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b),     —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or     optionally substituted C₃-C₁₂ heterocyclyl (e.g.     1-propyl-1,2,3-triazol-4-yl, 4-butyl-1,2,3-triazolyl-1-yl,     4-chloroisoindolin-1-one, or     7-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-on-1-yl); -   R^(7a), R^(7b)     -   are hydrogen, or -   n1 is 1; -   R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     3-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, or     3-OCF₃-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     6-CF₃-pyrimid-4-yl, 4-CF₃-pyrid-2-yl, or 2-CF₃-pyrid-4-yl); -   R^(7c), R^(7d)     -   are hydrogen, or -   n2 is 1; -   R^(11a) is C₁-C₈-alkyl (e.g. methyl, ethyl, n-propyl, n-butyl, or     n-heptyl), C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl (e.g. cyclopropyl-methyl)     C₁-C₆-alkoxy-C₁-C₆-alkyl (2-methoxy-ethyl, 2-ethoxy-ethyl,     2-isopropyloxy-ethyl, 1-methyl-2-methoxy-ethyl, 3-methoxy-propyl,     3-ethoxy-propyl, or 3-isopropyloxy-propyl), C₆-C₁₂-aryl-C₁-C₄-alkyl     (e.g. benzyl), optionally substituted C₆-C₁₂-aryl (e.g. phenyl,     4-F-phenyl, 3-Cl-phenyl, 3,5-diCl-phenyl, 3-Cl-4-F-phenyl,     3-Me-phenyl, 3-(aminomethyl)-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     2-Cl-4-CF₃-phenyl, 3-Cl-4-CF₃-phenyl, 3-CF₃-4-F-phenyl,     3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl, or     3-(aminocarbonyl)-phenyl); -   R^(11b) is hydrogen; -   R^(7e), R^(7f)     -   are hydrogen, or -   n3 is 1; -   R¹² is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-Cl-phenyl,     or 3-Br-phenyl) or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     4-CF₃-pyrid-2-yl or 1-propyl-1,2,3-triazol-4-yl); -   R^(8a), R^(8b), R^(8c), R^(8d), R^(8e)     -   are independently hydrogen or C₁-C₆-alkyl (e.g. pentyl or         hexyl), or -   R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e)     -   together are optionally substituted C₁-C₅-alkylene, wherein one         or more —CH₂— of C₁-C₅-alkylene may be independently replaced by         a an oxygen atom or C═O; -   R^(9a), R^(9b)     -   are independently hydrogen, halogen, C₁-C₆-alkyl (e.g. methyl,         ethyl, tert-butyl, 2,3-dimethyl-propyl), or C₁-C₆-alkoxy (e.g.         methoxy or ethoxy); -   n4 is 0, 1, 2, 3, or 4; -   R¹³ is hydrogen, C₁-C₈-alkyl (e.g. methyl, ethyl, n-butyl,     tert-butyl, pentyl, or hexyl), halogenated C₁-C₆-alkyl (e.g. —CF₃ or     —CF₂Me), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. methoxy-methyl), optionally     substituted C₃-C₁₂-cycloalkyl (e.g. cyclopropyl,     2-propyl-cyclopropyl, 1-(methoxymethyl)-cyclopropyl,     2-phenyl-cyclopropyl, cyclopentyl, 1-methyl-cyclohexyl,     1-CF₃-cyclopropyl, 4-CF₃-cyclohexyl, or 4,4-diF-cyclohexyl),     C₂-C₆-alkenyl (e.g. hex-2-enyl), optionally substituted     C₃-C₆-cycloalkenyl (e.g. 1,3,3-trimethylcyclohexen-2-yl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 4-F-phenyl,     3-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl,     2,4-diF-phenyl, 2,5-diF-phenyl, 3,4-diF-phenyl, 2,3,4-triF-phenyl,     2,4-diCl-phenyl, 3,4-diCl-phenyl, 3-F-4-Cl-phenyl, 3-Cl-4-F-phenyl,     3-Cl-5-F-phenyl, 3,4-diF-5-Cl-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 3-iPr-phenyl, 3-tBu-phenyl, 3-Me-4-F-phenyl,     3-Me-4-Cl-phenyl, 3-iPr-4 Cl-phenyl, 3-(1-OH-1-CF₃-Et)-phenyl,     3-CHF₂-4-F-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-F-3-CF₃-phenyl, 2-F-5-CF₃-phenyl,     3-F-5-CF₃-phenyl, 2-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CF₃-4-Cl-phenyl, 3-Me-4-CF₃-phenyl,     3-CF₃-4-Me-phenyl, 3,4-diCF₃-phenyl, 4-OMe-phenyl, 3-OiPr-phenyl,     3-CF₃-4-OMe-phenyl, 3-OCH₂CF₃-phenyl, 3-OCF₃-phenyl,     2-OCHF₂-5-Cl-phenyl, 3-OCF₃-4-F-phenyl, 3-OCF₃-4-Cl-phenyl,     3-OBn-phenyl, 3-OPh-phenyl, 3-CN-phenyl, 4-CN-phenyl,     2-F-3-CN-phenyl, 2-F-4-CN-phenyl, 3-F-4-CN-phenyl, 2-F-5-CN-phenyl,     3-F-5-CN-phenyl, 3-Cl-4-CN-phenyl, 2-Cl-5-CN-phenyl,     3-Cl-5-CN-phenyl, 3-CN-4-Cl-phenyl, 2-Me-3-CN-phenyl,     2-Me-5-CN-phenyl, 3-Me-5-CN-phenyl, 3-CF₃-4-CN-phenyl,     3-CN-4-OMe-phenyl, 3-CN-4-OCF₃-phenyl, 3-phenyl-phenyl,     3-MeSO₂-phenyl, 3-(piperidin-4-yl)-phenyl,     2-methylcarbonylamino-5-Cl-phenyl, 3-(pyrid-2-yl)-phenyl,     3-(pyrid-3-yl)-4F-phenyl, 3-(pyrid-4-yl)-4F-phenyl,     3-(pyrimid-5-yl)-4F-phenyl, indan-5-yl, or tetralin-6-yl),     C₁-C₆-alkoxy (e.g. methoxy, ethoxy, or n-propoxy),     C₁-C₆-alkoxy-C₁-C₄-alkoxy (e.g. 2-methoxy-ethoxy), optionally     substituted C₆-C₁₂-aryloxy (e.g. 4-F-phenoxy or     4-tertbutyl-phenoxy), optionally substituted C₃-C₁₂-heterocyclyl     (e.g. e.g. propyl-furan-2-yl, 2-CF₃-furan-5-yl,     1,2-dimethyl-5-CN-pyrrol-3-yl, 2,3-diMe-thiophen-5-yl,     2-Me-thiophen-5-yl, 2-Cl-thiophen-5-yl, 3-Cl-thiophen-2-yl,     2,5-diCl-thiophen-3-yl, 2-tetrahydropyranyl-thiophen-5-yl,     1,3-thiazol-5-yl, 4-Me-1,3-thiazol-2-yl, 2-Me-1,3-thiazol-5-yl,     5-Me-1,3-thiazol-2-yl, 4-Me-1,3-thiazol-5-yl, 2-Me-1,3-thiazol-4-yl,     4-isopropyl-1,3-thiazol-2-yl, 2-phenyl-4-Me-1,3-thiazol-5-yl,     4-phenyl-1,3-thiazol-5-yl, 2-(4-Me-phenyl)-1,3-thiazol-5-yl,     4-(4-F-phenyl)-1,3-thiazol-2-yl, thiazol-4-yl,     4-Cl-1,3-thiazol-5-yl, 2-Br-1,3-thiazol-5-yl, 4-Br-1,3-thiazol-2-yl,     4-Me-5-Br-1,3-thiazol-2-yl, 2,4-dichloro-1,3-thiazol-5-yl,     1,5-dimethyl-1,2,4-triazol-3-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl,     4-F-pyrid-2-yl, 5-F-pyrid-2-yl, 6-F-pyrid-2-yl, 4-Cl-pyrid-2-yl,     5-F-pyrid-3-yl, 2-F-pyrid-4-yl, 3,5-diCl-pyrid-4-yl,     4,5-diCl-pyrid-2-yl, 2-Cl-3F-pyrid-4-yl, 5-Me-pyrid-2-yl,     4-iPr-pyrid-2-yl, 4-Me-5-F-pyrid-2-yl, 4-CF₃-pyrid     2-yl-5-CF₃-pyrid-2-yl, 6-CF₃-pyrid-2-yl, 5-CF₃-pyrid-3-yl,     2-CF₃-pyrid-4-yl, 3-F-4-CF₃-pyrid-2-yl, 4-CF₃-5-F-pyrid-2-yl     4-CF₃-5-Cl-pyrid-2-yl, 3,5-diF-4-CF₃-pyrid-2-yl,     4-OCH₂CF₃-pyrid-2-yl, 4-OCH₂CF₃-5-F-pyrid-2-yl,     4-OCH₂CF₃-5-Cl-pyrid-2-yl, 4-OBn-5-F-pyrid-2-yl,     3-(4-F-phenyl)-pyrid-5-yl, 2-(4-F-phenyl)-pyrid-3-yl,     4-(pyrid-4-yl)-pyrid-2-yl, 4-(pyrid-3-yl)-pyrid-2-yl,     5-cyclopropyl-pyraz-2-yl, 5-cyclobutyl-pyraz-2-yl,     5-pyrrolidin-pyraz-2-yl, pyridaz-3-yl, 4-CF₃-pyridaz-3-yl,     5-CF₃-pyridaz-3-yl, 5-F-pyrimid-2-yl, 6-Cl-pyrimid-4-yl,     6-Me-pyrimid-4-yl, 6-Et-pyrimid-4-yl, 6-Pr-pyrimid-4-yl,     6-iPr-pyrimid-4-yl, 2-Me-6-Cl-pyrimid-4-yl, 2-Me-6-CF₃-pyrimid-4-yl,     2-OMe-6-CF₃-pyrimid-4-yl, 2-OMe-pyrimid-4-yl, 6-OMe-pyrimid-4-yl,     6-OEt-pyrimid-4-yl, 6-OPr-pyrimid-4-yl, 6-OiPr-pyrimid-4-yl,     6-OiBu-pyrimid-4-yl, 6-OBu-pyrimid-4-yl, 6-OBn-pyrimid-4-yl,     6-cyclobutyloxy-pyrimid-4-yl, 6-cyclopentyloxy-pyrimid-4-yl,     6-cyclohexyloxy-pyrimid-4-yl, 6-cyclopropyl-pyrimid-4-yl,     6-phenyl-pyrimid-4-yl, 6-(2-F-phenyl)-pyrimid-4-yl,     6-(3-F-phenyl)-pyrimid-4-yl, 6-(4-F-phenyl)-pyrimid-4-yl,     6-Cl-pyrimid-4-yl, 6-(2-Me-phenyl)pyrimid-4-yl,     6-(3-Me-phenyl)-pyrimid-4-yl, 6-(4-Me-phenyl)-pyrimid-4-yl,     6-(3-Cl-phenyl)-pyrimid-4-yl, 6-(4-Cl-phenyl)-pyrimid-4-yl,     2-(morpholin-1-yl)-pyrimid-4-yl,     6-(azetidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-3-yl-methoxy)-pyrimid-4-yl,     6-(pyrrolidin-2-yl-methoxy)-pyrimid-4-yl, benzofuran-5-yl,     2-Me-benzofuran-3-yl, 2-Et-benzofuran-3-yl, benzothiophen-5-yl,     benzothiophen-6-yl, 5-Me-benzothiophen-2-yl, 5-F-benzothiophen-2-yl,     3-Cl-benzothiophen-2-yl, benzothiazol-2-yl, isoquinolin-6-yl,     isoquinolin-7-yl, quinolin-6-yl, quinolin-7-yl,     4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, dihydrobenzofuran-5-yl,     7H-pyrrolo[2,3-d]pyrimidin-4-yl, pyrazolo[1,5-a]pyridine-3-yl,     pyrazolo[1,5-a]pyridine-7-yl, imidazo[1,2-a]pyridin-8-yl,     5-methyl-imidazo[1,2-a]pyridin-3-yl,     6-chloro-2-methyl-imidazo[1,2-a]pyridin-3-yl,     6-bromo-2-methyl-imidazo[1,2-a]pyridin-3-yl,     thieno[2,3-b]pyridin-2-yl, N-benzyl-indolin-6-yl, indolinon-4-yl,     chroman-6-yl, 4,4-dimethylchroman-6-yl,     4,4-dimethyl-1,3-dioxan-2-yl, tetrahydrofuran-3-yl,     tetrahydropyran-4-yl, 4-Me-tetrahydropyran-4-yl,     2,2-diMe-tetrahydropyran-4-yl, 1-isopropyl-piperidin-4-yl, or     2-CF₃-piperazin-5-yl), or tri-(C₁-C₄-alkyl)-silyloxy; -   R¹⁴ is C₁-C₈-alkyl (e.g. pentyl, n-butyl, or hexyl), halogenated     C₁-C₆-alkyl (e.g. 1,1-diF-butyl, 3,3-diF-butyl, 4,4,4-triF-butyl,     1,1-diF-pentyl, or 4,4-diF-pentyl), (optionally substituted     C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g. cyclopropyl-methyl),     hydroxy-C₁-C₆-alkyl (e.g. hydroxylmethyl or 1-hydroxy-pentyl),     (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl (e.g.     phenoxy-methyl or (4-F-phenoxy)-methyl),     C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl (e.g. 2-methylcarbonyl-ethyl or     3-methylcarbonyl-propyl), C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl (e.g.     3-methoxycarbonyl-propyl), optionally substituted C₃-C₁₂-cycloalkyl     (e.g. 1-CF₃-cyclopropyl or 4-CF₃-cyclohexyl), optionally substituted     C₆-C₁₂-aryl (e.g. phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl,     2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diCl-phenyl,     3,5-diCl-phenyl, 2-Cl-4-F-phenyl, 2-Me-phenyl, 3-Me-phenyl,     4-Me-phenyl, 2-CF₃-phenyl, 3-CF₃-phenyl, 4-CF₃-phenyl,     3-Cl-4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 2-Cl-4-CF₃-phenyl,     2-OMe-phenyl, 3-OMe-phenyl, 2-CN-phenyl, or 3-CN-phenyl,     4-CN-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl (e.g.     3-Cl-pyridazin-6-yl, 2-Cl-pyrazin-5-yl, or 2-CF₃-pyrazin-5-yl); -   R¹⁵ is C₁-C₆-alkyl (e.g. ethyl, n-propyl, n-butyl, iso-butyl, or     tert-bu) or C₆-C₁₂-aryl (e.g. phenyl); -   R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g.     benzyl or (2-Cl-phenyl)-methyl) or optionally substituted     C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-F-phenyl, 2F-phenyl,     4-Cl-phenyl, or 2-Cl-phenyl); -   R^(16b) is hydrogen; -   R^(9c), R^(9d)     -   are hydrogen; -   n5 is 0, 1, or 2; -   R¹⁸ is hydrogen, optionally substituted C₁-C₈-alkyl (e.g. methyl,     ethyl, iso-propyl, or pentyl), C₁-C₆-alkoxycarbonyl (e.g.     methoxycarbonyl or n-butoxycarbonyl), C₁-C₆-alkylaminocarbonyl (e.g.     n-propylaminocarbonyl or n-butylaminocarbonyl), (halogenated     C₁-C₄-alkyl)aminocarbonyl (e.g. 2,2-diF-ethylaminocarbonyl),     optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 4-Me-phenyl, 3-MeSO₂-phenyl, or 4-MeSO₂-phenyl),     C₁-C₆-alkylamine (e.g. propylamine), (halogenated C₁-C₆-alkyl)amino     (e.g. 2,2,2-triF-ethylamine), optionally substituted     C₆-C₁₂-arylamine (e.g. 4-Cl-phenylamine), or optionally substituted     C₃-C₁₂-heterocyclyl (e.g. 4-CF₃-pyrid-2-yl or 6-CF₃-pyrimid-4-yl); -   R¹⁹ is optionally substituted C₆-C₁₂-aryl (e.g. phenyl, 3-F-phenyl,     4-F-phenyl, 3-Cl-phenyl, 3,4-diF-phenyl, 3,4-diCl-phenyl,     3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Me-phenyl,     3-CF₃-phenyl, 3-OCF₃-phenyl, or 4-OCF₃-phenyl); -   R^(20a) is C₁-C₈-alkyl (e.g. n-propyl, n-butyl, hexyl, pentyl, or     6-Me-heptyl), (C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl (e.g.     cyclopropyl-methyl), C₁-C₆-alkoxy-C₁-C₆-alkyl (e.g. 2-methoxy-ethyl,     2-ethoxy-ethyl, 2-isopropoxy-ethyl, 1-methyl-2-methoxy-ethyl,     3-methoxy-propyl, 3-ethoxy-propyl, or 3-isopropoxy-propyl),     (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl (e.g. benzyl,     (4-F-phenyl)methyl, (3-Cl-phenyl)methyl, (4-Cl-phenyl)methyl,     (3,4-diF-phenyl)methyl, (3-Cl-4-F-phenyl)methyl,     (3-CF₃-phenyl)methyl, (2-Cl-4-CF₃-phenyl)methyl,     (2-Cl-5-CF₃-phenyl)methyl, or (3-OCF₃-phenyl)methyl)), (optionally     substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl (e.g.     (pyrid-2-yl)-methyl or (4-CF₃-pyrid-2-yl)methyl), optionally     substituted C₆-C₁₂-aryl (e.g. phenyl, 4-F-phenyl, 3-Cl-phenyl,     3,5-diCl-phenyl, 3-Cl-4-F-phenyl, 3-Me-phenyl, 3-CF₃-phenyl,     4-CF₃-phenyl, 2-Cl-3-CF₃-phenyl, 3-Cl-4-CF₃-phenyl,     3-CF₃-4-F-phenyl, 3-CN-phenyl, 3-OCF₃-phenyl, 3-OCF₃-4-F-phenyl, or     3-OCF₃-4-Cl-phenyl), or optionally substituted C₃-C₁₂-heterocyclyl     (e.g. 4-CF₃-pyrid-2-yl). -   R^(20b) is hydrogen or C₁-C₈-alkyl (e.g. methyl, ethyl, or n-butyl); -   R²¹ is C₆-C₁₂-aryl (e.g phenyl); and -   R^(5a), R^(5b)     -   are hydrogen; or -   R^(5a), R^(5b)     -   together with the carbon atom to which they are bound may form a         C═O.

Further particular compounds of the present invention are the individual pyrrolidine derivatives of the formula (Id2) as listed in the following tables 1 to 8 and physiologically tolerated salts thereof:

Table 1 Compounds of the formula (Id2) wherein X is ═CH—, Z is ═CR^(13c)—, R^(13c) is H and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

Table 2 Compounds of the formula (Id2) wherein X is ═CH—, Z is ═CR^(13c)—, R^(13c) is F and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

Table 3 Compounds of the formula (Id2) wherein X is ═CH—, Z is ═CR^(13c)—, R^(13c) is Cl and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

Table 4 Compounds of the formula (Id2) wherein X is ═N—, Z is ═CR^(13c)—, R^(13c) is H and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

Table 5 Compounds of the formula (Id2) wherein X is ═N—, Z is ═CR^(13c)—, R^(13c) is F and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

Table 6 Compounds of the formula (Id2) wherein X is ═N—, Z is ═CR^(13c)—, R^(13c) is Cl and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-44).

Table 7 Compounds of the formula (Id2) wherein X is ═N—, Z is ═N— and the combination of R¹, R^(3a) and R^(13b) for a compound in each case corresponds to one line of Table A (A-1 to A-344).

R¹ R^(3a) R^(13b) A-1. 1-methyl-1,3-diazol-4-yl Ph H A-2. 1-methyl-1,3-diazol-4-yl 4-F—Ph H A-3. 1-methyl-1,3-diazol-4-yl 2-THP H A-4. 1-methyl-1,3-diazol-4-yl 2-THF H A-5. 1-methyl-1,2,3-triazol-4-yl Ph H A-6. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph H A-7. 1-methyl-1,2,3-triazol-4-yl 2-THP H A-8. 1-methyl-1,2,3-triazol-4-yl 2-THF H A-9. 1-methyl-1,3-diazol-4-yl Ph F A-10. 1-methyl-1,3-diazol-4-yl 4-F—Ph F A-11. 1-methyl-1,3-diazol-4-yl 2-THP F A-12. 1-methyl-1,3-diazol-4-yl 2-THF F A-13. 1-methyl-1,2,3-triazol-4-yl Ph F A-14. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph F A-15. 1-methyl-1,2,3-triazol-4-yl 2-THP F A-16. 1-methyl-1,2,3-triazol-4-yl 2-THF F A-17. 1-methyl-1,3-diazol-4-yl Ph Cl A-18. 1-methyl-1,3-diazol-4-yl 4-F—Ph Cl A-19. 1-methyl-1,3-diazol-4-yl 2-THP Cl A-20. 1-methyl-1,3-diazol-4-yl 2-THF Cl A-21. 1-methyl-1,2,3-triazol-4-yl Ph Cl A-22. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph Cl A-23. 1-methyl-1,2,3-triazol-4-yl 2-THP Cl A-24. 1-methyl-1,2,3-triazol-4-yl 2-THF Cl A-25. 1-methyl-1,3-diazol-4-yl Ph —CH₃ A-26. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CH₃ A-27. 1-methyl-1,3-diazol-4-yl 2-THP —CH₃ A-28. 1-methyl-1,3-diazol-4-yl 2-THF —CH₃ A-29. 1-methyl-1,2,3-triazol-4-yl Ph —CH₃ A-30. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CH₃ A-31. 1-methyl-1,2,3-triazol-4-yl 2-THP —CH₃ A-32. 1-methyl-1,2,3-triazol-4-yl 2-THF —CH₃ A-33. 1-methyl-1,3-diazol-4-yl Ph —CH₂CH₃ A-34. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CH₂CH₃ A-35. 1-methyl-1,3-diazol-4-yl 2-THP —CH₂CH₃ A-36. 1-methyl-1,3-diazol-4-yl 2-THF —CH₂CH₃ A-37. 1-methyl-1,2,3-triazol-4-yl Ph —CH₂CH₃ A-38. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CH₂CH₃ A-39. 1-methyl-1,2,3-triazol-4-yl 2-THP —CH₂CH₃ A-40. 1-methyl-1,2,3-triazol-4-yl 2-THF —CH₂CH₃ A-41. 1-methyl-1,3-diazol-4-yl Ph —CH₂CH₂CH₃ A-42. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CH₂CH₂CH₃ A-43. 1-methyl-1,3-diazol-4-yl 2-THP —CH₂CH₂CH₃ A-44. 1-methyl-1,3-diazol-4-yl 2-THF —CH₂CH₂CH₃ A-45. 1-methyl-1,2,3-triazol-4-yl Ph —CH₂CH₂CH₃ A-46. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CH₂CH₂CH₃ A-47. 1-methyl-1,2,3-triazol-4-yl 2-THP —CH₂CH₂CH₃ A-48. 1-methyl-1,2,3-triazol-4-yl 2-THF —CH₂CH₂CH₃ A-49. 1-methyl-1,3-diazol-4-yl Ph —CH(CH₃)₂ A-50. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CH(CH₃)₂ A-51. 1-methyl-1,3-diazol-4-yl 2-THP —CH(CH₃)₂ A-52. 1-methyl-1,3-diazol-4-yl 2-THF —CH(CH₃)₂ A-53. 1-methyl-1,2,3-triazol-4-yl Ph —CH(CH₃)₂ A-54. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CH(CH₃)₂ A-55. 1-methyl-1,2,3-triazol-4-yl 2-THP —CH(CH₃)₂ A-56. 1-methyl-1,2,3-triazol-4-yl 2-THF —CH(CH₃)₂ A-57. 1-methyl-1,3-diazol-4-yl Ph —C(CH₃)₃ A-58. 1-methyl-1,3-diazol-4-yl 4-F—Ph —C(CH₃)₃ A-59. 1-methyl-1,3-diazol-4-yl 2-THP —C(CH₃)₃ A-60. 1-methyl-1,3-diazol-4-yl 2-THF —C(CH₃)₃ A-61. 1-methyl-1,2,3-triazol-4-yl Ph —C(CH₃)₃ A-62. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —C(CH₃)₃ A-63. 1-methyl-1,2,3-triazol-4-yl 2-THP —C(CH₃)₃ A-64. 1-methyl-1,2,3-triazol-4-yl 2-THF —C(CH₃)₃ A-65. 1-methyl-1,3-diazol-4-yl Ph —CF₃ A-66. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CF₃ A-67. 1-methyl-1,3-diazol-4-yl 2-THP —CF₃ A-68. 1-methyl-1,3-diazol-4-yl 2-THF —CF₃ A-69. 1-methyl-1,2,3-triazol-4-yl Ph —CF₃ A-70. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CF₃ A-71. 1-methyl-1,2,3-triazol-4-yl 2-THP —CF₃ A-72. 1-methyl-1,2,3-triazol-4-yl 2-THF —CF₃ A-73. 1-methyl-1,3-diazol-4-yl Ph —CHF₂ A-74. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CHF₂ A-75. 1-methyl-1,3-diazol-4-yl 2-THP —CHF₂ A-76. 1-methyl-1,3-diazol-4-yl 2-THF —CHF₂ A-77. 1-methyl-1,2,3-triazol-4-yl Ph —CHF₂ A-78. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CHF₂ A-79. 1-methyl-1,2,3-triazol-4-yl 2-THP —CHF₂ A-80. 1-methyl-1,2,3-triazol-4-yl 2-THF —CHF₂ A-81. 1-methyl-1,3-diazol-4-yl Ph —CH(OH)(CF₃)CH₃ A-82. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CH(OH)(CF₃)CH₃ A-83. 1-methyl-1,3-diazol-4-yl 2-THP —CH(OH)(CF₃)CH₃ A-84. 1-methyl-1,3-diazol-4-yl 2-THF —CH(OH)(CF₃)CH₃ A-85. 1-methyl-1,2,3-triazol-4-yl Ph —CH(OH)(CF₃)CH₃ A-86. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CH(OH)(CF₃)CH₃ A-87. 1-methyl-1,2,3-triazol-4-yl 2-THP —CH(OH)(CF₃)CH₃ A-88. 1-methyl-1,2,3-triazol-4-yl 2-THF —CH(OH)(CF₃)CH₃ A-89. 1-methyl-1,3-diazol-4-yl Ph cyclopropyl A-90. 1-methyl-1,3-diazol-4-yl 4-F—Ph cyclopropyl A-91. 1-methyl-1,3-diazol-4-yl 2-THP cyclopropyl A-92. 1-methyl-1,3-diazol-4-yl 2-THF cyclopropyl A-93. 1-methyl-1,2,3-triazol-4-yl Ph cyclopropyl A-94. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph cyclopropyl A-95. 1-methyl-1,2,3-triazol-4-yl 2-THP cyclopropyl A-96. 1-methyl-1,2,3-triazol-4-yl 2-THF cyclopropyl A-97. 1-methyl-1,3-diazol-4-yl Ph phenyl A-98. 1-methyl-1,3-diazol-4-yl 4-F—Ph phenyl A-99. 1-methyl-1,3-diazol-4-yl 2-THP phenyl A-100. 1-methyl-1,3-diazol-4-yl 2-THF phenyl A-101. 1-methyl-1,2,3-triazol-4-yl Ph phenyl A-102. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph phenyl A-103. 1-methyl-1,2,3-triazol-4-yl 2-THP phenyl A-104. 1-methyl-1,2,3-triazol-4-yl 2-THF phenyl A-105. 1-methyl-1,3-diazol-4-yl Ph 4-Cl-phenyl A-106. 1-methyl-1,3-diazol-4-yl 4-F—Ph 4-Cl-phenyl A-107. 1-methyl-1,3-diazol-4-yl 2-THP 4-Cl-phenyl A-108. 1-methyl-1,3-diazol-4-yl 2-THF 4-Cl-phenyl A-109. 1-methyl-1,2,3-triazol-4-yl Ph 4-Cl-phenyl A-110. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 4-Cl-phenyl A-111. 1-methyl-1,2,3-triazol-4-yl 2-THP 4-Cl-phenyl A-112. 1-methyl-1,2,3-triazol-4-yl 2-THF 4-Cl-phenyl A-113. 1-methyl-1,3-diazol-4-yl Ph 3-Cl-phenyl A-114. 1-methyl-1,3-diazol-4-yl 4-F—Ph 3-Cl-phenyl A-115. 1-methyl-1,3-diazol-4-yl 2-THP 3-Cl-phenyl A-116. 1-methyl-1,3-diazol-4-yl 2-THF 3-Cl-phenyl A-117. 1-methyl-1,2,3-triazol-4-yl Ph 3-Cl-phenyl A-118. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 3-Cl-phenyl A-119. 1-methyl-1,2,3-triazol-4-yl 2-THP 3-Cl-phenyl A-120. 1-methyl-1,2,3-triazol-4-yl 2-THF 3-Cl-phenyl A-121. 1-methyl-1,3-diazol-4-yl Ph 4-F-phenyl A-122. 1-methyl-1,3-diazol-4-yl 4-F—Ph 4-F-phenyl A-123. 1-methyl-1,3-diazol-4-yl 2-THP 4-F-phenyl A-124. 1-methyl-1,3-diazol-4-yl 2-THF 4-F-phenyl A-125. 1-methyl-1,2,3-triazol-4-yl Ph 4-F-phenyl A-126. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 4-F-phenyl A-127. 1-methyl-1,2,3-triazol-4-yl 2-THP 4-F-phenyl A-128. 1-methyl-1,2,3-triazol-4-yl 2-THF 4-F-phenyl A-129. 1-methyl-1,3-diazol-4-yl Ph 3-F-phenyl A-130. 1-methyl-1,3-diazol-4-yl 4-F—Ph 3-F-phenyl A-131. 1-methyl-1,3-diazol-4-yl 2-THP 3-F-phenyl A-132. 1-methyl-1,3-diazol-4-yl 2-THF 3-F-phenyl A-133. 1-methyl-1,2,3-triazol-4-yl Ph 3-F-phenyl A-134. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 3-F-phenyl A-135. 1-methyl-1,2,3-triazol-4-yl 2-THP 3-F-phenyl A-136. 1-methyl-1,2,3-triazol-4-yl 2-THF 3-F-phenyl A-137. 1-methyl-1,3-diazol-4-yl Ph 2-F-phenyl A-138. 1-methyl-1,3-diazol-4-yl 4-F—Ph 2-F-phenyl A-139. 1-methyl-1,3-diazol-4-yl 2-THP 2-F-phenyl A-140. 1-methyl-1,3-diazol-4-yl 2-THF 2-F-phenyl A-141. 1-methyl-1,2,3-triazol-4-yl Ph 2-F-phenyl A-142. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 2-F-phenyl A-143. 1-methyl-1,2,3-triazol-4-yl 2-THP 2-F-phenyl A-144. 1-methyl-1,2,3-triazol-4-yl 2-THF 2-F-phenyl A-145. 1-methyl-1,3-diazol-4-yl Ph 2-Me-phenyl A-146. 1-methyl-1,3-diazol-4-yl 4-F—Ph 2-Me-phenyl A-147. 1-methyl-1,3-diazol-4-yl 2-THP 2-Me-phenyl A-148. 1-methyl-1,3-diazol-4-yl 2-THF 2-Me-phenyl A-149. 1-methyl-1,2,3-triazol-4-yl Ph 2-Me-phenyl A-150. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 2-Me-phenyl A-151. 1-methyl-1,2,3-triazol-4-yl 2-THP 2-Me-phenyl A-152. 1-methyl-1,2,3-triazol-4-yl 2-THF 2-Me-phenyl A-153. 1-methyl-1,3-diazol-4-yl Ph 3-Me-phenyl A-154. 1-methyl-1,3-diazol-4-yl 4-F—Ph 3-Me-phenyl A-155. 1-methyl-1,3-diazol-4-yl 2-THP 3-Me-phenyl A-156. 1-methyl-1,3-diazol-4-yl 2-THF 3-Me-phenyl A-157. 1-methyl-1,2,3-triazol-4-yl Ph 3-Me-phenyl A-158. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 3-Me-phenyl A-159. 1-methyl-1,2,3-triazol-4-yl 2-THP 3-Me-phenyl A-160. 1-methyl-1,2,3-triazol-4-yl 2-THF 3-Me-phenyl A-161. 1-methyl-1,3-diazol-4-yl Ph 4-Me-phenyl A-162. 1-methyl-1,3-diazol-4-yl 4-F—Ph 4-Me-phenyl A-163. 1-methyl-1,3-diazol-4-yl 2-THP 4-Me-phenyl A-164. 1-methyl-1,3-diazol-4-yl 2-THF 4-Me-phenyl A-165. 1-methyl-1,2,3-triazol-4-yl Ph 4-Me-phenyl A-166. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 4-Me-phenyl A-167. 1-methyl-1,2,3-triazol-4-yl 2-THP 4-Me-phenyl A-168. 1-methyl-1,2,3-triazol-4-yl 2-THF 4-Me-phenyl A-169. 1-methyl-1,3-diazol-4-yl Ph —CN A-170. 1-methyl-1,3-diazol-4-yl 4-F—Ph —CN A-171. 1-methyl-1,3-diazol-4-yl 2-THP —CN A-172. 1-methyl-1,3-diazol-4-yl 2-THF —CN A-173. 1-methyl-1,2,3-triazol-4-yl Ph —CN A-174. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —CN A-175. 1-methyl-1,2,3-triazol-4-yl 2-THP —CN A-176. 1-methyl-1,2,3-triazol-4-yl 2-THF —CN A-177. 1-methyl-1,3-diazol-4-yl Ph —OCH₃ A-178. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₃ A-179. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₃ A-180. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₃ A-181. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₃ A-182. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₃ A-183. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₃ A-184. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₃ A-185. 1-methyl-1,3-diazol-4-yl Ph —OCH₂CH₃ A-186. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂CH₃ A-187. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂CH₃ A-188. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂CH₃ A-189. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂CH₃ A-190. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂CH₃ A-191. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂CH₃ A-192. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂CH₃ A-193. 1-methyl-1,3-diazol-4-yl Ph —O(CH₂)₂CH₃ A-194. 1-methyl-1,3-diazol-4-yl 4-F—Ph —O(CH₂)₂CH₃ A-195. 1-methyl-1,3-diazol-4-yl 2-THP —O(CH₂)₂CH₃ A-196. 1-methyl-1,3-diazol-4-yl 2-THF —O(CH₂)₂CH₃ A-197. 1-methyl-1,2,3-triazol-4-yl Ph —O(CH₂)₂CH₃ A-198. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —O(CH₂)₂CH₃ A-199. 1-methyl-1,2,3-triazol-4-yl 2-THP —O(CH₂)₂CH₃ A-200. 1-methyl-1,2,3-triazol-4-yl 2-THF —O(CH₂)₂CH₃ A-201. 1-methyl-1,3-diazol-4-yl Ph —O(CH₂)₃CH₃ A-202. 1-methyl-1,3-diazol-4-yl 4-F—Ph —O(CH₂)₃CH₃ A-203. 1-methyl-1,3-diazol-4-yl 2-THP —O(CH₂)₃CH₃ A-204. 1-methyl-1,3-diazol-4-yl 2-THF —O(CH₂)₃CH₃ A-205. 1-methyl-1,2,3-triazol-4-yl Ph —O(CH₂)₃CH₃ A-206. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —O(CH₂)₃CH₃ A-207. 1-methyl-1,2,3-triazol-4-yl 2-THP —O(CH₂)₃CH₃ A-208. 1-methyl-1,2,3-triazol-4-yl 2-THF —O(CH₂)₃CH₃ A-209. 1-methyl-1,3-diazol-4-yl Ph —OCH(CH₃)₂ A-210. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH(CH₃)₂ A-211. 1-methyl-1,3-diazol-4-yl 2-THP —OCH(CH₃)₂ A-212. 1-methyl-1,3-diazol-4-yl 2-THF —OCH(CH₃)₂ A-213. 1-methyl-1,2,3-triazol-4-yl Ph —OCH(CH₃)₂ A-214. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH(CH₃)₂ A-215. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH(CH₃)₂ A-216. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH(CH₃)₂ A-217. 1-methyl-1,3-diazol-4-yl Ph —OCH₂(CH₃)₂ A-218. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂(CH₃)₂ A-219. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂(CH₃)₂ A-220. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂(CH₃)₂ A-221. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂(CH₃)₂ A-222. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂(CH₃)₂ A-223. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂(CH₃)₂ A-224. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂(CH₃)₂ A-225. 1-methyl-1,3-diazol-4-yl Ph —OCH₂(pyrrolyd-3yl) A-226. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂(pyrrolyd-3yl) A-227. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂(pyrrolyd-3yl) A-228. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂(pyrrolyd-3yl) A-229. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂(pyrrolyd-3yl) A-230. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂(pyrrolyd-3yl) A-231. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂(pyrrolyd-3yl) A-232. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂(pyrrolyd-3yl) A-233. 1-methyl-1,3-diazol-4-yl Ph —OCH₂(pyrrolyd-2yl) A-234. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂(pyrrolyd-2yl) A-235. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂(pyrrolyd-2yl) A-236. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂(pyrrolyd-2yl) A-237. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂(pyrrolyd-2yl) A-238. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂(pyrrolyd-2yl) A-239. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂(pyrrolyd-2yl) A-240. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂(pyrrolyd-2yl) A-241. 1-methyl-1,3-diazol-4-yl Ph —OCH₂(azetid-3yl) A-242. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂(azetid-3yl) A-243. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂(azetid-3yl) A-244. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂(azetid-3yl) A-245. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂(azetid-3yl) A-246. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂(azetid-3yl) A-247. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂(azetid-3yl) A-248. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂(azetid-3yl) A-249. 1-methyl-1,3-diazol-4-yl Ph —OCF₃ A-250. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCF₃ A-251. 1-methyl-1,3-diazol-4-yl 2-THP —OCF₃ A-252. 1-methyl-1,3-diazol-4-yl 2-THF —OCF₃ A-253. 1-methyl-1,2,3-triazol-4-yl Ph —OCF₃ A-254. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCF₃ A-255. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCF₃ A-256. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCF₃ A-257. 1-methyl-1,3-diazol-4-yl Ph —OCH₂CF₃ A-258. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂CF₃ A-259. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂CF₃ A-260. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂CF₃ A-261. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂CF₃ A-262. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂CF₃ A-263. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂CF₃ A-264. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂CF₃ A-265. 1-methyl-1,3-diazol-4-yl Ph —O-cyclobutyl A-266. 1-methyl-1,3-diazol-4-yl 4-F—Ph —O-cyclobutyl A-267. 1-methyl-1,3-diazol-4-yl 2-THP —O-cyclobutyl A-268. 1-methyl-1,3-diazol-4-yl 2-THF —O-cyclobutyl A-269. 1-methyl-1,2,3-triazol-4-yl Ph —O-cyclobutyl A-270. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —O-cyclobutyl A-271. 1-methyl-1,2,3-triazol-4-yl 2-THP —O-cyclobutyl A-272. 1-methyl-1,2,3-triazol-4-yl 2-THF —O-cyclobutyl A-273. 1-methyl-1,3-diazol-4-yl Ph —O-cyclopentyl A-274. 1-methyl-1,3-diazol-4-yl 4-F—Ph —O-cyclopentyl A-275. 1-methyl-1,3-diazol-4-yl 2-THP —O-cyclopentyl A-276. 1-methyl-1,3-diazol-4-yl 2-THF —O-cyclopentyl A-277. 1-methyl-1,2,3-triazol-4-yl Ph —O-cyclopentyl A-278. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —O-cyclopentyl A-279. 1-methyl-1,2,3-triazol-4-yl 2-THP —O-cyclopentyl A-280. 1-methyl-1,2,3-triazol-4-yl 2-THF —O-cyclopentyl A-281. 1-methyl-1,3-diazol-4-yl Ph —O-cyclohexyl A-282. 1-methyl-1,3-diazol-4-yl 4-F—Ph —O-cyclohexyl A-283. 1-methyl-1,3-diazol-4-yl 2-THP —O-cyclohexyl A-284. 1-methyl-1,3-diazol-4-yl 2-THF —O-cyclohexyl A-285. 1-methyl-1,2,3-triazol-4-yl Ph —O-cyclohexyl A-286. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —O-cyclohexyl A-287. 1-methyl-1,2,3-triazol-4-yl 2-THP —O-cyclohexyl A-288. 1-methyl-1,2,3-triazol-4-yl 2-THF —O-cyclohexyl A-289. 1-methyl-1,3-diazol-4-yl Ph —OCH₂Ph A-290. 1-methyl-1,3-diazol-4-yl 4-F—Ph —OCH₂Ph A-291. 1-methyl-1,3-diazol-4-yl 2-THP —OCH₂Ph A-292. 1-methyl-1,3-diazol-4-yl 2-THF —OCH₂Ph A-293. 1-methyl-1,2,3-triazol-4-yl Ph —OCH₂Ph A-294. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —OCH₂Ph A-295. 1-methyl-1,2,3-triazol-4-yl 2-THP —OCH₂Ph A-296. 1-methyl-1,2,3-triazol-4-yl 2-THF —OCH₂Ph A-297. 1-methyl-1,3-diazol-4-yl Ph —SO₂Me A-298. 1-methyl-1,3-diazol-4-yl 4-F—Ph —SO₂Me A-299. 1-methyl-1,3-diazol-4-yl 2-THP —SO₂Me A-300. 1-methyl-1,3-diazol-4-yl 2-THF —SO₂Me A-301. 1-methyl-1,2,3-triazol-4-yl Ph —SO₂Me A-302. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph —SO₂Me A-303. 1-methyl-1,2,3-triazol-4-yl 2-THP —SO₂Me A-304. 1-methyl-1,2,3-triazol-4-yl 2-THF —SO₂Me A-305. 1-methyl-1,3-diazol-4-yl Ph 2-pyridyl A-306. 1-methyl-1,3-diazol-4-yl 4-F—Ph 2-pyridyl A-307. 1-methyl-1,3-diazol-4-yl 2-THP 2-pyridyl A-308. 1-methyl-1,3-diazol-4-yl 2-THF 2-pyridyl A-309. 1-methyl-1,2,3-triazol-4-yl Ph 2-pyridyl A-310. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 2-pyridyl A-311. 1-methyl-1,2,3-triazol-4-yl 2-THP 2-pyridyl A-312. 1-methyl-1,2,3-triazol-4-yl 2-THF 2-pyridyl A-313. 1-methyl-1,3-diazol-4-yl Ph 3-pyridyl A-314. 1-methyl-1,3-diazol-4-yl 4-F—Ph 3-pyridyl A-315. 1-methyl-1,3-diazol-4-yl 2-THP 3-pyridyl A-316. 1-methyl-1,3-diazol-4-yl 2-THF 3-pyridyl A-317. 1-methyl-1,2,3-triazol-4-yl Ph 3-pyridyl A-318. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 3-pyridyl A-319. 1-methyl-1,2,3-triazol-4-yl 2-THP 3-pyridyl A-320. 1-methyl-1,2,3-triazol-4-yl 2-THF 3-pyridyl A-321. 1-methyl-1,3-diazol-4-yl Ph 4-pyridyl A-322. 1-methyl-1,3-diazol-4-yl 4-F—Ph 4-pyridyl A-323. 1-methyl-1,3-diazol-4-yl 2-THP 4-pyridyl A-324. 1-methyl-1,3-diazol-4-yl 2-THF 4-pyridyl A-325. 1-methyl-1,2,3-triazol-4-yl Ph 4-pyridyl A-326. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 4-pyridyl A-327. 1-methyl-1,2,3-triazol-4-yl 2-THP 4-pyridyl A-328. 1-methyl-1,2,3-triazol-4-yl 2-THF 4-pyridyl A-329. 1-methyl-1,3-diazol-4-yl Ph 5-pyrimidyl A-330. 1-methyl-1,3-diazol-4-yl 4-F—Ph 5-pyrimidyl A-331. 1-methyl-1,3-diazol-4-yl 2-THP 5-pyrimidyl A-332. 1-methyl-1,3-diazol-4-yl 2-THF 5-pyrimidyl A-333. 1-methyl-1,2,3-triazol-4-yl Ph 5-pyrimidyl A-334. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 5-pyrimidyl A-335. 1-methyl-1,2,3-triazol-4-yl 2-THP 5-pyrimidyl A-336. 1-methyl-1,2,3-triazol-4-yl 2-THF 5-pyrimidyl A-337. 1-methyl-1,3-diazol-4-yl Ph 4-piperidyl A-338. 1-methyl-1,3-diazol-4-yl 4-F—Ph 4-piperidyl A-339. 1-methyl-1,3-diazol-4-yl 2-THP 4-piperidyl A-340. 1-methyl-1,3-diazol-4-yl 2-THF 4-piperidyl A-341. 1-methyl-1,2,3-triazol-4-yl Ph 4-piperidyl A-342. 1-methyl-1,2,3-triazol-4-yl 4-F—Ph 4-piperidyl A-343. 1-methyl-1,2,3-triazol-4-yl 2-THP 4-piperidyl A-344. 1-methyl-1,2,3-triazol-4-yl 2-THF 4-piperidyl

Further particular compounds of the present invention are the pyrrolidine derivatives disclosed in preparation examples and physiologically tolerated salts thereof. These include for each preparation example the exemplified compound as well as the corresponding free base and any other physiologically tolerated salts of the free base (if the exemplified compound is a salt), or any physiologically tolerated salt of the free base (if the exemplified compound is a free base). These further include enantiomers, diastereomers, tautomers and any other isomeric forms of said compounds, be they explicitly or implicitly disclosed.

It is noted that the following compounds of formula (Il)

-   -   wherein R¹, R^(3a) and R¹⁴ are as defined in the following table

R¹ R^(3a) R¹⁴

4-F—Ph

4-CF₃—Ph

2-OMe—Ph

2-OMe-4-OCF₃—Ph

4-F-phenyl

4-CF₃-phenyl

2-OMe-phenyl

2-OMe-4-OCF₃-phenyl

4-F-phenyl 4-CF₃-phenyl

4-F-phenyl

4-F-phenyl 2-OMe-phenyl

4-F-phenyl

4-OMe-phenyl 4-F-phenyl

2-furyl 4-F-phenyl are described in Baumann Marcus, et al., ACS Comb. Sci. 2011, 13, 405-413 and therefore the present invention does not encompass these compounds and physiologically tolerated salts thereof per se. However, the present invention does encompass pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes, as described herein.

The compounds of the formula (I) can be prepared by analogy to methods which are well known in the art. Suitable methods for the preparation of compounds of formula (I) are outlined in the following schemes.

The process depicted in scheme 1 is useful for obtaining pyrrolidine derivatives, wherein Y¹ is >CH— and R⁴ is —N(CR^(9a)R^(9b))_(n4)R¹³, —NHCOR¹⁴ or —NHCONHR^(16a).

In scheme 1, the variables R¹, R^(3a), R¹³, R¹⁴, R^(16a) are as defined herein.

As shown in the above scheme 1, the intermediate of general formula 1 can be alkylated to give compounds of formula 2. Alternatively, 1 can be transformed to compounds 3 via reductive amination or can yield amides of formula 4 by coupling reaction with the corresponding acid. Reaction with isocyanates of formula 5 affords compounds of formula 6.

The process depicted in scheme 2 is useful for obtaining pyrrolidine derivatives, wherein Y¹ is >CH— and R⁴ is —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b) or —CONR^(20a)R^(20b).

As shown in the above scheme 2, cycloaddition followed by benzyl deprotection afford pyrrolidine 7. Sulfonylation, methylester hydrolysis and coupling with amines yield compounds of formula 8. Reduction of compounds of formula 8 affords the corresponding amines 9.

The process depicted in scheme 3 is useful for obtaining pyrrolidine derivatives, wherein Y¹ is >CH— and R⁴ is —(CR^(7a)R^(7b))_(n1)NR¹⁰.

As shown in the above scheme 3, reduction with LiAlH₄ of intermediate 10 affords the corresponding alcohol which then can be transformed in the alkoxy derivatives of formula 11 via Mitsunobu coupling.

The process depicted in scheme 4 is useful for obtaining pyrrolidine derivatives, wherein Y¹ is >CH— and R⁴ is —COR¹⁹.

As shown in the above scheme 4, the pyrrolidine intermediate 12 can be converted in the corresponding Weinreb amide. Treatment of the Weinreb amide with Grignard reagents affords the ketones of formula 13.

The process depicted in scheme 5 is useful for obtaining pyrrolidine derivatives, wherein Y¹ is >CH— and R⁴ is —O(CR^(9c)R^(9d))_(n5)R¹⁸.

As shown in the above scheme 5, alkylation of alcohol 14 affords the compounds of formula 15.

Schemes 1 to 5 refer also to the preparation of the enantiomers, diastereomers, tautomers and any other isomeric forms of said compounds, be they explicitly or implicitly disclosed.

The acid addition salts of the pyrrolidine derivatives of formula (I) are prepared in a customary manner by mixing the free base with a corresponding acid, optionally in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl tert-butyl ether or diisopropyl ether, a ketone, such as acetone or methyl ethyl ketone, or an ester, such as ethyl acetate.

The compounds of the formula (I) are capable of inhibiting the activity of glycine transporter, in particular glycine transporter 1 (GlyT1).

The utility of the compounds in accordance with the present invention as inhibiting the glycine transporter activity, in particular GlyT1 activity, may be demonstrated by methodology known in the art. For instance, human GlyT1c expressing recombinant hGlyT1c_5_CHO cells can be used for measuring glycine uptake and its inhibition (IC₅₀) by a compound of formula (I).

Amongst the compounds of the formula (I) those are preferred which achieve effective inhibition at low concentrations. In particular, compounds of the formula (I) are preferred which inhibit glycine transporter 1 (GlyT1) at a level of IC₅₀<1 μMol, more preferably at a level of IC₅₀<0.5 μMol, particularly preferably at a level of IC₅₀<0.2 μMol and most preferably at a level of IC₅₀<0.1 μMol.

The compounds of formula (I) display good to moderate metabolic stability.

The metabolic stability of a compound can be measured for example by incubating a solution of this compound with liver microsomes from particular species (for example rat, dog or human) and determining the half-life of the compound under these conditions (R S Obach, Curr Opin Drug Discov Devel. 2001, 4, 36-44). It is possible in this connection to conclude from an observed longer half-life that the metabolic stability of the compound is improved. The stability in the presence of human liver microsomes is of particular interest because it makes it possible to predict the metabolic degradation of the compound in the human liver. Compounds with increased metabolic stability (measured in the liver microsome test) are therefore probably also degraded more slowly in the liver. The slower metabolic degradation in the liver may lead to higher and/or longer-lasting concentrations (active levels) of the compound in the body, so that the elimination half-life of the compounds of the invention is increased. Increased and/or longer-lasting active levels may lead to a better activity of the compound in therapeutic treatment. In addition, an improved metabolic stability may lead to an increased bioavailability after oral administration, because the compound is subject, after absorption in the intestine, to less metabolic degradation in the liver (so-called first pass effect). An increased oral bioavailability may, owing to an increased concentration (active level) of the compound, lead to a better activity of the compound after oral administration.

Amongst the compounds of the formula (I) those are particularly preferred which display good to moderate metabolic stability towards human liver microsomes. In particular, compounds of the formula (I) are preferred which display a microsomal clearance at a level of mCl <1000 μl/min/mg, more preferably at a level of mCl <500 μl/min/mg, particularly preferably at a level of mCl <100 μl/min/mg and most preferably at a level of mCl <50 μl/min/mg.

The compounds of the formula (I) according to the present invention are thus useful as pharmaceuticals.

The present invention therefore also relates to pharmaceutical compositions which comprise an inert carrier and a compound of the formula (I).

The present invention also relates to the use of the compounds of the formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GlyT1, and to corresponding methods of inhibiting the glycine transporter GlyT1.

The NMDA receptor is central to a wide range of CNS processes, and its role in a variety of diseases in humans or other species has been described. GlyT1 inhibitors slow the removal of glycine from the synapse, causing the level of synaptic glycine to rise. This in turn increases the occupancy of the glycine binding site on the NMDA receptor, which increases activation of the NMDA receptor following glutamate release from the presynaptic terminal Glycine transport inhibitors and in particular inhibitors of the glycine transporter GlyT1 are thus known to be useful in treating a variety of neurologic and psychiatric disorders. Further, glycine A receptors play a role in a variety of diseases in humans or other species. Increasing extracellular glycine concentrations by inhibiting glycine transport may enhance the activity of glycine A receptors. Glycine transport inhibitors and in particular inhibitors of the glycine transporter GlyT1 are thus useful in treating a variety of neurologic and psychiatric disorders.

The present invention thus further relates to the use of the compounds of the formula (I) for the manufacture of a medicament for treating a neurologic or psychiatric disorder, and to corresponding methods of treating said disorders.

According to a particular embodiment, the disorder is associated with glycinergic or glutamatergic neurotransmission dysfunction.

According to a further particular embodiment, the disorder is one or more of the following conditions or diseases: schizophrenia or a psychotic disorder including schizophrenia (paranoid, disorganized, catatonic or undifferentiated), schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance-induced psychotic disorder, including both the positive and the negative symptoms of schizophrenia and other psychoses; cognitive disorders including dementia (associated with Alzheimer's disease, ischemia, multi-infarct dementia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jacob disease, perinatal hypoxia, other general medical conditions or substance abuse); delirium, amnestic disorders or cognitive impairment including age related cognitive decline; anxiety disorders including acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety due to a general medical condition; substance-related disorders and addictive behaviors (including substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder; tolerance, dependence or withdrawal from substances including alcohol, amphetamines, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics); obesity, bulimia nervosa and compulsive eating disorders; bipolar disorders, mood disorders including depressive disorders; depression including unipolar depression, seasonal depression and post-partum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PDD), mood disorders due to a general medical condition, and substance-induced mood disorders; learning disorders, pervasive developmental disorder including autistic disorder, attention deficit disorders including attention-deficit hyperactivity disorder (ADHD) and conduct disorder; movement disorders, including akinesias and akinetic-rigid syndromes (including Parkinson's disease, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification), medication-induced parkinsonism (such as neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor), Gilles de la Tourette's syndrome, epilepsy, muscular spasms and disorders associated with muscular spasticity or weakness including tremors; dyskinesias [including tremor (such as rest tremor, postural tremor and intention tremor), chorea (such as Sydenham's chorea, Huntington's disease, benign hereditary chorea, neuroacanthocytosis, symptomatic chorea, drug-induced chorea and hemiballism), myoclonus (including generalised myoclonus and focal myoclonus), tics (including simple tics, complex tics and symptomatic tics), and dystonia (including generalised dystonia such as iodiopathic dystonia, drug-induced dystonia, symptomatic dystonia and paroxymal dystonia, and focal dystonia such as blepharospasm, oromandibular dystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia, dystonic writer's cramp and hemiplegic dystonia)]; urinary incontinence; neuronal damage including ocular damage, retinopathy or macular degeneration of the eye, tinnitus, hearing impairment and loss, and brain edema; emesis; and sleep disorders including insomnia and narcolepsy.

According to a further particular embodiment, the disorder is pain, in particular chronic pain and especially neuropathic pain.

Pain can be classified as acute and chronic pain. Acute pain and chronic pain differ in their etiology, pathophysiology, diagnosis and treatment.

Acute pain, which occurs following tissue injury, is self-limiting, serves as an alert to ongoing tissue damage and following tissue repair it will usually subside. There are minimal psychological symptoms associated with acute pain apart from mild anxiety. Acute pain is nociceptive in nature and occurs following chemical, mechanical and thermal stimulation of A-delta and C-polymodal pain receptors.

Chronic pain, on the other hand, serves no protective biological function. Rather than being the symptom of tissue damage it is a disease in its own right. Chronic pain is unrelenting and not self-limiting and can persist for years, perhaps decades after the initial injury. Chronic pain can be refractory to multiple treatment regimes. Psychological symptoms associated with chronic pain include chronic anxiety, fear, depression, sleeplessness and impairment of social interaction. Chronic non-malignant pain is predominantly neuropathic in nature and involves damage to either the peripheral or central nervous systems.

Acute pain and chronic pain are caused by different neuro-physiological processes and therefore tend to respond to different types of treatments. Acute pain can be somatic or visceral in nature. Somatic pain tends to be a well localised, constant pain and is described as sharp, aching, throbbing or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing or colicky in nature. Examples of acute pain include post-operative pain, pain associated with trauma and the pain of arthritis. Acute pain usually responds to treatment with opioids or non-steroidal anti-inflammatory drugs.

Chronic pain, in contrast to acute pain, is described as burning, electric, tingling and shooting in nature. It can be continuous or paroxysmal in presentation. The hallmarks of chronic pain are chronic allodynia and hyperalgesia. Allodynia is pain resulting from a stimulus that normally does not ellicit a painful response, such as a light touch. Hyperalgesia is an increased sensitivity to normally painful stimuli. Primary hyperalgesia occurs immediately within the area of the injury. Secondary hyperalgesia occurs in the undamaged area surrounding the injury. Examples of chronic pain include complex regional pain syndrome, pain arising from peripheral neuropathies, post-operative pain, chronic fatigue syndrome pain, tension-type headache, pain arising from mechanical nerve injury and severe pain associated with diseases such as cancer, metabolic disease, neurotropic viral disease, neurotoxicity, inflammation, multiple sclerosis or any pain arising as a consequence of or associated with stress or depressive illness.

Although opioids are cheap and effective, serious and potentially life-threatening side effects occur with their use, most notably respiratory depression and muscle rigidity. In addition the doses of opioids which can be administered are limited by nausea, emesis, constipation, pruritis and urinary retention, often resulting in patients electing to receive sub-optimal pain control rather than suffer these distressing side-effects. Furthermore, these side-effects often result in patients requiring extended hospitalisation. Opioids are highly addictive and are scheduled drugs in many territories.

The compounds of formula (I) are particularly useful in the treatment of schizophrenia, bipolar disorder, depression including unipolar depression, seasonal depression and post-partum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PDD), learning disorders, pervasive developmental disorder including autistic disorder, attention deficit disorders including Attention-Deficit/Hyperactivity Disorder, tic disorders including Tourette's disorder, anxiety disorders including phobia and post traumatic stress disorder, cognitive disorders associated with dementia, AIDS dementia, Alzheimer's, Parkinson's, Huntington's disease, spasticity, myoclonus, muscle spasm, tinnitus and hearing impairment and loss are of particular importance.

Particular cognitive disorders are dementia, delirium, amnestic disorders and cognitive impairment including age-related cognitive decline.

Particular anxiety disorders are generalized anxiety disorder, obsessive-compulsive disorder and panic attack.

Particular schizophrenia or psychosis pathologies are paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorder.

Particular neurologic disorders that can be treated with the compounds of the formula (I) include in particular a cognitive disorder such as dementia, cognitive impairment, attention deficit hyperactivity disorder.

Particular psychiatric disorders that can be treated with the compounds of the formula (I) include in particular an anxiety disorder, a mood disorder such as depression or a bipolar disorder, schizophrenia, a psychotic disorder.

Within the context of the treatment, the use according to the invention of the compounds of the formula (I) involves a method. In this method, an effective quantity of one or more compounds or the formula (I), as a rule formulated in accordance with pharmaceutical and veterinary practice, is administered to the individual to be treated, preferably a mammal, in particular a human being. Whether such a treatment is indicated, and in which form it is to take place, depends on the individual case and is subject to medical assessment (diagnosis) which takes into consideration signs, symptoms and/or malfunctions which are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.

As a rule, the treatment is effected by means of single or repeated daily administration, where appropriate together, or alternating, with other drugs or drug-containing preparations.

The invention also relates to the manufacture of pharmaceutical compositions for treating an individual, preferably a mammal, in particular a human being. Thus, the compounds of the formula (I) are customarily administered in the form of pharmaceutical compositions which comprise an inert carrier (e.g. a pharmaceutically acceptable excipient) together with at least one compound according to the invention and, where appropriate, other drugs. These compositions can, for example, be administered orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly or intranasally.

Examples of suitable pharmaceutical formulations are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar-coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, suppositories or vaginal medicinal forms, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example lotions, injection preparations and infusion preparations, and eyedrops and eardrops. Implanted release devices can also be used for administering inhibitors according to the invention. In addition, it is also possible to use liposomes or microspheres.

When producing the compositions, the compounds according to the invention are optionally mixed or diluted with one or more carriers (excipients). Carriers (excipients) can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound.

Suitable carriers (excipients) are listed in the specialist medicinal monographs. In addition, the formulations can comprise pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resin; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refatting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils. A formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H. P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4^(th) edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.

The compounds of formula (I) may also be suitable for combination with other therapeutic agents.

Thus, the present invention also provides:

i) a combination comprising a compound of formula (I) with one or more further therapeutic agents;

ii) a pharmaceutical composition comprising a combination product as defined in i) above and at least one carrier, diluent or excipient;

iii) the use of a combination as defined in i) above in the manufacture of a medicament for treating or preventing a disorder, disease or condition as defined herein;

iv) a combination as defined in i) above for use in treating or preventing a disorder, disease or condition as defined herein;

v) a kit-of-parts for use in the treatment of a disorder, disease or condition as defined herein, comprising a first dosage form comprising a compound of formula (I) and one or more further dosage forms each comprising one or more further therapeutic agents for simultaneous therapeutic administration,

vi) a combination as defined in i) above for use in therapy;

vii) a method of treatment or prevention of a disorder, disease or condition as defined herein comprising administering an effective amount of a combination as defined in i) above;

viii) a combination as defined in i) above for treating or preventing a disorder, disease or condition as defined herein.

The combination therapies of the invention may be administered adjunctively. By adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) and at least one further therapeutic agent are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilized on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.

The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.

In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one antipsychotic agent. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.

In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I). The invention further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I).

In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one antipsychotic agent. The invention further provides the use of a combination of compounds of formula (I) and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides a combination of compounds of formula (I) and at least one antipsychotic agent for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder. The invention further provides at least one antipsychotic agent for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a psychotic disorder.

In further aspects, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent, the use of a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent in the manufacture of a medicament for the treatment of a psychotic disorder, and a pharmaceutical composition comprising compounds of formula (I) and at least one mood stabilising or antimanic agent for use in the treatment of a psychotic disorder.

Antipsychotic agents include both typical and atypical antipsychotic drugs. Examples of antipsychotic drugs that are useful in the present invention include, but are not limited to: butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benziso-thiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole; and derivatives thereof that have antipsychotic activity.

Examples of tradenames and suppliers of selected antipsychotic drugs are as follows: clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldlinc, UDL, Novartis); olanzapine (available under the tradename ZYPREX®, from Lilly); ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); haloperidol (available under the tradename HALDOL®, from OrthoMcNeil); chlorpromazine (available under the tradename THORAZINE®, from SmithKline Beecham (GSK)); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); thiothixene (available under the tradename NAVANE®, from Pfizer); trifluoperazine (10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from Smith Klein Beckman); perphenazine (available under the tradename TRILAFON®; from Schering); thioridazine (available under the tradename MELLARIL®; from Novartis, Roxane, HiTech, Teva, and Alpharma); molindone (available under the tradename MOBAN®, from Endo); and loxapine (available under the tradename LOXITANE (D; from Watson). Furthermore, benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®) may be used. Other antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), ziprasidone, and hoperidone.

In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease.

In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by adjunctive therapeutic administration of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I). The invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for adjunctive therapeutic administration for the treatment of a neurodegenerative disorder such as Alzheimer Disease in a patient receiving therapeutic administration of compounds of formula (I).

In a further aspect, the invention provides a method of treatment of a neurodegenerative disorder such as Alzheimer Disease by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides the use of at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease. The invention further provides at least one agent suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease for simultaneous therapeutic administration with compounds of formula (I) in the treatment of a neurodegenerative disorder such as Alzheimer Disease.

Examples of agents suitable for the treatment of a neurodegenerative disorder such as Alzheimer Disease that are useful in the present invention include, but are not limited to: cholinesterase inhibitors, agents targeting nicotinic or muscarinic acethylcholine receptors, NMDA receptors, amyloid formation, mitochondrial dysfunctions, disease associated calpain activity, neuroinflamation, tumor necrosis factor receptors, NF-kappaB, peroxisome proliferator activator receptor gamma, Apolipoprotein E variant 4 (ApoE4), disease-associated increase of the HPA axis, epileptic discharges, vascular dysfunction, vascular risk factors, and oxidative stress.

Suitable cholinesterase inhibitors which may be used in combination with the compounds of the inventions include for example tacrine, donepezil, galantamine and rivastigmine.

Suitable NMDA receptors targeting agents which may be used in combination with the compounds of the inventions include for example memantine.

Suitable agents affecting increased HPA axis activity which may be used in combination with the compounds of the inventions include for example CRF1 antagonists or V1b antagonists.

In a further aspect therefore, the invention provides a method of treatment of pain by adjunctive therapeutic administration of compounds of formula (I) to a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain. In a further aspect, the invention provides the use of compounds of formula (I) in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain. The invention further provides compounds of formula (I) for use for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of at least one agent suitable for the treatment of pain.

In a further aspect, the invention provides a method of treatment of pain by adjunctive therapeutic administration of at least one agent suitable for the treatment of pain to a patient receiving therapeutic administration of compounds of formula (I). In a further aspect, the invention provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of compounds of formula (I). The invention further provides at least one agent suitable for the treatment of pain for adjunctive therapeutic administration for the treatment of pain in a patient receiving therapeutic administration of compounds of formula (I).

In a further aspect, the invention provides a method of treatment of pain by simultaneous therapeutic administration of compounds of formula (I) in combination with at least one agent suitable for the treatment of pain. The invention further provides the use of a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of pain. The invention further provides a combination of compounds of formula (I) and at least one agent suitable for the treatment of pain for simultaneous therapeutic administration in the treatment of pain. The invention further provides the use of compounds of formula (I) in the manufacture of a medicament for simultaneous therapeutic administration with at least one agent suitable for the treatment of pain in the treatment of pain. The invention further provides compounds of formula (I) for use for simultaneous therapeutic administration with at least one agent suitable for the treatment of pain in the treatment of pain. The invention further provides the use of at least one agent suitable for the treatment of pain in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain. The invention further provides at least one agent suitable for the treatment of pain for simultaneous therapeutic administration with compounds of formula (I) in the treatment of pain.

Examples of agents suitable for the treatment of pain that are useful in the present invention include, but are not limited to: NSAIDs (Nonsteroidal Antiinflammatory Drugs), anticonvulsant drugs such as carbamazepine and gabapentin, sodium channel blockers, antidepressant drugs, cannabinoids and local anaesthetics.

Suitable agents used in combination with the compounds of the inventions include for example celecoxib, etoricoxib, lumiracoxib, paracetamol, tramadol, methadone, venlafaxine, imipramine, duloxetine, bupropion, gabapentin, pregabalin, lamotrigine, fentanyl, parecoxib, nefopam, remifentanil, pethidine, diclofenac, rofecoxib, nalbuphine, sufentanil, pethidine, diamorphine and butorphanol.

It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, antidepressant agents such as 5HT3 antagonists, serotonin agonists, NK-1 antagonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants, dopaminergic antidepressants, H3 antagonists, 5HT1A antagonists, 5HT1B antagonists, 5HT1D antagonists, D1 agonists, M1 agonists and/or anticonvulsant agents, as well as cognitive enhancers.

Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.

Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.

Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.

Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.

Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptiline, chlomipramine and nortriptiline.

Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.

Suitable anticonvulsant agents which may be used in combination of the compounds of the invention include for example divalproex, carbamazepine and diazepam.

The following examples serve to explain the invention without limiting it.

The compounds were characterized by mass spectrometry, generally recorded via HPLC-MS in a fast gradient on C18-material (electrospray-ionisation (ESI) mode).

Preparation Examples

Abbreviations:

APCI for atmospheric pressure chemical ionization; AcOH for acetic acid; Boc for tert-butoxy carbonyl; Bu for butyl; DCI for desorption chemical ionization; DCM for dichloromethane; dimethylsulfoxide for dimethyl sulfoxide; eq for equivalent(s); ESI for electrospray ionization; EtOAc for ethyl acetate; HATU for [o-(azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate]; HCl for hydrochloric acid; HPLC for high performance liquid chromatography; id for internal diameter; LCMS for liquid chromatography/mass spectrometry; MeOH for methanol; MgSO4 for magnesium sulfate; MP for macroporous resin; NaOAc for sodium acetate; PS for polymer supported; psi for pounds per square inch; SFC for supercritical fluid chromatography; SPE for solid phase extraction, and tBu for tert-butyl.

Definitions:

Similarly indicates that that reactants may be substituted for other the reactants described, the temperature may vary by 50° C., the equivalents may differ by upto 2 fold, or any combination thereof.

Preparative HPLC Procedure:

Samples were purified by preparative HPLC on a Phenomenex® Luna® C8(2) 5 μm 100 Å AXIA™ column (30 mm×75 mm) A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/minute (0-0.5 minutes 10% A, 0.5-7.0 minutes linear gradient 10-95% A, 7.0-10.0 minutes 95% A, 10.0-12.0 minutes linear gradient 95-10% A). Samples were injected in 1.5 mL dimethyl sulfoxide:methanol (1:1). With specified samples, ammonium acetate was used instead of trifluoroacetic acid. A custom purification system was used, consisting of the following modules: Waters LC4000 preparative pump; Waters 996 diode-array detector; Waters 717+ autosampler; Waters SATIN module, Alltech Varex III evaporative light-scattering detector; Gilson 506C interface box; and two Gilson FC204 fraction collectors. The system was controlled using Waters Millennium32 software, automated using an Abbott developed Visual Basic application for fraction collector control and fraction tracking. Fractions were collected based upon UV signal threshold and selected fractions subsequently analyzed by flow injection analysis mass spectrometry using positive APCI ionization on a Finnigan LCQ using 70:30 methanol:10 mM NH₄OH(aqueous) at a flow rate of 0.8 mL/minute. Loop-injection mass spectra were acquired using a Finnigan LCQ running LCQ Navigator 1.2 software and a Gilson 215 liquid handler for fraction injection controlled by an Abbott developed Visual Basic application.

For chiral compounds the absolute configuration is indicated in their chemical names. A chemical name with “trans” or no stereochemistry information does not refer to a chiral compound (even if the corresponding formula depicts a chiral compound).

Example 1 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide Example 1A

To a solution of trans-tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate (0.305 g, 1.163 mmol) and 2-chloro-3-(trifluoromethyl)benzoic acid (0.261 g, 1.163 mmol) in dichloromethane (4.65 ml) was added triethylamine (0.486 ml, 3.49 mmol) and HATU (0.663 g, 1.744 mmol) and the mixture was stirred at room temperature for 2 hours. The reaction mixture was partitioned with water, the organic fraction was collected, and the aqueous fraction was washed with dichloromethane. The organic fractions were combined, dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (Anal ogix IntelliFlash 280, SF15-12) eluting with 30% ethyl acetate hexanes to afford the title compound. MS (ESI) m/z 469.3 [M+H]⁺

Example 1B 2-chloro-N-(trans-4-phenylpyrrolidin-3-yl)-3-(trifluoromethyl)benzamide hydrochloride

To a solution of Example 1A (0.32 g, 0.682 mmol) in dioxane (0.682 ml) was added HCl in dioxane (4M, 1.706 ml, 6.82 mmol) and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated and the solid was triturated twice with dichloromethane and the solvent was evaporated to afford the title compound. MS (ESI) m/z 369.2 [M+H]+

Example 1C 2-chloro-N-(trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-yl)-3-(trifluoromethyl)benzamide

To a solution of Example 1B (0.075 g, 0.185 mmol) in dichloromethane (0.740 ml) was added triethylamine (0.077 ml, 0.555 mmol) and 1-methyl-1H-imidazole-4-sulfonyl chloride (0.033 g, 0.185 mmol). The mixture was stirred at room temperature for 1 hour. The solvent was evaporated. The crude product was purified by HPLC to afford the title compound. MS (ESI) m/z 513.1 [M+H]+

Example 2 2-chloro-N-{trans-4-(4-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide Example 2A trans-1-benzyl-3-(4-methoxyphenyl)-4-nitropyrrolidine

To a solution of (E)-1-methoxy-4-(2-nitrovinyl)benzene (5.09 g, 28.4 mmol) and N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (8.07 g, 34.0 mmol) in 75 mL of dichloromethane at 0° C. under nitrogen was added trifluoroacetic acid (388 mg, 3.4 mmol) in one portion. The reaction was allowed to warm to ambient temperature and stirred for 16 hours. The reaction was then partitioned between dichloromethane and saturated sodium bicarbonate solution. The organic fraction was collected. The aqueous portion was washed with additional dichloromethane and the combined organic fractions were washed with water, brine and dried over sodium sulfate. The mixture was filtered, concentrated and purified on a silica gel flash column (7:3 hexane:ethyl acetate) to afford the title compound. MS (DCI) m/z 313.1 (M+H)⁺.

Example 2B trans-1-benzyl-4-(4-methoxyphenyl)pyrrolidin-3-amine

Example 2A (4.85 mg, 15.5 mmol) and tetrahydrofuran (100 mL) were added to a Raney nickel water slurry (Grace 2800, 5.00 g) in a stainless steel reactor. The vessel was pressurized with 30 psi of hydrogen and shaken at room temperature for 16 hours. The mixture was filtered through a nylon membrane concentrated and purified on a silica gel flash column (95:5 dichloromethane: 2N ammonia in methanol) to afford the title compound as colorless oil. MS (DCI) m/z 283.1 (M+H)⁺.

Example 2C tert-Butyl trans-1-benzyl-4-(4-methoxyphenyl)pyrrolidin-3-ylcarbamate

To a solution of 2.5 g (8.86 mmol) of Example 2B in tetrahydrofuran (20 ml) was added saturated sodium bicarbonate solution (20 ml) followed by di-tert-butyl dicarbonate (1.0 M solution in tetrahydrofuran, 10 ml, 10.0 mmol) at room temperature under nitrogen. The reaction was stirred for 1 hour and then partitioned between ethyl acetate and water. The organic fraction was collected. The aqueous portion was washed several additional times with ethyl acetate and the combined organic extracts were washed with brine and dried over sodium sulfate. The mixture was filtered, concentrated and purified on a silica gel flash column (3:2 ethyl acetate hexane) to afford the title compound. MS (DCI) m/z 383.2 (M+H)⁺.

Example 2D tert-butyl (3S,4R)-4-(4-methoxyphenyl)pyrrolidin-3-ylcarbamate

Example 2C (2.65 mg, 6.93 mmol) and 2,2,2-trifluoroethanol or tetrahydrofuran (40 mL) were added to 20% Pd(OH)₂/C (50% water, 0.530 g) in a stainless steel reactor. The vessel was pressurized with 30 psi of hydrogen and shaken at 50° C. for 30 minutes. The mixture was filtered through a nylon membrane, and the product was purified on a silica gel column (95:5 dichloromethane:2N ammonia in methanol) to afford the title compound. MS (DCI) m/z 293.1 (M+H)⁺.

Example 2E tert-butyl (trans-4-(4-methoxyphenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)carbamate

To a solution of the product from Example 2D (154 mg, 0.53 mmol), and triethylamine (152 mg, 1.5 mmol) in dichloromethane (8 ml) was added 1-methyl-1H-imidazole-4-sulfonyl chloride (108 mg, 0.60 mmol) in one portion at room temperature. 4-(dimethylamino)-pyridine (4 mg, 0.03 mmol) was added and the reaction stirred for two hours at room temperature. The reaction was concentrated and purified on a silica gel flash column (97:3 dichloromethane: 2N ammonia in methanol) to afford the title compound. MS (DCI) m/z 425.1 (M+H)⁺.

Example 2F trans-4-(4-methoxyphenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-amine

The product from Example 2E (195 mg, 0.46 mmol) was stirred with 1,4-dioxane (4 ml) and hydrogen chloride in 1,4-dioxane (4M, 4 ml, 16.0 mmol) at room temperature under nitrogen overnight. The reaction was concentrated and concentrated to afford the title compound as the hydrochloride salt. MS (DCI) m/z 325.0 (M+H)⁺.

Example 2G 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

A mixture of Example 2F, 2-chloro-3-(trifluoromethyl)benzoic acid (101 mg, 0.45 mmol), and N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (86 mg, 0.45 mmol) was stirred in a 1:1 solution of pyridine and N,N-dimethylformamide (5 ml) at room temperature under nitrogen for 16 hours. The reaction was concentrated and the residue was partitioned between ethyl acetate and water. The organic fraction was collected and the aqueous portion was washed with additional ethyl acetate. The combined organic fractions were washed with water, brine and dried over sodium sulfate. The mixture was filtered, concentrated and purified on a silica gel flash column (95:5 dichloromethane 2N ammonia in methanol) to afford the title compound. MS (ESI) m/z 543.2 (M+H)⁺.

Example 3 2-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide Example 3A trans-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedures described in Example 2A-2F substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 3B 2-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 2G substituting Example 3A for Example 2F. MS (ESI) m/z 531 (M+H)⁺.

Example 4 2-chloro-N-[trans-1-(methylsulfonyl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide Example 4A (E)-1,2,4-trifluoro-5-(2-nitrovinyl)benzene

A stirred solution containing 2,4,5-trifluorobenzaldehyde (16.2 g, 80.1 mmol), ammonium acetate (17.3 g, 225 mmol), nitromethane (12.2 mL, 225 mmol), and acetic acid (75 mL) was heated to 100° C. for 3 hours. The mixture was cooled to room temperature and partitioned between water and dichloromethane. The organic fraction was collected and the aqueous fraction was washed with dichloromethane. The organic fractions were combined and washed with sodium bicarbonate (aq.), brine, and water. The organic fraction was dried with sodium sulfate and purified via flash chromatography (0-100% EtOAc/hexanes) to provide the title compound.

Example 4B trans-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Examples 2A-2B substituting Example 4A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 4C N-(trans-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl)-2-chloro-3-(trifluoromethyl)benzamide

To a stirred solution of Example 4B (3.3 g, 10.7 mmol) in a 1:1 dimethylformamide:pyridine solution (20 mL) was added 2-chloro-3-(trifluoromethyl)benzoic acid (2.9 g, 12.9 mmol) and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.85 g, 15 mmol). The reaction was stirred at room temperature for 18 hours. The reaction mixture was concentrate. The reaction mixture was partitioned between, EtOAc (100 mL) and 1 M HCl (200 mL). The organic layer was collected. The aqueous fraction was washed with EtOAc (100 mL). The organic fractions were combined. Purification via flash chromatography (0-100% EtOAc/hexanes) provided the title compound.

2-chloro-3-(trifluoromethyl)-N-(trans-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl)benzamide

To a stirred solution of Example 4C (3.4 g, 6.63 mmol) in dichloroethane was added 1-chloroethyl carbonochloridate (1.0 g, 7.29 mmol). The reaction mixture was stirred at 80° C. for 2 hours. Some precipitate was collected via filtration to provide the title compound. The filtrate was concentrated and purified via flash chromatography (0-30% methanol/DCM) to provide the title compound.

Example 4E 2-chloro-N-[(trans-1-(methylsulfonyl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

To a stirred solution of Example 4D (50 mg, 0.18 mmol) in pyridine (2 mL) was added methanesulfonyl chloride (16 mg, 0.14 mmol). The reaction mixture stirred at 60° C. for 18 hours. The reaction mixture was then concentrated and purified via HPLC. MS (ESI) m/z 501 (M+H)⁺.

Example 13 2-chloro-N-{trans-4-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedures described in Example 2 substituting (E)-1-chloro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene. MS (DCI) m/z 547.0 (M+H)⁺

Example 14 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide Example 14A trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the conditions described in Example 2A-2F substituting (E)-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 14B 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-chloro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 445 (M+H)⁺.

Example 15 3-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-chloro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 445 (M+H)⁺.

Example 16 4-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 4-chloro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 445 (M+H)⁺.

Example 17 2-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-fluoro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 429 (M+H)⁺.

Example 18 3-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-fluoro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 429 (M+H)⁺.

Example 19 4-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 4-fluoro-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 429 (M+H)⁺.

Example 20 2-methoxy-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-methoxy-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 441 (M+H)⁺.

Example 21 3-methoxy-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-methoxy-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 441 (M+H)⁺.

Example 22 2-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-methyl-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 425 (M+H)⁺.

Example 23 3-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-methyl-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 425 (M+H)⁺.

Example 24 4-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 4-methyl-benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 425 (M+H)⁺.

Example 25 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 411 (M+H)⁺.

Example 26 2,4-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2,4-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 27 2-chloro-4-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-chloro-4-fluorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 463 (M+H)⁺.

Example 29 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N,4-diphenylpyrrolidin-3-amine

Under nitrogen, a pressure vial was charged with Example 14A (50 mg, 0.15 mmol), bromobenzene (23 mg, 0.15 mmol), 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine (5.0 mg, 0.02 mmol), tris(dibenzylidene-acetone)dipalladium(0) (6.7 mg, 7.3 μmol), sodium tert-butoxide (18 mg, 0.19 mmol), and toluene (1 mL). The reaction mixture was stirred at 80° C. for 3 hours. Then, the reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 383 (M+H)⁺.

Example 30 3,5-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 31 2,3-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2,3-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 32 2-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-cyanobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 436 (M+H)⁺.

Example 33 3-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-cyanobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 436 (M+H)⁺.

Example 34 4-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 4-cyanobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 436 (M+H)⁺.

Example 35 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 36 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 37 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 38 2-chloro-N-([trans-1-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide Example 38A (trans)-1-benzyl-4-phenylpyrrolidin-3-amine 2-chloro-N-(trans-4-phenylpyrrolidin-3-yl)-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedures described in Examples 2A-2B substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 38B 2-chloro-N-(trans-4-phenylpyrrolidin-3-yl)-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C-4D substituting Example 38A for Example 4B.

Example 38C 2-chloro-N-[trans-1-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4E substituting Example 38B for Example 4D and substituting 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 581 (M+H)⁺.

Example 39 2-chloro-N-[trans-1-{[1-(difluoromethyl)-3,5-dimethyl-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1-(difluoromethyl)-3,5-dimethyl-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (EST) m/z 577 (M+H)⁺.

Example 40 2-chloro-N-{trans-1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tort-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 561 (M+H)⁺.

Example 41 2-chloro-N-{trans-1-[(1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1,5-dimethyl-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 527 (M+H)⁺.

Example 42 2-chloro-N-{trans-1-[(1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 527 (M+H)⁺.

Example 43 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1-methyl-1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 513 (M+H)⁺.

Example 44 2-chloro-N-{trans-1-[(6-methoxypyridin-3-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 6-methoxypyridine-3-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 540 (M+H)⁺.

Example 45 2-chloro-N-[trans-4-phenyl-1-(pyridin-3-ylsulfonyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting pyridine-3-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 510 (M+H)⁺.

Example 46 2-chloro-N-[trans-4-phenyl-1-(1-pyrazol-4-ylsulfonyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1H-pyrazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 499 (M+H)⁺.

Example 47 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1-methyl-1H-pyrazole-5-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 513 (M+H)⁺.

Example 48 2-chloro-N-{trans-1-[(5-chloro-1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 5-chloro-1-methyl-1H-imidazole-4-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 547 (M+H)⁺.

Example 49 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4E substituting Example 38B for tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate and substituting 1-methyl-1H-pyrazole-3-sulfonyl chloride for methanesulfonyl chloride. MS (ESI) m/z 513 (M+H)⁺.

Example 50 trans-N-(4-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 29 substituting 1-bromo-4-methoxybenzene for bromobenzene. MS (ESI) m/z 413 (M+H)⁺.

Example 51 3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 29 substituting 3-bromobenzenenitrile for bromobenzene. MS (EST) m/z 408 (M+H)⁺.

Example 52 4-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 29 substituting 4-bromobenzenenitrile for bromobenzene. MS (ESI) m/z 408 (M+H)⁺.

Example 53 3-fluoro-4-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 29 substituting 4-bromo-3-fluorobenzonitrile for bromobenzene. MS (ESI) m/z 426 (M+H)⁺.

Example 54 2-chloro-N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedures described in Example 2 substituting (E)-1-fluoro-2-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene in Example 2A. MS (DCI) m/z 530.9 (M+H)⁺

Example 55 2-chloro-N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedures as described in Example 2 substituting (E)-1-fluoro-3-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene in Example 2A. MS (DCI) m/z 531.2 (M+H)⁺

Example 56 2-chloro-N-{trans-4-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to procedures described in Example 2 substituting (E)-1-chloro-3-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene in Example 2A. MS (DCI) m/z 547.5 (M+H)⁺

Example 57 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylphenyl)-4-phenylpyrrolidin-3-amine

Under nitrogen, a pressure vial was charged with Example 14A as a hydrochloric salt (100 mg, 0.30 mmol), 1-bromo-2-methylbenzene (55 mg, 0.32 mmol), 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine (10 mg, 0.03 mmol), tris(dibenzylidene-acetone)dipalladium(0) (13 mg, 0.02 mmol), sodium tert-butoxide (70 mg, 0.729 mmol), and toluene (2 mL). The reaction mixture was stirred at 80° C. for 6 hours. Then, the reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 397 (M+H)⁺.

Example 58 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-3-methylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 397 (M+H)⁺.

Example 59 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(4-methylphenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-methylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 397 (M+H)⁺.

Example 60 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 2-chloro-4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 513 (M+H)⁺.

Example 61 3-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 14A for Example 4B and substituting 3-chloro-4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 513 (M+H)⁺.

Example 62 2-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 3A for Example 4B and substituting 2-chloro-4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 531 (M+H)⁺.

Example 63 3-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 3A for Example 4B and substituting 3-chloro-4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 531 (M+H)⁺.

Example 64 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 3A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 65 3,5-dichloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the conditions described in Example 4C substituting Example 3A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 66 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 67 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 68 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 69 trans-N-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-2-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 401 (M+H)⁺.

Example 70 trans-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (APCI) m/z 401 (M+H)⁺.

Example 71 trans-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 401 (M+H)⁺.

Example 72 3-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 3-bromo-benzenonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 426 (M+H)⁺.

Example 73 trans-N-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-2-chlorobenzene for 1-bromo-2-methylbenzene. MS (APCI) m/z 418 (M+H)⁺.

Example 74 trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-3-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 417 (M+H)⁺.

Example 75 trans-N-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 417 (M+H)⁺.

Example 76 4-fluoro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-4-fluorobenzonitrile for 1-bromo-2-methylbenzene. MS (APCI) m/z 426 (M+H)⁺.

Example 77 2-fluoro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-2-fluorobenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 426 (M+H)⁺.

Example 78 3-fluoro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-5-fluorobenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 426 (M+H)⁺.

Example 79 2-chloro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 5-bromo-2-chlorobenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 442 (M+H)⁺.

Example 80 3-chloro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-5-chlorobenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 442 (M+H)⁺.

Example 81 4-chloro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-4-chlorobenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 442 (M+H)⁺.

Example 82 4-methyl-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-4-methylbenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 422 (M+H)⁺.

Example 83 2-methyl-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-2-methylbenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 422 (M+H)⁺.

Example 84 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylphenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A. MS (ESI) m/z 415 (M+H)⁺.

Example 85 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-methylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 415 (M+H)⁺.

Example 86 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(4-methylphenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-4-methylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 415 (M+H)⁺.

Example 87 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 88 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 89 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-4-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 90 trans-N-(2-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 91 trans-N-(3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 92 trans-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 93 trans-N-(2-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 94 trans-N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 95 trans-N-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-4-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 100 2-methoxy-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 5-bromo-2-methoxybenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 438 (M+H)⁺.

Example 101 3-methyl-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 3-bromo-5-methylbenzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 422 (M+H)⁺.

Example 102 5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-2-(trifluoromethoxy)benzonitrile

The title compound was prepared similarly to the conditions described in Example 57 substituting 5-bromo-2-(trifluoromethoxy)benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 476 (M-CH₃)⁺.

Example 115 2-chloro-N-{trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedures described in Example 2 substituting (E)-1-chloro-2-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene in Example 2A. MS (DCI) m/z 547.2 (M+H)⁺.

Example 122 N-[trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-yl]-4-(trifluoromethyl)benzamide Example 122A trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to Example 2A-2F substituting (E)(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting ethanesulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 122B N-[trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-yl]-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C substituting Example 122A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 427 (M+H)⁺.

Example 123 3,5-dichloro-N-[trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-yl]benzamide

The title compound was prepared similarly to Example 4C substituting Example 122A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 427 (M+H)⁺.

Example 124 2-chloro-N-[trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C substituting Example 122A for Example 4B. MS (ESI) m/z 461 (M+H)⁺.

Example 125 N-[trans-4-phenyl-1-(propyl sulfonyl)pyrrolidin-3-yl]-4-(trifluoromethyl)benzamide Example 125A

The title compound was prepared as an HCl salt similarly to the procedures described for Examples 2A-2F substituting (E)-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting propanesulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 125B N-[trans-4-phenyl-1-(propylsulfonyl)pyrrolidin-3-yl]-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 125A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 441 (M+H)⁺.

Example 126 3,5-dichloro-N-[trans-4-phenyl-1-(propylsulfonyl)pyrrolidin-3-yl]benzamide

The title compound was prepared similarly to Example 4C substituting Example 125A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 441 (M+H)⁺.

Example 127 2-chloro-N-[trans-4-phenyl-1-(propylsulfonyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C substituting Example 125A for Example 4B. MS (ESI) m/z 475 (M+H)⁺.

Example 128 N-{trans-1-[(cyclopropylmethyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide Example 128A trans-1-(cyclopropylmethylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedure described in Example 2A-2F substituting (E)-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting cyclopropylmethanesulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 128B N-{trans-1-[(cyclopropylmethyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C substituting Example 128A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (EST) m/z 453 (M+H)⁺.

Example 129 3,5-dichloro-N-{trans-1-[(cyclopropylmethyl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to Example 4C substituting Example 128A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 453 (M+H)⁺.

Example 130 2-chloro-N-{trans-1-[(cyclopropylmethyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to Example 4C substituting Example 128A for Example 4B. MS (ESI) m/z 487 (M+H)⁺.

Example 131 3-{[trans-1-(ethylsulfonyl)-4-phenylpyrrolidin-3-yl]amino}benzonitrile

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 122A for Example 14A and substituting 3-bromo-benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 356 (M+H)⁺.

Example 132 3-{[trans-4-phenyl-1-(propylsulfonyl)pyrrolidin-3-yl]amino}benzonitrile

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 125A for Example 14A and substituting 3-bromo-benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 370 (M+H)⁺.

Example 133 3-({trans-1-[(cyclopropylmethyl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 128A for Example 14A and substituting 3-bromo-benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 382 (M+H)⁺.

Example 134 N-{trans-1-[(4-methoxyphenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide Example 134A trans-1-(4-methoxyphenylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to Example 2A-2F substituting (E)(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting 4-methoxybenzene-1-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 134B N-{trans-1-[(4-methoxyphenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 134A for Example 4B and substituting 4-(trifluoromethyl)benzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 505 (M+H)⁺.

Example 135 3,5-dichloro-N-{trans-1-[(4-methoxyphenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 134A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 505 (M+H)⁺.

Example 136 2-chloro-N-{trans-1-[(4-methoxyphenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 134A for Example 4B. MS (ESI) m/z 539 (M+H)⁺.

Example 137 3-({trans-1-[(4-methoxyphenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 134A for Example 14A and substituting 3-bromo-benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 434 (M+H)⁺.

Example 142 3,5-dichloro-N-[trans-4-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}pyrrolidin-3-yl]benzamide Example 142A trans-4-phenyl-1-(4-(trifluoromethyl)phenylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to Example 2A-2F substituting (E)(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 142B 3,5-dichloro-N-[trans-4-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}pyrrolidin-3-yl]benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 142A for Example 4B and substituting 3,5-dichlorobenzoic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 543 (M+H)⁺.

Example 143 2-chloro-N-[trans-4-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 142A for Example 4B. MS (ESI) m/z 577 (M+H)⁺.

Example 144 3-{[trans-4-phenyl-1-{[4-(trifluoromethyl)phenyl]sulfonyl}pyrrolidin-3-yl]amino}benzonitrile

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 142A for Example 14A and substituting 3-bromo-benzonitrile for 1-bromo-2-methylbenzene. MS (ESI) m/z 472 (M+H)⁺.

Example 145 4-{[trans-3-benzyl-4-phenylpyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 145A (1-benzyl-4-phenylpyrrolidin-3-yl)(phenyl)methanone

A solution of N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (5.9 g, 0.025 mole) in dichloromethane (30 mL) was stirred under nitrogen, in an ice/methanol bath. Chalcone (4.16 g, 0.02 mole) was added dropwise and the mixture was stirred in the cold bath overnight. The reaction mixture was washed with aqueous sodium bicarbonate, brine, and dried over sodium sulfate. The solvent was evaporated to provide the title compound. MS (ESI) m/z 342 [M+H]⁺.

Example 145B 3-benzyl-4-phenylpyrrolidine hydrochloride

Example 145A (8.5 g, 0.025 mole) was hydrogenated with 10% Pd/C (0.25 g) in methanol (200 mL). The reaction mixture was filtered, dissolved in methanol (100 mL) and passed through Amberlite resin. The filtrate was concentrated, redissolved in toluene and concentrated. This procedure was repeated several times until the residue was dry. MS (ESI) m/z 338 [M+H]⁺.

Example 145C 4-(trans-3-benzyl-4-phenylpyrrolidin-1-ylsulfonyl)-1-methyl-1H-imidazole

To a solution of Example 145B (0.0767 g, 0.280 mmol) in dichloromethane (1.121 ml) was added triethylamine (0.156 ml, 1.121 mmol) and 1-methyl-1H-imidazole-4-sulfonyl chloride (0.051 g, 0.280 mmol), The mixture was stirred at room temperature for 15 minutes. The solvent was evaporated. The crude material was purified by HPLC to afford the title compound. MS (ESI) m/z 382.2 [M+H]⁺.

Example 148 trans-N-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

To a stirred solution of Example 3A (100 mg, 0.28 mmol) in a buffer 4 pH solution (5 mL, made from 48 g AcOH and 30.5 g NaOAc in 1 L methanol) was added benzaldehyde (24 mg, 0.22 mmol) and MgSO₄ (334 mg, 2.77 mmol). The reaction was allowed to stir for 1 hour at room temperature before MgSO₄ was removed via filtration. To the filtrate was added MP-cyanoborohydride (2.19 mmol/g, 380 mg, 0.83 mmol) and the reaction was allowed to stir for 24 hours. The resin was removed via filtration and purification via HPLC provided the title compound. MS (ESI) m/z 415 (M+H)⁺.

Example 149 trans-N-[2-chloro-3-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-chloro-3-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 150 trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 151 trans-N-[3-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 152 3-[({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)methyl]benzonitrile

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-cyanobenzaldehyde for benzaldehyde. MS (ESI) m/z 440 (M+H)⁺.

Example 153 trans-4-(4-fluorophenyl)-N-(2-methylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-methylbenzaldehyde for benzaldehyde. MS (ESI) m/z 429 (M+H)⁺.

Example 154 trans-4-(4-fluorophenyl)-N-(3 ethylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-methylbenzaldehyde for benzaldehyde. MS (ESI) m/z 429 (M+H)⁺.

Example 155 trans-4-(4-fluorophenyl)-N-(4-methylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 4-methylbenzaldehyde for benzaldehyde. MS (ESI) m/z 429 (M+H)⁺.

Example 156 trans-N-(4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 4-fluorobenzaldehyde for benzaldehyde. MS (ESI) m/z 433 (M+H)⁺.

Example 157 (cis)-N-benzyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 157A 1-benzyl-3-(benzylamino)-4-chloro-1H-pyrrole-2,5-dione

To a stirred solution of 3,4-dichlorofuran-2,5-dione (5 g, 30 mmol) in acetic acid (17 mL) was added benzylamine (3.2 g, 30 mmol) and the reaction was stirred at room temperature for 1 hour. More benzylamine (3.2 g, 30 mmol) was added and the reaction was heated to 100° C. for 2 hours. The reaction mixture was concentrated. The mixture was neutralized with aqueous sodium hydroxide and partitioned with ethyl acetate. The organic fraction was collected and concentrated. Purification via flash chromatography (0-60% EtOAc/hexanes) provided the title compound.

Example 157B 1-benzyl-3-(benzylamino)-4-chloro-1H-pyrrole-2,5-dione

To a solution of Example 157A (5.5 g, 16.8 mmol) in 1,2-dimethoxyethane (60 mL) was added phenylboronic acid (2.46 g, 20.2 mmol), dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (691 mg, 1.68 mmol), palladium(II) acetate (189 mg, 0.848 mmol), and potassium carbonate (2 M, 16.8 mL, 33.7 mmol). The reaction mixture was refluxed for 2 hours. The reaction was partitioned between water and EtOAc. The organic layer was collected and concentrated. Purification via flash chromatography (0-80% EtOAc/hexanes) provided the title compound.

Example 157C tert-butyl benzyl (1-benzyl-2,5-dioxo-4-phenyl-2,5-dihydro-1H-pyrrol-3-yl)carbamate

To a stirred solution of Example 157B (4.13 g, 11.2 mmol) and triethylamine (113 mg, 1.12 mmol) in dichloromethane (50 mL) at 0° C. was added di-tert-butyl dicarbonate (1 M in tetrahydrofuran, 12.3 mL, 12.3 mmol) and N,N-dimethylpyridin-4-amine (137 mg, 1.12 mmol). The reaction was allowed to warm to room temperature after 1 hour and stirred at room temperature for 24 hours. More di-tert-butyl dicarbonate (1 M in tetrahydrofuran, 3 mL, 3 mmol) was added and the reaction mixture stirred for 2 more hours. The reaction mixture was then concentrated. Purification via flash chromatography (0-10% methanol/DCM) provided the title compound.

Example 157D tert-butyl benzyl(cis-1-benzyl-2,5-dioxo-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 157C (25 mg, 0.053 mmol) in trifluoroethane (4 ml) in a 50 ml pressure bottle was added 20% Pd(OH)₂/C, wet (6.25 mg, 0.045 mmol). The reaction mixture stirred for 16 hours at 30 psi hydrogen and 50° C. The mixture was filtered through a nylon membrane and the filtrate was concentrated to provide the title compound.

Example 157E tert-butyl benzyl((cis)-1-benzyl-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 157D (2.5 g, 5.3 mmol) in tetrahydrofuran (50 mL) was added borane (1 M in tetrahydrofuran, 21.3 mL, 21.3 mmol). The reaction mixture was heated to 70° C. for 18 hours. The reaction was cooled to 50° C. and methanol (20 mL) was added slowly. The reaction mixture stirred for 1 hour. The reaction mixture was concentrated. Purification via flash chromatography (0-100% EtOAc/hexanes) provided the title compound.

Example 157F tert-butyl benzyl((cis)-4-phenylpyrrolidin-3-yl)carbamate

To a pressure vial was added Example 157E (801 mg, 1.810 mmol), tetrahydrofuran (20 ml) and Pd(OH)₂/C, (20%, wet, 160 mg, 1.141 mmol) and the reaction mixture was stirred for 16 hours at 30 psi of hydrogen at 50° C. The mixture was filtered through a nylon membrane and the filtrate was concentrated to provide the title compound.

Example 157G (cis)-N-benzyl-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2E-2F substituting Example 157F for Example 2D. MS (ESI) m/z 397 (M+H)⁺.

Example 158 trans-N-(3,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-1,2-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 159 trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 160 trans-N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 161 trans-N-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-1,2-dichlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 162 trans-N-(4-chloro-3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-1-chloro-2-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 163 trans-N-(2,3-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2,3-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 164 trans-N-(2,5-di fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2,5-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 165 trans-N-(2,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2,4-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 166 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2,3,4-trifluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2,3,4-trifluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 455 (M+H)⁺.

Example 167 trans-4-(4-fluorophenyl)-N-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2-fluoro-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 487 (M+H)⁺.

Example 168 trans-4-(4-fluorophenyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-fluoro-5-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 487 (M+H)⁺.

Example 169 trans-4-(4-fluorophenyl)-N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-2-fluoro-5-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 487 (M+H)⁺.

Example 170 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-isopropylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 443 (M+H)⁺.

Example 171 trans-N-(3-tert-butylphenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-tert-butylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 457 (M+H)⁺.

Example 172 trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-1-chloro-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 503 (M+H)⁺.

Example 173 trans-N-[3-chloro-4-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-2-chloro-1-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 503 (M+H)⁺.

Example 174 trans-N-(3-chloro-5-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-chloro-5-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 175 trans-N-(3-chloro-4,5-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-chloro-4,5-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 471 (M+H)⁺.

Example 176 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 485 (M+H)⁺.

Example 177 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromopyridine hydrochloride for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 178 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 2-bromopyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 179 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 3-bromopyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 180 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 2-bromo-6-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 181 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 3-bromo-5-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 182 4-{[3-(3-chlorobenzyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 182A 2-(3-chlorobenzyl)-3-(4-fluorophenyl)-4-nitrobutanal

To a solution of (E)-1-fluoro-4-(2-nitrovinyl)benzene (1 g, 6.0 mmol) in dichloromethane (10 mL) was added 3-(3-chlorophenyl)propanal (1 g, 5.9 mmol), triethylamine (50 mL), and L-proline (50 mg, 0.43 mmol). The mixture was allowed to stir for 16 hours and the crude material was purified by silica gel column chromatography e(25% ethyl acetate/hexanes) to provide the title compound (4:1 mixture of 2 diastereomers).

Example 182B 3-(3-chlorobenzyl)-4-(4-fluorophenyl)pyrrolidine

To a solution of Example 182A (0.92 g, 2.7 mmol) in methanol (5 mL) was added 50% acetic acid (aq) (5 mL) followed by zinc (6×200 mg, 19 mmol) and sodium cyanoborohydride (120 mg, 1.9 mmol). The mixture was allowed to stir for 30 minutes. Sodium hydroxide (1 M) was added to adjust the pH value to 8. Ethyl acetate was added and the solution partitioned. The organic fraction was collected and concentrated to provide the crude title compound.

Example 182C 4-{[3-(3-chlorobenzyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

To a solution of Example 182B (289 mg, 1.0 mmol) in dichloromethane (5 mL) was added triethylamine (130 mg, 1.3 mmol), and 1-methyl-1H-imidazole-4-sulfonyl chloride (180 mg, 1.0 mmol). The mixture was allowed to stir for 20 minutes and purified by silica gel column chromatography (100% ethyl acetate). The product was recrystallized in ethyl acetate to provide the title compound. MS (ESI) m/z 434/436 (3:1) (M+H)⁺.

Example 183 2-chloro-N-{(cis)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide Example 183A

A 20 mL pressure vial was charged with Example 157 (891.1 mg, 2.247 mmol), ethanol (6 mL) and dihydroxypalladium (60.2 mg, 0.429 mmol). The mixture was stirred under 60 psi of hydrogen at 50° C. for 1.5 hours. Another 60 mg of catalyst was added, and the hydrogenation was continued for 2 hours more. The mixture was filtered through a polypropylene membrane and concentrated to provide the title compound.

Example 183B 2-chloro-N-{(cis)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 183A for Example 4B. MS (ESI) m/z 513 (M+H)⁺.

Example 184 (cis)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N,4-diphenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 183A for Example 14A and substituting bromobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 383 (M+H)⁺.

Example 185 trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidin-3-amine Example 185A (E)-1-fluoro-3-(2-nitrovinyl)benzene

A stirred solution containing 3-fluorobenzaldehyde (9.95 g, 80.1 mmol), ammonium acetate (17.3 g, 225 mmol), nitromethane (12.2 mL, 225 mmol), and acetic acid (75 mL) was heated to 100° C. for 3 hours. The mixture was cooled to room temperature and partitioned between water and dichloromethane. The organic fraction was collected and the aqueous fraction was washed with dichloromethane. The organic fractions were combined and washed with sodium bicarbonate (aq.), brine, and water. The organic fraction was dried with sodium sulfate and purification via flash chromatography (10% EtOAc/hexanes) provided the title compound.

Example 185B trans-4-(3-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as the HCl salt similarly to the procedures described in Example 2A-2F substituting Example 185A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 185C trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting bromobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 401 (M+H)⁺.

Example 186 trans-N,4-bis(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 187 trans-4-(3-fluorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 188 trans-N-(3-chlorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 189 trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3-(trifluoromethane)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 190 trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-4-(trifluoromethane)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 191 N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 4-bromopyridine hydrochloride for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 192 trans-N-(3,4-dichlorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3,4-dichlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 193 trans-N-(4-chloro-3-fluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-4-chloro-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 194 trans-N-(3-chloro-4-fluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3-chloro-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 195 N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 2-bromo-6-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 196 N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 3-bromo-5-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 197 trans-N-(3,4-difluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 185B for Example 14A and substituting 1-bromo-3,4-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 198 trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl) sulfonyl]-N-phenylpyrrolidin-3-amine Example 198A trans-4-(2-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting (E)-1-fluoro-2-(2-nitrovinyl)benzene for (E)-(2-nitrovinyl)benzene.

Example 198B trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting bromobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 401 (M+H)⁺.

Example 199 trans-4-(2-fluorophenyl)-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 1-bromo-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 200 trans-4-(2-fluorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 1-bromo-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 201 trans-N-(3-chlorophenyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 1-bromo-3-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 202 trans-N-(4-chlorophenyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 1-bromo-4-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 203 N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 2-bromo-6-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 204 N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 198A for Example 14A and substituting 4-bromo-2-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 205 4-{[3-(2-bromobenzyl)-4-(2-bromophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 205A 2-(2-bromobenzyl)-3-(2-bromophenyl)-4-nitrobutanal

The title compound was prepared using the conditions described in Example 182A substituting (E)-1-bromo-2-(2-nitrovinyl)benzene for (E)-1-fluoro-4-(2-nitrovinyl)benzene and 3-(2-bromophenyl)propanal for 3-(3-chlorophenyl)propanal.

Example 205B 3-(2-bromobenzyl)-4-(2-bromophenyl)pyrrolidine

The title compound was prepared using the conditions described in Example 182B substituting Example 205A for Example 182A.

Example 205C 4-{[3-(2-bromobenzyl)-4-(2-bromophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the conditions described in Example 182C substituting Example 205B for Example 182B. MS (ESI) m/z 537/539/541 (1:2:1) (M+H)⁺.

Example 206 {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanol

To a solution of Example 242C (620 mg, 1.69 mmol) in 6 mL of tetrahydrofuran at −30° C. was added lithium aluminum hydride (2N in tetrahydrofuran, 0.93 mL, 1.86 mmol). The reaction mixture stirred at −30° C. for 30 min. The reaction mixture was quenched with a saturated sodium bicarbonate solution, and the solution was partitioned with EtOAc. The organic fraction was collected, washed with water dried over sodium sulfate, and concentrated to give the title compound. MS (ESI) m/z 340.0 (M+H)⁺.

Example 207 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromopyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 384 (M+H)⁺.

Example 208 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 3-bromopyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 384 (M+H)⁺.

Example 209 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromopyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 384 (M+H)⁺.

Example 210 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromo-6-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 452 (M+H)⁺.

Example 211 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-2-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 452 (M+H)⁺.

Example 212 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 452 (M+H)⁺.

Example 213 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 3-bromo-5-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 452 (M+H)⁺.

Example 214 trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 215 trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 216 trans-N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-1,2-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 217 trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-1-chloro-2-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 485 (M+H)⁺.

Example 218 trans-N-(3,4-dichlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-1,2-dichlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 219 trans-N-(3-chloro-4,5-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 5-bromo-1-chloro-2,3-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 220 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(propan-2-yl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-isopropylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 425 (M+H)⁺.

Example 221 trans-N-(3-tert-butylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-tert-butyl-benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 439 (M+H)⁺.

Example 222 trans-N-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2-fluoro-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 223 trans-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-fluoro-5-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 224 trans-N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2-fluoro-5-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 225 trans-N-(3-chloro-5-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-chloro-5-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 226 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 467 (M+H)⁺.

Example 227 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyrimidin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromo-4-(trifluoromethyl)pyrimidine for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 228 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}quinolin-7-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 7-bromoquinoline for 1-bromo-2-methylbenzene. MS (ESI) m/z 434 (M+H)⁺.

Example 229 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}quinolin-6-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 6-bromoquinoline for 1-bromo-2-methylbenzene. MS (ESI) m/z 434 (M+H)⁺.

Example 230 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}isoquinolin-6-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 6-bromoisoquinoline for 1-bromo-2-methylbenzene. MS (ESI) m/z 434 (M+H)⁺.

Example 231 trans-N-(2,3-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2,3-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 232 trans-N-(2,5-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2,5-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 233 trans-N-(2,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2,4-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 234 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2,3,4-trifluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-2,3,4-trifluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 437 (M+H)⁺.

Example 235 6-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromo-6-fluoropyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 236 2-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-2-fluoropyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 237 5-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 3-bromo-5-fluoropyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 402 (M+H)⁺.

Example 238 6-fluoro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 2-bromo-6-fluoropyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 420 (M+H)⁺.

Example 239 2-fluoro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-2-fluoropyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 420 (M+H)⁺.

Example 240 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 1-bromo-2-methylbenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 241 N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}isoquinolin-7-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 7-bromoisoquinoline for 1-bromo-2-methylbenzene. MS (ESI) m/z 434 (M+H)⁺.

Example 242 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidine-3-carboxamide Example 242A

A solution of (E)-methyl 3-(4-fluorophenyl)acrylate (10.52 g, 58.4 mmol) and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (19.41 g, 81.8 mmol) in 110 mL of dichloromethane was cooled to 0° C. Trifluoroacetic acid (0.495 ml, 6.42 mmol) was slowly added under N₂. The reaction mixture was stirred at 0° C. for 1 hour, then stirred at room temperature for 18 hours. The reaction mixture was partitioned with saturated sodium bicarbonate. The organic fraction was collected, concentrated, and purified by flash-chromatography on silica gel (20-30% ethyl acetate in hexane) to provide the title compound. MS (ESI) m/z 314.3 (M+H)⁺

Example 242B Trans-methyl 4-(4-fluorophenyl)pyrrolidine-3-carboxylate

Example 242A (17.98 g, 57.4 mmol) and tetrahydrofuran (10 ml) were added to 20% Pd(OH)₂/C, wet (3.60 g, 25.6 mmol) in a 250 mL SS pressure bottle and stirred for 16 hours under 30 psi of hydrogen at room temperature. The mixture was filtered through a nylon membrane and concentrated to provide the title compound. MS (ESI) m/z 224.0 (M+H)⁺.

Example 242C Trans-methyl 4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidine-3-carboxylate

To Example 242 B (12.74 g, 57.1 mmol) in 15 mL of dichloromethane were added triethylamine (12.13 g, 120 mmol) and 4-dimethylaminopyridine (0.35 g, 2.85 mmol). The reaction mixture was cooled to 0° C. 1-methyl-1H-imidazole-4-sulfonyl chloride (10.82 g, 59.9 mmol) was added portion wise at 0° C. The reaction mixture was slowly warmed up to room temperature and stirred for 1 hour. The reaction mixture was partitioned with dichloromethane, and water. The organic fraction was collected, washed with water, concentrated, and purified by flash-chromatography on silica gel (100% ethyl acetate) to afford the title compound. MS (ESI) m/z 368.0 (M+H)⁺.

Example 242D Trans-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidine-3-carboxylic acid

To Example 242C (3.67 g, 9.99 mmol) was added 4 mL of methanol. To this solution was added lithium hydroxide (1 M, methanol:water=5:3, 15 mL, 15 mmol). The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated, and the residue was then treated with hydrochloric acid (1 M, aq.) until pH=5. The reaction mixture was partitioned with ethyl acetate and the organic fraction was collected. The aqueous fraction was washed with ethyl acetate (3×), and the organic fractions were combined and concentrated to provide the title product. MS (ESI) m/z 354.0 (M+H)⁺.

Example 242E Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidine-3-carboxamide

To solution of Example 242D (150 mg, 0.42 mmol) in dimethylformamide/pyridine (1:1. 15 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (85 mg, 0.45 mmol) and aniline (41.5 mg, 0.45 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated purified by HPLC to provide the title product. MS (ESI) m/z 429.1 (M+H)⁺.

Example 243 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide

The title compound was prepared using the same sequence of steps described in Example 242 substituting 4-(trifluoromethyl)aniline for aniline. MS (ESI) m/z 497.0 (M+H)⁺.

Example 244 Trans-N-(3,5-dichlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedures described in Example 242 substituting 3,5-dichloroaniline for aniline. MS (ESI) m/z 497.1 (M+H)⁺.

Example 245 4-{[trans-3-(4-fluorophenyl)-4-(phenoxymethyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

To a solution of Example 206 (52 mg, 0.15 mmol) in tetrahydrofuran (1 mL) was added phenol (21.6 mg, 0.23 mmol), PS-triphenylphosphine (105 mg, 0.34 mmol, 3.2 mmol/g), and di-tert-butylazodicarboxylate (70.6 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was filtered and washed with methanol. The filtrate was concentrated and purified by HPLC to provide the title compound. MS (ESI) m/z 416.1 (M+H)⁺.

Example 246 4-{[trans-3-[(2,4-dichlorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedure described in Example 245 substituting 2,4-dichlorophenol for phenol. MS (ESI) m/z 484.1 (M+H)⁺.

Example 247 4-{[trans-3-(4-fluorophenyl)-4-{[3-(trifluoromethoxy)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedure described in Example 245 substituting 3-(trifluoromethoxy)phenol for phenol. MS (ESI) m/z 500.1 (M+H)⁺.

Example 248 4-{[trans-3-[(3-chlorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedure described in Example 245 substituting 3-chlorophenol for phenol. MS (ESI) m/z 450.1 (M+H)⁺.

Example 249 4-{[trans-3-{[4-chloro-3-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedures described in Example 245 substituting 4-chloro-3-(trifluoromethyl)phenol for phenol. MS (ESI) m/z 518.2 (M+H)⁺.

Example 250 4-{[trans-3-{[2-chloro-3-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedures as in Example 245 substituting 2-chloro-3-(trifluoromethyl)phenol for phenol. MS (ESI) m/z 518.1 (M+H)⁺.

Example 251 4-{[trans-3-[(3-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the procedure described in Example 245 substituting 3-fluorophenol for phenol. MS (ESI) m/z 434.1 (M+H)⁺.

Example 252 trans-4-(2-chlorophenyl)-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 252A trans-4-(2-chlorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting (E)-1-chloro-2-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 252B trans-4-(2-chlorophenyl)-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 252A for Example 14A and substituting 1-bromo-3-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 253 trans-4-(2-chlorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 253A trans-4-(2-chlorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 3A substituting (E)-1-chloro-2-(2-nitrovinyl)benzene for (E)-(2-nitrovinyl)benzene.

Example 253B trans-4-(2-chlorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 435 (M+H)⁺.

Example 254 trans-4-(2-chlorophenyl)-N-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-4-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 255 trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 485 (M+H)⁺.

Example 256 trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-4-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 485 (M+H)⁺.

Example 257 trans-N-(3-chloro-4-fluorophenyl)-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-3-chloro-4-fluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 469 (M+H)⁺.

Example 258 trans-4-(2-chlorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 1-bromo-4-fluoro-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 503 (M+H)⁺.

Example 259 N-{trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 253A for Example 14A and substituting 4-bromo-2-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 486 (M+H)⁺.

Example 260 trans-N-(2-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-chlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 449 (M+H)⁺.

Example 261 trans-N-(3-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-chlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 449 (M+H)⁺.

Example 262 trans-N-(4-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 4-chlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 449 (M+H)⁺.

Example 263 trans-N-(2-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-fluorobenzaldehyde for benzaldehyde. MS (ESI) m/z 433 (M+H)⁺.

Example 264 trans-N-(3-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-fluorobenzaldehyde for benzaldehyde. MS (ESI) m/z 433 (M+H)⁺.

Example 265 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(trifluoromethyl)benzyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 483 (M+H)⁺.

Example 266 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)benzyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 3-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 483 (M+H)⁺.

Example 267 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 483 (M+H)⁺.

Example 268 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-2-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting picolinaldehyde for benzaldehyde. MS (ESI) m/z 416 (M+H)⁺.

Example 269 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-3-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting nicotinaldehyde for benzaldehyde. MS (ESI) m/z 416 (M+H)⁺.

Example 270 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-4-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting isonicotinaldehyde for benzaldehyde. MS (ESI) m/z 416 (M+H)⁺.

Example 271 {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}(phenyl)methanone Example 271A Trans-4-(4-fluorophenyl)-N-methoxy-N-methyl-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidine-3-carboxamide

To a solution of Example 242D (610 mg, 1.73 mmol) in dimethylformamide (5 mL) was added triethylamine (0.52 mL, 3.71 mmol), N,O-dimethylhydroxylamine hydrochloride (236 mg. 2.42 mmol), and 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate (665 mg, 2.07 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic fraction was collected. The aqueous fraction was washed with ethyl acetate 3 more times. The combined organic fractions were dried over sodium sulfate, concentrated, and purified by flash-chromatography on silica gel (5-10% methanol in dichloromethane (with 0.5% volume triethylamine added)) to afford the title compound. MS (ESI) m/z 397.0 (M+H)⁺.

Example 271B {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}(phenyl)methanone

To a solution of Example 271A (113 mg, 0.29 mmol) in tetrahydrofuran (0.5 mL) was added phenylmagnesium bromide (0.57 mL, 0.57 mmol, 1.0 M in tetrahydrofuran) slowly at room temperature. The solution stirred for 1 hour. The reaction mixture was partitioned with saturated ammonium chloride (aq.) and the organic fraction was collected. The organic fraction was dried over sodium sulfate, concentrated, and purified by HPLC to afford the title compound. MS (ESI) m/z 414.1 (M+H)⁺.

Example 272 Trans-N-[2-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting 2-chloro-3-(trifluoromethyl)aniline for aniline. MS (ESI) m/z 531.1 (M+H)⁺.

Example 273 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting 3-(trifluoromethoxy)aniline for aniline. MS (ESI) m/z 513.1 (M+H)⁺.

Example 274 trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-fluoro-3-(trifluoromethyl)aniline for aniline. MS (ESI) m/z 515.1 (M+H)⁺.

Example 275 trans-N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting 3-chloro-4-fluoroaniline for aniline. MS (ESI) m/z 481.1 (M+H)⁺.

Example 276 trans-N-[3-chloro-4-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting 3-chloro-4-(trifluoromethyl)aniline for aniline. MS (ESI) m/z 531.1 (M+H)⁺.

Example 277 1-methyl-4-[(3-phenoxy-4-phenylpyrrolidin-1-yl)sulfonyl]-1H-imidazole

To a stirred solution of tert-butyl 3-hydroxy-4-phenylpyrrolidine-1-carboxylate (200 mg, 0.76 mmol) in tetrahydrofuran (5 mL) was added (Z)-di-tert-butyl diazene-1,2-dicarboxylate (262 mg, 1.1 mmol), phenol (72 mg, 0.76 mmol), and polystyrene triphenylphosphine resin (2.37 mmol/g, 961 mg, 2.3 mmol). The reaction mixture was stirred at room temperature for 18 hours before the resin was filtered off. The filtrate was concentrated. The concentrate was dissolved in dichloromethane (2 mL) and HCl (4M in dioxane, 2 mL, 8 mmol) was added. When LCMS showed that the reaction was complete the reaction mixture was concentrated. To a stirred solution of the concentrate in pyridine (4 mL) was added 1-methyl-1H-imidazole-4-sulfonyl chloride (165 mg, 0.91 mmol). The reaction mixture was warmed to 60° C. for 18 hours. The reaction was then concentrated. Purification via HPLC provided the title compound.

Example 278 trans-4-(2-chlorophenyl)-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 252A for Example 14A and substituting 1-bromo-3-chlorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 451 (M+H)⁺.

Example 279 trans-N-(2,4-dichlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 483 (M+H)⁺.

Example 280 trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 14A for Example 3A and substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 465 (M+H)⁺.

Example 281 trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 14A for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 499 (M+H)⁺.

Example 282 trans-N-(2,4-dichlorobenzyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 282A trans-4-(2-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as the HCl salt similarly to the procedure described in Example 2A-2F substituting (E)-1-fluoro-2-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 282B trans-N-(2,4-dichlorobenzyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 282A for Example 3A and substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 483 (M+H)⁺.

Example 283 trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 282A for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 284 trans-4-(2-chlorophenyl)-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 252A for Example 3A and substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 501 (M+H)⁺.

Example 285 trans-4-(2-chlorophenyl)-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 252A for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 533 (M+H)⁺.

Example 286 trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-3-yl)pyrrolidin-3-amine Example 286A trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-(pyridin-3-yl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the conditions described in Example 2A-2F substituting (E)-3-(2-nitrovinyl)pyridine for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 286B trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting 286A for Example 3A and substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 466 (M+H)⁺.

Example 287 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 288 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 3A for Example 14A and substituting 4-bromo-2-(trifluoromethyl)pyridine for 1-bromo-2-methylbenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 289 Trans-N-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting phenylmethanamine for aniline. MS (ESI) m/z 443.1 (M+H)⁺.

Example 290 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

To a solution of Example 242E (106.7 mg, 0.25 mmol) in dry tetrahydrofuran (0.7 mL) under argon, was added borane dimethyl sulfide complex (0.5 mL, 1.0 mmol, 2M in tetrahydrofuran). The reaction mixture was stirred at 60° C. for 5 hours and stirred at room temperature for 18 hours. Hydrochloric acid (0.5 mL of 0.5 N HCl) was carefully added. The reaction mixture was refluxed for 2 hours, then treated with sodium hydroxide (1N) to pH=8-9. The reaction mixture was portioned with ethyl acetate. The organic fraction was collected. The aqueous fraction was washed with dichloromethane. The organic fractions were combined, dried over sodium sulfate, concentrated, and purified by HPLC to afford the title compound. MS (ESI) m/z 415.1 (M+H)⁺.

Example 291 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline

The title compound was prepared using the procedure described in Example 290 substituting Example 243 for Example 242E. MS (ESI) m/z 483.1 (M+H)⁺.

Example 292 3,5-dichloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

The title compound was prepared using the procedure described in Example 290 substituting Example 244 for Example 242E. MS (ESI) m/z 483.1 (M+H)⁺.

Example 293 4-{[trans-3-(4-fluorophenyl)-4-{[3-(trifluoromethyl)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting 3-(trifluoromethyl)phenol for phenol. MS (ESI) m/z 484.1 (M+H)⁺

Example 294 4-{[trans-3-{[2-chloro-4-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting 3-chloro-4-hydroxybenzotrifluoride for phenol. MS (ESI) m/z 518.1 (M+H)⁺

Example 295 4-{[trans-3-(4-fluorophenyl)-4-{[4-fluoro-3-(trifluoromethyl)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting 4-fluoro-3-(trifluoromethyl)phenol for phenol. MS (ESI) m/z 502.1 (M+H)⁺.

Example 296 4-({trans-3-(4-fluorophenyl)-4-[(3-methylphenoxy)methyl]pyrrolidin-1-yl}sulfonyl)-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting m-cresol for phenol. MS (ESI) m/z 430.1 (M+H)⁺.

Example 297 (3-chlorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3-chlorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 448.1 (M+H)⁺.

Example 298 trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-fluoro-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 485 (M+H)⁺.

Example 299 trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting 1-bromo-4-chloro-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 501 (M+H)⁺.

Example 300 {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}(3-methylphenyl)methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting m-tolylmagnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 428.0 (M+H)⁺.

Example 301 (3-fluorophenyl){(trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3-fluorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 432.1 (M+H)⁺.

Example 302 {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[3-(trifluoromethyl)phenyl]methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3-(trifluoromethyl)phenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 482.1 (M+H)⁺.

Example 303 (4-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methasone

The title compound was prepared similarly to the procedure described in Example 271B substituting (4-fluorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 432.1 (M+H)⁺.

Example 304 trans-N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-chloro aniline for aniline. MS (ESI) m/z 463.0 (M+H)⁺.

Example 305 trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A For Example 14A and substituting 1-bromo-4-fluoro-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (EST) m/z 503 (M+H)⁺.

Example 306 trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the conditions described in Example 57 substituting Example 3A For Example 14A and substituting 1-bromo-4-chloro-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 519 (M+H)⁺.

Example 307 trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine Example 307A (E)-2-(2-nitrovinyl)pyridine

To a stirred solution of nitromethane (15.2 mL, 280 mmol) and 2-pyridinecarboxaldeyde (8.9 mL, 93 mmol) in toluene (100 mL) at room temperature was added 1,1,2,2,-tetramethylguanidine (1.2 mL, 9.3 mmol) followed by methanesulfonyl chloride (14.5 mL, 187 mmol). The reaction mixture was stirred for 5 minutes before triethylamine (26.1 mL, 187 mmol) was added. The reaction mixture was stirred for 30 minutes, then quenched with sodium bicarbonate (aq.) The organic fraction was collected. The aqueous fraction was washed with dichloromethane. All organic fractions were combined. Purification via flash chromatography provided the title compound.

Example 307B trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-(pyridin-2-yl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedures described in Example 2A-2F substituting Example 307A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 307C trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 307B for Example 3A and substituting 2,4-dichlorobenzaldehyde for benzaldehyde. MS (ESI) m/z 466 (M+H)⁺.

Example 308 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 286A for Example 14A and substituting 1-bromo-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 452 (M+H)⁺.

Example 309 4-{[3-(3-chlorobenzyl)-4-cyclopropylpyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 309A 2-(3-chlorobenzyl)-3-cyclopropyl-4-nitrobutanal

The title compound was prepared using the conditions described in Example 182A substituting (E)-(2-nitrovinyl)cyclopropane for (E)-1-fluoro-4-(2-nitrovinyl)benzene.

Example 309B 3-(3-chlorobenzyl)-4-cyclopropylpyrrolidine

The title compound was prepared using the conditions described in Example 182B substituting Example 309A for Example 182A.

Example 309 4-{[3-(3-chlorobenzyl)-4-cyclopropylpyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared using the conditions described in Example 182C substituting Example 309B for Example 182B. MS (ESI) m/z 380/382 (3:1) (M+H)⁺.

Example 310 N-[3-(difluoromethyl)-4-fluorophenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

To a 10 mL microwave vial was added 4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine hydrochloride (100 mg, 0.277 mmol) and premixed tris(dibenzylidene-acetone)dipalladium(0)sodium tert-butoxide 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (100 mg, 0.05:0.15:2), aldrich 715530). The solids were suspended in 1,2-dimethoxyethane, and 4-bromo-2-(difluoromethyl)-1-fluorobenzene (74.8 mg, 0.333 mmol) was added. The reaction vessel was capped and the reaction mixture was heated in a microwave (Biotage Initiator™, maximum 400 Watts) for 15 min at 130° C. The mixture was filtered through celite, concentrated, dissolved in 2 ml 50% methanol/dimethylsulfoxide, and purified by HPLC to provide the title compound. MS (ESI) m/z 469 (M+H)⁺.

Example 311 3-chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 276 for Example 242E. MS (ESI) m/z 517.0 (M+H)⁺.

Example 312 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 273 for Example 242E. MS (ESI) m/z 499 (M+H)⁺.

Example 313 4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 274 for Example 242E. MS (ESI) m/z 501.1 (M+H)⁺.

Example 314 3-chloro-4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 275 for Example 242E. MS (ESI) m/z 467.1 (M+H)⁺.

Example 315 N-benzyl-1-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 289 for Example 242E. MS (ESI) m/z 429.1 (M+H)⁺.

Example 316 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting m-toluidine for aniline. MS (ESI) m/z 443.0 (M+H)⁺

Example 317 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide

The title compound was prepared using the procedure described in Example 242E substituting 3-(trifluoromethyl)aniline for aniline. MS (ESI) m/z 497.0 (M+H)⁺.

Example 318 4-{[Trans-3-[(3-chloro-4-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting 3-chloro-4-fluorophenol for phenol. MS (ESI) m/z 468.1 (M+H)⁺.

Example 319 (4-Chloro-3-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (4-chloro-3-fluorophenyl) magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 466.1 (M+H)⁺.

Example 320 trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 286A for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 500 (M+H)⁺.

Example 321 (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 321A tert-butyl (3S,4R)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-ylcarbamate

The title compound was prepared similarly to the conditions described in Example 2A-2E substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene. A Chiral SFC separation provided the title compound. (Instrument: SFC200 Column: AD-H, 50×250 mm, 5 μm; Column Temperature: 35° C.; Mobile Phase: CO₂/methanol/diethylamine=80200.1; Flow rate: 180 g/min; Back Pressure: 100 Bar; Wavelength: 214 nm; Cycle time: 5.1 min; Injection: 2.0 mL Sample solution: 55 g in 500 mL methanol). Retention Time=4.03 minutes.

Example 321B (3S,4R)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedure described in Example 2F substituting Example 321A for Example 2E.

Example 321C (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 321B for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 322 (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 322A tert-butyl (3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-ylcarbamate

The title compound was prepared similarly to Example 321A. RT=5.73 minutes.

Example 322B (3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedure described in Example 2F substituting Example 322A for Example 2E.

Example 322C (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for benzaldehyde. MS (ESI) m/z 517 (M+H)⁺.

Example 323 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

Under nitrogen, a pressure vial was charged with Example 321B (100 mg, 0.27 mmol), 1-bromo-3-(trifluoromethoxy)benzene (67 mg, 0.27 mmol), 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine (9.5 mg, 0.03 mmol), tris(dibenzylidene-acetone)dipalladium(0) (13 mg, 0.014 mmol), sodium tert-butoxide (107 mg, 1.1 mmol), and dioxane (4 mL). The reaction mixture was stirred at 80° C. for 2 hours. Then, the reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 485 (M+H)⁺.

Example 324 (3S,4R)—N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 323 substituting 1-bromo-4-fluorobenzene for bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 419 (M+H)⁺.

Example 325 (3S,4R)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 323 substituting 1-bromo-3-chlorobenzene for bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 435 (M+H)⁺.

Example 326 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 323 substituting 1-bromo-3-(trifluoromethyl)benzene for bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 469 (M+H)⁺.

Example 327 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

Under nitrogen, a pressure vial was charged with Example 322B (100 mg, 0.28 mmol), 1-bromo-3-(trifluoromethyl)benzene (62 mg, 0.28 mmol), 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine (9.5 mg, 0.03 mmol), tris(dibenzylidene-acetone)dipalladium(0) (13 mg, 0.014 mmol), sodium tert-butoxide (107 mg, 1.1 mmol), and dioxane (4 mL). The reaction mixture was stirred at 80° C. for 2 hours. Then, the reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 469 (M+H)⁺.

Example 328 (3R,4S)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene, but the reaction only stirred for 1 hour. MS (ESI) m/z 435 (M+H)⁺.

Example 329 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 485 (M+H)⁺.

Example 330 (3R,4S)-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-4-fluorobenzene for 1-bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 419 (M+H)⁺.

Example 331 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-2-one Example 331A methyl 2-(3-chlorobenzyl)-4-nitro-3-phenylbutanoate

To a solution of diisopropylamine (210 mg, 2 mmol) in tetrahydrofurane (1 mL) at −78° C. was added butyllithium (1 mL, 2N, 2 mmol). The mixture was allowed to stir for 10 minutes. Then methyl 3-(3-chlorophenyl)propanoate in tetrahydrofurane (1 mL) was added. The mixture was allowed to stir for 30 minutes. (E)-(2-nitrovinyl)benzene in tetrahydrofuran (1 mL) was added. The mixture was allowed to stir for 1 hour, and partitioned with ammonium chloride (aq) and ethyl acetate. The organic fraction was collected and concentrated to provide the crude title compound.

Example 331B 3-(3-chlorobenzyl)-4-phenylpyrrolidin-2-one

To a solution of Example 331A in methanol (2 mL) was added an acetic acid solution (2 mL. 50% aq.), and zinc (6×130 mg, 12 mmol). The reaction mixture stirred for 2 hours. The reaction mixture was concentrated and partitioned between ethyl acetate and enough NaOH (1M aq.) to adjust the pH value to 10. The insoluble material was filtered off through celite. The organic fraction was collected, and dried over sodium hydroxide pellets for 16 hours. The mixture was washed with HCl(aq) and purified by silica gel flash chromatography (100% ethyl acetate) to afford the title compound.

Example 331C 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-2-one

To a solution of Example 331B (150 mg, 0.53 mmol) in tetrahydrofuran (1 mL) at −78° C. was added butyllithium (0.3 mL, 2 N, 0.6 mmol). The mixture was allowed to stir for 10 minutes. 1-Methyl-1H-imidazole-4-sulfonyl chloride (95 mg, 0.53 mmol) was added. The reaction stirred for 2 hours. The mixture was warmed to 20° C. and quenched with ammonium chloride (aq.) The mixture was extracted with ethyl acetate and purified by flash chromatography (10% methanol/ethyl acetate) followed by trituration in methanol. The precipitates were collected to afford the title compound. MS (ESI) m/z 430432 (3:1) (M+H)⁺.

Example 332 2-Chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline Example 332A Trans-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidine-3-carb aldehyde

To a solution of Example 206 (180 mg, 0.53 mmol) in dichloromethane (2 mL) was added Dess-MartinPeriodinane (450 mg, 1.06 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered and washed with dichloromethane. The filtrate was concentrated to afford the title compound. MS (EST) m/z 338.0 (M+H)⁺.

Example 332B 2-Chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline

To Example 332A (150 mg, 0.45 mmol) in methanol acetate buffer (2 mL, made from 48 g AcOH and 30.5 g NaOAc in 1 L methanol) was added 2-chloro-4-(trifluoromethyl)aniline (104 mg, 0.53 mmol) and sodium cyanoborohydride (42 mg, 0.67 mmol). The mixture was allowed to stir overnight. It was partitioned between dichloromethane and saturated sodium bicarbonate. Purification via HPLC afford the title compound. MS (ESI) m/z 517.0 (M+H)⁺.

Example 333 3-Chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 304 for Example 242E. MS (EST) m/z 449.1 (M+H)⁺.

Example 334 N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-methylaniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 316 for Example 242E. MS (ESI) m/z 429.1 (M+H)⁺.

Example 335 N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethyl)aniline

The title compound was prepared using the procedure as described in Example 290 substituting Example 317 for Example 242E. MS (ESI) m/z 483.1 (M+H)⁺.

Example 336 4-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-6-(trifluoromethyl)pyrimidine

The title compound was prepared using the procedure as described in Example 245 substituting 6-(trifluoromethyl)pyrimidin-4-ol for phenol. MS (ESI) m/z 486.1 (M+H)⁺.

Example 337 Trans-4-cyclopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine Example 337A Trans-1-benzyl-3-cyclopropyl-4-nitropyrrolidine

The title compound was prepared similarly to the procedure described in Example 2A substituting (E)-(2-nitrovinyl)cyclopropane for trans-4-methoxy-beta-nitrostyrene.

Example 337B Trans-1-benzyl-4-cyclopropylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 2B substituting Example 337A for Example 2A.

Example 337C tert-butyl (trans-1-benzyl-4-cyclopropylpyrrolidin-3-yl)carbamate

To a solution of Example 337B (1.0 g, 4.6 mmol) in ethyl acetate (10 mL) was added di-tert-butyl dicarbonate (1.4 g, 6.4 mmol). The mixture was allowed to stir for 1 hour. The mixture was concentrated and purified by silica gel column chromatography (50% ethyl acetate/hexanes) to afford the title compound.

Example 337D tert-butyl ((trans-4-cyclopropylpyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 337C for 2C.

Example 337E tert-butyl ((trans-4-cyclopropyl-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 2E substituting Example 337D for Example 2D.

Example 337F Trans-4-cyclopropyl-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-amine

To Example 337E (0.82 g, 2.2 mmol) in dioxane (5 mL), was added hydrochloric acid (4N in dioxane, 3 mL). The mixture was stirred overnight, concentrated, and partitioned between ethyl acetate and sodium hydroxide (1M). The organic fraction was dried over potassium carbonate, filtered, and concentrated to provide the title compound.

Example 337G Trans-4-cyclopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

To a solution of Example 337F (135 mg, 0.5 mmol) in dioxane (1 mL) was added 1-bromo-3-(trifluoromethyl)benzene (101 mg, 0.5 mmol), tris(dibenzylidene-acetone)dipalladium(0) (46 mg, 0.05 mmol), dicyclohexyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine (48 gm, 0.1 mmol), and sodium 2-methylpropan-2-olate (48 mg, 0.5 mmol). The mixture was heated at 110° C. for 2 hours, partitioned between ethyl acetate and ammonium chloride (aq), and purified by HPLC to give the title compound. MS (ESI) m/z 415 (M+H)⁺.

Example 338 Trans-N-(3-chlorophenyl)-4-cyclopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 381/383 (3:1) (M+H)⁺.

Example 339 4-{[3-(2-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 339A 2-(2-chlorophenyl)acetaldehyde

To 2-(2-chlorophenyl)ethanol (1 g, 6.39 mmol) in 10 mL of dichloromethane was added Dess-MartinPeriodinane (3.52 g, 8.3 mmol) at 0° C. This mixture was stirred at 0° C. for 1 hour. The mixture was filtered and washed with dichloromethane. The filtrate was concentrated to afford the title product.

Example 339B 2-(2-Chlorophenyl)-3-(4-fluorophenyl)-4-nitrobutanal

The title compound was prepared similarly to the procedure described in Example 182A substituting Example 339A for 3-(3-chlorophenyl)propanal.

Example 339C Trans-3-(2-chlorophenyl)-4-(4-fluorophenyl)pyrrolidine

The title compound was prepared similarly to the procedure described in Example 182B substituting Example 339B for Example 182A.

Example 339D 4-{[3-(2-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 182C substituting Example 339C for Example 182 B. MS (ESI) m/z 420.3 (M+H)⁺.

Example 340 4-{[3-(4-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 340A 2-(4-Chlorophenyl)acetaldehyde

The title compound was prepared similarly to the procedure described in Example 339A substituting 2-(4-chlorophenyl)ethanol for 2-(2-chlorophenyl)ethanol.

Example 340B 2-(4-Chlorophenyl)-3-(4-fluorophenyl)-4-nitrobutanal

The title compound was prepared similarly to the procedure described in Example 182A substituting Example 340A for 3-(3-chlorophenyl)propanal.

Example 340C

The title compound was prepared similarly to the procedure described in Example 182B substituting Example 340B for Example 182A.

Example 340D 4-{[3-(4-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 182C substituting Example 340C for Example 182B. MS (ESI) m/z 420.2 (M+H)⁺.

Example 341 2-chloro-4-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile

A 10 mL microwave vial was charged with Example 322B (100 mg, 0.277 mmol) and 100 mg of premixed tris(dibenzylidene-acetone)dipalladium(0)sodium tert-butoxide/2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.05:0.15:2), aldrich 715530). The solids were suspended in 1,2-dimethoxyethane and 4-bromo-2-chlorobenzonitrile (72.1 mg, 0.333 mmol) was added. The reaction vessel was capped and the reaction mixture heated under microwave conditions for 15 min at 130° C. The mixture was filtered through celite, concentrated, dissolved in 2 ml 50% MeOH/dimethylsulfoxide, and purified by reverse phase HPLC to obtain the title compound. MS (ESI) m/z 460 (M+H)⁺.

Example 342 2-fluoro-4-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the procedure described in Example 341 substituting 4-bromo-2-fluorobenzonitrile for 4-bromo-2-(difluoromethyl)benzonitrile. MS (ESI) m/z 444 (M+H)⁺.

Example 343 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylimidazolidin-2-one Example 343A N1-(3-chlorobenzyl)-1-phenylethane-1,2-diamine

To (3-chlorophenyl)methanamine (0.28 g, 2 mmol) in methanol (5 mL) was added (E)-(2-nitrovinyl)benzene (0.30 g, 2 mmol). The mixture was allowed to stir for 4 hours. A solution of acetic acid in water (50%, 2 mL) was added, followed by zinc (5×130 mg, 10 mmol). The mixture was allowed to stir for 1 hour and concentrated. NaOH (1 M) was added to adjust the pH to 10. Ethyl acetate was added and the solution partitioned. The organic fraction was collected, dried over potassium carbonate, filtered, and concentrated to provide the title compound.

Example 343B 1-(3-chlorobenzyl)-5-phenylimidazolidin-2-one

To a solution of Example 343A in dichloromethane (5 mL) at −78° C. was added triethylamine (100 mg, 1 mmol) and triphosgene (60 mg, 0.2 mmol). The reaction mixture was allowed to warm to room temperature and stir for 18 hours. The crude material was purified by flash chromatography (100% ethyl acetate) to afford the title compound.

Example 343C 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylimidazolidin-2-one

To a solution of Example 343B (60 mg, 0.2 mmol) in tetrahydrofuran (1 mL) at 0° C. was added sodium hydride (40 mg, 60%, 1 mmol) and 1-methyl-1H-imidazole-4-sulfonyl chloride (38 mg, 0.2 mmol). The mixture was stirred for 18 hours, quenched with ammonium chloride (aq). Ethyl acetate was added then the solution partitioned. The organic fraction was collected and concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 431433 (3:1) (M+H)⁺.

Example 344 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 307B for Example 337F. MS (ESI) m/z 452 (M+H)⁺.

Example 345 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 307B for Example 337F and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 418420 (3:1) (M+H)⁺.

Example 346 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-4-(trifluoromethyl)pyridine

The title compound was prepared similarly to the procedure described in Example 245 substituting 4-(trifluoromethyl)pyridin-2-ol for phenol. MS (ESI) m/z 485.1 (M+H)⁺.

Example 347 Trans-N-(3-cyanophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-aminobenzonitrile for aniline. MS (ESI) m/z 454.1 (M+H)⁺.

Example 348 4-{[Trans-3-[(4-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 245 substituting 4-fluorophenol for phenol. MS (ESI) m/z 434.1 (M+H)⁺.

Example 349 4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yloxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 341 substituting 1-bromo-3-isopropoxybenzene for 4-bromo-2-(difluoromethyl)-1-fluorobenzene. MS (ESI) m/z 459 (M+H)⁺

Example 350 N-[4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl]pyridazin-3-amine Example 350A 6-chloro-N-(4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)pyridazin-3-amine

4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine (100 mg, 0.308 mmol), 3,6-dichloro-pyridazine (46 mg, 0.308 mmol), N,N-diisopropylethyl amine (53.8 μl, 0.308 mmol), and 4 mL ethanol were placed in a 2-5 mL microwave vial and irradiated in a microwave (Biotage Initiator™, maximum 400 Watts) for 1 hour at 175° C. The reaction contents were concentrated, redissolved in 2 mL 50% dimethylsulfoxide/methanol and purified via reverse phase HPLC to yield the title compound.

Example 350B N-{4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridazin-3-amine

Example 350A (18 mg, 0.041 mmol) and methanol (4 ml) were added to 5% Pd/C, wet (4 mg, 0.940 μmol) and triethyl amine (8 mg, 0.082 mmol) in a 50 ml pressure bottle. The mixture stirred for 2 hours under 30 psi of hydrogen until HPLC indicated complete conversion. The mixture was filtered through a nylon membrane. Purification via HPLC provided the title compound. MS (ESI) m/z 459 (M+H)⁺.

Example 351 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 341 substituting 2-bromo-6-(trifluoromethyl)pyridine for 4-bromo-2-(difluoromethyl)-1-fluorobenzene. MS (ESI) m/z 470 (M+H)⁺.

Example 352 (3R,4S)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 341 substituting 4-bromo-2-chloro-1-fluorobenzene for 4-bromo-2-(difluoromethyl)-1-fluorobenzene. MS (ESI) m/z 453 (M+H)⁺.

Example 353 (3R,4S)—N-(3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 341 substituting 1-bromo-3-fluorobenzene for 4-bromo-2-(difluoromethyl)-1-fluorobenzene. MS (ESI) m/z 419 (M+H)⁺.

Example 354 Trans-N-(4-chlorobenzyl)-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 354A Trans-1-benzyl-3-methyl-3-nitro-4-phenylpyrrolidine

The title compound was prepared similarly to the procedure described in Example 2A substituting Example (E)-(2-nitroprop-1-en-1-yl)benzene for 4-methoxy-beta-nitrostyrene.

Example 354B Trans-1-benzyl-3-methyl-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 2B substituting Example 354A for Example 2A.

Example 354C Trans-3-methyl-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 354B for 2C.

Example 354D Trans-3-methyl-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 182C substituting Example 354C for Example 182B.

Example 354E Trans-N-(4-chlorobenzyl)-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

To a solution of Example 354D (100 mg, 0.28 mmol) in methanol acetate buffer (pH4, 1M, 1 mL, made from 48 g AcOH and 30.5 g NaOAc in 1 L methanol) was added 4-chlorobenzaldehyde (40 mg, 0.28 mmol) and sodium cyanoborohydride (40 mg, 0.65 mmol). The mixture was stirred for 18 hours and partitioned between ethyl acetate and NaOH (1 M). The organic fraction was collected, concentrated, and purified by HPLC to afford the title compound. MS (ESI) m/z 445447 (3:1) (M+H)⁺.

Example 355 Trans-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 479 (M+H)⁺.

Example 356 Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 514/516 (3:1) (M+H)⁺.

Example 357 (3,4-Difluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3,4-difluorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 450.2 (M+H)⁺.

Example 358 Trans-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-fluoroaniline for aniline. MS (ESI) m/z 447.1 (M+H)⁺.

Example 359 (3,4-Dichlorophenyl) {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3,4-dichlorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 482.1 (M+H)⁺.

Example 360 (3,5-Dichlorophenyl) {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3,5-dichlorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 482.1 (M+H)⁺.

Example 361 (3-Chloro-5-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3-chloro-5-fluorophenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 466.2 (M+H)⁺.

Example 362 {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[3-(trifluoromethoxy)phenyl]methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (3-(trifluoromethoxy)phenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 498.1 (M+H)⁺.

Example 363 {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[4-(trifluoromethoxy)phenyl]methanone

The title compound was prepared similarly to the procedure described in Example 271B substituting (4-(trifluoromethoxy)phenyl)magnesium bromide for phenylmagnesium bromide. MS (ESI) m/z 498.1 (M+H)⁺.

Example 364 3-[({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)amino]benzamide

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 347 for Example 242E. MS (ESI) m/z 458.1 (M+H)⁺.

Example 365 3-(Aminomethyl)-N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 347 for Example 242E. MS (ESI) m/z 444.1 (M+H)⁺.

Example 366 4-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-2-(trifluoromethyl)pyridine

The title compound was prepared similarly to the procedure described in Example 245 substituting 2-(trifluoromethyl)pyridin-4-ol for phenol. MS (ESI) m/z 485.1 (M+H)⁺.

Example 367 4-Fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 358 for Example 242E. MS (ESI) m/z 433.1 (M+H)⁺.

Example 368 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-bromo-4-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 470 (M+H)⁺.

Example 369 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)pyridin-2-yl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-(trifluoromethyl)pyridin-2-amine for aniline. MS (ESI) m/z 498.1 (M+H)⁺.

Example 370 Trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-fluoro-3-(trifluoromethoxy)aniline for aniline. MS (ESI) m/z 531.1 (M+H)⁺.

Example 371 Trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-chloro-3-(trifluoromethoxy)aniline for aniline. MS (ESI) m/z 547.1 (M+H)⁺.

Example 372 N-[4-chloro-2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)phenyl]acetamide

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 3A for Example 337F and N-(2-bromo-4-chlorophenyl)acetamide for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 492/494 (3:1) (M+H)⁺.

Example 373 Trans-4-[(3-chlorophenyl)amino]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-ol Example 373A (trans)-tert-butyl 3-((3-chlorophenyl)amino)-4-hydroxypyrrolidine-1-carboxylate

A mixture of 3-chloroaniline (0.38 g, 3 mmol) and tert-butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (0.56 g, 3 mmol) in ethanol (3 mL) was heated at 100° C. for 3 days. The mixture was concentrated and purified by flash chromatography (50% ethyl acetate/hexanes) to afford the title compound.

Example 373B Trans-4-((3-chlorophenyl)amino)pyrrolidin-3-ol

To a solution of Example 373A (0.97 g, 3.1 mmol) in dioxane (3 mL) at 0° C. was added hydrochloric acid (4N in dioxane, 5 mL). The mixture was allowed to stir for 5 hours. Concentration provided the title compound as the hydrochloride salt.

Example 373C Trans-4-[(3-chlorophenyl)amino]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin

To a solution of Example 373B in dichloromethane (5 mL) was added triethylamine (1 g, 10 mmol) and 1-methyl-1H-imidazole-4-sulfonyl chloride (540 mg, 3.0 mmol). The mixture was allowed to stir for 16 hours. The reaction mixture was concentrated and partitioned between ethyl acetate and NaOH (1 M). The organic fraction was collected, concentrated, and purified by flash chromatography (100% ethyl acetate) to afford the title compound. MS (ESI) m/z 357359 (3:1) (M+H)⁺.

Example 374 N-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-yl]-1-(trifluoromethyl)cyclopropanecarboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 307B for 242D and substituting 1-(trifluoromethyl)cyclopropanecarboxylic acid for aniline. MS (ESI) m/z 444.0 (M+H)⁺

Example 375 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-1-(trifluoromethyl)cyclopropanecarboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 322B for Example 242D and substituting 1-(trifluoromethyl)cyclopropanecarboxylic acid for aniline. MS (ESI) m/z 461.1 (M+H)⁺.

Example 376 4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 370 for Example 242E. MS (ESI) m/z 517.2 (M+H)⁺.

Example 377 4-chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 371 for Example 242E. MS (ESI) m/z 533.2 (M+H)⁺.

Example 378 Trans-N-(3-chlorophenyl)-4-(4-fluorophenoxy)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

To a solution of Example 373 (142 mg, 0.4 mmol) in dimethylformamide (0.2 mL) was added copper(I) iodide (40 mg, 0.2 mmol), cesium carbonate (300 mg, 0.92 mmol), and 1-fluoro-4-iodobenzene (88 mg, 0.4 mmol). The mixture was stirred at 110° C. for 16 hours, then partitioned between ethyl acetate and water. The organic fraction was collected, concentrated and purified by HPLC to provide the title compound. MS (ESI) m/z 452/454 (3:1) (M+H)⁺.

Example 379 2-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-4-(trifluoromethyl)pyridine Example 379A Trans-tert-butyl 3-(4-fluorophenyl)-4-hydroxypyrrolidine-1-carboxylate

To a solution of tert-butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (0.93 g, 5 mmol) in tetrahydrofuran (5 mL) at −78° C. was added copper(I) iodide (85 mg, 0.5 mmol) then (4-fluorophenyl)magnesium bromide (7 mL, 1 M, 7 mol). The mixture was warmed to room temperature and, allowed to stir for 3 hours. The reaction mixture was partitioned with ammonium chloride (aq). The organic fraction was collected dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 379B Trans-4-(4-fluorophenyl)pyrrolidin-3-ol

The title compound was prepared as the hydrochloride salt similarly to the procedure described in Example 373B substituting Example 379A for Example 373A.

Example 379C Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-ol

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 379B for Example 373B.

Example 379D 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-4-(trifluoromethyl)pyridine

To a solution of Example 379C (110 mg, 0.34 mmol) in dimethylsulfoxide (0.3 mL) was added potassium 2-methylpropan-2-olate (50 mg, 0.45 mmol) and 2-fluoro-4-(trifluoromethyl)pyridine (70 mg, 0.43 mmol). The mixture was stirred at 100° C. for 16 hours, then partitioned between ethyl acetate and water. Purification by HPLC provided the title compound. MS (ESI) m/z 471 (M+H)⁺.

Example 380 3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-amino)benzonitrile Example 380A (3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

Example 322B (2.53 g, 7.03 mmol) was partitioned between ethyl acetate (25 mL) and saturated sodium bicarbonate (aq. 10 mL). The organic fraction was collected. The aqueous fraction was washed with ethyl acetate 3 times. The combined organic fractions were dried over sodium sulfate and concentrated to give the title compound. MS (EST) m/z 325.3 (M+H)⁺.

Example 380B 3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting 3-bromobenzonitrile for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 426.1 (M+H)⁺.

Example 381 6-chloro-2-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-yl]-2,3-dihydro-1H-isoindol-1-one Example 381A Trans-N-(2-bromo-4-chlorobenzyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(pyridin-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 307B for Example 354D and 2-bromo-4-chlorobenzaldehyde for 4-chlorobenzaldehyde.

Example 381B 6-chloro-2-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-yl]-2,3-dihydro-1H-isoindol-1-one

To a solution of Example 381A (500 mg, 0.98 mmol) in methanol (5 mL) in a 50 mL pressure bottle was added 1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), (36 mg, 0.048 mmol) and triethylamine (0.27 mL, 2 mmol). The mixture was pressurized with Carbon Monoxide (60 psi), and stirred for 4 hours at 80° C. The insoluble materials were filtered off and the filtrate was purified by HPLC to provide the title compound. MS (ESI) m/z 458460 (3:1) (M+H)⁺.

Example 382 3-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-ol Example 382A 4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-one

To a solution of Example 379C (0.43 g, 1.3 mmol) in dichloromethane (3 mL) was added Dess-Martin periodinane (0.67 g, 1.6 mmol). The mixture was stirred overnight and partitioned between ethyl acetate and sodium hydroxide (1M aq.). The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 382B 3-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-

To a solution of Example 382A (50 mg) in tetrahydrofuran (0.5 mL) at −78° C. was added benzylmagnesiumbromide (1 M, 1 mL, 1 mmol). The mixture was allowed to stir at room temperature for 1 hour. The reaction mixture was partitioned between Ammonium chloride (aq) and ethyl acetate. The organic fraction was collected, concentrated, and purified by flash chromatography (100% ethyl acetate) to afford the title compound. MS (ESI) m/z 416 (M+H)⁺.

Example 383 N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridazin-3-amine Example 383A Trans-6-chloro-N-(4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)-5-(trifluoromethyl)pyridazin-3-amine

Example 3A (100 mg, 0.308 mmol), 3,6-dichloro-4-(trifluoromethyl)pyridazine (67 mg, 0.308 mmol), diisopropylethylamine (53.8 μl, 0.308 mmol), and ethanol (4 mL) were placed in a 2-5 mL microwave vial and irradiated for 1 hr at 175° C. The reaction contents were concentrated, redissolved in 2 mL 50% dimethylsulfoxide/methanol and purified via HPLC to provide the title compound. MS (ESI) m/z 505 (M+H)⁺.

Example 383B N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridazin-3-amine

The title compound was prepared similarly to the procedure described in Example 350B substituting 6-chloro-N-(4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-5-yl)-4-(trifluoromethyl)pyridazin-3-amine for 6-chloro-N-(4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)pyridazin-3-amine. MS (ESI) m/z 471 (M+H)+

Example 384 N-{4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridazin-3-amine

The title compound was prepared similarly to the procedure described in Example 350A-350B As both isomers are formed in 350A. MS (ESI) m/z 471 (M+H)+

Example 385 1-methyl-4-{[trans-3-phenyl-4-(phenylsulfonyl)pyrrolidin-1-yl]sulfonyl}-1H-imidazole Example 385A Trans-1-benzyl-3-phenyl-4-(phenylsulfonyl)pyrrolidine

The title compound was prepared similarly to the procedure described in Example 2A substituting phenyl trans-styryl sulfone for 4-methoxy-beta-nitrostyrene. MS (ESI) m/z 378.1 (M+H)⁺.

Example 385B Trans-3-phenyl-4-(phenylsulfonyl)pyrrolidine

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 385A for 2C. MS (ESI) m/z 288.1 (M+H)⁺.

Example 385C 1-Methyl-4-{trans-3-phenyl-4-(phenylsulfonyl)pyrrolidin-1-yl]sulfonyl}-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 2E substituting Example 385B for Example 2D. MS (ESI) m/z 432.1 (M+H)⁺.

Example 386 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[1-(trifluoromethyl)cyclopropyl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 375 for Example 242E. MS (ESI) m/z 447.1 (M+H)⁺.

Example 387 (3S,4R)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 389A for Example 337F and 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 453.2 (M+H)⁺.

Example 388 N-{Trans-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 354D for Example 337F and 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 466 (M+H)⁺.

Example 389 3-({(3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile Example 389A (3S,4R)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 321B for Example 322B. MS (ESI) m/z 307.1 (M+H)⁺.

Example 389B 3-({(3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile

The title compound was prepared similarly to the procedure described in Example 337G substituting 389A for Example 337F and substituting 3-bromobenzonitrile for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 426.3 (M+H)⁺.

Example 390 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 471.2 (M+H)⁺.

Example 391 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[5-(trifluoromethyl)furan-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 380A for Example 354D and substituting 5-(trifluoromethyl)furan-2-carbaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 473.1 (M+H)⁺.

Example 392 1,1,1-trifluoro-2-[3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)phenyl]propan-2-ol Example 392A 2-(3-Bromophenyl)-1,1,1-trifluoropropan-2-ol

To 1-(3-bromophenyl)ethanone (364 mg, 1.83 mmol) and (trifluoromethyl)trimethylsilane (3 mL, 1.46 mmol, 0.5 M in tetrahydrofuran) was added tetrabutylammonium fluoride (1 M in tetrahydrofurane, 2.0 mL, 2.0 mmol) at 0° C. The reaction mixture stirred at room temperature for 3 hours. The reaction mixture was partitioned with saturated sodium carbonate (aq.) and dichloromethane. The organic fraction was collected. The aqueous fraction was washed with dichloromethane 3 times. The combined organic fractions were washed with saturated brine, dried over sodium sulfate, concentrated, and purified by flash chromatography (5:1 EtOAc/hexanes) to afford the title compound.

Example 392B 1,1,1-trifluoro-2-[3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)phenyl]propan-2-ol

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting Example 392A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 513.3 (M+H)⁺.

Example 393 (3R,4S)—N-[(5-chlorothiophen-2-yl)methyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 380A for Example 354D and substituting 5-chlorothiophene-2-carbaldehyde for 4-chlorobenzaldehyde and. MS (ESI) m/z 455.3 (M+H)⁺.

Example 394 (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 380A for Example 354D and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 455.3 (M+H)⁺.

Example 395 (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 395A (3S,4R)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine hydrochloride

The title compound was prepared similarly to the conditions described in Example 2A-2F substituting (E)-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and separating the enantiomers produced from the procedure of Example 2C via Chiral SFC separation (SFC 200 Column: Whelk-O1, 50×250 mm, 5 μm Column Temperature: 35° C. Mobile Phase: CO₂/IPA/DEA=70/30/0.1 Flow rate: 70 g/min Back Pressure: 100 Bar Wavelength: 214 nm Cycle time: 5.0 min Injection: 4.0 mL Sample solution: 41000 mg in 250 mL methanol) RT=6.00 minutes.

Example 395B (3S,4R)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 395A for Example 322B. MS (ESI) m/z 307.1 (M+H)⁺.

Example 395 C (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 395B for Example 354D and substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 499.2 (M+H)⁺.

Example 396 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine Example 396A N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 574A for Example 322B. MS (ESI) m/z 307.1 (M+H)⁺.

Example 396B N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 452.2 (M+H)⁺.

Example 397 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F. MS (ESI) m/z 452.2 (M+H)⁺.

Example 398 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and Example 396A Example 354D. MS (ESI) m/z 465.1 (M+H)⁺.

Example 399 1,1,1-trifluoro-2-[3-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)phenyl]propan-2-ol

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and Example 392A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 495.1 (M+H)⁺.

Example 400 Trans-4-(benzyloxy)-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

To a solution of Example 373C (71 mg, 0.2 mmol) in tetrahydrofuran (0.5 mL) was added potassium tert-butoxide (22 mg, 0.2 mmol) and benzyl bromide (40 mg, 0.23 mmol). The mixture was allowed to stir at room temperature for 2 hours. The reaction mixture was then partitioned with water and ethyl acetate. The organic fraction was collected, concentrate, and purified by HPLC to provide the title compound. MS (ESI) m/z 447/449 (3:1) (M+H)⁺.

Example 401 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-3-{[4-(trifluoromethyl)benzyl]amino}pyrrolidin-3-yl]methanol Example 401A (E)-2-nitro-3-phenylprop-2-en-1-ol

To (E)-(2-nitrovinyl)benzene (1.5 g, 10 mmol) in tetrahydrofuran (10 mL) was added formaldehyde (37%, aq., 10 mL), imidazole (0.68 g, 10 mmol), and anthranilic acid (14 mg, 0.1 mmol). The mixture was allowed to stir for 16 hours. The reaction mixture was partitioned between ethyl acetate and hydrochloric acid (1N). The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 401B (E)-((2-nitro-3-phenylallyl)oxy)methyl acetate

To a solution of Example 401A (900 mg, 5 mmol) in dichloromethane (5 mL) was added triethylamine (600 mg, 6 mmol) and acetyl chloride (400 mg, 5.1 mmol) at 0° C. The mixture was allowed to stir for 1 hour. Water was added and the solution partitioned. The organic fraction was collected, concentrated, and purified by flash chromatography (15% ethyl acetate/hexanes) to afford the title compound.

Example 401C ((1-benzyl-3-nitro-4-phenylpyrrolidin-3-yl)methoxy)methyl acetate

The title compound was prepared similarly to the procedure described in Example 2A substituting Example 401B for 4-methoxy-beta-nitrostyrene.

Example 401D 7-benzyl-9-phenyl-3-oxa-1,7-diazaspiro[4.4]nonane

The title compound was prepared similarly to the procedure described in Example 2B substituting Example 401C for Example 2A.

Example 401E tert-butyl 7-benzyl-9-phenyl-3-oxa-1,7-diazaspiro[4.4]nonane-1-carboxylate

The title compound was prepared similarly to the procedure described in Example 337C substituting Example 401D for Example 337B.

Example 401F tert-butyl 9-phenyl-3-oxa-1,7-diazaspiro[4.4]nonane-1-carboxylate

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 401E for 2C.

Example 401G tert-butyl 7-((1-methyl-1H-imidazol-4-yl)sulfonyl)-9-phenyl-3-oxa-1,7-diazaspiro[4.4]nonane-1-carboxylate

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 401F for Example 373B.

Example 401H 7-((1-methyl-1H-imidazol-4-yl)sulfonyl)-9-phenyl-3-oxa-1,7-diazaspiro[4.4]nonane

The title compound was prepared as the hydrochloride salt similarly to the procedure described in Example 373B substituting Example 401G for Example 373A

Example 401I [Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-3-{[4-(trifluoromethyl)benzyl]amino}pyrrolidin-3-yl]methanol

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and Example 401H for Example 354D MS (ESI) m/z 495 (M+H)⁺.

Example 402 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(prop-2-en-1-yloxy)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 400 substituting allyl bromide for benzyl bromide. MS (ESI) m/z 397/399 (3:1) (M+H)⁺.

Example 403 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2-methylprop-2-en-1-yl)oxy]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 400 substituting 3-bromo-2-methylprop-1-ene for benzyl bromide. MS (ESI) m/z 411413 (3:1) (M+H)⁺.

Example 404 3-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one Example 404A N-(Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)-2-nitro-5-(trifluoromethyl)benzamide

To Example 14A (140 mg, 0.4 mmol) in dimethylformamide (0.5 mL) was added 2-nitro-5-(trifluoromethyl)benzoic acid (96 mg, 0.4 mmol), triethylamine (100 mg, 1 mmol), and O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (160 mg, 0.5 mmol). The mixture was allowed to stir overnight. Water was added and the precipitates were collected to provide the title compound.

Example 404B Trans-N-(2-amino-5-(trifluoromethyl)benzyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-amine

To a solution of Example 404A (110 mg, 0.21 mmol) in tetrahydrofuran (1 mL) was added borane dimethyl sulfide complex (2N, 1.4 mL, 2.8 mmol). The mixture was stirred at 60° C. for 2 days and quenched with hydrochloric acid (1 M aq.). The mixture was allowed to stir for 30 minutes. Sodium hydroxide (1 M, aq.) was added to adjust the pH value to 10. The mixture was partitioned with ethyl acetate. The organic fraction was collected and dried over potassium carbonate, filtered, and concentrated to provide the title compound.

Example 404C 3-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one

To a solution of Example 404B (130 mg, 0.27 mmol) in dichloromethane (10 mL) was added triethylamine (100 mg, 1 mmol) and triphosgene (28 mg, 0.094 mmol). The mixture was allowed to stir for 1 hour, and then methanol was added. The mixture was concentrated and purified by HPLC to provide the title compound. MS (ESI) m/z 506 (M+H)⁺.

Example 405 4-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and 2-bromo-4-fluoropyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 402.1 (M+H)⁺.

Example 406 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 4-bromo-7H-pyrrolo[2,3-D]pyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 424.2 (M+H)⁺.

Example 407 Trans-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-9-phenyl-1-[4-(trifluoromethyl)benzyl]-3-oxa-1,7-diazaspiro[4.4]nonan-2-one

The title compound was prepared similarly to the procedure described in Example 404C substituting Example 401I for Example 404B. MS (ESI) m/z 521 (M+H)⁺.

Example 408 3,5-difluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

To Example 396A (100 mg, 0.33 mmol) in dimethylsulfoxide (0.5 mL) was added potassium tert-butoxide (50 mg, 0.45 mmol) and 2,3,5-trifluoro-4-(trifluoromethyl)pyridine (80 mg, 0.4 mmol). The mixture was stirred at 80° C. for 2 hours, and then partitioned between water and ethyl acetate. The organic fraction was collected, dried over potassium carbonate, filtered, concentrated, and purified by reversed phase HPLC to provide the title compound. MS (ESI) m/z 488 (M+H)⁺.

Example 409 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 574A for Example 354D and substituting 5-(trifluoromethyl)picolinaldehyde for 4-chlorobenzaldehyde. MS (ESI) m/z 466.1 (M+H)⁺.

Example 410 5-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and 2-bromo-5-cyclopropyl-pyrazine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 425.3 (M+H)⁺.

Example 411 5-cyclobutyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and 2-bromo-5-cyclobutylpyrazine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 439.3 (M+H)⁺.

Example 412 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(2-methylprop oxy)pyrrolidin-3-amine

To Example 403 (17 mg, 0.041 mmol) in tetrahydrofuran (4 mL) was added 5% Pt/C (20 mg, 0.041 mmol). The mixture was stirred for 45 minutes under 30 psi of hydrogen at room temperature. The mixture was filtered through a nylon membrane and purified by reversed phase HPLC to provide the title compound. MS (ESI) m/z 413415 (3:1) (M+H)⁺.

Example 413 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(pyrrolidin-1-yl)pyrazin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 2-bromo-5-(pyrrolidin-1-yl)pyrazine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 454.3 (M+H)⁺.

Example 414 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(trifluoromethyl)pyrazine-2-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 574A for aniline and 5-(trifluoromethyl)pyrazine-2-carboxylic acid for Example 242D. MS (ESI) m/z 481.2 (M+H)⁺.

Example 415 5-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazine-2-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 574A for aniline and 5-chloropyrazine-2-carboxylic acid for Example 242D. MS (ESI) m/z 447.1 (M+H)⁺.

Example 416 (3R,4S)—N-(4-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 574A for Example 354D. MS (ESI) m/z 431.1 (M+H)⁺

Example 417 (3R,4S)—N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene MS (ESI) m/z 435.1 (M+H)⁺.

Example 418 (3R,4S)—N-(3,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting 1-bromo-3,4-difluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 437.1 (M+H)⁺.

Example 419 6-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridazine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 574A for aniline and substituting 6-chloropyridazine-3-carboxylic acid for Example 242D. MS (ESI) m/z 447.2 (M+H)⁺.

Example 420 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(morpholin-4-yl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 4-(4-bromopyrimidin-2-yl)morpholine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 470.2 (M+H)⁺.

Example 421 4-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-2,3-dihydro-1H-isoindol-1-one

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 4-(4-bromopyrimidin-2-yl)morpholine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 470.2 (M+H)⁺.

Example 422 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(methylsulfonyl)phenyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 1-bromo-3-(methylsulfonyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 461.2 (M+H)⁺.

Example 423 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(trifluoromethyl)piperazin-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared using the same procedures as described in Example 290 substituting Example 414 for Example 242E. MS (ESI) m/z 473.2 (M+H)⁺.

Example 424 5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-2-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 2-bromo-5-fluoropyrimidine for 1-bromo-2-methylbenzene MS (ESI) m/z 403.2 (M+H)⁺

Example 425 Trans-4-cyclohexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine Example 425A (E)-(2-nitrovinyl)cyclohexane

A solution of cyclohexane carboxaldehyde (5.0 g, 44.6 mmol) and nitromethane (4.1 g, 66.9 mmol) in tetrahydrofuran (25 ml) and tert butanol (25 ml) was stirred and chilled in an ice bath under nitrogen. Potassium-t-butoxide (1.0 g, 9.0 mmol) was added as a solid in one portion and the reaction was allowed to stir and warm to room temperature over one hour. The reaction was stirred for an additional four hours and was then partitioned with a saturated solution of ammonium chloride. The organic fraction was collected, and the aqueous portion was washed with dichloromethane. The combined organic fractions were washed with brine, dried over sodium sulfate, filtered, and concentrated. The resulting liquid was dissolved in dichloromethane (100 ml) and chilled in an ice bath. Trifluoroacetic anhydride (9.8 g, 46.7 mmol) was added in one portion, and the solution stirred for five minutes. Triethylamine (9.5 g, 93.5 mmol) was added dropwise. Stirring was continued for one hour, and then the reaction was allowed to warm to room temperature and stir for two hours. The reaction was partitioned with a solution of saturated ammonium chloride. The organic fraction was collected. The aqueous portion was washed with dichloromethane. The organic fractions were combined and washed with water and brine, and dried over sodium sulfate. The mixture was filtered, concentrated and chromatographed on a silica gel flash column eluting with 98:2 heptane:ethyl acetate to afford 5.1 g of a slightly tinted liquid. MS (DCI) m/z 173.1 (M+NH₄)⁺

Example 425B trans-4-cyclohexyl-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedures described in Examples 2A-2F substituting Example 425A for trans-4-methoxy-beta-nitrostyrene in Example 2A. MS (DCI) m/z 313.1 (M+H)⁺

Example 425C trans-4-cyclohexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 57 substituting Example 425B for Example 14A and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 473.2 (M+H)⁺.

Example 426 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(4,4,4-trifluorobutyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4,4,4-trifluorobutanol for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 417.0 (M+H)⁺

Example 427 (3R,4S)—N-(2-cyclopentylethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-cyclopentylacetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 403.0 (M+H)⁺

Example 428 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(5-propylfuran-2-yl)methyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-propylfuran-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 429.0 (M+H)⁺.

Example 429 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-methyltetrahydro-2H-pyran-4-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 419.0 (M+H)⁺.

Example 430 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(4-phenyl-1,3-thiazol-5-yl)methyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-phenylthiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 480.0 (M+H)⁺

Example 431 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methyl-1,3-thiazol-2-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-methylthiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 418.0 (M+H)⁺

Example 432 (3R,4S)—N-[(3,5-dichloropyridin-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3,5-dichloroisonicotinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 467.0 (M+H)⁺

Example 433 (3R,4S)—N-(2-ethylhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-ethylhexanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 419.0 (M+H)⁺

Example 434 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-methylthiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 418.0 (M+H)⁺

Example 435 (3R,4S)—N-[(2,4-dichloro-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,4-dichlorothiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 473.0 (M+H)⁺

Example 436 (3R,4S)—N-(2,2-dimethylpropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pivalaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 377.0 (M+H)⁺

Example 437 (3R,4S)—N-[(5-methyl-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-methylbenzo[b]thiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 467.0 (M+H)⁺.

Example 438 (3R,4S)—N-[(2-bromo-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-bromothiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 483.0 (M+H)⁺.

Example 439 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylpropyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting isobutyraldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 363.0 (M+H)⁺.

Example 440 (3R,4S)—N-[(3-chloro-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3-chlorobenzo[b]thiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 487.0 (M+H)⁺.

Example 441 (3R,4S)—N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,4-dimethylthiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 432.0 (M+H)⁺.

Example 442 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(thieno[2,3-b]pyridin-2-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting thieno[2,3-b]pyridine-2-carbaldehyde for 4-chlorobenzaldehyde and Example 574A for Example 354D. MS (ESI) m/z 454.0 (M+H)⁺.

Example 443 (3R,4S)—N-[(2-methyl-1-benzofuran-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-methylbenzofuran-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 451.0 (M+H)⁺.

Example 444 (3R,4S)—N-[(6-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 6-chloro-2-methylimidazo[1,2-a]pyridine-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 485.0 (M+H)⁺.

Example 445 (3R,4S)—N-{[5-(4-fluorophenyl)pyridin-3-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-(4-fluorophenyl)nicotinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 492.0 (M+H)⁺.

Example 446 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylpentyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-methylpentanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 391.0 (M+H)⁺

Example 447 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(tetrahydro furan-3-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting tetrahydrofuran-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 391.0 (M+H)⁺

Example 448 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentyl-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pentanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 377.0 (M+H)⁺.

Example 449 (3R,4S)—N-(2-ethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-ethylbutanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 391.0 (M+H)⁺

Example 450 (3R,4S)—N-(2,2-dimethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,2-dimethylbutanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 391.0 (M+H)⁺.

Example 451 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(2-methyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-methylthiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 418.0 (M+H)⁺.

Example 452 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(tetrahydro-2H-pyran-4-yl)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 419.0 (M+H)⁺.

Example 453 (3R,4S)—N-(1,3-benzothiazol-2-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting benzo[d]thiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 454.0 (M+H)⁺.

Example 454 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-1,3-thiazol-2-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-methylthiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 418.0 (M+H)⁺.

Example 455 (3R,4S)—N-[(4,5-dimethylthiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4,5-dimethylthiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 431.0 (M+H)⁺.

Example 456 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4,5,6,7-tetrahydrobenzo[d]thiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 458.0 (M+H)⁺.

Example 457 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(1,3-thiazol-5-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting thiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 404.0 (M+H)⁺.

Example 458 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(2,6,6-trimethylcyclohex-1-en-1-yl)ethyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(2,6,6-trimethylcyclohex-1-en-1-yl)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 457.0 (M+H)⁺.

Example 459 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 1-isopropylpiperidine-4-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 446.0 (M+H)⁺.

Example 460 (3R,4S)—N-{[4-(4-fluorophenyl)-1,3-thiazol-2-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-(4-fluorophenyl)thiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 498.0 (M+H)⁺.

Example 461 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(4-methylphenyl)ethyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(p-tolyl)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 425.0 (M+H)⁺.

Example 462 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylthiophen-2-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-methylthiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 417.0 (M+H)⁺.

Example 463 (3R,4S)—N-(3-methylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3-methylbutanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 377.0 (M+H)⁺.

Example 464 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(3,5,5-trimethylhexyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3,5,5-trimethylhexanal for 4-chlorobenzaldehyde and Example 574A for Example 354D. MS (ESI) m/z 433.0 (M+H)⁺.

Example 465 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2-phenylpropyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-phenylpropanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 425.0 (M+H)⁺.

Example 466 (3R,4S)—N-(3,3-dimethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3,3-dimethylbutanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 391.0 (M+H)⁺.

Example 467 (3R,4S)—N-[(1-methylcyclohexyl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 1-methylcyclohexanecarbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 417.0 (M+H)⁺.

Example 468 (3R,4S)—N-[2-(3-chlorophenyl)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(3-chlorophenyl)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 445.0 (M+H)⁺.

Example 469 (3R,4S)—N-[2-(4-tert-butylphenoxy)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(4-(tert-butyl)phenoxy)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 483.0 (M+H)⁺.

Example 470 (3R,4S)—N-(2-ethyl-3-methylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-ethyl-3-methylbutanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 405.0 (M+H)⁺.

Example 471 (3R,4S)—N-[3-(3-chlorophenyl)propyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3-(3-chlorophenyl)propanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 459.0 (M+H)⁺.

Example 472 (3R,4S)—N-[(4-bromo-1,3-thiazol-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-bromothiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 482 (M+H)⁺.

Example 473 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-2-phenyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-methyl-2-phenylthiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 494 (M+H)⁺.

Example 474 N-(3,4-difluorophenyl)-1-[(2,4-dim ethyl-1,3-thiazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 474A N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

To a 100 mL round bottom flask with magnetic stir bar under argon was added cesium carbonate (28.7 g, 88 mmol)], 4-bromo-1,2-difluorobenzene (5.66 g, 29.3 mmol), 1-benzyl-4-phenylpyrrolidin-3-amine (7.4 g, 29.3 mmol), and Dichloro[1,3-bis(2,6-Di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II), (0.928 g, 1.173 mmol). 1,2-dimethoxyethane (25 mL) was added and the reaction mixture was stirred at 80° C. for 18 hours. The reaction mixture was cooled, concentrated onto celite, and purified via flash chromatography (5-50% EtOAc/Hex, 220 g column) to provide the title compound.

Example 474B N-(3,4-difluorophenyl)-1-[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

A 4 mL vial with a magnetic stir bar was charged with Example 474A (40 mg, 0.146 mmol) and a solution of diisopropylethylamine in dichloromethane (1 mL of a 5 wt % diisopropylethylamine). A solution of 2,4-dimethylthiazole-5-sulfonyl chloride (972 μl, 0.292 mmol, 0.3 mM in 5% diisopropylethylamine in dichloromethane) was added and the reaction mixture was allowed to stir for 4 hours. The reaction was concentrated, redissolved in 2 mL of 50% dimethylsulfoxide/methanol and purified via HPLC to provide the title compound. MS (ESI) m/z 450 (M+H)⁺.

Example 475 N-(3,4-difluorophenyl)-1-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-isopropyl-3-methyl-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 461 (M+H)⁺.

Example 476 N-(3,4-difluorophenyl)-1-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 487 (M+H)⁺.

Example 477 N-(3,4-difluorophenyl)-4-phenyl-1-(pyridin-3-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting pyridine-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 416 (M+H)⁺.

Example 478 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-3,3-dimethyl-1,3-dihydro-2H-indol-2-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 3,3-dimethyl-2-oxoindoline-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 498 (M+H)⁺.

Example 479 1-[(1-cyclopentyl-3-methyl-1H-pyrazol-4-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-cyclopentyl-3-methyl-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 487 (M+H)⁺.

Example 480 6-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)quinazoline-2,4(1H,3H)-dione

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 499 (M+H)⁺.

Example 481 7-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-6-methyl-2H-1,4-benzoxazin-3(4H)-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 6-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 500 (M+H)⁺.

Example 482 N-(3,4-difluorophenyl)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1,3-dimethyl-1H-pyrazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 433 (M+H)⁺.

Example 483 N-(3,4-difluorophenyl)-1-[(1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1,5-dimethyl-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 433 (M+H)⁺.

Example 484 N-(3,4-difluorophenyl)-1-[(4-methylthiophen-2-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 4-methylthiophene-2-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 435 (M+H)⁺.

Example 485 N-(3,4-difluorophenyl)-4-phenyl-1-(pyrrolidin-1-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting pyrrolidine-1-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 408 (M+H)⁺.

Example 486 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 467 (M+H)⁺.

Example 487 N-(3,4-difluorophenyl)-1-[(5-methyl-1,2-oxazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 5-methylisoxazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 420 (M+H)⁺.

Example 488 N-(3,4-difluorophenyl)-1-[(2,5-dimethylfuran-3-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,5-dimethylfuran-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 433 (M+H)⁺.

Example 489 methyl 3-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)thiophene-2-carboxylate

The title compound was prepared similarly to the procedure described in Example 474B substituting methyl 3-(chlorosulfonyl)thiophene-2-carboxylate for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 479 (M+H)⁺.

Example 490 N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1,2-dimethyl-1H-imidazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 433 (M+H)⁺.

Example 491 methyl 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-4-methoxythiophene-3-carboxylate

The title compound was prepared similarly to the procedure described in Example 474B substituting methyl 5-(chlorosulfonyl)-4-methoxythiophene-3-carboxylate for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 509 (M+H)⁺.

Example 492 N-(3,4-difluorophenyl)-1-[(5-ethylthiophen-2-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 5-ethylthiophene-2-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 449 (M+H)⁺.

Example 493 N-(3,4-difluorophenyl)-1-[(4-methylpiperidin-1-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 4-methylpiperidine-1-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 436 (M+H)⁺.

Example 494 N-(3,4-difluorophenyl)-1-{[6-(morpholin-4-yl)pyridin-3-yl]sulfonyl}-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 6-morpholinopyridine-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 501 (M+H)⁺

Example 495 1-(1,3-benzodioxol-5-ylsulfonyl)-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting benzo[d][1,3]dioxole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 459 (M+H)⁺.

Example 496 N-(3,4-difluorophenyl)-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 473 (M+H)⁺.

Example 497 N-(3,4-difluorophenyl)-1-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 445 (M+H)⁺.

Example 498 N-(3,4-difluorophenyl)-4-phenyl-1-[(tetrahydro-2H-pyran-2-ylmethyl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting (tetrahydro-2H-pyran-2-yl)methanesulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 437 (M+H)⁺.

Example 499 N-[5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1,3-thiazol-2-yl]acetamide

The title compound was prepared similarly to the procedure described in Example 474B substituting 2-acetamidothiazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 479 (M+H)⁺.

Example 500 N-(3,4-difluorophenyl)-4-phenyl-1-{[6-(trifluoromethyl)pyridin-3-yl]sulfonyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 6-(trifluoromethyl)pyridine-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 484 (M+H)⁺.

Example 501 6-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1,4-dihydroquinoxaline-2,3-dione

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 499 (M+H)⁺.

Example 502 N-(3,4-difluorophenyl)-1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-methyl-1H-pyrazole-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 419 (M+H)⁺.

Example 503 N-(3,4-difluorophenyl)-1-[(1-methyl-1H-indol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-methyl-1H-indole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 468 (M+H)⁺.

Example 504 methyl 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1-methyl-1H-pyrrole-2-carboxylate

The title compound was prepared similarly to the procedure described in Example 474B substituting methyl 5-(chlorosulfonyl)-1-methyl-1H-pyrrole-2-carboxylate 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 476 (M+H)⁺.

Example 505 1-(1,2-benzoxazol-5-ylsulfonyl)-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting benzo[d]isoxazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 456 (M+H)⁺.

Example 506 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1,3-dihydro-2H-benzimidazol-2-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 471 (M+H)⁺.

Example 507 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1,3-dihydro-2H-indol-2-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 2-oxoindoline-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 470 (M+H)⁺.

Example 508 N-(3,4-difluorophenyl)-4-phenyl-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1,3,5-trimethyl-1H-pyrazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 447 (M+H)⁺.

Example 509 1-(cyclobutylsulfonyl)-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting cyclobutanesulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 393 (M+H)⁺.

Example 510 1-(cyclohexylsulfonyl)-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting cyclohexanesulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 421 (M+H)⁺.

Example 511 1-[(5-chlorothiophen-2-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 5-chlorothiophene-2-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 455 (M+H)⁺.

Example 512 6-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-3,4-dihydroquinolin-2(1H)-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 484 (M+H)⁺.

Example 513 N-(3,4-difluorophenyl)-1-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 3,5-dimethylisoxazole-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 434 (M+H)⁺.

Example 514 5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-1,3-benzoxazol-2(3H)-one

The title compound was prepared similarly to the procedure described in Example 474B substituting 2-oxo-2,3-dihydrobenzo[d]oxazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 472 (M+H)⁺.

Example 515 N-(3,4-difluorophenyl)-1-(isoquinolin-5-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting isoquinoline-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 466 (M+H)⁺.

Example 516 N-(3,4-difluorophenyl)-1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-methyl-1H-pyrazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 419 (M+H)⁺.

Example 517 N-(3,4-difluorophenyl)-1-[(2,5-dimethylthiophen-3-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,5-dimethylthiophene-3-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 449 (M+H)⁺.

Example 518 N-(3,4-difluorophenyl)-1-[(5-methylthiophen-2-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 5-methylthiophene-2-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 435 (M+H)⁺.

Example 519 N-(3,4-difluorophenyl)-1-(2,3-dihydro-1-benzo furan-5-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 2,3-dihydrobenzofuran-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 457 (M+H)⁺.

Example 520 1-[(6-chloro imidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting 6-chloroimidazo[2,1-b]thiazole-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 495 (M+H)⁺.

Example 521 N-(3,4-difluorophenyl)-1-(morpholin-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 474B substituting morpholine-4-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 424 (M+H)⁺.

Example 522 1-[5-({3-[(3,4-difluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)-2,3-dihydro-1H-indol-1-yl]ethanone

The title compound was prepared similarly to the procedure described in Example 474B substituting 1-acetylindoline-5-sulfonyl chloride for 2,4-dimethylthiazole-5-sulfonyl chloride. MS (ESI) m/z 498 (M+H)⁺.

Example 523 tert-butyl {trans-1-[(2-cyanophenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate Example 523A Tert-butyl-trans-4-phenylpyrrolidin-3-ylcarbamate

The title compound was prepared similarly to the procedures described in Example 2A-2D substituting (E)-(2-nitrovinyl)benzene for trans-4-methoxy-beta-nitrostyrene.

Example 523B Tert-butyl {trans-1-[(2-cyanophenyl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate

The title compound was prepared similarly to the procedure described in Example 2E substituting Example 523A for Example 2D and substituting 2-cyanobenzene-1-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride. MS (DCI) m/z 444.8 (M+NH4)⁺.

Example 524 tert-butyl [trans-1-[(2-cyanophenyl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-yl]carbamate Example 524A Tert-butyl-trans-4-(4-fluorophenyl)pyrrolidin-3-ylcarbamate

The title compound was prepared similarly to the procedures described in Example 2A-2D substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for trans-4-methoxy-beta-nitrostyrene.

Example 524 B Tert-butyl [trans-1-[(2-cyanophenyl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-yl]carbamate

The title compound was prepared similarly to the procedure described in Example 2E substituting Example 524A for Example 2D and substituting 2-cyanobenzene-1-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride. MS (DCI) m/z 444.4 (M−H)⁻.

Example 525 2-{[trans-3-phenyl-4-{[4-(trifluoromethyl)pyridin-2-yl]amino}pyrrolidin-1-yl]sulfonyl}benzonitrile

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 527 for Example 337F and substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 473.2 (M+H)⁺.

Example 526 2-{[trans-3-phenyl-4-{[4-(trifluoromethyl)pyridin-2-yl]amino}pyrrolidin-1-yl]sulfonyl}benzamide

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 527 for Example 337F and substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 491.2 (M+H)⁺.

Example 527 2-(Trans-3-amino-4-phenylpyrrolidin-1-ylsulfonyl)benzonitrile

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 523 for Example 322B. MS (ESI) MS m/z 328.2 (M+H)⁺.

Example 528 2-({Trans-3-[(3-chlorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)benzonitrile

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 527 for Example 337F and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 438.2 (M+H)⁺.

Example 529 2-({Trans-3-[(4-fluorophenyl)amino]-4-phenylpyrrolidin-1-yl}sulfonyl)benzonitrile

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 527 for Example 337F and substituting 1-bromo-4-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 422.2 (M+H)⁺.

Example 530 Trans-N-(3-chlorophenyl)-4-(cyclopropylmethoxy)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 400 substituting (bromomethyl)cyclopropane for benzyl bromide. MS (ESI) m/z 411/413 (3:1) (M+H)⁺.

Example 531 N-{trans-4-cyclohexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 425C substituting 4-bromo-6-trifluoromethylpyrimidine for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 459.4 (M+H)⁺.

Example 532 2-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 396A for Example 337F and substituting 4-bromo-2-methoxypyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 415.2 (M+H)⁺.

Example 533 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(2-methyl-1,3-thiazol-4-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-methylthiazole-4-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 418 (M+H)⁺.

Example 534 (3R,4S)—N-[(2-ethyl-1-benzofuran-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-ethylbenzofuran-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 465 (M+H)⁺.

Example 535 (3R,4S)—N-(imidazo[1,2-a]pyridin-8-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting imidazo[1,2-a]pyridine-8-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 536 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylpyridin-2-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-methylpicolinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 412 (M+H)⁺.

Example 537 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(pyrazolo[1,5-a]pyridin-3-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pyrazolo[1,5-a]pyridine-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 538 N-{Trans-4-hydroxy-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide Example 538A Trans-tert-butyl 3-hydroxy-4-(4-(trifluoromethyl)benzamido)pyrrolidine-1-carboxylate

To a solution of trans-tert-butyl 3-amino-4-hydroxypyrrolidine-1-carboxylate (600 mg, 3 mmol) in dichloromethane (10 mL) at 0° C., was added triethylamine (350 mg, 3.5 mmol) and 4-(trifluoromethyl)benzoyl chloride (620 mg, 3 mmol). The mixture was allowed to stir for 16 hours. The mixture was concentrated and dissolved in methanol (5 mL). Sodium methoxide (21% in methanol, 0.5 mL) was added. The mixture was stirred for 6 hours, concentrated, and partitioned between ethyl acetate and water. The organic fractions were collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 538B N-(trans-4-hydroxypyrrolidin-3-yl)-4-(trifluoromethyl)benzamide

The title compound was prepared as the hydrochloride salt similarly to the procedure described in Example 373B substituting Example 538A for Example 373A.

Example 538C N-(trans-4-hydroxy-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 538B for Example 373B.

Example 538D N-(1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-oxopyrrolidin-3-yl)-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 382A substituting Example 538C for Example 379C.

Example 538E N-{Trans-4-hydroxy-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide

The title compound was prepared similarly to the procedure described in Example 382B substituting Example 538D for Example 382A and phenylmagnesium bromide for benzylmagnesium bromide. MS (ESI) m/z 495 (M+H)⁺.

Example 539 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenyl-4-{[4-(trifluoromethyl)benzyl]amino}pyrrolidin-3-ol

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 538E for Example 404A. MS (ESI) m/z 481 (M+H)⁺.

Example 540 (3R,4S)—N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-4-chloro-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethoxy)benzene, but only heating for 1 hour. MS (ESI) m/z 503 (M+H)⁺.

Example 541 ethyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate

To Example 396A (50 mg, 0.16 mmol) in dichloromethane (0.5 mL) was added triethylamine (20 mg, 0.2 mmol) and ethyl chloroformate (22 mg, 0.2 mmol). The mixture was stirred for 1 hour, concentrated, and purified by HPLC to provide the title compound. MS (ESI) m/z 379 (M+H)⁺.

Example 542 propyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate

The title compound was prepared similarly to the procedure described in Example 541 substituting propyl chloroformate for ethyl chloroformate. MS (ESI) m/z 393 (M+H)⁺.

Example 543 2-methylpropyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate

The title compound was prepared similarly to the procedure described in Example 541 substituting isobutyl chloroformate for ethyl chloroformate. MS (ESI) m/z 407 (M+H)⁺.

Example 544 butyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate

The title compound was prepared similarly to the procedure described in Example 541 substituting butyl chloroformate for ethyl chloroformate. MS (ESI) m/z 407 (M+H)⁺.

Example 545 (3R,4S)—N-(2-cyclopropylethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 546 for Example 404A. MS (ESI) m/z 375 (M+H)⁺.

Example 546 2-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}acetamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and substituting 2-cyclopropylacetic acid for 2-nitro-5-(trifluoromethyl)benzoic acid. MS (ESI) m/z 388 (M+H)⁺.

Example 547 (3R,4S)—N-[(2E)-hex-2-en-1-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting (E)-hex-2-enal for 4-chlorobenzaldehyde and substituting Example 396A for Example 354D. Both Example 547 and Example 548 were isolated. MS (ESI) m/z 389 (M+H)⁺.

Example 548 (3R,4S)—N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting (E)-hex-2-enal for 4-chlorobenzaldehyde and Example 396A for Example 354D. Both Example 547 and Example 548 were isolated. MS (ESI) m/z 391 (M+H)⁺.

Example 549 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pentanamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and pentanoic acid for 2-nitro-5-(trifluoromethyl)benzoic acid. MS (ESI) m/z 391 (M+H)⁺.

Example 550 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}hexanamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and substituting hexanoic acid for 2-nitro-5-(trifluoromethyl)benzoic acid. MS (ESI) m/z 405 (M+H)⁺.

Example 551 (3R,4S)—N-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting (tert-butyldimethylsilyloxy)acetaldehyde for 4-chlorobenzaldehyde and substituting Example 396A for Example 354D. MS (ESI) m/z 465.2 (M+H)⁺.

Example 552 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[6-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 6-(trifluoromethyl)picolinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 466 (M+H)⁺.

Example 553 (3R,4S)—N-[(3-chlorothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3-chlorothiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 554 (3R,4S)—N-[(4,4-difluorocyclohexyl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4,4-difluorocyclohexanecarbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 439 (M+H)⁺.

Example 555 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(pyrazolo[1,5-a]pyridin-7-ylmethyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pyrazolo[1,5-a]pyridine-7-carbaldehyde for 4-chlorobenzaldehyde and Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 556 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[4-(propan-2-yl)-1,3-thiazol-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-isopropylthiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 446 (M+H)⁺.

Example 557 (3R,4S)—N-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,2-dimethyltetrahydro-2H-pyran-4-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (EST) m/z 433 (M+H)⁺.

Example 558 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(tetrahydro-2H-pyran-2-yl)thiophen-2-yl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-(tetrahydro-2H-pyran-2-yl)thiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 487 (M+H)⁺.

Example 559 (3R,4S)—N-[(5-bromo-4-methyl-1,3-thiazol-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-bromo-4-methylthiazole-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 497 (M+H)⁺.

Example 560 (3R,4S)—N-(imidazo[1,5-a]pyridin-5-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting imidazo[1,5-a]pyridine-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 561 (3R,4S)—N-(2,3-dimethylpentyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,3-dimethylpentanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 405 (M+H)⁺.

Example 562 (3R,4S)—N-[(2-chloro-1,3-thiazol-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chlorothiazole-4-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 438 (M+H)⁺.

Example 563 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-methylimidazo[1,2-a]pyridine-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 451 (M+H)⁺.

Example 564 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-phenylcyclopropyl)methyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-phenylcyclopropanecarbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 437 (M+H)⁺.

Example 565 (3R,4S)—N-[(4-chloro-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 4-chlorothiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 438 (M+H)⁺.

Example 566 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(3,3,3-trifluoro-2-methylpropyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 3,3,3-trifluoro-2-methylpropanal for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 417 (M+H)⁺.

Example 567 (3R,4S)—N-[(2-chloro-3-fluoropyridin-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-3-fluoroisonicotinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 450 (M+H)⁺.

Example 568 (3R,4S)—N-[(5-fluoro-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-fluorobenzo[b]thiophene-2-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 471 (M+H)⁺.

Example 569 (3R,4S)—N-[5-chloro-2-(difluoromethoxy)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5-chloro-2-(difluoromethoxy)benzaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 497 (M+H)⁺.

Example 570 (3R,4S)—N-[(2,5-dichlorothiophen-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2,5-dichlorothiophene-3-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 471 (M+H)⁺.

Example 571 (3R,4S)—N-{[2-(4-fluorophenyl)pyridin-3-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(4-fluorophenyl)nicotinaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 492 (M+H)⁺.

Example 572 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[2-(4-methylphenyl)-1,3-thiazol-5-yl]methyl}-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-(p-tolyl)thiazole-5-carbaldehyde for 4-chlorobenzaldehyde and substituting Example 574A for Example 354D. MS (ESI) m/z 494 (M+H)⁺.

Example 573 (3R,4S)—N-(3-cyclopropylpropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 573A 3-cyclopropyl-N-((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)propanamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and substituting 3-cyclopropylpropanoic acid for 2-nitro-5-(trifluoromethyl)benzoic acid.

Example 573B (3R,4S)—N-(3-cyclopropylpropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 573A for Example 404A. MS (ESI) m/z 389 (M+H)⁺.

Example 574 5-fluoro-4-methyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine Example 574A (3R,4S)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the conditions described in Example 2A-2F substituting (E)-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and separating the enantiomers produced from the procedure of Example 2C via Chiral SFC separation (SFC 200 Column: Whelk-O1, 50×250 mm, 5 μm Column Temperature: 35° C. Mobile Phase: CO₂/IPA/DEA=70300.1 Flow rate: 70 g/min Back Pressure: 100 Bar Wavelength: 214 nm Cycle time: 5.0 min Injection: 4.0 mL Sample solution: 41000 mg in 250 mL methanol) The enantiomer with a retention time of 4.41 minutes was used to make the title compound.

Example 574B 5-fluoro-4-methyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 2-bromo-4-methyl-5-fluoropyridine for 1-bromo-3-(trifluoromethoxy)benzene. MS (APCI) m/z 416 (M+H)⁺.

Example 575 1,5-dimethyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-1H-1,2,4-triazol-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 3-bromo-1,5-dimethyl-1H-1,2,4-triazole for 1-bromo-3-(trifluoromethoxy)benzene. MS (ESI) m/z 402 (M+H)⁺.

Example 576 1,5-dimethyl-4-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-1H-pyrrole-2-carbonitrile

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-1,5-dimethyl-1H-pyrrole-2-carbonitrile for 1-bromo-3-(trifluoromethoxy)benzene. MS (APCI) m/z 425 (M+H)⁺.

Example 577 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yloxy)propyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-isopropoxypropylamine for aniline. MS (ESI) m/z 453.2 (M+H)⁺.

Example 578 (3S,4R)—N-(3-ethoxypropyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-ethoxypropylamine for aniline. MS (ESI) m/z 439.2 (M+H)⁺.

Example 579 (3S,4R)-4-(4-fluorophenyl)-N-(2-methoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 2-methoxyethylamine for aniline. MS (ESI) m/z 411.2 (M+H)⁺.

Example 580 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-propylpyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting propylamine for aniline. MS (ESI) m/z 395.2 (M+H)⁺.

Example 581 (3S,4R)—N-butyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting butylamine for aniline. MS (ESI) m/z 409.2 (M+H)⁺.

Example 582 (3S,4R)-4-(4-fluorophenyl)-N-[1-methoxypropan-2-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 2-methoxyisopropylamine for aniline. MS (ESI) m/z 425.2 (M+H)⁺.

Example 583 (3R,4S)-4-(4-fluorophenyl)-N-(3-methoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-methoxypropylamine for aniline. MS (ESI) m/z 425.2 (M+H)⁺.

Example 584 (3S,4R)—N-(2-ethoxyethyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 2-ethoxyethylamine for aniline. MS (ESI) m/z 425.2 (M+H)⁺.

Example 585 (3R,4S)—N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to Example 327 substituting 1-bromo-4-chloro-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene, but the reaction mixture was only heated for 1 hour. MS (APCI) m/z 519 (M+H)⁺.

Example 586 (3S,4R)—N-(cyclopropylmethyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting cyclopropylmethylamine for aniline. MS (ESI) m/z 407.1 (M+H)⁺.

Example 587 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(propan-2-yloxy)ethyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 2-isopropoxy-ethylamine for aniline. MS (ESI) m/z 439.1 (M+H)⁺.

Example 588 (3R,4S)—N-(3-methoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 588A (3R,4S)—N-(3-(benzyloxy)propyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 396A for Example 354D and substituting 3-(benzyloxy)propanal for 4-chlorobenzaldehyde.

Example 588B tert-butyl (3-(benzyloxy)propyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 337C substituting Example 588A for Example 337B.

Example 588C tert-butyl (3-hydroxypropyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

To Example 588B (200 mg, 0.36 mmol) in tetrahydrofuran (10 mL) was added 20% palladium hydroxide on carbon, (80 mg, 0.058 mmol). The mixture was allowed to stir under 30 psi of hydrogen at 50° C. for 16 hours. The mixture was filtered through a nylon membrane and concentrated to provide the title compound.

Example 588D (3R,4S)—N-(3-methoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

To Example 588C (60 mg, 0.13 mmol) in tetrahydrofuran (0.5 mL) was added iodomethane (70 mg, 0.5 mmol) and sodium hydride (60%, 20 mg, 0.5 mmol). The mixture was stirred at 60° C. for 2 hours. Hydrochloric acid (4N in dioxane, 1 mL) was added. The mixture was stirred for 2 hours, concentrated, and partitioned between ethyl acetate and NaOH (1 M aq). The organic fraction was collected, concentrated, and purified HPLC to provide the title compound. MS (ESI) m/z 379 (M+H)⁺.

Example 589 (3R,4S)—N-(3-ethoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 588D substituting iodoethane for iodomethane. MS (ESI) m/z 393 (M+H)⁺.

Example 590 (3R,4S)—N-{[1-(methoxymethyl)cyclopropyl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 590A 1-(methoxymethyl)-N-((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)cyclopropanecarboxamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and substituting 1-(methoxymethyl)cyclopropanecarboxylic acid for 2-nitro-5-(trifluoromethyl)benzoic acid.

Example 590 (3R,4S)—N-{[1-(methoxymethyl)cyclopropyl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 590A for Example 404A. MS (ESI) m/z 405 (M+H)⁺.

Example 591 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(propan-2-yloxy)propan-1-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 577 for Example 242E. MS (ESI) m/z 439.1 (M+H)⁺.

Example 592 3-ethoxy-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)propan-1-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 578 for Example 242E. MS (ESI) m/z 425.1 (M+H)⁺.

Example 593 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-2-methoxyethanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 579 for Example 242E. MS (ESI) m/z 397.1 (M+H)⁺.

Example 594 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)propan-1-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 580 for Example 242E. MS (ESI) m/z 381.1 (M+H)⁺.

Example 595 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)butan-1-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 581 for Example 242E. MS (ESI) m/z 394.1 (M+H)⁺.

Example 596 (2S)-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-1-methoxypropan-2-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 582 for Example 242E. MS (ESI) m/z 411.1 (M+H)⁺.

Example 597 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-methoxypropan-1-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 583 for Example 242E. MS (ESI) m/z 411.1 (M+H)⁺.

Example 598 2-ethoxy-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)ethanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 584 for Example 242E. MS (ESI) m/z 411.1 (M+H)⁺.

Example 599 N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-2-(propan-2-yloxy)ethanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 587 for Example 242E. MS (ESI) m/z 425.1 (M+H)⁺.

Example 600 (3R,4S)—N-(2-methoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 600A Tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl((3R,4S)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 551 (686 mg, 1.48 mmol) in ethyl acetate (7 mL), was added di-tert-butyldicarbonate (644 mg, 2.95 mmol). This solution was stirred at room temperature for 16 hours. The solution was then concentrated and purified by flash-chromatography (30-50% ethyl acetate/heptanes) to provide the title compound. MS (ESI) m/z 565.0 (M+H)⁺.

Example 600 B Tert-butyl 2-hydroxyethyl((3R,4S)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 600A (626 mg, 1.11 mmol) in 8 mL of dichloromethane (5 mL) was added tetrabutylammonium fluoride hydrate (620 mg, 2.22 mmol). This solution was stirred at room temperature for 16 hours, concentrated, and purified by flash-chromatography (5% methanol/dichloromethane with 0.5% triethylamine added) to provide the title compound. MS (ESI) m/z 450.8 (M+H)⁺.

Example 600 C (3R,4S)—N-(2-methoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

Powdered potassium hydroxide (30 mg, 0.53 mmol) was added dimethylsulfoxide (7 mL) and the mixture was stirred for 2 minutes. To this solution was added Example 600 B (60 mg, 0.13 mmol) and iodomethane (66.2 mg, 0.47 mmol). This mixture was stirred at room temperature for 16 hours then partitioned between ethyl acetate and water, The organic fraction was collected, and the aqueous fraction was washed with ethyl acetate 3 times. All organic fractions were combined and concentrated. To this concentrate was added dichloromethane (1 mL) and trifluoroacetic acid (0.3 mL), and the solution stirred at room temperature for 2 hours. The mixture was concentrated and purified by HPLC to provide the title compound. MS (ESI) m/z 365.1 (M+H)⁺.

Example 601 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine Example 601A (E)-2-(2-nitrovinyl)tetrahydrofuran

A solution of tetrahydrofuran-2-carboxaldehyde (2.0 g, 20.0 mmol) and nitromethane (3.66 g, 60.0 mmol) in tetrahydrofuran (20 ml) was stirred at room temperature under nitrogen and 1,1,3,3-tetramethylguanidine (230 mg, 2.0 mmol) was added in one portion. The reaction mixture was stirred for thirty minutes. The mixture was then chilled in an ice bath to 0° C. Trifluoroacetic anhydride (5.25 g, 25 mmol) was added in one portion. The reaction mixture was stirred for thirty minutes after which time triethylamine (5.06 g, 50.0 mmol) was added dropwise. The reaction was stirred for 30 minutes and then partitioned between ethyl acetate and a saturated solution of ammonium chloride. The organic fraction was collected, and the aqueous portion was washed with additional ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, concentrated, and purified via flash column (1:2 ethyl acetate:heptanes) to afford the title compound.

Example 601B 1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-((S)-tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting Example 601A for trans-4-methoxy-beta nitrostyrene.

Example 601C 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A. Purification via flash chromatography (4:1 ethyl acetate:heptanes) provided the title compound. MS (ESI) m/z 461.1 (M+H)⁺.

Example 602 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A. Purification via flash chromatography (4:1 ethyl acetate:heptanes) provided the title compound. MS (ESI) m/z 461.1 (M+H)⁺.

Example 603 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 1-bromo-3-trifluoromethylbenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (3:1 ethyl acetate:heptane) provided the title compound. MS (ESI) m/z 445.1 (M+H)⁺.

Example 604 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro furan-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 1-bromo-3-trifluoromethylbenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (3:1 ethyl acetate:heptane) provided the title compound. MS (ESI) m/z 445.1 (M+H)⁺.

Example 605 2-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine Example 605A N-((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)-2-(methylthio)-6-(trifluoromethyl)pyrimidin-4-amine

To Example 396A (80 mg, 0.26 mmol) in dimethylsulfoxide (0.3 mL) was added 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine (80 mg, 0.35 mmol) and cesium carbonate (120 mg, 0.37). The mixture was stirred at 120° C. for 4 hours and then partitioned between ethyl acetate and water. The organic fraction was dried over MgSO₄, filtered, and concentrated to provide the crude title compound.

Example 605B N-((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)-2-(methylsulfonyl)-6-(trifluoromethyl)pyrimidin-4-amine

To Example 605A in dichloromethane (1 mL) was added meta-chloroperbenzoic acid (<77%, 320 mg, 1.4 mmol). The mixture was allowed to stir for 3 days. Then the mixture was partition between sodium metabisulfite (aq.) and ethyl acetate. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the crude title compound.

Example 605C 2-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine

To a solution of Example 605B (0.19 g, 0.36 mmol) in methanol (1 mL) was added sodium methoxide (21% in methanol, 1 mL). The mixture was stirred at 100° C. for 2 hours and, partitioned between ethyl acetate and water. The organic fraction was collected, concentrated, and purified by HPLC to provide the title compound. MS (EST) m/z 483 (M+H)⁺.

Example 606 6-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

To a solution of Example 574A (586 mg, 1.85 mmol) in methanol (10 mL) was added 4,6-dichloropyrimidine (829 mg, 5.6 mmol) and triethylamine (0.52 mL, 3.7 mmol). The reaction heated at 50 C for 1 hour. More 4,6-dichloropyrimidine (800 mg) was added and the reaction stirred for 18 hours. The reaction mixture was concentrated. Purification via flash chromatography (0-100% EtOAc/Hexanes) provided the title compound. MS (ESI) m/z 419 (M+H)⁺.

Example 607 1-cyclopropyl-N-({(3R,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)methanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 586 for Example 242E. MS (ESI) m/z 393.1 (M+H)⁺.

Example 608 (3R,4S)—N-(2-ethoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

To a solution of Example 600B (70 mg, 0.16 mmol) in tetrahydrofuran (7 ml) under nitrogen was added iodoethane (43.6 mg, 0.28 mmol) and sodium hydride (18.6 mg, 0.47 mmol). This solution was stirred at 60° C. for 1 hour, and then it was cooled to room temperature. To the reaction mixture was added hydrochloric acid (4N in dioxane 0.7 mL) and the solution stirred at room temperature for 1 hour. The reaction mixture was then concentrated and partitioned between ethyl acetate and saturated sodium bicarbonate (aq.). The organic fraction was collected, concentrated, and purified by HPLC to afford the title product. MS (ESI) m/z 379.1 (M+H)⁺.

Example 609 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2-propoxyethyl)pyrrolidin-3-amine Example 609A Tert-butyl 2-(allyl oxy)ethyl((3R,4S)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 600B (73 mg, 0.16 mmol) in dimethylformamide (0.5 mL) under nitrogen at 0° C. was added allyl bromide (98 mg, 0.81 mmol) and sodium hydride (19.44 mg, 0.49 mmol). This mixture was stirred at 0° C. for 30 minutes, partitioned between ethyl acetate and water. The organic fraction was collected and concentrated to afford the title compound. MS (ESI) m/z 491.3 (M+H)⁺.

Example 609B (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2-prop oxyethyl)pyrrolidin-3-amine

To a solution of Example 609A (79 mg, 0.161 mmol) in tetrahydrofuran (15 ml) in a 50 ml pressure bottle was added 5% Pd/C, wet (8 mg, 1.879 μmol). The solution was stirred for 30 minutes under 50 psi of hydrogen at room temperature. The mixture was filtered through a nylon membrane and concentrated. The concentrate was dissolved in dichloromethane (0.5 mL) and trifluoroacetic acid (0.3 mL) was added. This solution was stirred at room temperature for 1 hour, concentrated, and purified via HPLC to afford the title compound. MS (ESI) m/z 393.1 (M+H)⁺.

Example 610 N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydrofuran-2-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 3,4-difluoro-1-bromobenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (100% ethyl acetate) provided the title compound. MS (ESI) m/z 413.0 (M+H)⁺.

Example 611 N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 3,4-difluoro-1-bromobenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (100% ethyl acetate) provided the title compound. MS (ESI) m/z 413.0 (M+H)⁺.

Example 612 6-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-6-cyclopropylpyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 425 (M+H)⁺.

Example 613 6-ethyl-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting 4-bromo-6-ethylpyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 431.1 (M+H)⁺.

Example 614 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(propan-2-yl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 380A for Example 337F and substituting 4-bromo-6-isopropylpyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 445.1 (M+H)⁺.

Example 615 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-methyl-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 605A substituting Example 380A for Example 396A and substituting 4-chloro-2-methyl-6-(trifluoromethyl)pyrimidine for 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine. MS (ESI) m/z 485 (M+H)⁺.

Example 616 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-propylpyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 605A substituting Example 380A for Example 396A and substituting 4-chloro-6-propylpyrimidine for 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine. MS (ESI) m/z 445 (M+H)⁺.

Example 617 5-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 605A substituting Example 380A for Example 396A and substituting 2,5-dichloro-4-(trifluoromethyl)pyridine for 4-chloro-2-(methylthio)-6-(trifluoromethyl)pyrimidine. MS (ESI) m/z 504506 (3:1) (M+H)⁺.

Example 618 (3S,4R)—N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 1-bromo-4-chloro-3-trifluoromethylbenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (3:1 ethyl acetate:heptane) provided the title compound. MS (ESI) m/z 479.3 (M+H)⁺.

Example 619 (3R,4S)—N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 601B for Example 14A and substituting 1-bromo-4-chloro-3-fluoromethylbenzene for 1-bromo-2-methylbenzene. Purification via flash chromatography (3:1 ethyl acetate:heptane) provided the title compound. MS (ESI) m/z 479.3 (M+H)⁺.

Example 620 6-ethoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

A microwave vial was charged with Example 606 (100 mg, 0.24 mmol), ethanol (2 mL), and sodium tert-butoxide (115 mg, 1.2 mmol). The reaction mixture was heated in a microwave (Biotage Initiator™, maximum 400 Watts) at 120° C. for 10 minutes. Purification via HPLC provided the title compound. MS (ESI) m/z 429 (M+H)⁺.

Example 621 6-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to Example 620 substituting methanol for ethanol. MS (ESI) m/z 415 (M+H)⁺.

Example 622 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-propoxypyrimidin-4-amine

The title compound was prepared similarly to Example 620 substituting propanol for ethanol. MS (ESI) m/z 443 (M+H)⁺.

Example 623 6-butoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to Example 620 substituting butanol for ethanol. MS (ESI) m/z 457 (M+H)⁺.

Example 624 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(2-methylpropoxy)pyrimidin-4-amine

The title compound was prepared similarly to Example 620 substituting isobutanol for ethanol. MS (ESI) m/z 457 (M+H)⁺.

Example 625 4-{[(3S,4R)-3-(4-fluorophenyl)-4-(hexyloxy)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole Example 625A Trans-tert-butyl 3-(4-fluorophenyl)-4-(hexyloxy)pyrrolidine-1-carboxylate

To Example 379A (140 mg, 0.5 mmol) in dimethylformamide (0.5 mL) was added sodium hydride (35 mg, 60%, 0.9 mmol) and 1-bromohexane (150 mg, 0.91 mmol). The mixture was stirred at 100° C. for 2 hours. The mixture was partitioned between ethyl acetate and water. The organic fraction was collected, and the aqueous fraction was washed with ethyl acetate 3 time. The organic fractions were combined, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 625B Trans-3-(4-fluorophenyl)-4-(hexyloxy)pyrrolidine

The title compound was prepared as the hydrochloride salt similarly to the procedure described in Example 373B substituting Example 625A for Example 373A.

Example 625C 4-{[Trans-3-(4-fluorophenyl)-4-(hexyloxy)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 625B for Example 373B. MS (ESI) m/z 410 (M+H)⁺.

Example 626 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting pentan-1-amine for aniline. MS (ESI) m/z 423.1 (M+H)⁺.

Example 627 Trans-4-(4-fluorophenyl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting hexan-1-amine for aniline. MS (ESI) m/z 437.1 (M+H)⁺.

Example 628 Trans-N-(3-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 3-chlorobenzylamine for aniline. MS (ESI) m/z 477.2 (M+H)⁺.

Example 629 Trans-N-(4-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-chlorobenzylamine for aniline. MS (ESI) m/z 477.2 (M+H)⁺.

Example 630 Trans-N-(4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 4-fluorobenzylamine for aniline. MS (ESI) m/z 461 (M+H)⁺.

Example 631 Trans-N-(3,4-difluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (3,4-difluorophenyl)methanamine for aniline. MS (ESI) m/z 479.3 (M+H)⁺.

Example 632 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)benzyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (3-(trifluoromethyl)phenyl)methanamine for aniline. 45 mg (31%) of the product was obtained. MS (ESI) m/z 511.3 (M+H)⁺.

Example 633 Trans-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (2-chloro-5-(trifluoromethyl)phenyl)methanamine for aniline. MS (ESI) m/z 545.3 (M+H)⁺.

Example 634 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-2-ylmethyl)pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting pyridin-2-ylmethanamine for aniline. MS (ESI) m/z 444.2 (M+H)⁺.

Example 635 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[4-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (4-(trifluoromethyl)pyridin-2-yl)methanamine hydrochloride for aniline. MS (ESI) m/z 512.2 (M+H)⁺.

Example 636 Trans-N,N-dibutyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting dibutylamine for aniline. MS (EST) m/z 465.2 (M+H)⁺.

Example 637 6-methyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-6-methylpyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 399 (M+H)⁺.

Example 638 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-4-methyl-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 483 (M+H)⁺.

Example 639 4-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)-2-(trifluoromethyl)benzonitrile

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-bromo-2-(trifluoromethyl)benzonitrile for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 494 (M+H)⁺.

Example 640 4-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-1-propyl-1H-1,2,3-triazole Example 640A 4-((trans-3-(2,2-dibromovinyl)-4-(4-fluorophenyl)pyrrolidin-1-yl)sulfonyl)-1-methyl-1H-imidazole

To a solution of Example 332A (0.39 g, 1.2 mmol) in dichloromethane (10 mL) was added carbon tetrabromide (0.38 g, 1.2 mmol) and triphenylphosphine (0.61 g, 2.3 mmol) in portions. The mixture was stirred for 2 hours, concentrated, and purified by flash chromatography (100% ethyl acetate) to afford the title compound.

Example 640B 4-(((3S,4S)-3-ethynyl-4-(4-fluorophenyl)pyrrolidin-1-yl)sulfonyl)-1-methyl-1H-imidazole

To a solution of Example 640A (0.24 g, 0.49 mmol) in tetrahydrofuran (1 mL) at −78° C. was added butyllithium (2N, 0.5 mL, 1 mmol). The mixture was stirred for 1 hour and then warmed to room temperature. The mixture was stirred for 1 hour at room temperature, and then partitioned between ammonium chloride (aq.) and ethyl acetate. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 640C 1-azidopropane

To a solution of 1-bromo propane (2.4 g, 20 mmol) in tetrahydrofuran (15 mL) was added sodium azide (1.3 g, 20 mmol) and water (1 mL). The mixture was stirred at 70° C. for 2 hours and this solution containing the title compound was used for Example 604D.

Example 640D 4-{Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-1-propyl-1H-1,2,3-triazole

To Example 640B (0.18 g, 0.54 mmol) in half of Example 604C solution was added CuI (90 mg, 0.5 mmol). The mixture was heated at 70° C. for 5 hours, concentrated, and partitioned between ethyl acetate and water. The organic fraction was collected, concentrated, and purified by HPLC to provide the title compound. MS (ESI) m/z 419 (M+H)⁺.

Example 641 4-[-1-cyclopropyl)piperidin-3-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine Example 641A tert-Butyl (-1-benzyl-4-(pyridin-3-yl)pyrrolidin-3-yl)carbamate

The title compound was prepared in similarly to the procedures described in Example 2A-2C substituting 3-(2-nitroethenyl)pyridine for trans-4-methoxy-beta-nitrostyrene. MS (DCI) m/z 354.2 (+H)⁺.

Example 641B tert-butyl 1-benzyl-4-(piperidin-3-yl)pyrrolidin-3-ylcarbamate

A solution of Example 641A (3.9 g, 11.03 mmol) in acetic acid (80 mL) was added to 5% platinum on carbon (50% water, 1.1 g) in a stainless steel pressure bottle. The vessel was pressurized with 30 psi of hydrogen and shaken for 8 hours at room temperature. The mixture was filtered through a nylon membrane and concentrated to provide the title compound.

Example 641C tert-butyl 1-benzyl-4-(1-cyclopropylpiperidin-3-yl)pyrrolidin-3-ylcarbamate

641B (1.0 g, 2.78 mmol), 1-ethoxycyclopropoxy-trimethylsilane (1.16 g, 6.68 mmol) and sodium cyanoborohydride (327 mg, 5.2 mmol) in methanol (10 ml) was stirred and heated to 60° C. under nitrogen for six hours. The reaction was then concentrated and the residue was taken up in ethyl acetate. The organic solution was washed with water, brine, and dried over sodium sulfate. The organic mixture was filtered, concentrated, and purified via flash chromatography (97.5:2.5 dichloromethane:2N ammonia in methanol) to afford the title compound.

Example 641D 4-(1-cyclopropylpiperidin-3-yl)-1-(1-methyl-1H-1,2,3-triazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Examples 2D-2F substituting the 641C for Example 2C.

Example 641E 4-[-1-cyclopropylpiperidin-3-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 641D for Example 14A and substituting 1-bromo-3-trifluoromethylbenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 514.2 (M+H)⁺.

Example 642 Trans-N-(3-chloro-4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (3-chloro-4-fluorophenyl)methanamine for aniline. MS (ESI) m/z 495.2 (M+H)⁺.

Example 643 Trans-4-(4-fluorophenyl)-N-(6-methylheptyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 6-methylheptan-1-amine for aniline. MS (ESI) m/z 465.2 (M+H)⁺.

Example 644 2-(4-fluorophenoxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}acetamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 4-fluorophenoxyacetic acid for Example 242D. MS (ESI) m/z 477.5 (M+H)⁺.

Example 645 (3R,4S)—N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (EST) m/z 469 (M+H)⁺.

Example 646 (3R,4S)—N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-1-fluoro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 485 (M+H)⁺.

Example 647 (3R,4S)—N-(4-methoxybutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 647A methyl 4-(((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)amino)butanoate

The title compound was prepared similarly to the procedure described in Example 354E substituting methyl 4-oxobutanoate for 4-chlorobenzaldehyde and substituting Example 396A for Example 354D.

Example 647B methyl 4-((tert-butoxycarbonyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)amino)butanoate

The title compound was prepared similarly to the procedure described in Example 337C substituting Example 647A for Example 337B.

Example 647C tert-butyl (4-hydroxybutyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

To a solution of Example 647B (140 mg, 0.28 mmol) in dichloromethane (1 mL) at −78° C. was added diisobutylaluminum hydride (0.5 mL, 1N in hexanes, 0.5 mmol). The mixture was allowed to stir for 45 minutes. The mixture was quenched and partitioned with ethyl acetate and sodium hydrideCO₃(aq). The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the crude title compound.

Example 647D (3R,4S)—N-(4-methoxybutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 588D substituting Example 647C for Example 588C. MS (ESI) m/z 393 (M+H)⁺.

Example 648 (3R,4S)—N-(4-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 648A tert-butyl ((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)(4-oxobutyl)carbamate

To a solution of Example 647B (140 mg, 0.28 mmol) in dichloromethane (1 mL) at −78° C. was added Diisobutylaluminum hydride (0.5 mL, 1N in hexanes, 0.5 mmol). The mixture was stirred for 45 minutes, and then quenched with ethyl acetate and sodium bicarbonate. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the crude title compound.

Example 648B tert-butyl (4-hydroxyhexyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 382B substituting Example 648A for Example 382A and substituting EtMgBr for BnMgBr.

Example 648C (3R,4S)—N-(4-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 588D substituting Example 648B for Example 588C. MS (ESI) m/z 421 (M+H)⁺.

Example 649 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine Example 649A Cis-2-propylcyclopropyl)methanol

To a solution of (Z)-hex-2-en-1-ol (200 mg, 2 mmol) in dichloromethane (4 mL) was added diiodomethane (0.66 g, 2.5 mmol), then diethylzinc (4 mL, 1N), 4 mmol) dropwise under nitrogen. The mixture was allowed to stir for 16 hours, and was then quenched with ammonium chloride (aq) hydrochloric acid (aq). Ethyl acetate was added and the mixture partitioned. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 649B Cis-2-propylcyclopropanecarbaldehyde

To a solution of Example 649A (200 mg, 1.75 mmol) in dichloromethane (1 mL) was added Dess-Martin periodinane (424 mg, 1 mmol). The mixture was stirred for 1 hour, and then quenched with sodium bisulfate (aq), and extracted with dichloromethane. The organic extracts were dried over MgSO₄, filtered, and concentrated to nearly dry to provide a concentrated dichloromethane solution of the title compound.

Example 649C (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 649B for 4-chlorobenzaldehyde and Example 396A for Example 354D. MS (ESI) m/z 403

Example 650 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine Example 650A (Trans-2-propylcyclopropyl)methanol

The title compound was prepared similarly to the procedure described in Example 649A substituting (E)-hex-2-en-1-ol for (Z)-hex-2-en-1-ol.

Example 650B Trans-2-propylcyclopropanecarbaldehyde

The title compound was prepared similarly to the procedure described in Example 649B substituting Example 650A for Example 649A.

Example 650C (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting Example 650B for 4-chlorobenzaldehyde and substituting Example 396A for Example 354D. MS (ESI) m/z 403 (M+H)⁺

Example 651 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-bromo-1-fluoro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 503 (M+H)⁺.

Example 652 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (EST) m/z 503 (M+H)⁺.

Example 653 (3R,4S)—N-[4-methoxy-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 4-bromo-1-methoxy-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 481 (M+H)⁺.

Example 654 (3R,4S)—N-(1-benzothiophen-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 5-bromobenzo[b]thiophene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 439 (M+H)⁺.

Example 655 (3R,4S)—N-(2,3-dihydro-1H-inden-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 5-bromo-2,3-dihydro-1H-indene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 423 (M+H)⁺.

Example 656 (3R,4S)—N-[3,4-bis(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 1-bromo-3,4-bis(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 519 (M+H)⁺.

Example 657 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(5,6,7,8-tetrahydronaphthalen-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 6-bromo-1,2,3,4-tetrahydronaphthalene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 437 (M+H)⁺.

Example 658 (3R,4S)—N-(3,4-dihydro-2H-chromen-6-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 6-bromochroman for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 439 (M+H)⁺.

Example 659 4-({(3S,4R)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-1-propyl-1H-1,2,3-triazole Example 659A 1-benzyl-4-phenylpyrrolidin-2-one

To a solution of 4-phenylpyrrolidin-2-one (1 g, 6.2 mmol) in tetrahydrofuran (6 mL) was added sodium hydride (60%, 280 mg, 7 mmol). Benzylbromide was added after 10 minutes. The mixture was allowed to stir at. 65° C. for 2 hours. The reaction mixture was, quenched with ammonium chloride (aq) and partitioned with ethyl acetate. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 659B Trans-1-benzyl-4-phenyl-3-(prop-2-yn-1-yl)pyrrolidin-2-one

To a solution of diisopropylamine (700 mg, 7 mmol) in tetrahydrofuran (7 mL) at −78° C. was added butyllithium (2N, 3.1 mL, 6.2 mmol). The mixture was allowed to stir for 10 minutes. Example 659A (1.56 g, 6.2 mmol) in tetrahydrofuran (5 mL) was added. The mixture was allowed to stir for 30 minutes. Propargyl bromide (0.7 mL, 80% toluene solution, 6.2 mmol) in tetrahydrofuran (3 mL) was added. The mixture was allowed to stir for 1 hour, quenched with ammonium chlorid (aq), and partitioned with ethyl acetate. The organic fraction was collected, concentrated, and purified via flash chromatography (50% ethyl acetate/hexanes) to afford the title compound.

Example 659C Trans-1-benzyl-4-phenyl-3-((1-propyl-1H-1,2,3-triazol-4-yl)methyl)pyrrolidin-2-one

The title compound was prepared similarly to the procedure described in Example 640D substituting Example 659B for Example 640B.

Example 659D 4-((trans-1-benzyl-4-phenylpyrrolidin-3-yl)methyl)-1-propyl-1H-1,2,3-triazole

To a solution of Example 659C (0.32 g, 0.86 mmol) in tetrahydrofuran (3 mL) was added lithium aluminumhydride in tetrahydrofuran (2N, 1 mL, 2 mmol). The mixture was allowed to stir for 3 hours. It was then quenched with methanol, followed by sodium bicarbonate (aq). The mixture was partitioned with ethyl acetate. The organic fraction was dried over potassium carbonate, filtered, and concentrated to provide the title compound.

Example 659E 4-((trans-4-phenylpyrrolidin-3-yl)methyl)-1-propyl-1H-1,2,3-triazole

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 659D for Example 2C.

Example 659F 4-({Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-1-propyl-1H-1,2,3-triazole

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 659E for Example 373B. MS (ESI) m/z 415 (M+H)⁺.

Example 660 (3R,4S)—N-(1-benzo furan-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 5-bromobenzofuran for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 423 (M+H)⁺.

Example 661 Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)benzyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (3-(trifluoromethoxy)phenyl)methanamine for aniline. MS (ESI) m/z 527.2 (M+H)⁺.

Example 662 methyl 5-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)-5-oxopentanoate

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline, methyl hydrogen glutarate for Example 242D. MS (ESI) m/z 453.3 (M+H)⁺.

Example 663 (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting (2-chloro-4-(trifluoromethyl)phenyl)methanamine for aniline. MS (ESI) m/z 545.3 (M+H)⁺.

Example 664 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting valeraldehyde for 4-chlorobenzaldehyde and substituting Example 380A for Example 354D. MS (ESI) m/z 395.2 (M+H)⁺.

Example 665 (3R,4S)-4-(4-fluorophenyl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting Example 380A for Example 354D. MS (ESI) m/z 409.2 (M+H)⁺.

Example 666 (3R,4S)—N-[2-(2-methoxyethoxy)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 666A 2-(2-methoxyethoxy)-N-((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)acetamide

The title compound was prepared similarly to the procedure described in Example 404A substituting Example 396A for Example 14A and substituting 2-(2-methoxyethoxy)acetic acid for 2-nitro-5-(trifluoromethyl)benzoic acid.

Example 666B (3R,4S)—N-[2-(2-methoxyethoxy)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 666A for Example 404A. MS (ESI) m/z 409 (M+H)⁺.

Example 667 (3R,4S)—N-[2-(4-fluorophenoxy)ethyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 644 for Example 242E. MS (ESI) m/z 463.1 (M+H)⁺.

Example 668 4-butyl-1-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-31)sulfonyl]-4-phenylpyrrolidin-3-yl}-1H-1,2,3-triazole Example 668A Ethyl 2-(4-butyl-1H-1,2,3-triazol-1-yl)acetate

The title compound was prepared similarly to the procedure described in Example 640D substituting hex-1-yne for Example 640B and substituting ethyl 2-azidoacetate for Example 640C.

Example 668B ethyl 2-(4-butyl-1H-1,2,3-triazol-1-yl)-4-nitro-3-phenylbutanoate

The title compound was prepared similarly to the procedure described in Example 331A substituting Example 668A for methyl 3-(3-chlorophenyl)propanoate.

Example 668C Trans-3-(4-butyl-1H-1,2,3-triazol-1-yl)-4-phenylpyrrolidin-2-one

To Example 668B (530 mg, 1.5 mmol) in ethanol (10 mL) was added Raney nickel, water slurry (616 mg, 10.5 mmol) in a 20 mL pressure bottle. The mixture was stirred under 60 psi of hydrogen at room temperature for 2 days. The mixture was filtered through a polypropylene membrane and concentrated to provide the title compound.

Example 668D 4-Butyl-1-(Trans-4-phenylpyrrolidin-3-yl)-1H-1,2,3-triazole

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 668C for Example 404A.

Example 668E 4-butyl-1-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-1H-1,2,3-triazole

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 668D for Example 373B. MS (ESI) m/z 375 (M+H)⁺. MS (ESI) m/z 415 (M+H)⁺.

Example 669 (3R,4S)—N-(4-chloro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 1-bromo-4-chloro-3-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (APCI) m/z 431 (M+H)⁺.

Example 670 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 481 (M+H)⁺.

Example 671 (3R,4S)—N-(2,3-dihydro-1-benzofuran-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 5-bromo-2,3-dihydrobenzofuran for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 425 (M+H)⁺.

Example 672 (3R,4S)—N-(4,4-dimethyl-3,4-dihydro-2H-chromen-6-yl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 6-bromo-4,4-dimethylchroman for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 485 (M+H)⁺.

Example 673 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-hydroxyhexanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting DL-alpha-hydroxycaproic acid for Example 242D. MS (ESI) m/z 439.2 (M+H)⁺.

Example 674 (3R,4S)—N-(3-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine Example 674A tert-butyl (3-hydroxyhexyl)((3R,4S)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-phenylpyrrolidin-3-yl)carbamate

A mixture of hex-1-en-3-one (38 mg, 0.4 mmol) and Example 396A (120 mg, 0.4 mmol) in methanol (0.5 mL) was allowed to stir overnight. Sodium borohydride (15 mg, 0.4 mmol) was added to the solution. The mixture was stirred for 30 minutes, di-tert-butyl dicarbonate (100 mg, 0.45 mmol) was added. The mixture was stirred for 2 hours and partitioned between ethyl acetate and water. The organic fraction was collected, concentrated, and purified by flash chromatography (100% ethyl acetate). to afford the title compound.

Example 674B (3R,4S)—N-(3-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 588D substituting Example 674A for Example 588C. MS (ESI) m/z 421 (M+H)⁺.

Example 675 (3R,4S)—N-[4-chloro-3-(propan-2-yl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-bromo-1-chloro-2-isopropylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 477 (M+H)⁺.

Example 676 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-methyl-4-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-bromo-3-methyl-1-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 483 (M+H)⁺.

Example 677 (3R,4S)—N-(1-benzothiophen-6-yl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 6-bromobenzo[b]thiophene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 457 (M+H)⁺.

Example 678 4-(1-cyclopropylpiperidin-4-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine Example 678A (E)-tert-butyl 4-(2-nitrovinyl)piperidine-1-carboxylate

The title compound was prepared similarly to the procedure described in Example 601A substituting 4-formylpiperidine-1-carboxylic acid-t-butyl ester for tetrahydrofuran-2-carboxaldehyde. MS (DCI) m/z 274.1 (M+NH₄)⁺

Example 678B 4-(1-cyclopropylpiperidin-4-yl)-1-(1-methyl-1H-1,2,3-triazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting Example 678A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 678C 4-(1-cyclopropylpiperidin-4-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 514.2 (M+H)+

Example 679 (3R,4S)—N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine Example 679A tetrahydro-2H-pyran-2-carbaldehyde

To a solution of oxalyl chloride (1.3 g, 10 mmol) in dichloromethane (20 mL) at −78° C. was added dimethylsulfoxide (1.3 g, 17 mmol). The mixture was stirred for 10 minutes. A solution of (tetrahydro-2H-pyran-2-yl)methanol (1.2 g, 10 mmol) in dichloromethane (20 mL) was added. The mixture was stirred for 15 minutes at room temperature. The mixture was washed with water. The organic fraction was dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 679B (E)-2-(2-nitrovinyl)tetrahydro-2H-pyran

To a solution of Example 679A (1.2 g, 10 mmol) in nitromethane (5 mL) was added pyrrolidine (100 mL). The mixture was allowed to stir overnight and concentrated to afford the title compound.

Example 679C Trans-1-benzyl-3-nitro-4-(-tetrahydro-2H-pyran-2-yl)pyrrolidine

The title compound was prepared similarly to the procedure described in Example 2A substituting Example 679B for 4-methoxy-beta-nitrostyrene.

Example 679D Trans-1-benzyl-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 2B substituting Example 679C for Example 2A

Example 679E tert-butyl (trans-1-benzyl-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 337C substituting Example 679D for Example 337B.

Example 679F tert-butyl (trans-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 2D substituting Example 679E for 2C

Example 679G tert-butyl (trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl)carbamate

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 679F for Example 373B

Example 679H Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337F substituting Example 679G for Example 337E.

Example 679I Trans-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting Example 679H for Example 354D. MS (ESI) m/z 399 (M+H)⁺.

Example 680 Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and substituting Example 679H for Example 354D. MS (ESI) m/z 507509 (3:1) (M+H)⁺.

Example 681 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F. MS (ESI) m/z 459 (M+H)⁺.

Example 682 N-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 460 (M+H)⁺.

Example 683 N-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 2-bromo-4-(trifluoromethyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 460 (M+H)⁺.

Example 684 (3R,4S)—N-[4-(4,4-dimethyl-1,3-dioxan-2-yl)butyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 5,5-dimethyl-2-(3′-formylpropyl)-1,3-dioxane for 4-chlorobenzaldehyde and substituting Example 380A for Example 354D. MS (ESI) m/z 495.1 (M+H)⁺.

Example 685 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 475 (M+H)⁺.

Example 686 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 475 (M+H)⁺.

Example 687 N-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 461 (M+H)⁺.

Example 688 N-[2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]propan-1-amine

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 689E for Example 404A. MS (ESI) m/z 411 (M+H)⁺.

Example 689 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-N-propylacetamide Example 689A Trans-tert-butyl 3-(4-fluorophenyl)-4-(2-methoxy-2-oxoethoxy)pyrrolidine-1-carboxylate

To a solution of Example 379A (0.56 g, 2 mmol) in dimethylformamide (2 mL) was added methyl 2-bromoacetate (0.38 g, 2.5 mmol) and sodium hydride (60%, 120 mg, 3 mmol). The mixture was stirred at 80° C. for 4 hours. The mixture was partitioned with water and ethyl acetate. The organic fraction was collected, concentrated, and purified by flash chromatography (50% ethyl acetate/hexanes) to afford the title compound.

Example 689B methyl 2-((trans-4-(4-fluorophenyl)pyrrolidin-3-yl)oxy)acetate

The title compound was prepared as the hydrochloride salt similarly to the procedure described in Example 373B substituting Example 689A for Example 373A.

Example 689C methyl 2-((trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)acetate

The title compound was prepared similarly to the procedure described in Example 373C substituting Example 689B for Example 373B.

Example 689D 2-((Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)acetic acid

Example 689C (0.11 g, 0.28 mmol) was dissolved in a solution of lithium hydroxide (methanol:water. 5:3, 1N, 3 mL). The mixture was stirred for 2 hours. Hydrochloric acid (aq) was added to adjust the pH value to 2. The mixture was partitioned with ethyl acetate. The organic fraction was collected, dried over MgSO₄, filtered, and concentrated to provide the title compound.

Example 689E 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-N-propylacetamide

The title compound was prepared similarly to the procedure described in Example 404A substituting propyl amine for Example 14A and Example 689D for 2-nitro-5-(trifluoromethyl)benzoic acid. MS (ESI) m/z 425 (M+H)⁺.

Example 690 6-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-methylpyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 606 substituting Example 322B for Example 574A and substituting 4,6-dichloro-2-methylpyrimidine for 4,6-dichloropyrimidine. MS (ESI) m/z 451 (M+H)⁺.

Example 691 6-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 606 substituting Example 322B for Example 574A but heated at 120° C. for 10 minutes in a microwave (Biotage Initiator™, maximum 400 Watts). MS (ESI) m/z 437 (M+H)⁺.

Example 692 1-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-phenylurea

A microwave vial was charged with Example 322B (50 mg, 0.15 mmol), isocyanatobenzene (20 mg, 0.17 mmol), triethylamine (65 μL, 0.46 mmol) and tetrahydrofuran (2 mL). The reaction mixture was heated in a microwave (Biotage Initiator™, maximum 400 Watts) at 100° C. for 10 minutes. Purification via HPLC provided the title compound. MS (ESI) m/z 444 (M+H)⁺.

Example 693 phenyl {(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}carbamate

The title compound was prepared similarly to Example 692 substituting phenyl carbonochloridate for isocyanatobenzene. MS (ESI) m/z 445 (M+H)⁺.

Example 694 1-(2-chlorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-chloro-2-isocyanatobenzene for isocyanatobenzene. MS (ESI) m/z 478 (M+H)⁺.

Example 695 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-oxohexanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 4-acetylbutyric acid for Example 242D. MS (ESI) m/z 437.1 (M+H)⁺.

Example 696 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)cyclohexanecarboxamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 4-(trifluoromethyl)cyclohexanecarboxylic acid for Example 242D. MS (ESI) m/z 503.3 (M+H)⁺.

Example 697 butyl (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl carbonate Example 697A Trans-tert-butyl 3-(butoxycarbonyloxy)-4-(4-fluorophenyl)pyrrolidine-1-carboxylate

The title compound was prepared similarly to the procedure described in Example 699A substituting butyl carbonochloridate for 1-isocyanatobutane.

Example 697B Butyl-trans-4-(4-fluorophenyl)pyrrolidin-3-yl carbonate

The title compound was prepared similarly to the procedure described in Example 699B substituting Example 697A for Example 699A.

Example 697C Butyl-trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl carbonate

The title compound was prepared similarly to the procedure described in Example 699C substituting Example 697B for Example 699B. MS (ESI) m/z 426.0 (M+H)⁺.

Example 698 5,5,5-trifluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pentanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 5,5,5-trifluoropentanoic acid for Example 242D. MS (ESI) m/z 463.1 (M+H)⁺.

Example 699 (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl butylcarbamate Example 699A Trans-tert-butyl 3-(butylcarbamoyloxy)-4-(4-fluorophenyl)pyrrolidine-1-carboxylate

To a solution of Example 379A (155 mg, 0.55 mmol) in dichloromethane (1.5 mL) was added triethylamine (167 mg, 1.65 mmol) and 1-isocyanatobutane (109 mg, 1.10 mmol). The solution was stirred at room temperature for 16 hours. The mixture was partitioned between dichloromethane and water. The organic fraction was collected, dried over sodium sulfate, concentrated, and purified by flash chromatography (25% ethyl acetate/hexanes) to provide the title compound.

Example 699B Trans-4-(4-fluorophenyl)pyrrolidin-3-yl butylcarbamate

To a solution of Example 699A (85.5 mg, 0.23 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.4 mL). The mixture was stirred at room temperature for 1 hour, and was then concentrated to afford title compound.

Example 699C Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl butylcarbamate

To a solution of Example 699B (63 mg, 0.23 mmol) in dichloromethane (1 mL) was added triethylamine (68.2 mg, 0.67 mmol) and 4-dimethylaminopyridine (1.4 mg, 0.011 mmol). The solution was cooled 0° C. To the chilled solution was added 1-methyl-1H-imidazole-4-sulfonyl chloride (42.6 mg, 0.24 mmol) portionwise. This mixture was slowly warmed up to room temperature over 1 hour and stirred at room temperature for 1 hour. The reaction mixture was partitioned with dichloromethane and water. The organic layer was collected, concentrated, and purified via HPLC to provide the title compound. MS (ESI) m/z 425.1 (M+H)⁺.

Example 700 2,2-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pentanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 2,2-difluorohexanoic acid for Example 242D. MS (ESI) m/z 459.2 (M+H)⁺.

Example 701 1-(4-chlorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-chloro-4-isocyanatobenzene for isocyanatobenzene. MS (ESI) m/z 478 (M+H)⁺.

Example 702 1-(2-fluorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-fluoro-2-isocyanatobenzene for isocyanatobenzene. MS (ESI) m/z 462 (M+H)⁺.

Example 703 1-(3-fluorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-fluoro-3-isocyanatobenzene for isocyanatobenzene. MS (ESI) m/z 462 (M+H)⁺.

Example 704 1-(4-fluorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-fluoro-4-isocyanatobenzene for isocyanatobenzene. MS (ESI) m/z 462 (M+H)⁺.

Example 705 1-(2-chlorobenzyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to Example 692 substituting 1-chloro-2-(isocyanatomethyl)benzene for isocyanatobenzene. MS (ESI) m/z 492 (M+H)⁺.

Example 706 4,5-dichloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

To a stirred solution of Example 322B (100 mg, 0.31 mmol) in dimethylsulfoxide (4 mL) was added 2,4,5-trichloropyridine (112 mg, 0.62 mmol) and sodium tert-butoxide (59 mg, 0.062 mmol). The reaction mixture was heated at 90° C. for 18 hours, then concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 470.5 (M+H)⁺.

Example 707 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[4-(trifluoromethyl)cyclohexyl]methyl}pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 696 for Example 242E. MS (ESI) m/z 489.1 (M+H)⁺.

Example 708 2,2-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}hexanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 2,2-difluorohexanoic acid for Example 242D. MS (EST) m/z 459.2 (M+H)⁺.

Example 709 Trans-N-[3,4-difluorophenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-2-yl)pyrrolidin-3-amine Example 709A (E)-2-(2-nitrovinyl)oxazole

The title compound was prepared similarly to the procedure described in Example 601A substituting oxazole-2-carboxaldehyde for tetrahydrofuran-2-carboxaldehyde. MS (DCI) m/z 141.0 (M+H)⁺

Example 709B (3R,4S)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-(oxazol-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Examples 2A-2F substituting Example 709A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 709C Trans-N-[3,4-difluorophenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 709C for Example 14A and substituting 1-bromo-3,4-difluorobenzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 410.1 (M+H)⁺.

Example 710 N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-2-yl)pyrrolidin-3-amine

The title compound was prepared as described in Example 709C substituting 1-bromo-4-chloro-3-(trifluoromethyl)benzene for 1-bromo-3,4-difluorobenzene. MS (ESI) m/z 476.0 (M+H)⁺

Example 711 4-{[trans-3-[(4-fluorobenzyl)oxy]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 625A substituting Example 379C for Example 379A and substituting 4-fluorobenzyl bromide for 1-bromohexane. MS (ESI) m/z 434 (M+H)⁺.

Example 712 4-{[trans-3-[(3-fluorobenzyl)oxy]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 625A substituting Example 379C for Example 379A and substituting 3-fluorobenzyl bromide for 1-bromohexane. MS (ESI) m/z 434 (M+H)⁺.

Example 713 4-{[trans-3-(4-fluorophenyl)-4-{[4-(methylsulfonyl)benzyl]oxy}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 625A substituting Example 379C for Example 379A and substituting 4-methylsulfonylbenzyl bromide for 1-bromohexane. MS (ESI) m/z 494 (M+H)⁺.

Example 714 4-{[trans-3-(4-fluorophenyl)-4-{[3-(methylsulfonyl)benzyl]oxy}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 625A substituting Example 379C for Example 379A and substituting 3-methylsulfonylbenzyl bromide for 1-bromohexane. MS (ESI) m/z 494 (M+H)⁺.

Example 715 6-ethoxy-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606. MS (ESI) m/z 447 (M+H)⁺.

Example 716 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(propan-2-yloxy)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting isopropanol for ethanol. MS (ESI) m/z 461 (M+H)⁺.

Example 717 6-butoxy-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting n-butanol for ethanol. MS (ESI) m/z 473 (M+H)⁺.

Example 718 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(2-methylpropoxy)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting iso-butanol for ethanol. MS (ESI) m/z 473 (M+H)⁺.

Example 719 6-(cyclobutyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting cyclobutanol for ethanol. MS (ESI) m/z 473 (M+H)⁺.

Example 720 6-(cyclopentyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting cyclopentanol for ethanol. MS (ESI) m/z 487 (M+H)⁺.

Example 721 6-(cyclohexyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 620 substituting Example 691 for Example 606 and substituting cyclohexanol for ethanol. MS (ESI) m/z 487 (M+H)⁺.

Example 722 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-phenylpyrimidin-4-amine

A microwave vial was charged with Example 722 (50 mg, 0.11 mmol), phenylboronic acid (14 mg, 0.12 mmol), dicyclohexyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine (4.7 mg, 11 μmol), potassium carbonate (2M, 57 μL, 0.14 mmol)), palladium(II) acetate (1.3 mg, 5.7 μmol), and 1,2-dimethoxyethane (2 mL). The reaction mixture was heated to 100° C. in a microwave (Biotage Initiator™, maximum 400 Watts) for 10 minutes. The reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 479 (M+H)⁺.

Example 723 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(2-methylphenyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting o-tolylboronic acid for phenylboronic acid. MS (ESI) m/z 493 (M+H)⁺.

Example 724 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(3-methylphenyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting m-tolylboronic acid for phenylboronic acid. MS (ESI) m/z 493 (M+H)⁺.

Example 725 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(4-methylphenyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting p-tolylboronic acid for phenylboronic acid. MS (ESI) m/z 493 (M+H)⁺.

Example 726 6-(2-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting 2-(fluorophenyl)boronic acid for phenylboronic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 727 6-(3-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting 3-(fluorophenyl)boronic acid for phenylboronic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 728 6-(4-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting 4-(fluorophenyl)boronic acid for phenylboronic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 729 6-(3-chlorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting 3-(chlorophenyl)boronic acid for phenylboronic acid. MS (ESI) m/z 513 (M+H)⁺.

Example 730 6-(4-chlorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 722 substituting 4-(chlorophenyl)boronic acid for phenylboronic acid. MS (ESI) m/z 513 (M+H)⁺.

Example 731 4-({(3S,4R)-3-(4-fluorophenyl)-4-[(4-methylbenzyl)oxy]pyrrolidin-1-yl}sulfonyl)-1-methyl-1H-imidazole

The title compound was prepared similarly to the procedure described in Example 625A substituting Example 379C for Example 379A and substituting 4-methylbenzyl bromide for 1-bromohexane. MS (ESI) m/z 430 (M+H)⁺.

Example 732 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(5,5,5-trifluoropentyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 698 for Example 242E. MS (ESI) m/z 449.1 (M+H)⁺.

Example 733 (3R,4S)—N-(2,2-difluorohexyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 700 for Example 242E. MS (ESI) m/z 445.1 (M+H)⁺.

Example 734 (3R,4S)—N-(2,2-difluoropentyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 700 for Example 242E. MS (ESI) m/z 431.1 (M+H)⁺.

Example 735 5,5-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}hexanamide

To a solution of Example 695 (200 mg, 0.46 mmol) in dichloromethane (2.5 mL) at 0° C. was added diethylaminosulfur trifluoride (258 mg, 1.60 mmol). The reaction mixture stirred at 0° C. for 1 hour and then room temperature for 2 days. The reaction mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. The organic fraction was collected, washed with water, concentrated, and purified by HPLC to provide the title compound. MS (ESI) m/z 459.1 (M+H)⁺.

Example 736 4-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-chloro-4-fluoropyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (DCI) m/z 420.1 (M+H)⁺.

Example 737 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-chloro-5-fluoropyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (DCI) m/z 420 (M+H)⁺.

Example 738 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-oxopentanamide

The title compound was prepared similarly to the procedure described in Example 242E substituting Example 380A for aniline and substituting 4-oxopentanoic acid for Example 242D. MS (ESI) m/z 423.0 (M+H)⁺.

Example 739 (3R,4S)—N-(5,5-difluorohexyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 735 for Example 242E. MS (ESI) m/z 445.2 (M+H)⁺

Example 740 4-chloro-N-[2-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]aniline Example 740A N-(4-fluorophenyl)-2-((trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)acetamide

The title compound was prepared similarly to the procedure described in Example 404A substituting 4-fluoroaniline for Example 14A and substituting Example 689D for 2-nitro-5-(trifluoromethyl)benzoic acid.

Example 740B 4-chloro-N-[2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]aniline

The title compound was prepared similarly to the procedure described in Example 404B substituting Example 740A for Example 404A. MS (ESI) m/z 479481 (3:1) (M+H)⁺.

Example 741 (3S,4R)—N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 493 (M+H)⁺.

Example 742 1-benzyl-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea

The title compound was prepared similarly to the procedure described in Example 692 substituting (isocyanatomethyl)benzene for isocyanatobenzene. MS (ESI) m/z 458 (M+H)⁺.

Example 743 (3R,4S)—N-(4-chloro-3-methylphenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to Example 327 substituting 1-bromo-4-chloro-3-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 449 (M+H)⁺.

Example 744 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to Example 327 substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 499 (M+H)⁺.

Example 745 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyridin-3-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

A solution of Example 352 (100 mg, 0.22 mmol), pyridine-3-ylboronic acid (41 mg, 0.33 mmol), tricyclohexylphosphine (6.2 mg, 22 μmol), potassium phosphate (1.2 M (aq.), 0.36 mL, 442 mmol)) and palladium(II) acetate (10 mg, 11 μmol) in dioxane (2 mL) was stirred at 100° C. for 18 hours. The reaction mixture was concentrated. Purification via HPLC provided the title compound. MS (ESI) m/z 496 (M+H)⁺.

Example 746 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyridin-4-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 745 substituting pyridin-4-ylboronic acid for pyridine-3-ylboronic acid. MS (ESI) m/z 496 (M+H)⁺.

Example 747 (3R,4S)—N-(4-fluoro-3-methylphenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 1-bromo-4-fluoro-3-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 433 (M+H)⁺.

Example 748 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-methylpyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-bromo-5-fluoro-4-methylpyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 434 (M+H)⁺.

Example 749 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 745 substituting pyrimidin-5-ylboronic acid for pyridine-3-ylboronic acid. MS (ESI) m/z 497 (M+H)⁺.

Example 750 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3,4′-bipyridin-2′-amine

The title compound was prepared similarly to the procedure described in Example 745 substituting Example 759 for Example 352. MS (ESI) m/z 479 (M+H)⁺.

Example 751 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4,4′-bipyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 745 substituting Example 759 for Example 352 and substituting pyridin-4-ylboronic acid for pyridine-3-ylboronic acid. MS (ESI) m/z 479 (M+H)⁺.

Example 752 4-({(3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-6-(trifluoromethyl)pyrimidine

The title compound was prepared similarly to the procedure described in Example 379D substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 2-fluoro-4-(trifluoromethyl)pyridine. MS (ESI) m/z 472 (M+H)⁺.

Example 753 N-[(3R,4S)-4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-4-yl)pyrrolidin-3-amine Example 753A (E)-4-(2-nitrovinyl) oxazole

The title compound was prepared similarly to the procedure described in Example 601A substituting 4-oxazolecarboxaldehyde for tetrahydrofuran-2-carboxaldehyde.

Example 753B (trans)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-(oxazol-4-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting Example 753A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 753C N-[(3R,4S)-4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-4-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 57 substituting Example 753B for Example 14a and substituting 1-bromo-4-chloro-3-(trifluoromethyl)benzene for 1-bromo-2-methylbenzene. MS (ESI) m/z 476.0 (M+H)⁺.

Example 754 4,4-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pentanamide

The title compound was prepared similarly to the procedure described in Example 735 substituting Example 738 for Example 695. MS (ESI) m/z 445.1 (M+H)⁺.

Example 755 (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine Example 755 A (3R,4S)-1-(1,2-dimethyl-1H-imidazol-4-ylsulfonyl)-4-(4-fluorophenyl)pyrrolidin-3-amine hydrochloride

The title compound was prepared similarly to the procedures described in Example 2A-2F substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting 1,2-dimethyl-1H-imidazole-4-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 755 B (3R,4S)-1-(1,2-dimethyl-1H-imidazol-4-ylsulfonyl)-4-(4-fluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 755 A for Example 322B. MS (ESI) m/z 339.1 (M+H)⁺.

Example 755 C (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 755B for Example 337F and substituting 4-bromo-1,2-difluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 451.2 (M+H)⁺.

Example 756 (3R,4S)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 755B for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 501.1 (M+H)⁺.

Example 757 (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine Example 757 A (3R,4S)-1-(1,2-dimethyl-1H-imidazol-5-ylsulfonyl)-4-(4-fluorophenyl)pyrrolidin-3-amine hydrochloride

The title compound was prepared similarly to the conditions described in Example 2A-2F substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting 1,2-dimethyl-1H-imidazole-5-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 757 B (3R,4S)-1-(1,2-dimethyl-1H-imidazol-5-ylsulfonyl)-4-(4-fluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 757A for Example 322B. MS (ESI) m/z 339.1 (M+H)⁺.

Example 757 C (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 757B for Example 337F and substituting 4-bromo-1,2-difluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 451.2 (M+H)⁺

Example 758 (3R,4S)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 757B for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 501.1 (M+H)⁺

Example 759 4-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-bromo-4-chloropyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 436 (M+H)⁺.

Example 760 5-chloro-N-[(3R,4S)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 848 substituting Example 755B for Example 679H. MS (ESI) m/z 518.1 (M+H)⁺

Example 761 Trans-chloro-4-(trifluoromethyl)benzyl]-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 761A Trans-4-(3-fluoropyridin-2-yl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine hydrochloride

The title compound was prepared similarly to the procedures described in Examples 2A-2F substituting (E)-3-fluoro-2-(2-nitrovinyl)pyridine for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 761B Trans-4-(3-fluoropyridin-2-yl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 380A substituting Example 761A for Example 322B.

Example 761 C Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde, Example 761 A for 354D amine MS (ESI) m/z 517.9 (M+H)⁺

Example 762 Trans-4-(3-fluoropyridin-2-yl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting Example 761 A for 354D amine. MS (ESI) m/z 410.1 (M+H)⁺.

Example 763 Trans-4-(3-fluoropyridin-2-yl)-N,N-dihexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting Example 761A for 354D. MS (ESI) m/z 494.1 (M+H)⁺

Example 764 Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N,N-dipentylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pentanal for 4-chlorobenzaldehyde and substituting Example 761 A for 354D. MS (ESI) m/z 466.1 (M+H)⁺

Example 765 Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting pentanal for 4-chlorobenzaldehyde and substituting Example 761 A for 354D. MS (ESI) m/z 396.1 (M+H)⁺

Example 766 Trans-N-(3,4-difluorophenyl)-4-(3-fluoropyridin-2-31)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761 B for Example 337F and substituting 4-bromo-1,2-difluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 438.0 (M+H)⁺

Example 767 Trans-4-(3-fluoropyridin-2-yl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 488.0 (M+H)⁺

Example 768 Trans-4-(3-fluoropyridin-2-yl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 504.0 (M+H)⁺

Example 769 5-fluoro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-methylpyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and 2-bromo-5-fluoro-4-methylpyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 435.1 (M+H)⁺

Example 770 N-{Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 472.0 (M+H)⁺

Example 771 Trans-N-(3-chloro-4-fluorophenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 453.9 (M+H)⁺

Example 772 6-chloro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

To a microwave vial charged with Example 761B (100 mg, 0.31 mmol) and methanol (1 mL) was added triethylamine (62.2 mg, 0.62 mmol) and 4,6-dichloropyrimidine (137 mg, 0.93 mmol). The reaction mixture was stirred in a microwave at 120° C. for 1 hour. The mixture was concentrated and purified via HPLC to afford the title compound. MS (ESI) m/z 438.0 (M+H)⁺

Example 773 (3R,4S)—N-[3-(benzyloxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 1-(benzyloxy)-3-bromobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (APCI) m/z 489 (M+H)⁺.

Example 774 6-(benzyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 4-(benzyloxy)-6-bromopyrimidine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 509 (M+H)⁺.

Example 775 Trans-N-(4-fluoro-3-methylphenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 4-bromo-1-fluoro-2-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 434.0 (M+H)⁺

Example 776 4-(benzyloxy)-5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine Example 776A 4-(benzyloxy)-2-bromo-5-fluoropyridine

To a stirred solution of 2-bromo-5-fluoropyridin-4-ol (100 mg, 0.52 mmol) in dimethylformamide (4 mL) was added (bromomethyl)benzene (89 mg, 0.52 mmol) and potassium carbonate (144 mg, 1.0 mmol). The reaction mixture was stirred at 60° C. for 3 hours. Water and EtOAc were added. The organic fraction was collected and concentrated. Purification via flash chromatography (0-50% EtOAc/heptanes) provided the title compound.

Example 776B 4-(benzyloxy)-5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting Example 776A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 508 (M+H)⁺.

Example 777 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(piperidin-4-yl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting tert-butyl 4-(3-bromophenyl)piperidine-1-carboxylate for 1-bromo-3-(trifluoromethyl)benzene followed by dissolving the crude mixture in dichloromethane (5 mL) and treating the crude mixture with HCl (4 M, 3 mL) and purifying via HPLC. MS (APCI) m/z 466 (M+H)⁺.

Example 778 6-(azetidin-3-ylmethoxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine

Tert-butyl 3-((6-((3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-ylamino)pyrimidin-4-yloxy)methyl)azetidine-1-carboxylate was prepared similarly to the procedure described in Example 691 substituting Example 606 for Example 691 and substituting tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (3 eq.) for ethanol and adding tert-butanol (5 mL). The reaction mixture was concentrated, dissolved in dichloromethane, and treated with HCl (4 M, 10 eq.). Purification via HPLC provided the title compound. MS (ESI) m/z 488 (M+H)⁺.

Example 779 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(pyrrolidin-3-ylmethoxy)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 778 substituting tert-butyl-3-hydroxymethyl-pyrrolidine-1-carboxylate for tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate. MS (ESI) m/z 502 (M+H)⁺.

Example 780 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(pyrrolidin-2-ylmethoxy)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 778 substituting tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate for tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate. MS (ESI) m/z 502 (M+H)⁺.

Example 781 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine Example 781A (E)-3-(2-nitrovinyl)tetrahydro-2H-pyran

The title compound was prepared similarly to the procedure described in Example 307A substituting tetrahydropyran-3-carbaldehyde for 2-pyridinecarboxaldeyde.

Example 781B trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-((S)-tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedures described in Examples 2A-2F substituting Example 781A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 781C trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 1-bromo-3-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 405 (M+H)⁺.

Example 782 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B. MS (ESI) m/z 459 (M+H)⁺.

Example 783 trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 425 (M+H)⁺.

Example 784 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 475 (M+H)⁺.

Example 785 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 489 (M+H)⁺.

Example 786 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-phenoxyphenyl)-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781 B for Example 322B and substituting 1-bromo-3-phenoxybenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 483 (M+H)⁺.

Example 787 trans-N-(biphenyl-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 3-bromo-1,1′-biphenyl for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 467 (M+H)⁺.

Example 788 Trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)tetrahydro-2 H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-fluoro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 493 (M+H)⁺.

Example 789 Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-fluoro-2-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 443 (M+H)⁺.

Example 790 Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-fluoro-2-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 423 (M+H)⁺.

Example 791 Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 477 (M+H)⁺.

Example 792 Trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-chloro-2-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 509 (M+H)⁺.

Example 793 Trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 4-bromo-1-chloro-2-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 497 (M+H)⁺.

Example 794 Trans-N-[3-(benzyloxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 781B for Example 322B and substituting 1-(benzyloxy)-3-bromobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 497 (M+H)⁺.

Example 795 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

To a solution of Example 368 (0.12 g, 0.26 mmol) in dimethylformamide (0.4 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium tetrafluoroborate (SelectFluo, 91 mg, 0.26 mmol). The mixture was stirred at room temperature for 16 hours. More 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium tetrafluoroborate (60 mg) was added. The mixture was stirred at room temperature for another 16 hours, concentrated, and purified by HPLC to afford the title compound. MS (ESI) m/z 488 (M+H)⁺.

Example 796 3-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

To a solution of Example 368 (0.12 g, 0.26 mmol) in dimethylformamide (0.4 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium tetrafluoroborate (SelectFluo, 91 mg, 0.26 mmol). The mixture was stirred at room temperature for 16 hours. More 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane-1,4-diium tetrafluoroborate (60 mg) was added. The mixture was stirred at room temperature for another 16 hours, concentrated, and purified by HPLC to afford the title compound. MS (EST) m/z 488 (M+H)⁺.

Example 797 N-(2,2-difluoroethyl)-2-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)acetamide

The title compound was prepared similarly to the procedure described in Example 242E substituting 2,2-difluoroethanamine for aniline and substituting Example 689D for Example 242D. MS (ESI) m/z 447.0 (M+H)⁺

Example 798 Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761 B for Example 337F. MS (ESI) m/z 470.0 (M+H)⁺

Example 799 Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 486.0 (M+H)⁺

Example 800 Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 500.0 (M+H)⁺

Example 801 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(pyridin-2-yl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to Example 327 substituting 2-(3-bromophenyl)pyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 478 (M+H)⁺.

Example 802 (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(pyridin-2-yl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to Example 327 substituting Example 574A for Example 322B and substituting 2-(3-bromophenyl)pyridine. MS (ESI) m/z 460 (M+H)⁺.

Example 803 5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine Example 803A 2-bromo-5-fluoro-4-(2,2,2-trifluoroethoxy)pyridine

A microwave vial was charged with 2-bromo-5-fluoropyridin-4-ol (1 g, 5.2 mmol), 1,1,1-trifluoro-2-iodoethane (3.3 g, 15.6 mmol), potassium carbonate (1.44 g, 10.4 mmol), and dimethylsulfoxide (10 mL). The reaction mixture was stirred in a microwave (Biotage Initiator™ maximum 400 Watts) at 150° C. for 1 hour. The reaction mixture was partitioned between water and EtOAc. The organic fraction was collected and concentrated. Flash chromatography (0-50% EtOAc/heptanes) provided the title compound.

Example 803B 5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting Example 803A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 500 (M+H)⁺.

Example 804 5-Chloro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared as described in Example 848 substituting Example 761B for Example 679H. MS (ESI) m/z 505.0 (M+H)⁺

Example 805 Trans-N-(3-fluorophenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 761B for Example 337F and substituting 1-bromo-3-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 420.0 (M+H)⁺

Example 806 5-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine Example 806A 2-bromo-5-chloro-4-(2,2,2-trifluoroethoxy)pyridine

The title compound was prepared similarly to Example 803A substituting 2-bromo-5-chloropyridin-4-ol for 2-bromo-5-fluoropyridin-4-ol.

Example 806B 5-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 806A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 534 (M+H)⁺.

Example 807 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine Example 807A 2-bromo-4-(2,2,2-trifluoroethoxy)pyridine

The title compound was prepared similarly to the procedure described in Example 803A substituting 2-bromopyridin-4-ol for 2-bromo-5-fluoropyridin-4-ol.

Example 807B N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 807A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 500 (M+H)⁺.

Example 808 5-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting Example 806A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 516 (M+H)⁺.

Example 809 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting Example 807A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 482 (M+H)⁺.

Example 810 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 803A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 518 (M+H)⁺.

Example 811 Trans-4-(3-fluoropyridin-2-yl)-N-hexyl-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine Example 811 A Trans-4-(3-fluoropyridin-2-yl)-1-(1-methyl-1H-1,2,3-triazol-4-ylsulfonyl)pyrrolidin-3-amine hydrochloride

The title compound was prepared similarly to the conditions described in Example 2A-2F substituting (E)-3-fluoro-2-(2-nitrovinyl)pyridine for (E)-1-methoxy-4-(2-nitrovinyl)benzene and 1-methyl-1H-1,2,3-triazole-4-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 811 B Trans-4-(3-fluoropyridin-2-yl)-N-hexyl-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting Example 811 A for 354D. MS (ESI) m/z 411.0 (M+H)⁺

Example 812 N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(propan-2-yl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting 2-bromo-4-isopropylpyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 444 (M+H)⁺.

Example 813 N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(propan-2-yl)pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting 2-bromo-4-isopropylpyridine for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 426 (M+H)⁺.

Example 814 2,2,2-trifluoro-N-[2-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]ethanamine

The title compound was prepared similarly to the procedure described in Example 290 substituting Example 797 for Example 242E. MS (ESI) m/z 451.1 (M+H)⁺

Example 815 Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 443.0 (M+H)⁺

Example 816 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 489.1 (M+H)⁺

Example 817 2-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-4-(trifluoromethyl)pyridine Example 817A (E)-ethyl 3-(4-(trifluoromethyl)pyridin-2-yl)acrylate

To a solution of ethyl 2-(diethoxyphosphoryl)acetate (0.45 g, 2 mmol) in tetrahydrofuran (3 mL) at −20° C. was added sodium hydride (100 mg, 60%, 2.5 mmol) followed by the addition of 4-(trifluoromethyl)picolinaldehyde in tetrahydrofuran (1 mL). The mixture was warmed to room temperature over 1 hour. Aqueous ammonium chloride was added and the solution was partitioned with ethyl acetate. The organic fraction was collected, concentrated, and purified by flash chromatography (25% ethyl acetate/hexanes) to afford the title compound.

Example 817B ethyl 3-(4-(trifluoromethyl)pyridin-2-yl)propanoate

To a solution of Example 817A (460 mg, 1.8 mmol) in ethanol (20 mL) in a 50 mL pressure bottle was added 5% palladium on carbon, (95 mg, 0.022 mmol). The mixture was stirred for 2 hours under 30 psi of hydrogen at room temperature. The mixture was filtered through a nylon membrane and concentrated to afford the title compound.

Example 817C ethyl 4-nitro-3-phenyl-2-((4-(trifluoromethyl)pyridin-2-yl)methyl)butanoate

The title compound was prepared similarly to the procedure described in Example 331A substituting Example 817B for methyl 3-(3-chlorophenyl)propanoate.

Example 817D 4-phenyl-3-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyrrolidin-2-one

The title compound was prepared similarly to the procedure described in Example 331B substituting Example 817C for Example 331A.

Example 817E 2-((4-phenylpyrrolidin-3-yl)methy 1)-4-(trifluoromethyl)pyridine

To a solution of Example 817D (450 mg, 1.4 mmol) in tetrahydrofuran (3 mL) was added lithiumaluminum hydride (2N, 1.5 mL, 3 mmol). The mixture was stirred for 16 hours. Aqueous sodium bicarbonate followed by ethyl acetate was added. The organic fraction was collected, dried over potassium carbonate, filtered, and concentrated to provide the title compound.

Example 817F 2-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-4-(trifluoromethyl)pyridine

The title compound was prepared similarly to the procedure described in Example 182C substituting Example 817E for Example 182B. MS (ESI) m/z 451 (M+H)⁺.

Example 818 Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and substituting example 811A for 354D. MS (ESI) m/z 519.0 (M+H)⁺

Example 819 Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared as described in Example 603 substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 475.1 (M+H)⁺

Example 820 N-Hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2R)-tetrahydrofuran-2-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting example 601B for 354D. MS (ESI) m/z 385.2 (M+H)⁺.

Example 821 N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)-tetrahydrofuran-2-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting hexanal for 4-chlorobenzaldehyde and substituting example 601B for 354D. MS (ESI) m/z 385.2 (M+H)⁺.

Example 822 Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and substituting example 601B for 354D. MS (ESI) m/z 493.1 (M+H)⁺.

Example 823 N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)tetrahydrofuran-2-yl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 354E substituting 2-chloro-4-(trifluoromethyl)benzaldehyde for 4-chlorobenzaldehyde and substituting example 601B for 354D. MS (ESI) m/z 493.1 (M+H)⁺.

Example 824 Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared as described in Example 603 substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 429.1 (M+H)⁺

Example 825 N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)-tetrahydrofuran-2-yl]pyrrolidin-3-amine

The title compound was prepared as described in Example 603 substituting 4-bromo-2-chloro-1-fluorobenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 429.1 (M+H)⁺

Example 826 1-benzyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2,3-dihydro-1H-indol-6-amine Example 826A 1-benzyl-6-bromoindoline

To a stirred solution of 6-bromoindoline (100 mg, 0.50 mmol) in dimethylformamide (5 mL) was added (bromomethyl)benzene (95 mg, 0.55 mmol) and potassium carbonate (140 mg, 1.0 mmol). The reaction was stirred at 60° C. for 18 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic fraction was collected, washed with brine, dried with magnesium sulfate, and concentrated to provide the title compound.

Example 826B 1-benzyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2,3-dihydro-1H-indol-6-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 574A for Example 322B and substituting Example 826A for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 514 (M+H)⁺.

Example 827 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine Example 827A (E)-3-(2-nitrovinyl)tetrahydrofuran

To a solution of oxalyl chloride (5.1 mL, 60 mmol) in dichloromethane (100 mL) under a nitrogen atmosphere at −78° C. was added dropwise dimethylsulfoxide (4.6 mL, 65 mmol) in dichloromethane (10 mL). The reaction mixture stirred for 10 minutes. Tetrahydro-3-furan methanol (5.5 g, 54 mmol) was added in dichloromethane (20 mL) over several minutes, and the reaction mixture was stirred for 10 minutes. Triethylamine (17.4 mL, 125 mmol) was added drop wise. The reaction mixture was allowed to warm to room temperature. Diethyl ether was added and the solution was filtered. The filtrate was concentrated to provide crude tetrahydrofuran-3-carbaldehyde.

To a stirred solution of this crude tetrahydrofuran-3-carbaldehyde in tetrahydrofuran (50 mL) under a nitrogen atmosphere was added nitromethane (8.1 mL, 150 mmol), 1,1,2,2-tetramethyl guanidine (0.69 mL, 5.5 mmol). The reaction was stirred at room temperature for 1 hour. The reaction mixture was then cooled to 0° C. and trifluoroacetic anhydride (6.3 mL, 100 mmol) was added. The reaction mixture stirred for 15 minutes. Triethylamine (13.9 mL, 100 mmol) was added dropwise and the reaction mixture stirred for 1 hour. The reaction mixture was concentrated and partitioned between ethyl acetate and water. The organic fraction was collected, washed with brine, and concentrated. Purification via flash chromatography (40% EtOAc/heptanes) provided the title compound.

Example 827B trans-1-(1-methyl-1H-imidazol-4-ylsulfonyl)-4-((S)-tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepare as an HCl salt similarly to the procedures described in Example 2A-2F substituting Example 827A for (E)-1-methoxy-4-(2-nitrovinyl)benzene.

Example 827C trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B. MS (ESI) m/z 445 (M+H)⁺.

Example 828 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-3-methylbenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 391 (M+H)⁺.

Example 829 trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 411 (M+H)⁺.

Example 830 trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-3-chloro-4-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene, but only stirring for 1 hour. MS (APCI) m/z 429 (M+H)⁺.

Example 831 trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-4-fluoro-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 479 (M+H)⁺.

Example 832 trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro furan-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-4-fluoro-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (APCI) m/z 463 (M+H)⁺.

Example 833 trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-4-chloro-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 479 (M+H)⁺.

Example 834 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 475 (M+H)⁺.

Example 835 trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 827B for Example 322B and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (EST) m/z 461 (M+H)⁺.

Example 836 trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine Example 836A 1-methyl-1H-1,2,3-triazole-4-sulfonyl chloride

To an ice-cooled solution of sodium 1H-1,2,3-triazole-4-thiolate (34.5 g, 280 mmol) in ethanol (400 mL) was added benzylbromide (18.8 mL, 158 mmol) drop-wise. The mixture stirred at 25° C. for 2 hours, and was then diluted with EtOAc (600 mL), washed with water (500 mL), brine (500 mL), dried over sodium sulfate filtered, and concentrated under reduced pressure to afford 4-(benzylthio)-1H-1,2,3-triazole.

To a solution of 4-(benzylthio)-1H-1,2,3-triazole (55.0 g, 288 mmol) in dimethylformamide (550 mL) at 0° C. was added potassium carbonate (87.0 g, 630 mmol) followed by dimethyl sulfate (55.0 mL, 575 mmol) dropwise. Then the reaction mixture was stirred at 20° C. for 16 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (500 mL) and washed with water (500 mL). The organic fraction was dried with sodium sulfate, and concentrated. The residue was purified via flash chromatography (Petroleum ether:EtOAc=1:0, 10:1, 5:1 to 3:1) to afford 4-(benzylthio)-1-methyl-1H-1,2,3-triazole.

1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (40.3 g, 205 mmol) was added portion wise to a mixture of 4-(benzylthio)-1-methyl-1H-1,2,3-triazole (28.0 g, 137 mmol) in acetonitrile (1200 mL), AcOH (50 mL) and water (34 mL), which had been cooled to 0° C. The addition was slow enough to maintain the internal temperature of the reaction mixture below 5° C. Upon complete addition, the mixture stirred for an additional 2 hours at 0° C. The reaction mixture was then quenched slowly with aqueous sodium hydrideCO₃ solution (5%, 700 mL). The resulting mixture was stirred for 15 minutes and then diluted with dichloromethane (2000 mL). The organic fraction was collected, washed with brine (1000 mL), dried over sodiumsulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether/EtOAc=1:0 to 5:1) to afford the title compound.

Example 836B trans-4-(4-fluorophenyl)-1-(1-methyl-1H-1,2,3-triazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared as an HCl salt similarly to the procedures described in Examples 2A-2F substituting (E)-1-fluoro-4-(2-nitrovinyl)benzene for (E)-1-methoxy-4-(2-nitrovinyl)benzene and substituting 1-methyl-1H-1,2,3-triazole-4-sulfonyl chloride for 1-methyl-1H-imidazole-4-sulfonyl chloride.

Example 836C trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-3-(2,2,2-trifluoroethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 500 (M+H)⁺.

Example 837 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 486 (M+H)⁺.

Example 838 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-4-fluoro-3-(trifluoromethoxy)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 504 (M+H)⁺.

Example 839 (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 470 (M+H)⁺.

Example 840 (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-4-fluoro-3-(trifluoromethyl)benzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 488 (M+H)⁺.

Example 841 (3R,4S)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-(trifluoromethyl)benzene. MS (ESI) m/z 436 (M+H)⁺.

Example 842 (3R,4S)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 327 substituting Example 836B for Example 322B and substituting 1-bromo-3-chloro-4-fluorobenzene for 1-bromo-3-(trifluoromethyl)benzene, but only stirring for 1 hour. MS (ESI) m/z 454 (M+H)⁺.

Example 843 Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 603 substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 463.1 (M+H)⁺

Example 844 5-Chloro-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine

The title compound was prepared similarly to the procedure in Example 848 substituting Example 601B for Example 679H. MS (ESI) m/z 480.1 (M+H)⁺

Example 845 Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 603 substituting 4-bromo-1-fluoro-2-methylbenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 409.1 (M+H)⁺

Example 846 Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 4-bromo-1-fluoro-2-(trifluoromethyl)benzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 477.1 (M+H)⁺

Example 847 Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 4-bromo-1-fluoro-2-methylbenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 423.1 (M+H)⁺

Example 848 5-Chloro-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine

To a microwave vial charged with Example 679H (80 mg, 0.254 mmol) and N-methyl-2-pyrrolidone (0.5 mL) was added cesium carbonate (141 mg, 0.43 mmol) and 2,5-dichloro-4-(trifluoromethyl)pyridine (71.4 mg, 0.33 mmol) under Argon. This mixture was stirred at 120° C. for 5 hours. The mixture was then partitioned between water and ethyl acetate. The organic fraction was collected, concentrated, and purified by flash chromatography to provide the title compound. MS (ESI) m/z 494.1 (M+H)⁺

Example 849 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 1-bromo-3-chlorobenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 425.1 (M+H)⁺

Example 850 Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 603 substituting 1-bromo-3-chlorobenzene for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 411.1 (M+H)⁺

Example 851 5-Fluoro-4-methyl-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 603 substituting 2-bromo-5-fluoro-4-methylpyridine for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 410.2 (M+H)⁺

Example 852 5-Fluoro-4-methyl-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]pyridin-2-amine

The title compound was prepared similarly to the procedure described in Example 337G substituting Example 679H for Example 337F and substituting 2-bromo-5-fluoro-4-methylpyridine for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 424.2 (M+H)⁺

Example 853 N-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]-6-(trifluoromethyl)pyrimidin-4-amine

The title compound was prepared similarly to the procedure described in Example 603 substituting 4-bromo-6-(trifluoromethyl)pyrimidine for 1-bromo-3-trifluoromethylbenzene. MS (ESI) m/z 447.1 (M+H)⁺

Example 854 (3R,4S)—N-cyclohexyl-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting cyclohexanone for benzaldehyde. MS (ESI) m/z 407 (M+H)⁺.

Example 855 (3R,4S)—N-(3,3-dimethylcyclohexyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 3,3-dimethylcyclohexanone for benzaldehyde. MS (ESI) m/z 435 (M+H)⁺.

Example 856 (3R,4S)—N-(4,4-dimethylcyclohexyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 4,4-dimethylcyclohexanone for benzaldehyde. MS (ESI) m/z 435 (M+H)⁺.

Example 857 (3R,4S)—N-cyclopentyl-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting cyclopentanone for benzaldehyde. MS (ESI) m/z 393 (M+H)⁺.

Example 858 (3R,4S)—N-(3,3-dimethylcyclopentyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 3,3-dimethylcyclopentanone for benzaldehyde. MS (ESI) m/z 421 (M+H)⁺.

Example 859 (3R,4S)—N-(1-(2,4-dichlorophenyl)ethyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 1-(2,4-dichlorophenyl)ethanone for benzaldehyde. MS (ESI) m/z 497 (M+H)⁺.

Example 860 (3R,4S)—N-(2,3-dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-yl sulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 2,3-dihydro-1H-inden-1-one for benzaldehyde. MS (ESI) m/z 441 (M+H)⁺.

Example 861 (3R,4S)—N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 5-chloro-2,3-dihydro-1H-inden-1-one for benzaldehyde. MS (ESI) m/z 475 (M+H)⁺.

Example 862 N-(4-chlorobenzyl)-N-((3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)acetamide Example 862A (3R,4S)—N-(4-chlorobenzyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine

The title compound was prepared similarly to the procedure described in Example 148 substituting Example 322B for Example 3A and substituting 4-chlorobenzaldehyde for benzaldehyde.

Example 862B N-(4-chlorobenzyl)-N-((3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)acetamide

The title compound was prepared similarly to the procedure described in Example 4C substituting Example 862A for Example 4B and substituting acetic acid for 2-chloro-3-(trifluoromethyl)benzoic acid. MS (ESI) m/z 491 (M+H)⁺.

Further exemplary compounds include:

-   1-(Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)pyrrolidin-3-yl)azepane; -   4-(Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)pyrrolidin-3-yl)morpholine; -   4-((Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(2-methylpiperidin-1-yl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(3-methylpiperidin-1-yl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(4-methylpiperidin-1-yl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-4-(4-fluoropiperidin-1-yl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-4-(4,4-difluoropiperidin-1-yl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-4-(3-fluoroazetidin-1-yl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   4-((Trans-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4-(piperidin-1-yl)pyrrolidin-3-yl)oxy)-6-(trifluoromethyl)pyrimidine; -   Trans-1′-((1-methyl-1H-imidazol-4-yl)sulfonyl)-4′-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)-1,3′-bipyrrolidine; -   Trans-3-((3-chlorophenyl)amino)-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-2-one; -   Trans-3-((3-chloro-4-fluorophenyl)amino)-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-2-one; -   Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-3-((3-(trifluoromethyl)phenyl)amino)pyrrolidin-2-one; -   Trans-3-((4-fluoro-3-(trifluoromethoxy)phenyl)amino)-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-2-one; -   3-(Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydroisoxazole; -   2-(Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)-5-(4-(trifluoromethyl)phenyl)oxazole; -   5-(3-Chlorophenyl)-2-(trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)-1H-imidazole; -   4-((Trans-3-(4-fluoro-3-(trifluoromethyl)phenoxy)-4-(4-fluorophenyl)pyrrolidin-1-yl)sulfonyl)-1-methyl-1H-imidazole; -   Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-N-(3-(trifluoromethyl)cyclohexyl)pyrrolidin-3-amine; -   N-(Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)-1-isopropylpiperidin-4-amine; -   Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)-N-(2-methyltetrahydrofuran-3-yl)pyrrolidin-3-amine; -   1-Ethyl-N-(Trans-4-(4-fluorophenyl)-1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-3-yl)piperidin-3-amine.     Biological Testing

1. [³H]-Glycine uptake into recombinant CHO cells expressing human GlyT1: Human GlyT1c expressing recombinant hGlyT1c_5_CHO cells were plated at 20,000 cells per well in 96 well Cytostar-T scintillation microplates (Amersham Biosciences) and cultured to sub-confluency for 24 h. For glycine uptake assays the culture medium was aspirated and the cells were washed once with 100 μl HBSS (Gibco BRL, #14025-050) with 5 mM L-Alanine (Merck #1007). 80 μl HBSS buffer were added, followed by 10 μl inhibitor or vehicle (10% DMSO) and 10 μl [³H]-glycine (TRK71, Amersham Biosciences) to a final concentration of 200 nM for initiation of glycine uptake.

The plates were placed in a Wallac Microbeta (PerkinElmer) and continuously counted by solid phase scintillation spectrometry during up to 3 hours. Nonspecific uptake was determined in the presence of 10 μM Org24598. IC₅₀ calculations were made by four-parametric logistic nonlinear regression analysis (GraphPad Prism) using determinations within the range of linear increase of [³H]-glycine incorporation between 60 and 120 min.

2. Radioligand binding assays using recombinant CHO cell membranes expressing human GlyT1:

Radioligand binding to human GlyT1c transporter-expressing membranes was determined as described in Mezler et al., Molecular Pharmacology 74:1705-1715, 2008.

The following results were obtained with the compounds disclosed in the examples:

Ex. Ki [μM] 1 — 2 ≦1 3 ≦0.1 4 ≧10 13 ≦1 14 ≦1 15 ≦10 16 ≦1 17 ≦10 18 ≦10 19 ≦10 20 ≦10 21 ≦10 22 ≦10 23 ≦10 24 ≦10 25 ≦10 26 ≦1 27 ≦1 29 ≦1 30 ≦10 31 ≦1 32 ≦10 33 ≦10 34 ≦10 35 ≦10 36 ≦1 37 ≦1 38 ≦10 39 ≦10 40 ≧10 41 ≦10 42 ≦10 43 ≦10 44 ≦10 45 ≧10 46 ≧10 47 ≧10 48 ≦10 49 ≦10 50 ≦10 51 ≦0.1 52 ≦10 53 ≦10 54 ≦1 55 ≦1 56 ≦1 57 ≦10 58 ≦0.1 59 ≦10 60 ≦0.1 61 ≦1 62 ≦0.1 63 ≦0.1 64 ≦0.1 65 ≦1 66 ≦10 67 ≦0.01 68 ≦1 69 ≦10 70 ≦1 71 ≦1 72 — 73 ≦10 74 ≦0.1 75 ≦1 76 ≦10 77 ≦1 78 ≦1 79 ≦1 80 ≦1 81 ≦10 82 ≦10 83 ≦1 84 ≦1 85 ≦0.01 86 ≦1 87 ≦10 88 ≦0.01 89 ≦0.1 90 ≦1 91 ≦0.1 92 ≦0.1 93 ≦1 94 ≦0.01 95 ≦1 100 ≦10 101 ≦1 102 ≦1 115 ≦0.1 122 ≦10 123 ≦10 124 ≦10 125 >10 126 ≦10 127 ≦10 128 ≦10 129 >10 130 >10 131 >10 132 ≦10 133 ≦10 134 ≦10 135 >10 136 ≦10 137 ≦10 142 ≦10 143 ≦10 144 >10 145 ≦0.1 148 ≦10 149 ≦0.1 150 ≦0.001 151 ≦0.1 152 ≦1 153 ≦1 154 ≦0.1 155 ≦0.1 156 ≦0.1 157 ≦10 158 ≦0.1 159 ≦0.01 160 ≦0.01 161 ≦1 162 ≦1 163 ≦1 164 ≦10 165 ≦1 166 ≦1 167 ≦0.1 168 ≦0.1 169 ≦10 170 ≦0.1 171 ≦0.1 172 ≦0.1 173 ≦1 174 ≦1 175 ≦1 176 ≦0.01 177 ≦10 178 ≦1 179 ≦10 180 ≦1 181 ≦10 182 ≦0.1 183 ≦10 184 ≦10 185 ≦10 186 ≦1 187 ≦10 188 ≦0.1 189 ≦0.1 190 ≦1 191 ≦10 192 ≦1 193 ≦10 194 ≦0.1 195 ≦10 196 ≦10 197 ≦1 198 ≦1 199 ≦1 200 ≦1 201 ≦0.1 202 ≦1 203 ≦10 204 ≦0.1 205 ≦1 206 ≦10 207 ≦10 208 ≦10 209 ≦10 210 ≦10 211 ≦1 212 ≦0.10 213 ≦1 214 ≦0.1 215 ≦0.1 216 ≦1 217 ≦1 218 ≦1 219 ≦10 220 ≦0.01 221 ≦1 222 ≦1 223 ≦0.1 224 ≦1 225 ≦10 226 ≦0.01 227 ≦10 228 ≦10 229 ≦10 230 ≦10 231 ≦1 232 ≦10 233 ≦10 234 ≦1 235 ≦10 236 ≦10 237 ≦10 238 ≦10 239 ≦10 240 ≦0.1 241 ≦10 242 ≦10 243 ≦1 244 ≦1 245 ≦0.1 246 ≦0.1 247 ≦0.01 248 ≦1 249 ≦1 250 ≦10 251 ≦0.1 252 ≦1 253 ≦1 254 ≦10 255 ≦0.1 256 ≦1 257 ≦0.1 258 ≦1 259 ≦1 260 ≦0.1 261 ≦1 262 ≦0.01 263 ≦0.1 264 ≦1 265 ≦1 266 ≦1 267 ≦0.01 268 ≦10 269 ≦10 270 ≦10 271 ≦1 272 ≦1 273 ≦1 274 ≦0.1 275 ≦1 276 ≦1 277 ≦10 278 ≦0.1 279 ≦10 280 ≦0.01 281 ≦0.01 282 ≦0.1 283 ≦0.1 284 ≦0.1 285 ≦0.1 286 ≦10 287 ≦0.01 288 ≦1 289 ≦1 290 ≦10 291 ≦0.1 292 ≦1 293 ≦0.1 294 ≦0.01 295 ≦0.1 296 ≦0.1 297 ≦0.01 298 ≦0.01 299 ≦1 300 ≦1 301 ≦1 302 ≦0.1 303 ≦10 304 ≦1 305 ≦0.01 306 ≦0.1 307 ≦0.1 308 ≦1 309 ≦1 310 ≦0.1 311 ≦1 312 ≦0.1 313 ≦1 314 ≦1 315 ≦1 316 ≦1 317 ≦1 318 ≦1 319 ≦0.1 320 ≦0.01 321 ≦1 322 ≦0.01 323 ≦1 324 ≦10 325 ≦1 326 ≦1 327 ≦0.01 328 ≦0.1 329 ≦0.01 329 ≦0.01 330 ≦0.1 330 ≦0.1 331 ≦1 332 ≦0.1 333 ≦1 334 ≦1 335 ≦1 336 ≦1 337 ≦1 338 ≦1 339 ≦10 340 ≦1 341 ≦10 342 ≦10 343 ≦10 344 ≦0.1 345 ≦0.1 346 ≦1 347 ≦10 348 ≦0.1 349 ≦0.1 350 >10 351 ≦1 352 ≦0.01 353 ≦0.1 354 ≦1 355 ≦1 356 ≦0.1 357 ≦1 358 ≦0.1 359 ≦1 360 ≦0.1 361 ≦1 362 ≦0.1 363 ≦0.1 364 ≦10 365 ≦10 366 ≦0.1 367 ≦0.1 368 ≦0.01 369 ≦1 370 ≦1 371 ≦1 372 ≦10 373 ≦10 374 ≧10 375 ≧10 376 ≦1 377 ≦1 378 ≦10 379 ≦0.1 380 ≦0.1 381 ≦10 382 ≦0.1 383 ≦1 384 ≦10 385 ≦10 386 ≦1 387 ≦10 388 ≦0.1 389 ≦10 390 ≦0.01 390 ≦0.01 391 ≦0.1 392 ≦0.1 393 ≦0.01 394 ≦0.01 395 ≦1 396 ≦0.01 397 ≦0.01 398 ≦0.01 399 ≦0.1 400 ≦10 401 ≦10 402 ≦10 403 ≦0.1 404 ≦10 405 ≦1 406 ≦10 407 ≦10 408 ≦10 409 ≦0.1 410 ≦10 411 ≦10 412 ≦1 413 ≦10 414 ≦10 415 ≦10 416 — 417 ≦0.01 418 ≦0.1 419 ≧10 420 ≦10 421 ≦10 422 ≦1 423 ≦10 424 ≦1 425 ≦0.01 426 ≦1 427 ≦0.1 428 ≦0.1 429 >10 430 >10 431 ≦10 432 ≦10 433 ≦0.1 434 ≦10 435 ≦0.1 436 ≦1 437 ≦0.1 438 ≦1 439 ≦1 440 ≦0.1 441 ≦10 442 ≦1 443 ≦1 444 — 445 ≦1 446 ≦0.1 447 ≦10 448 ≦0.1 449 ≦1 450 ≦1 451 — 452 — 453 ≦1 454 ≦10 455 ≦0.1 456 ≦1 457 ≦10 458 ≦10 459 ≦10 460 ≦10 461 ≦1 462 ≦0.1 463 ≦1 464 ≦1 465 ≦1 466 — 467 ≦1 468 ≦0.1 469 ≦1 470 ≦10 471 ≦0.1 472 ≦1 473 ≦0.1 474 ≦10 475 ≦10 476 ≦10 477 ≦10 478 ≦10 479 >10 480 >10 481 ≦10 482 ≦10 483 ≦10 484 ≦10 485 ≦10 486 ≦10 487 ≦10 488 ≦10 489 ≦10 490 ≦10 491 ≦10 492 ≧10 493 ≦10 494 ≦10 495 >10 496 ≧10 497 ≦10 498 ≦10 499 ≧10 500 ≦10 501 ≦10 502 ≦10 503 ≧10 504 ≦10 505 — 506 ≦10 507 ≦10 508 ≦10 509 ≦10 510 ≦10 511 ≦10 512 ≦10 513 >10 514 ≦10 515 ≦10 516 ≦10 517 ≦10 518 >10 519 >10 520 ≦10 521 ≦10 522 — 523 ≦10 524 ≦10 525 ≦10 526 ≦10 527 ≦10 528 >10 529 ≦10 530 ≦1 531 ≦0.1 532 ≦10 533 ≦10 534 ≦1 535 ≦10 536 ≦1 537 ≦10 538 ≦10 539 ≦10 540 ≦0.1 540 ≦0.1 541 ≦10 542 ≦10 543 ≦10 544 ≦10 545 ≦1 546 ≧10 547 ≦0.1 548 ≦0.01 549 ≦10 550 ≦10 551 ≦10 552 ≦10 553 ≦1 554 ≦1 555 ≦10 556 ≦10 557 ≦10 558 ≦10 559 ≦1 560 ≧10 561 ≦1 562 ≦10 563 ≦10 564 ≦1 565 ≦10 566 ≦10 567 ≦1 568 ≦0.1 569 ≦1 570 ≦0.01 571 ≦10 572 ≦1 573 ≦0.1 574 ≦0.1 575 ≦10 576 — 577 >10 578 ≦10 579 ≦10 580 ≦1 581 ≦0.1 582 ≦10 583 ≦10 584 ≦10 585 ≦0.1 586 ≦1 587 ≦10 588 ≦10 589 ≦1 590 ≦10 591 ≦10 592 ≦10 593 ≦10 594 ≦10 595 ≦10 596 ≦10 597 ≦10 598 ≦10 599 ≦10 600 ≦10 601 ≦0.1 602 ≦1 603 ≦0.1 604 ≦0.1 605 ≦1 606 ≦0.1 607 ≦10 608 ≦10 609 ≦1 610 ≦10 611 ≦10 612 ≦1 613 ≦1 614 ≦1 615 ≦1 616 ≦1 617 ≦0.01 618 ≦1 619 ≦1 620 ≦1 621 ≦10 622 ≦0.1 623 ≦0.1 624 ≦1 625 ≦0.01 626 ≦1 627 ≦1 628 ≦0.01 629 ≦1 630 ≦0.1 631 ≦0.01 632 ≦1 633 ≦1 634 ≦10 635 ≦1 636 ≦1 637 ≦10 638 ≦1 639 ≦10 640 ≦1 641 ≦0.1 642 ≦0.01 643 ≦10 644 ≦10 645 ≦0.01 646 ≦0.01 647 ≦10 648 ≦10 649 ≦0.1 650 ≦1 651 ≦0.01 651 ≦0.01 652 ≦0.01 653 ≦10 654 ≦1 655 ≦1 656 ≦1 657 ≦1 658 ≦1 659 ≦10 660 ≦1 661 ≦1 662 ≦10 663 ≦0.1 664 ≦0.1 665 ≦0.01 666 ≦10 667 ≦0.1 668 ≦10 669 ≦0.1 670 ≦0.01 671 ≦1 672 ≦1 673 ≦1 674 ≦1 675 ≦1 676 ≦1 677 ≦1 678 ≦1 679 ≦1 680 ≦0.1 681 ≦0.01 682 ≦0.1 683 ≦0.1 684 ≦1 685 ≦0.01 686 ≦0.01 687 ≦0.1 688 ≦1 689 ≦1 690 ≦1 691 ≦0.1 692 ≦1 693 ≦10 694 ≦1 695 ≦10 696 ≦10 697 ≦1 698 ≦1 699 ≦1 700 ≦10 701 ≦1 702 ≦10 703 ≦1 704 ≦1 705 ≦1 706 ≦10 707 ≦1 708 ≦10 709 ≦10 710 ≦1 711 — 712 ≦1 713 >10 714 ≦10 715 ≦1 716 ≦0.1 717 ≦0.1 718 ≦0.1 719 ≦0.1 720 ≦0.1 721 ≦0.1 722 ≦0.01 723 ≦0.1 724 ≦0.1 725 ≦0.01 726 ≦0.1 727 ≦0.01 728 ≦0.01 729 ≦0.01 730 ≦0.01 731 ≦0.1 732 ≦0.1 733 ≦0.01 734 ≦0.1 735 ≦10 736 ≦1 737 ≦0.1 738 >10 739 ≦0.1 740 ≦10 741 ≦0.1 742 ≦1 743 ≦0.1 744 ≦0.01 745 ≦0.01 746 ≦0.01 747 ≦0.01 748 ≦0.01 749 ≦0.01 750 ≦0.1 751 ≦0.1 752 ≦0.1 753 ≦1 754 ≦10 755 ≧10 756 ≦10 757 ≦10 758 ≦10 759 ≦0.01 760 >10 761 ≦0.1 762 ≦0.1 763 ≦1 764 ≦1 765 ≦1 766 ≦1 767 ≦0.1 768 ≦0.1 769 ≦1 770 ≦1 771 ≦0.1 772 ≦10 773 ≦0.1 774 ≦0.1 775 ≦1 776 ≦0.01 777 ≧10 778 ≧10 779 ≦10 780 ≦10 781 ≦10 782 ≦1 783 ≦1 784 ≦0.1 785 ≦0.1 786 ≦1 787 ≦1 788 ≦1 789 ≦1 790 ≦1 791 ≦1 792 ≦10 793 ≦10 794 ≦1 795 ≦0.01 796 ≦0.1 797 ≦10 798 ≦0.1 799 ≦0.1 800 ≦0.01 801 ≦0.01 802 ≦0.1 803 ≦0.01 804 — 805 ≦1 806 ≦0.01 807 ≦0.01 808 ≦0.01 809 ≦0.01 810 ≦0.01 811 ≦0.1 812 — 813 ≦0.1 814 ≦1 815 ≦0.1 816 ≦0.01 817 ≦1 818 ≦0.01 819 ≦0.1 820 ≦10 821 ≦10 822 ≦1 823 ≦1 824 ≦1 825 ≦1 826 ≦10 827 ≦1 828 ≦10 829 ≦10 830 ≦10 831 ≦1 832 ≦1 833 ≦10 834 ≦1 835 ≦1 836 ≦0.01 837 ≦0.01 838 ≦0.01 839 ≦0.01 840 ≦0.01 841 ≦0.01 842 ≦0.01 843 ≦0.1 844 ≦1 845 ≦1 846 ≦0.1 847 ≦0.1 848 ≦1 849 ≦0.1 850 ≦1 851 ≦10 852 ≦1 853 ≦1 854 — 855 — 856 — 857 — 858 — 859 — 860 — 861 — 862 — 

We claim:
 1. A compound of the formula (I)

wherein R¹ is a 5-membered heterocyclic ring selected from the group consisting of pyrazolyl, imidazolyl and triazolyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxycarbonyl and C₁-C₆-alkylcarbonylamino; R^(2a), R^(2b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(2a), R^(2b) together with the carbon atom to which they are bound may form a C═O; R^(3a) is C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, halogenated C₁-C₆-alkoxy, C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy, C₆-C₁₂-aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, C₃-C₁₂-heterocyclyloxy, or optionally substituted C₃-C₁₂-heterocyclyl; R^(3b) is hydrogen, C₁-C₆-alkyl, or hydroxy; Y¹ is >CR⁶— or >N—; R⁶ is hydrogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₄-alkoxy-C₁-C₆-alkyl, or hydroxy; R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b), —NR^(8e)SO₂R¹⁷, —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7a), R^(2b) are independently hydrogen or C₁-C₆-alkyl; n1 is 1, 2, 3, or 4; R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7c), R^(7d) are independently hydrogen or C₁-C₆-alkyl; n2 is 1, 2, 3, or 4; R^(11a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(11b) is hydrogen or C₂-C₈ alkyl; R^(7e), R^(7f) are independently hydrogen or C₁-C₆-alkyl; n3 is 1, 2, 3, or 4; R¹² is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(8a), R^(8b), R^(8e), R^(8d), R^(8e) are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl, or R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e) together are optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a), R^(9b) are independently hydrogen, halogen, C₁-C₆-alkyl, hydroxyl, or C₁-C₆-alkoxy; n4 is 0, 1, 2, 3, or 4; R¹³ is C₂-C₈-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₂-C₆-alkenyl, optionally substituted C₃-C₆-cycloalkenyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, optionally substituted C₃-C₁₂-heterocyclyloxy, optionally substituted C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; R¹⁴ is C₂-C₈ alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁵ is C₁-C₈-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16b) is hydrogen or C₁-C₆-alkyl; R¹⁷ is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(9c), R^(9d) are independently hydrogen, halogen, or C₁-C₆-alkyl; n5 is 0, 1, 2, 3, or 4; R¹⁸ is hydrogen, C₁-C₈-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, halogenated C₁-C₆-alkoxycarbonyl, C₆-C₁₂-aryloxycarbonyl, C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl, C₆-C₁₂-arylaminocarbonyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkylamine, (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino, (halogenated C₁-C₆-alkyl)amino, (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino, (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino, C₁-C₆-dialkylamine, optionally substituted C₆-C₁₂-arylamine, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁹ is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(20a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(20b) is hydrogen or C₁-C₈-alkyl; R²¹ is optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; and R^(5a), R^(5b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(5a), R^(5b) together with the carbon atom to which they are bound may form a C═O; or a physiologically tolerated salt thereof; provided that the following compounds are excluded: compounds of formula (II) and the physiologically tolerated salts thereof:

wherein R¹, R^(3a) and R¹⁴ are as defined in the following table R¹ R^(3a) R¹⁴

4-F—Ph

4-CF₃—Ph

2-OMe—Ph

2-OMe-4-OCF₃—Ph

4-F-phenyl 4-CF₃-phenyl

4-F-phenyl


2. The compound as claimed in claim 1, wherein R¹ is optionally substituted 1,3-diazolyl or optionally substituted 1,2,3-triazolyl.
 3. The compound as claimed in claim 1, wherein R¹ is 1,2-diazol-4-yl, 1-methyl-1,2-diazol-4-yl, 1-methyl-1,2-diazol-3-yl, 1-methyl-1,3-diazol-4-yl, 1-methyl-1,2-diazol-5-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-4-yl, 1,5-dimethyl-1,2-diazol-4-yl, 1,3-dimethyl-1,2-diazol-5-yl, 1,3-dimethyl-5-Cl-1,2-diazol-4-yl, 1-iso-propyl-3-methyl-1,2-diazol-4-yl, 1-Me-3-CF₃-1,2-diazol-4-yl, 1-cyclopentyl-3-Me-1,2-diazol-4-yl, 1,3,5-trimethyl-1,2-diazol-4-yl, 1-CHF₂-3,5-dimethyl-1,2-diazol-4-yl, 1,2-dimethyl-1,3-diazol-4-yl, 1,2-dimethyl-1,3-diazol-5-yl, 1-methyl-5-Cl-1,3-diazol-4-yl, 1-Me-1,2,3-triazol-4-yl, 1-ethyl-1,3-diazol-4-yl, or 1-methyl-1,2,4-triazol-3-yl.
 4. The compound as claimed in claim 1, wherein R^(2a) is hydrogen, halogen or C₁-C₃-alkyl, and R^(2b) is hydrogen.
 5. The compound as claimed in claim 1, wherein R^(3a) is C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-alkoxy.
 6. The compound as claimed in claim 1, wherein R^(3a) is C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl.
 7. The compound as claimed in claim 1, wherein R^(3b) is hydrogen.
 8. The compound as claimed in claim 1, wherein Y¹ is >CR⁶— and R⁶ is hydrogen, methyl, benzyl, hydroxy-methyl, or hydroxy.
 9. The compound as claimed in claim 1, wherein R^(5a) is hydrogen, halogen or C₁-C₃-alkyl, and R^(5b) is hydrogen.
 10. The compound as claimed in claim 1, having formula (Ia)


11. The compound as claimed in claim 1, having formula (Id)


12. The compound as claimed in claim 11, wherein R^(2a), R^(2b) are hydrogen; R^(3a) is C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, C₃-C12-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy, C₆-C₁₂-aryl-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, or optionally substituted C₃-C₁₂-heterocyclyl; R^(3b) is hydrogen or hydroxy; Y¹ is >CR⁶; R⁶ is hydrogen, C₁-C₆-alkyl, or hydroxy-C₁-C₆-alkyl; R^(8a) is hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl, or R⁶, R^(8a) are together optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a) is hydrogen, halogen, C₁-C₆-alkyl, or C₁-C₆-alkoxy; R^(9b) is hydrogen; and R^(5a), R^(5b) are hydrogen.
 13. The compound as claimed in claim 11, wherein R¹ is 1,3-diazolyl optionally substituted with halogen or C₁-C₄-alkyl, or 1,2,3-triazolyl optionally substituted with C₁-C₄-alkyl; R^(2a), R^(2b) are hydrogen; R^(3a) is C₃-C₁₂-cycloalkyl, C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl, or hydroxy, C₁-C₆-alkoxy, C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy, C₆-C₁₂-aryl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl, or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; R^(3b) is hydrogen or hydroxy; Y¹ is >CR⁶; R⁶ is hydrogen, C₁-C₆-alkyl, or hydroxy-C₁-C₆-alkyl; R^(8a) is hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl, or R⁶, R^(8a) are together optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a) is hydrogen, halogen, C₁-C₆-alkyl, or C₁-C₆-alkoxy; R^(9b) is hydrogen; R¹³ is C₂-C₈ alkyl, halogenated C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₁₂-cycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₆-C₁₂-aryl, or C₂-C₆-alkenyl, C₃-C₆-cycloalkenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C₁-C₄-alkyl, or C₆-C₁₂-aryl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), CN, C₆-C₁₂-aryl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy, C₁-C₄-alkyl-sulfonyl, carbonylamino and C₃-C₁₂-heterocyclyl, or C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen and C₁-C₄-alkyl, or C₃-C₁₂-heterocyclyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, C₃-C₆-cycloalkyl, hydroxy, CN, C₆-C₁₂-aryl optionally substituted with halogen and C₁-C₄-alkyl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₃-C₆-cycloalkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy and C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; and R^(5a), R^(5b) are hydrogen.
 14. The compound as claimed in claim 11, wherein R¹³ is a group of the formula (Id1):

wherein X is >CH— or >N—; Y is >C—R^(13c) or >N—; R^(13b) is halogen, C₁-C₄-alkyl, halogenated C₁-C₄-alkyl, hydroxy-(halogenated C₁-C₄-alkyl), C₆-C₁₂-aryl-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, CN, C₆-C₁₂-aryl optionally substituted with halogen or C₁-C₄-alkyl, C₁-C₄-alkoxy, halogenated C₁-C₄-alkoxy, C₃-C₆-cycloalkoxy, C₆-C₁₂ aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy, C₆-C₁₂-aryloxy, C₁-C₄-alkyl-sulfonyl, C₁-C₄-alkyl-carbonylamino or C₃-C₁₂-heterocyclyl; and R^(13c) is hydrogen or halogen.
 15. The compound as claimed in claim 14, wherein R^(8a) is hydrogen.
 16. The compound as claimed in claim 1, having formula (Ih)

wherein R^(9c), R^(9d) are independently hydrogen, halogen, or C₁-C₆-alkyl; n5 is 0, 1, 2, 3, or 4; and R¹⁸ is hydrogen, C₁-C₈-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, halogenated C₁-C₆-alkoxycarbonyl, C₆-C₁₂-aryloxycarbonyl, C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl, C₆-C₁₂-arylaminocarbonyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkylamine, (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino, (halogenated C₁-C₆-alkyl)amino, (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino, (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino, C₁-C₆-dialkylamine, optionally substituted C₆-C₁₂-arylamine, or optionally substituted C₃-C₁₂-heterocyclyl.
 17. The compound as claimed in claim 1, wherein R^(2a), R^(2b) are hydrogen; R^(3b) is hydrogen or hydroxy; R⁶ is hydrogen, C₁-C₆-alkyl, (C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, or hydroxy; R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b), —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7a), R^(7b) are hydrogen; n1 is 1; R^(7c), R^(7d) are hydrogen; n2 is 1; R^(11a) is C₁-C₈-alkyl, C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₆-C₁₂-aryl-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl; R^(11b) is hydrogen; R^(7e), R^(7f) are hydrogen; n3 is 1; R^(8a), R^(8b), R^(8c), R^(8d), R^(8e) are independently hydrogen or C₁-C₆-alkyl, or R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e) together are optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a), R^(9b) are independently hydrogen, halogen, C₁-C₆-alkyl, or C₁-C₆-alkoxy; R¹³ is C₂-C₈-alkyl, halogenated C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₂-C₆-alkenyl, optionally substituted C₃-C₆-cycloalkenyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, optionally substituted C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; R¹⁴ is C₂-C₈ alkyl, halogenated C₁-C₆-alkyl, C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl, C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁵ is C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl or optionally substituted C₆-C₁₂-aryl; R^(16b) is hydrogen; R^(9c), R^(9d) are hydrogen; n5 is 0, 1, or 2; R¹⁸ is hydrogen, C₁-C₈-alkyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkylamine, (halogenated C₁-C₆-alkyl)amino, optionally substituted C₆-C₁₂ arylamine, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁹ is optionally substituted C₆-C₁₂-aryl; R^(20a) is C₁-C₈-alkyl, C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R²¹ is C₆-C₁₂-aryl; and R^(5a), R^(5b) are hydrogen, or R^(5a), R^(5b) together with the carbon atom to which they are bound may form a C═O.
 18. The compound as claimed in claim 1 which is: 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(4-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 3-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 4-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 3-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 4-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2-methoxy-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 3-methoxy-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 3-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 4-methyl-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2,4-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2-chloro-4-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N,4-diphenylpyrrolidin-3-amine; 3,5-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2,3-dichloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 2-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 3-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; 4-cyano-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}benzamide; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(trifluoromethyl)benzamide; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 2-chloro-N-[trans-1-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide; 2-chloro-N-[trans-1-{[1-(difluoromethyl)-3,5-dimethyl-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-yl]-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-[trans-4-phenyl-1-(1H-pyrazol-4-ylsulfonyl)pyrrolidin-3-yl]-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(5-chloro-1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; trans-N-(4-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 4-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 3-fluoro-4-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 2-chloro-N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylphenyl)-4-phenylpyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-phenylpyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(4-methylphenyl)-4-phenylpyrrolidin-3-amine; 2-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 3-chloro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 2-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 3-chloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 3,5-dichloro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}benzamide; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-N-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 3-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile; trans-N-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 4-fluoro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 2-fluoro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 3-fluoro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 2-chloro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 3-chloro-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 4-chloro-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 4-methyl-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 2-methyl-3-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylphenyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(4-methylphenyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-N-(2-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 2-methoxy-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 3-methyl-5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)benzonitrile; 5-({trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-2-(trifluoromethoxy)benzonitrile; 2-chloro-N-{trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 4-{[trans-3-benzyl-4-phenylpyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; trans-N-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[2-chloro-3-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[3-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 3-[({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)methyl]benzonitrile; trans-4-(4-fluorophenyl)-N-(2-methylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-(3-methylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-(4-methylbenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (cis)-N-benzyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-chloro-3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,3-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,5-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2,3,4-trifluorophenyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yl)phenyl]pyrrolidin-3-amine; trans-N-(3-tert-butylphenyl)-4-(4-fluorophenyl)-4(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[3-chloro-4-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chloro-5-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chloro-4,5-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-3-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine; 4-{[3-(3-chlorobenzyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 2-chloro-N-{(cis)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; 2-chloro-N-{(cis)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-3-(trifluoromethyl)benzamide; trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidin-3-amine; trans-N,4-bis(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(3-fluorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chlorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine; N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine; trans-N-(3,4-dichlorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-chloro-3-fluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chloro-4-fluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine; N-{trans-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine; trans-N-(3,4-difluorophenyl)-4-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidin-3-amine; trans-4-(2-fluorophenyl)-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-fluorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chlorophenyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-chlorophenyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine; N-{trans-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine; 4-{[3-(2-bromobenzyl)-4-(2-bromophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanol; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-3-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-4-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(trifluoromethyl)pyridin-3-amine; trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3,4-dichlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3-chloro-4,5-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(propan-2-yl)phenyl]pyrrolidin-3-amine; trans-N-(3-tert-butylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[2-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[2-fluoro-5-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(3-chloro-5-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyrimidin-2-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}quinolin-7-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}quinolin-6-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}isoquinolin-6-amine; trans-N-(2,3-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(2,5-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(2,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2,3,4-trifluorophenyl)pyrrolidin-3-amine; 6-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine; 2-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-4-amine; 5-fluoro-N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-3-amine; 6-fluoro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine; 2-fluoro-N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-4-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine; N-{trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}isoquinolin-7-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-phenylpyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide; Trans-N-(3,5-dichlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; 4-{[trans-3-(4-fluorophenyl)-4-(phenoxymethyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-[(2,4-dichlorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-(4-fluorophenyl)-4-{[3-(trifluoromethoxy)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-[(3-chlorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-{[4-chloro-3-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-{[2-chloro-3-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-[(3-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; trans-4-(2-chlorophenyl)-N-(3-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-N-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-N-(4-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-N-(3-chloro-4-fluorophenyl)-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{trans-4-(2-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine; trans-N-(2-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(4-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(3-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(trifluoromethyl)benzyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)benzyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-2-ylmethyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-3-ylmethyl)pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-4-ylmethyl)pyrrolidin-3-amine; {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}(phenyl)methanone; Trans-N-[2-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidine-3-carboxamide; trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; trans-N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; trans-N-[3-chloro-4-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; 1-methyl-4-[(3-phenoxy-4-phenylpyrrolidin-1-yl)sulfonyl]-1H-imidazole; trans-4-(2-chlorophenyl)-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,4-dichlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-(2,4-dichlorobenzyl)-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(2-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-4-(2-chlorophenyl)-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-3-yl)pyrrolidin-3-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-(trifluoromethyl)pyridin-4-amine; Trans-N-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline; 3,5-dichloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; 4-{[trans-3-(4-fluorophenyl)-4-{[3-(trifluoromethyl)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-{[2-chloro-4-(trifluoromethyl)phenoxy]methyl}-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-(4-fluorophenyl)-4-{[4-fluoro-3-(trifluoromethyl)phenoxy]methyl}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-({trans-3-(4-fluorophenyl)-4-[(3-methylphenoxy)methyl]pyrrolidin-1-yl}sulfonyl)-1-methyl-1H-imidazole; (3-chlorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}(3-methylphenyl)methanone; (3-fluorophenyl){(trans-4-(4-fluorophenyl))-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; {trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[3-(trifluoromethyl)phenyl]methanone; (4-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; trans-N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; trans-N-(2,4-dichlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; 4-{[3-(3-chlorobenzyl)-4-cyclopropylpyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; N-[3-(difluoromethyl)-4-fluorophenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 3-chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline; 4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethyl)aniline; 3-chloro-4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; N-benzyl-1-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanamine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide; 4-{[Trans-3-[(3-chloro-4-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; (4-Chloro-3-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine; (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; (3S,4R)—N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3S,4R)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-2-one; 2-Chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-4-(trifluoromethyl)aniline; 3-Chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-methylaniline; N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethyl)aniline; 4-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-6-(trifluoromethyl)pyrimidine; Trans-4-cyclopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; Trans-N-(3-chlorophenyl)-4-cyclopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 4-{[3-(2-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[3-(4-chlorophenyl)-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 2-chloro-4-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile; 2-fluoro-4-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile; 3-(3-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylimidazolidin-2-one; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-amine; 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-4-(trifluoromethyl)pyridine; Trans-N-(3-cyanophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; 4-{[Trans-3-[(4-fluorophenoxy)methyl]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yloxy)phenyl]pyrrolidin-3-amine; N-{4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridazin-3-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine; (3R,4S)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-(3-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-N-(4-chlorobenzyl)-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; Trans-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine; Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3,4-Difluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; Trans-N,4-bis(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3,4-Dichlorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; (3,5-Dichlorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; (3-Chloro-5-fluorophenyl){trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methanone; {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[3-(trifluoromethoxy)phenyl]methanone; {Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}[4-(trifluoromethoxy)phenyl]methanone; 3-[({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)amino]benzamide; 3-(Aminomethyl)-N-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; 4-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methoxy)-2-(trifluoromethyl)pyridine; 4-Fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)aniline; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)pyridin-2-yl]pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; N-[4-chloro-2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)phenyl]acetamide; Trans-4-[(3-chlorophenyl)amino]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-ol; N-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-yl]-1-(trifluoromethyl)cyclopropanecarboxamide; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-1-(trifluoromethyl)cyclopropanecarboxamide; 4-fluoro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline; 4-chloro-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(trifluoromethoxy)aniline; Trans-N-(3-chlorophenyl)-4-(4-fluorophenoxy)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 2-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-4-(trifluoromethyl)pyridine; 3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile; 6-chloro-2-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(pyridin-2-yl)pyrrolidin-3-yl]-2,3-dihydro-1H-isoindol-1-one; 3-benzyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-ol; N-{trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-(trifluoromethyl)pyridazin-3-amine; N-{4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridazin-3-amine; 1-methyl-4-{[trans-3-phenyl-4-(phenyl sulfonyl)pyrrolidin-1-yl]sulfonyl}-1H-imidazole; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[1-(trifluoromethyl)cyclopropyl]methyl}pyrrolidin-3-amine; (3S,4R)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{Trans-3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; 3-({3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)benzonitrile; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[5-(trifluoromethyl)furan-2-yl]methyl}pyrrolidin-3-amine; 1,1,1-trifluoro-2-[3-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)phenyl]propan-2-ol; (3R,4S)—N-[(5-chlorothiophen-2-yl)methyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3S,4R)—N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[4-(trifluoromethyl)benzyl]pyrrolidin-3-amine; 1,1,1-trifluoro-2-[3-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)phenyl]propan-2-ol; Trans-4-(benzyloxy)-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-1-[[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-3-{[4-(trifluoromethyl)benzyl]amino}pyrrolidin-3-yl]methanol; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(prop-2-en-1-yloxy)pyrrolidin-3-amine; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2-methylprop-2-en-1-yl)oxy]pyrrolidin-3-amine; 3-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one; 4-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine; Trans-7-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-9-phenyl-1-[4-(trifluoromethyl)benzyl]-3-oxa-1,7-diazaspiro[4.4]nonan-2-one; 3,5-difluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidin-3-amine; 5-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazin-2-amine; 5-cyclobutyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazin-2-amine; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(2-methylpropoxy)pyrrolidin-3-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(pyrrolidin-1-yl)pyrazin-2-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-5-(trifluoromethyl)pyrazine-2-carboxamide; 5-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrazine-2-carboxamide; (3R,4S)—N-(4-chlorobenzyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(3,4-difluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 6-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridazine-3-carboxamide; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2-(morpholin-4-yl)pyrimidin-4-amine; 4-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-2,3-dihydro-1H-isoindol-1-one; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(methylsulfonyl)phenyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(trifluoromethyl)piperazin-2-yl]methyl}pyrrolidin-3-amine; 5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-2-amine; Trans-4-cyclohexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(4,4,4-trifluorobutyl)pyrrolidin-3-amine; (3R,4S)—N-(2-cyclopentylethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(5-propylfuran-2-yl)methyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(4-phenyl-1,3-thiazol-5-yl)methyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methyl-1,3-thiazol-2-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(3,5-dichloropyridin-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2-ethylhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2,4-dichloro-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2,2-dimethylpropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(5-methyl-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2-bromo-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylpropyl)-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(3-chloro-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(thieno[2,3-b]pyridin-2-ylmethyl)pyrrolidin-3-amine; (3R,4S)—N-[(2-methyl-1-benzofuran-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(6-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-{[5-(4-fluorophenyl)pyridin-3-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(2-methylpentyl)-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(tetrahydrofuran-3-ylmethyl)pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentyl-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2-ethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2,2-dimethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(2-methyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]pyrrolidin-3-amine; (3R,4S)—N-(1,3-benzothiazol-2-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-1,3-thiazol-2-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(4,5-dimethylthiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-ylmethyl)pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(1,3-thiazol-5-ylmethyl)pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[2-(2,6,6-trimethylcyclohex-1-en-1-yl)ethyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}pyrrolidin-3-amine; (3R,4S)—N-{[4-(4-fluorophenyl)-1,3-thiazol-2-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(4-methylphenyl)ethyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylthiophen-2-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(3-methylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(3,5,5-trimethylhexyl)pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2-phenylpropyl)pyrrolidin-3-amine; (3R,4S)—N-(3,3-dimethylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(1-methylcyclohexyl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[2-(3-chlorophenyl)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[2-(4-tert-butylphenoxy)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2-ethyl-3-methylbutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[3-(3-chlorophenyl)propyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(4-bromo-1,3-thiazol-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(4-methyl-2-phenyl-1,3-thiazol-5-yl)methyl]-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]sulfonyl}-4-phenylpyrrolidin-3-amine; 1-[(1-cyclopentyl-3-methyl-1H-pyrazol-4-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(3,4-difluorophenyl)-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-(3,4-difluorophenyl)-4-phenyl-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; Trans-N-(3-chlorophenyl)-4-(cyclopropylmethoxy)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{trans-4-cyclohexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine; 2-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(2-methyl-1,3-thiazol-4-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2-ethyl-1-benzofuran-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(imidazo[1,2-a]pyridin-8-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylpyridin-2-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(pyrazolo[1,5-a]pyridin-3-ylmethyl)pyrrolidin-3-amine; N-{Trans-4-hydroxy-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(trifluoromethyl)benzamide; 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenyl-4-{[4-(trifluoromethyl)benzyl]amino}pyrrolidin-3-ol; (3R,4S)—N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; ethyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate; propyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate; 2-methylpropyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate; butyl {(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}carbamate; (3R,4S)—N-(2-cyclopropylethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 2-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}acetamide; (3R,4S)—N-[(2E)-hex-2-en-1-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pentanamide; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}hexanamide; (3R,4S)—N-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[6-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidin-3-amine; (3R,4S)—N-[(3-chlorothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(4,4-difluorocyclohexyl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(pyrazolo[1,5-a]pyridin-7-ylmethyl)pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[4-(propan-2-yl)-1,3-thiazol-2-yl]methyl}pyrrolidin-3-amine; (3R,4S)—N-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-{[5-(tetrahydro-2H-pyran-2-yl)thiophen-2-yl]methyl}pyrrolidin-3-amine; (3R,4S)—N-[(5-bromo-4-methyl-1,3-thiazol-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(imidazo[1,5-a]pyridin-5-ylmethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2,3-dimethylpentyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2-chloro-1,3-thiazol-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[(5-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-phenylcyclopropyl)methyl]pyrrolidin-3-amine; (3R,4S)—N-[(4-chloro-1,3-thiazol-5-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(3,3,3-trifluoro-2-methylpropyl)pyrrolidin-3-amine; (3R,4S)—N-[(2-chloro-3-fluoropyridin-4-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(5-fluoro-1-benzothiophen-2-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[5-chloro-2-(difluoromethoxy)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[(2,5-dichlorothiophen-3-yl)methyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-{[2-(4-fluorophenyl)pyridin-3-yl]methyl}-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[2-(4-methylphenyl)-1,3-thiazol-5-yl]methyl-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(3-cyclopropylpropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 5-fluoro-4-methyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine; 1,5-dimethyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-1H-1,2,4-triazol-3-amine; 1,5-dimethyl-4-({(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}amino)-1H-pyrrole-2-carbonitrile; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(propan-2-yloxy)propyl]pyrrolidine-3-carboxamide; (3S,4R)—N-(3-ethoxypropyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3S,4R)-4-(4-fluorophenyl)-N-(2-methoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-propylpyrrolidine-3-carboxamide; (3S,4R)—N-butyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3S,4R)-4-(4-fluorophenyl)-N-[1-methoxypropan-2-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3R,4S)-4-(4-fluorophenyl)-N-(3-methoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3S,4R)—N-(2-ethoxyethyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3R,4S)—N-[4-chloro-3-(trifluoromethoxy)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3S,4R)—N-(cyclopropylmethyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[2-(propan-2-yloxy)ethyl]pyrrolidine-3-carboxamide; (3R,4S)—N-(3-methoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(3-ethoxypropyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-{[1-(methoxymethyl)cyclopropyl]methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-(propan-2-yloxy)propan-1-amine; 3-ethoxy-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)propan-1-amine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-2-methoxyethanamine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)propan-1-amine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)butan-1-amine; (2S)-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-1-methoxypropan-2-amine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-3-methoxypropan-1-amine; 2-ethoxy-N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)ethanamine; N-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)-2-(propan-2-yloxy)ethanamine; (3R,4S)—N-(2-methoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; 2-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine; 6-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; 1-cyclopropyl-N-({(3R,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}methyl)methanamine; (3R,4S)—N-(2-ethoxyethyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(2-propoxyethyl)pyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[-tetrahydrofuran-2-yl]pyrrolidin-3-amine; N-(3,4-difluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; 6-cyclopropyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; 6-ethyl-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(propan-2-yl)pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-methyl-6-(trifluoromethyl)pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-propylpyrimidin-4-amine; 5-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; (3S,4R)—N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; (3R,4S)—N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; 6-ethoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; 6-methoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-propoxypyrimidin-4-amine; 6-butoxy-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-6-(2-methylpropoxy)pyrimidin-4-amine; 4-{[(3S,4R)-3-(4-fluorophenyl)-4-(hexyloxy)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-N-(3-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-N-(4-chlorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-N-(4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-N-(3,4-difluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)benzyl]pyrrolidine-3-carboxamide; Trans-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(pyridin-2-ylmethyl)pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-(trifluoromethyl)pyridin-2-yl]methyl}pyrrolidine-3-carboxamide; Trans-N,N-dibutyl-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; 6-methyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyrimidin-4-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; 4-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)-2-(trifluoromethyl)benzonitrile; 4-{Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-1-propyl-1H-1,2,3-triazole; 4-[-1-cyclopropylpiperidin-3-yl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; Trans-N-(3-chloro-4-fluorobenzyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; Trans-4-(4-fluorophenyl)-N-(6-methylheptyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; 2-(4-fluorophenoxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}acetamide; (3R,4S)—N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(4-methoxybutyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(4-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[(2-propylcyclopropyl)methyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-[4-methoxy-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(1-benzothiophen-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(2,3-dihydro-1H-inden-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[3,4-bis(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-(5,6,7, 8-tetrahydronaphthalen-2-yl)pyrrolidin-3-amine; (3R,4S)—N-(3,4-dihydro-2H-chromen-6-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 4-({Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-1-propyl-1H-1,2,3-triazole; (3R,4S)—N-(1-benzofuran-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)benzyl]pyrrolidine-3-carboxamide; methyl 5-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}amino)-5-oxopentanoate; (3R,4S)—N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidine-3-carboxamide; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-[2-(2-methoxyethoxy)ethyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[2-(4-fluorophenoxy)ethyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 4-butyl-1-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-1H-1,2,3-triazole; (3R,4S)—N-(4-chloro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)—N-(2,3-dihydro-1-benzofuran-5-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-(4,4-dimethyl-3,4-dihydro-2H-chromen-6-yl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-hydroxyhexanamide; (3R,4S)—N-(3-methoxyhexyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; (3R,4S)—N-[4-chloro-3-(propan-2-yl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-methyl-4-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)—N-(1-benzothiophen-6-yl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; -4-(1-cyclopropylpiperidin-4-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; Trans-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; N-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; N-{Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; (3R,4S)—N-[4-(4,4-dimethyl-1,3-dioxan-2-yl)butyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[tetrahydro-2H-pyran-2-yl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; N-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]-6-(trifluoromethyl)pyrimidin-4-amine; N-[2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]propan-1-amine; 2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-N-propylacetamide; 6-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-2-methylpyrimidin-4-amine; 6-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 1-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3-phenylurea; phenyl {(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}carbamate; 1-(2-chlorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-5-oxohexanamide; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)cyclohexanecarboxamide; Butyl-trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl carbonate; 5,5,5-trifluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl pentanamide; (3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl butylcarbamate; 2,2-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl pentanamide; 1-(4-chlorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; 1-(2-fluorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; 1-(3-fluorophenyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; 1-(4-fluorophenyl)-3-(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; 1-(2-chlorobenzyl)-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; 4,5-dichloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-{[4-(trifluoromethyl)cyclohexyl]methyl}pyrrolidin-3-amine; 2,2-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}hexanamide; Trans-N-[3,4-difluorophenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-2-yl)pyrrolidin-3-amine; N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-2-yl)pyrrolidin-3-amine; 4-{[trans-3-[(4-fluorobenzyl)oxy]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-[(3-fluorobenzyl)oxy]-4-(4-fluorophenyl)pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-(4-fluorophenyl)-4-[4-(methyl sulfonyl)benzyl]oxy}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 4-{[trans-3-(4-fluorophenyl)-4-[3-(methyl sulfonyl)benzyl]oxy}pyrrolidin-1-yl]sulfonyl}-1-methyl-1H-imidazole; 6-ethoxy-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(propan-2-yloxy)pyrimidin-4-amine; 6-butoxy-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(2-methylpropoxy)pyrimidin-4-amine; 6-(cyclobutyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(cyclopentyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(cyclohexyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-phenylpyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(2-methylphenyl)pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(3-methylphenyl)pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(4-methylphenyl)pyrimidin-4-amine; 6-(2-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(3-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(4-fluorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(3-chlorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 6-(4-chlorophenyl)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; 4-({(3S,4R)-3-(4-fluorophenyl)-4-[(4-methylbenzyl)oxy]pyrrolidin-1-yl}sulfonyl)-1-methyl-1H-imidazole; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(5,5,5-trifluoropentyl)pyrrolidin-3-amine; (3R,4S)—N-(2,2-difluorohexyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-(2,2-difluoropentyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 5,5-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}hexanamide; 4-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine; 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyridin-2-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-oxopentanamide; (3R,4S)—N-(5,5-difluorohexyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 4-chloro-N-[2-({Trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]aniline; (3S,4R)—N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; 1-benzyl-3-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}urea; (3R,4S)—N-(4-chloro-3-methylphenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyridin-3-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyridin-4-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-(4-fluoro-3-methylphenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-methylpyridin-2-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(pyrimidin-5-yl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-3,4′-bipyridin-2′-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4,4′-bipyridin-2-amine; 4-({(3S,4R)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)-6-(trifluoromethyl)pyrimidine; N-[(3R,4S)-4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1,3-oxazol-4-yl)pyrrolidin-3-amine; 4,4-difluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl pentanamide; (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine; (3R,4S)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)—N-(3,4-difluorophenyl)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-amine; (3R,4S)-1-[(1,2-dimethyl-1H-imidazol-5-yl)sulfonyl]-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; 4-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl pyridin-2-amine; 5-chloro-N-[(3R,4S)-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(4-fluorophenyl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine; Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-N,N-dihexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N,N-dipentylpyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-pentylpyrrolidin-3-amine; Trans-N-(3,4-difluorophenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 5-fluoro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-methylpyridin-2-amine; N-{Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyrimidin-4-amine; Trans-N-(3-chloro-4-fluorophenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 6-chloro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; (3R,4S)—N-[3-(benzyloxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine; 6-(benzyloxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; Trans-N-(4-fluoro-3-methylphenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 4-(benzyloxy)-5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}pyridin-2-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(piperidin-4-yl)phenyl]pyrrolidin-3-amine; 6-(azetidin-3-ylmethoxy)-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(pyrrolidin-3-ylmethoxy)pyrimidin-4-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(pyrrolidin-2-ylmethoxy)pyrimidin-4-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-phenoxyphenyl)-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; trans-N-(biphenyl-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-[4-chloro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; Trans-N-[3-(benzyloxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(3S)-tetrahydro-2H-pyran-3-yl]pyrrolidin-3-amine; 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; 3-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; N-(2,2-difluoroethyl)-2-({(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)acetamide; Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; Trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-[3-(pyridin-2-yl)phenyl]pyrrolidin-3-amine; (3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenyl-N-[3-(pyridin-2-yl)phenyl]pyrrolidin-3-amine; 5-fluoro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; 5-Chloro-N-{trans-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(trifluoromethyl)pyridin-2-amine; Trans-N-(3-fluorophenyl)-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine; 5-chloro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; 5-chloro-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; 5-fluoro-N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(2,2,2-trifluoroethoxy)pyridin-2-amine; Trans-4-(3-fluoropyridin-2-yl)-N-hexyl-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-4-(propan-2-yl)pyridin-2-amine; N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-4-(propan-2-yl)pyridin-2-amine; 2,2,2-trifluoro-N-[2-({trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}oxy)ethyl]ethanamine; Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; 2-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}methyl)-4-(trifluoromethyl)pyridine; Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-4-(3-fluoropyridin-2-yl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; N-Hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2R)-tetrahydrofuran-2-yl]pyrrolidin-3-amine; N-hexyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)-tetrahydrofuran-2-yl]pyrrolidin-3-amine; Trans-N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; N-[2-chloro-4-(trifluoromethyl)benzyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)-tetrahydrofuran-2-yl]pyrrolidin-3-amine; Trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[(2S)-tetrahydrofuran-2-yl]pyrrolidin-3-amine; 1-benzyl-N-{(3R,4S)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-yl}-2,3-dihydro-1H-indol-6-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-N-(3-methylphenyl)-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-N-[4-chloro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-3-yl)-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; trans-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]-N-[3-(trifluoromethyl)phenyl]pyrrolidin-3-amine; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-(3-chlorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; (3R,4S)—N-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-1-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]pyrrolidin-3-amine; Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; 5-Chloro-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine; Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; Trans-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; Trans-N-(4-fluoro-3-methylphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; 5-Chloro-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]-4-(trifluoromethyl)pyridin-2-amine; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-amine; Trans-N-(3-chlorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-amine; 5-Fluoro-4-methyl-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]pyridin-2-amine; 5-Fluoro-4-methyl-N-[trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydro-2H-pyran-2-yl)pyrrolidin-3-yl]pyridin-2-amine; N-[Trans-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(tetrahydrofuran-2-yl)pyrrolidin-3-yl]-6-(trifluoromethyl)pyrimidin-4-amine; (3R,4S)—N-cyclohexyl-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-yl sulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(3,3-dimethylcyclohexyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-yl sulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(4,4-dimethylcyclohexyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-yl sulfonyl)pyrrolidin-3-amine; (3R,4S)—N-cyclopentyl-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-yl sulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(3,3-dimethylcyclopentyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(1-(2,4-dichlorophenyl)ethyl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(2,3-dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine; (3R,4S)—N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-amine; or N-(4-chlorobenzyl)-N-((3R,4S)-4-(4-fluorophenyl)-1-(1-methyl-1H-imidazol-4-ylsulfonyl)pyrrolidin-3-yl)acetamide; or a physiologically tolerated salt thereof.
 19. A pharmaceutical composition which comprises a carrier and a compound of the formula (I)

wherein R¹ is a 5-membered heterocyclic ring selected from the group consisting of pyrazolyl, imidazolyl and triazolyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxycarbonyl and C₁-C₆-alkylcarbonylamino; R^(2a), R^(2b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(2a), R^(2b) together with the carbon atom to which they are bound may form a C═O; R^(3a) is C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, halogenated C₁-C₆-alkoxy, C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy, C₆-C₁₂-aryl-C C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, C₃-C₁₂-heterocyclyloxy, or optionally substituted C₃-C₁₂-heterocyclyl; R^(3b) is hydrogen, C₁-C₆-alkyl, or hydroxy; Y¹ is >CR⁶— or >N—; R⁶ is hydrogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₄-alkoxy-C₁-C₆-alkyl, or hydroxy; R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b) (CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b), —NR^(8e)SO₂R¹⁷, —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7a), R^(7b) are independently hydrogen or C₁-C₆-alkyl; n1 is 1, 2, 3, or 4; R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7c), R^(7d) are independently hydrogen or C₁-C₆-alkyl; n2 is 1, 2, 3, or 4; R^(11a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(11b) is hydrogen or C₂-C₈ alkyl; R^(7e), R^(7f) are independently hydrogen or C₁-C₆-alkyl; n3 is 1, 2, 3, or 4; R¹² is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(8a), R^(8b), R^(8c), R^(8d), R^(8e) are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl, or R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e) together are optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a), R^(9b) are independently hydrogen, halogen, C₁-C₆-alkyl, hydroxyl, or C₁-C₆-alkoxy; n4 is 0, 1, 2, 3, or 4; R¹³ is C₂-C₈-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₂-C₆-alkenyl, optionally substituted C₃-C₆-cycloalkenyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, optionally substituted C₃-C₁₂-heterocyclyloxy, optionally substituted C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; R¹⁴ is C₂-C₈ alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl, C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁵ is C₁-C₈-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16b) is hydrogen or C₁-C₆-alkyl; R¹⁷ is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(9c), R^(9d) are independently hydrogen, halogen, or C₁-C₆-alkyl; n5 is 0, 1, 2, 3, or 4; R¹⁸ is hydrogen, C₁-C₈-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, halogenated C₁-C₆-alkoxycarbonyl, C₆-C₁₂-aryloxycarbonyl, C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl, C₆-C₁₂-arylaminocarbonyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkylamine, (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino, (halogenated C₁-C₆-alkyl)amino, (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino, (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino, C₁-C₆-dialkylamine, optionally substituted C₆-C₁₂-arylamine, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁹ is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(20a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(20b) is hydrogen or C₁-C₈-alkyl; R²¹ is optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; and R^(5a), R^(5b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(5a), R^(5b) together with the carbon atom to which they are bound may form a C═O; or a physiologically tolerated salt thereof.
 20. A method for inhibiting the glycine transporter GlyT1 in a mammal in need thereof which comprises the administration of an effective amount of a compound of the formula (I)

wherein R¹ is a 5-membered heterocyclic ring selected from the group consisting of pyrazolyl, imidazolyl and triazolyl, which is optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxycarbonyl and C₁-C₆-alkylcarbonylamino; R^(2a), R^(2b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(2a), R^(2b) together with the carbon atom to which they are bound may form a C═O; R^(3a) is C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, halogenated C₁-C₆-alkoxy, C₃-C₁₂-cycloalkyl-C₁-C₄-alkoxy, C₂-C₆-alkenyloxy, C₆-C₁₂-aryl-C₁-C₄-alkoxy, C₃-C₁₂-heterocyclyl-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, C₃-C₁₂-heterocyclyloxy, or optionally substituted C₃-C₁₂-heterocyclyl; R^(3b) is hydrogen, C₁-C₆-alkyl, or hydroxy; Y¹ is >CR⁶— or >N—; R⁶ is hydrogen, C₁-C₆-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₄-alkoxy-C₁-C₆-alkyl, or hydroxy; R⁴ is —(CR^(7a)R^(7b))_(n1)OR¹⁰, —(CR^(7c)R^(7d))_(n2)NR^(11a)R^(11b), —(CR^(7e)R^(7f))_(n3)R¹², optionally substituted C₆-C₁₂-aryl, —NR^(8a)(CR^(9a)R^(9b))_(n4)R¹³, —NR^(8b)COR¹⁴, —NR^(8c)COOR¹⁵, —NR^(8d)CONR^(16a)R^(16b), —NR^(8e)SO₂R¹⁷, —O(CR^(9c)R^(9d))_(n5)R¹⁸, —COR¹⁹, —CONR^(20a)R^(20b), —SO₂R²¹, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7a), R^(7b) are independently hydrogen or C₁-C₆-alkyl; n1 is 1, 2, 3, or 4; R¹⁰ is hydrogen, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(7c), R^(7d) are independently hydrogen or C₁-C₆-alkyl; n2 is 1, 2, 3, or 4; R^(11a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(11b) is hydrogen or C₂-C₈ alkyl; R^(7e), R^(f) are independently hydrogen or C₁-C₆-alkyl; n3 is 1, 2, 3, or 4; R¹² is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(8a), R^(8b), R^(8c), R^(8d), R^(8e) are independently hydrogen, C₁-C₆-alkyl, or C₁-C₆-alkylcarbonyl, or R⁶ and one of R^(8a), R^(8b), R^(8c), R^(8d), or R^(8e) together are optionally substituted C₁-C₅-alkylene, wherein one or more —CH₂— of C₁-C₅-alkylene may be independently replaced by a an oxygen atom or C═O; R^(9a), R^(9b) are independently hydrogen, halogen, C₁-C₆-alkyl, hydroxyl, or C₁-C₆-alkoxy; n4 is 0, 1, 2, 3, or 4; R¹³ is C₂-C₈-alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₂-C₆-alkenyl, optionally substituted C₃-C₆-cycloalkenyl, optionally substituted C₆-C₁₂-aryl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkoxy-C₁-C₄-alkoxy, optionally substituted C₆-C₁₂-aryloxy, optionally substituted C₃-C₁₂-heterocyclyloxy, optionally substituted C₃-C₁₂-heterocyclyl, or tri-(C₁-C₄-alkyl)-silyloxy; R¹⁴ is C₂-C₈ alkyl, halogenated C₁-C₆-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, hydroxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryloxy)-C₁-C₄-alkyl, C₁-C₆-alkylcarbonyl-C₁-C₄-alkyl, C₁-C₆-alkoxycarbonyl-C₁-C₄-alkyl, C₁-C₆-alkylaminocarbonyl-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁵ is C₁-C₈-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16a) is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, optionally substituted (C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(16b) is hydrogen or C₁-C₆-alkyl; R¹⁷ is (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(9c), R^(9d) are independently hydrogen, halogen, or C₁-C₆-alkyl; n5 is 0, 1, 2, 3, or 4; R¹⁸ is hydrogen, C₁-C₈-alkyl, optionally substituted C₃-C₁₂-cycloalkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, halogenated C₁-C₆-alkoxycarbonyl, C₆-C₁₂-aryloxycarbonyl, C₁-C₆-alkylaminocarbonyl, (halogenated C₁-C₄-alkyl)aminocarbonyl, C₆-C₁₂-arylaminocarbonyl, optionally substituted C₆-C₁₂-aryl, C₁-C₆-alkylamine, (C₃-C₁₂-cycloalkyl-C₁-C₄-alkyl)amino, (halogenated C₁-C₆-alkyl)amino, (C₁-C₆-alkoxy-C₁-C₆-alkyl)amino, (C₆-C₁₂-aryl-C₁-C₄-alkyl)amino, C₁-C₆-dialkylamine, optionally substituted C₆-C₁₂-arylamine, or optionally substituted C₃-C₁₂-heterocyclyl; R¹⁹ is optionally substituted C₆-C₁₂-aryl or optionally substituted C₃-C₁₂-heterocyclyl; R^(20a) is C₁-C₈-alkyl, (optionally substituted C₃-C₁₂-cycloalkyl)-C₁-C₄-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, (optionally substituted C₆-C₁₂-aryl)-C₁-C₄-alkyl, (optionally substituted C₃-C₁₂-heterocyclyl)-C₁-C₄-alkyl, optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; R^(20b) is hydrogen or C₁-C₈-alkyl; R²¹ is optionally substituted C₆-C₁₂-aryl, or optionally substituted C₃-C₁₂-heterocyclyl; and R^(5a), R^(5b) are independently hydrogen, halogen, or C₁-C₃-alkyl, or R^(5a), R^(5b) together with the carbon atom to which they are bound may form a C═O; or a physiologically tolerated salt thereof. 